Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.7.11.22 - cyclin-dependent kinase and Organism(s) Homo sapiens and UniProt Accession Q00534

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
GPR68 Contributes to Persistent Acidosis-Induced Activation of AGC Kinases and Tyrosine Phosphorylation in Organotypic Hippocampal Slices.
Acquired Immunodeficiency Syndrome
Characterization of isoform diversity among smooth muscle and nonmuscle myosin heavy chains.
Emerging Roles for Ciz1 in Cell Cycle Regulation and as a Driver of Tumorigenesis.
Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors.
miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma.
Role of Cdc42p in pheromone-stimulated signal transduction in Saccharomyces cerevisiae.
Acute Kidney Injury
Coordination of the cell cycle is an important determinant of the syndrome of acute renal failure.
Cyclin-dependent kinase inhibitor p18INK4c is involved in protective roles of heme oxygenase-1 in cisplatin-induced acute kidney injury.
Lack of a functional p21WAF1/CIP1 gene accelerates caspase-independent apoptosis induced by cisplatin in renal cells.
Overexpression of p18INK?C in LLC-PK1 cells increases resistance to cisplatin-induced apoptosis.
Role of the increase in p21 in cisplatin-induced acute renal failure in rats.
Vitamin D deficiency aggravates ischemic acute kidney injury in rats.
Acute Radiation Syndrome
Blocking cyclin-dependent kinase 4/6 during single dose vs. fractionated radiation therapy leads to opposite effects on acute gastrointestinal toxicity in mice.
Adenocarcinoma
Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma.
Antiproliferative activity of the dietary isothiocyanate erucin, a bioactive compound from cruciferous vegetables, on human prostate cancer cells.
CDK10 is not a target for aberrant DNA methylation in breast cancer.
CDK5 positively regulates Notch1 signaling in pancreatic cancer cells by phosphorylation.
Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.
Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis.
Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix.
Dysregulation of CDK Inhibitors and p53 in HPV-negative Endocervical Adenocarcinoma.
Effects of the environmental mammary carcinogen 6-nitrochrysene on p53 and p21(Cip1) protein expression and cell cycle regulation in MCF-7 and MCF-10A cells.
Evaluation of the cyclin-dependent kinase inhibitor p21Cip1 in epithelial ovarian tumors of low malignant potential and adenocarcinomas.
Expression and prognostic significance of cyclin-dependent kinase inhibitor 1A in patients with resected gastric adenocarcinoma.
Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity.
Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas.
Expression of cyclin B1, D1 and K in non?small cell lung cancer H1299 cells following treatment with sulforaphane.
Expression of p16 protein in gallbladder carcinoma and its precancerous conditions.
Expression of p21WAF1/CIP1 in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression.
Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
Expression patterns and prognostic values of the cyclin-dependent kinase 1 and cyclin A2 gene cluster in pancreatic adenocarcinoma.
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27(Kip1) in estrogen-related Endometrial adenocarcinomas.
Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11p110.
Helicobacter pylori inhibits activity of cdc2 kinase and delays G2/M to G1 progression in gastric adenocarcinoma cell line.
IFNgamma induction of p21WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential.
Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance.
Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours.
Immunohistochemical expression of TGF-beta1, p21WAF1, p53, Ki67, and angiogenesis in gastric carcinomas: a clinicopathologic study.
IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression.
Increased cyclin T1 expression as a favorable prognostic factor in treating gastric adenocarcinoma.
Inhibition of pRB Pathway Differentially Modulates Apoptosis in Esophageal Cancer Cells.
Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma.
Low Expression of CDK10 Correlates with Adverse Prognosis in Gastric Carcinoma.
Low expression of CDK12 in gastric cancer is correlated with advanced stage and poor outcome.
Molecular dissection of the chromosome band 7q21 amplicon in gastroesophageal junction adenocarcinomas identifies cyclin-dependent kinase 6 at both genomic and protein expression levels.
Mutational analysis of the P16-binding domain of cyclin-dependent kinase 4 in tumors in the head region of the pancreas.
p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma.
Pancreatic carcinoma surveillance in patients with familial melanoma.
Prediction of therapeutic outcome and survival in a transgenic mouse model of pancreatic ductal adenocarcinoma treated with dendritic cell vaccination or CDK inhibitor using MRI texture: a feasibility study.
Prognostic factors in gastric cancer.
Prognostic significance of p27(kip-1) expression in colorectal adenocarcinomas is associated with tumor stage.
Prognostic value of p27 expression in adenocarcinoma of the pancreatic head region.
Pulmonary fibroblasts stimulate the proliferation of cell lines from human lung adenocarcinomas.
Roles of cyclin-dependent kinase 8 and ?-catenin in the oncogenesis and progression of gastric adenocarcinoma.
Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy.
Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma.
Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma.
The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma.
The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2.
Adenocarcinoma in Situ
IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression.
Adenocarcinoma of Lung
Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma.
Association of lncRNA polymorphisms with triglyceride and total cholesterol levels among myocardial infarction patients in Chinese population.
Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells.
Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.
Elevated nuclear CDK6 is associated with an unfavorable prognosis in lung adenocarcinoma patients.
Knockdown of PFTK1 Expression by RNAi Inhibits the Proliferation and Invasion of Human Non-Small Lung Adenocarcinoma Cells.
Knockdown of SMAD3 inhibits the growth and enhances the radiosensitivity of lung adenocarcinoma via p21 in vitro and in vivo.
miR-363-3p inhibits tumor growth by targeting PCNA in lung adenocarcinoma.
Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879V.
Roles and Mechanisms of the Long Noncoding RNAs in Cervical Cancer.
Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells.
The lncRNA ALMS1-IT1 may promote malignant progression of lung adenocarcinoma via AVL9-mediated activation of the cyclin-dependent kinase pathway.
Adenoma
Aberrant expression of G1-phase cell cycle regulators in flat and exophytic adenomas of the human colon.
Activation of cyclin E-dependent kinase activity in colorectal cancer.
CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis.
Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients.
Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression.
Differential gene expression in pituitary adenomas by oligonucleotide array analysis.
Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity.
Expression of p21WAF1/CIP1 in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression.
Lineage-specific restraint of pituitary gonadotroph cell adenoma growth.
Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein.
Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas.
Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism.
Roles of cyclin-dependent kinase 8 and ?-catenin in the oncogenesis and progression of gastric adenocarcinoma.
Targeted inactivation of p27kip1 is sufficient for large and small intestinal tumorigenesis in the mouse, which can be augmented by a Western-style high-risk diet.
Uncontrolled insulin secretion from a childhood pancreatic beta-cell adenoma is not due to the functional loss of ATP-sensitive potassium channels.
Adenoma, Islet Cell
Immunohistochemical investigation of F344/N rat islet cell tumors from national toxicology program studies.
Adenoma, Pleomorphic
Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours.
Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization.
Adenomatous Polyposis Coli
Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma.
Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis.
CDK11 negatively regulates Wnt/?-catenin signaling in the endosomal compartment by affecting microtubule stability.
Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients.
DNA hypermethylation profiles in squamous cell carcinoma of the vulva.
DNA methylation markers and early recurrence in stage I lung cancer.
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study.
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) by the cyclin-dependent kinase p34.
Promoter hypermethylation of p16 and APC in gastrointestinal cancer patients.
Relation between normal rectal methylation, smoking status, and the presence or absence of colorectal adenomas.
Adrenocortical Carcinoma
Identification of NDRG Family Member 4 (NDRG4) and CDC28 Protein Kinase Regulatory Subunit 2 (CKS2) as Key Prognostic Genes in Adrenocortical Carcinoma by Transcriptomic Analysis.
Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors.
Agenesis of Corpus Callosum
A homozygous deleterious CDK10 mutation in a patient with agenesis of corpus callosum, retinopathy, and deafness.
Aicardi Syndrome
Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Screening in Rett Syndrome and Related Disorders.
Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.
Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
AIDS-Associated Nephropathy
Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation.
Albuminuria
Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice.
Alopecia
A new treatment of alopecia induced by palbociclib: Topical cetirizine.
Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors.
Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)-Like Pigmentation in a Metastatic Breast Cancer Patient.
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
[Prevention of chemotherapy-induced alopecia by cyclin-dependant kinase inhibitors]
Alzheimer Disease
A novel approach to cyclin-dependent kinase 5/p25 inhibitors: A potential treatment for Alzheimer's disease.
A novel mechanism of non-A? component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5).
AAV9-Mediated Cdk5 Inhibitory Peptide Reduces Hyperphosphorylated Tau and Inflammation and Ameliorates Behavioral Changes Caused by Overexpression of p25 in the Brain.
Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration.
Adeno-associated virus 9-mediated Cdk5 inhibitory peptide reverses pathologic changes and behavioral deficits in the Alzheimer's disease mouse model.
Advances in multiplex PCR for Alzheimer's disease diagnostics targeting CDK genes.
Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Alzheimer's disease: No effect of the CDK5 gene on CSF biomarkers, neuropathology or disease risk.
Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein.
Antipodal effects of p25 on synaptic plasticity, learning, and memory--too much of a good thing is bad.
Association between plasma biomarkers, CDK5 polymorphism and the risk of Alzheimer's disease.
Association of cyclin-dependent kinase 5 and neuronal activators p35 and p39 complex in early-onset Alzheimer's disease.
Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces A? and P25 accumulation in 5XFAD mice.
CDK5 activator protein p25 preferentially binds and activates GSK3?.
Cdk5 as a drug target for the treatment of Alzheimer's disease.
Cdk5 Inhibitory Peptide Prevents Loss of Dopaminergic Neurons and Alleviates Behavioral Changes in an MPTP Induced Parkinson's Disease Mouse Model.
Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer's disease.
Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration.
Cell cycle related signaling in neuro2a cells proceeds via the receptor for advanced glycation end products.
Cellular Localization of Debromohymenialdisine and Hymenialdisine in the Marine Sponge Axinella sp. Using a Newly Developed Cell Purification Protocol.
Clubbed thiazoles by MAOS: a novel approach to cyclin-dependent kinase 5/p25 inhibitors as a potential treatment for Alzheimer's disease.
Coexpression of human cdk5 and its activator p35 with human protein tau in neurons in brain of triple transgenic mice.
Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery.
Critical role of mitosis in spontaneous late-onset Alzheimer's disease; from a Shugoshin 1 cohesinopathy mouse model.
Curcumin Ameliorates Neuroinflammation, Neurodegeneration, and Memory Deficits in p25 Transgenic Mouse Model that Bears Hallmarks of Alzheimer's Disease.
Cyclin-dependent kinase 5 activator p25 is generated during memory formation and is reduced at an early stage in Alzheimer's disease.
Cyclin-dependent kinase 5 is associated with risk for Alzheimer's disease in a Dutch population-based study.
Cyclin-dependent kinase 5, Munc18a and Munc18-interacting protein 1/X11alpha protein up-regulation in Alzheimer's disease.
Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians.
Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions.
Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors.
Designing of dual inhibitors for GSK-3? and CDK5: Virtual screening and in vitro biological activities study.
Detection of a Cdc2-related kinase associated with Alzheimer paired helical filaments.
Determination of kinetic parameters and structure-activity relationships of ginsenosides as inhibitors of cyclin-dependent kinase 5/p25 using ultra-pressure liquid chromatography with triple quadrupole tandem mass spectrometry.
Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease.
Disruption of neuronal nitric oxide synthase dimerization contributes to the development of Alzheimer's disease: Involvement of cyclin-dependent kinase 5-mediated phosphorylation of neuronal nitric oxide synthase at Ser(293).
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Epistasis between tau phosphorylation regulating genes (CDK5R1 and GSK-3beta) and Alzheimer's disease risk.
Expression of p25 impairs contextual learning but not latent inhibition in mice.
Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease.
Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors.
Fuzhisan, a chinese herbal medicine, inhibits Beta-amyloid-induced neurotoxicity and tau phosphorylation through calpain/cdk5 pathway in cultured cortical neurons.
G-Protein Coupled Receptors and Tau-different Roles in Alzheimer's Disease.
Generation of the Cdk5 activator p25 is a memory mechanism that is affected in early Alzheimer's disease.
Glucose-induced expression of the cyclin-dependent protein kinase 5 activator p35 involved in Alzheimer's disease regulates insulin gene transcription in pancreatic beta-cells.
Hyperphosphorylation of RNA polymerase II and reduced neuronal RNA levels precede neurofibrillary tangles in Alzheimer disease.
Identification of non-muscle myosin heavy chain as a substrate for Cdk5 and tool for drug screening.
Identification of p10 as a neurotoxic product generated from the proteolytic cleavage of the neuronal Cdk5 activator.
Improved reversal learning and altered fear conditioning in transgenic mice with regionally restricted p25 expression.
Increased p27, an essential component of cell cycle control, in Alzheimer's disease.
Indirubin Derivative 7-Bromoindirubin-3-Oxime (7Bio) Attenuates A? Oligomer-Induced Cognitive Impairments in Mice.
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
Inhibition of p25/Cdk5 attenuates tauopathy in mouse and iPSC models of frontotemporal dementia.
Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing.
Investigation of the flexibility of protein kinases implicated in the pathology of Alzheimer's disease.
Is there a role of the cyclin-dependent kinase 5 activator p25 in Alzheimer's disease?
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
Kinetic mechanistic studies of Cdk5/p25-catalyzed H1P phosphorylation: metal effect and solvent kinetic isotope effect.
Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors.
Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease.
Localization and expression of cdc2 and cdk4 in Alzheimer brain tissue.
Negative regulation of Vps34 by Cdk mediated phosphorylation.
Networking with proline-directed protein kinases implicated in tau phosphorylation.
Neuroprotective effects of Tongmai Yizhi Decoction () against Alzheimer's disease through attenuating cyclin-dependent kinase-5 expression.
No association of CDK5 genetic variants with Alzheimer's disease risk.
No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro.
P21 gene variation and late-onset Alzheimer's disease in the italian population.
p25/cyclin-dependent kinase 5 promotes the progression of cell death in nucleus of endoplasmic reticulum-stressed neurons.
p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease.
Pharmacological relevance of CDK inhibitors in Alzheimer's disease.
Phosphoproteome and transcriptome analysis of the neuronal response to a CDK5 inhibitor.
Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease.
Potential neuroprotective flavonoid-based inhibitors of CDK5/p25 from Rhus parviflora.
Protein interaction module-assisted function X (PIMAX) approach to producing challenging proteins including hyperphosphorylated tau and active CDK5/p25 kinase complex.
Recent evidence regarding a role for Cdk5 dysregulation in Alzheimer's disease.
Relative resistance of Cdk5-phosphorylated CRMP2 to dephosphorylation.
Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies.
Role of protein kinases in neurodegenerative disease: cyclin-dependent kinases in Alzheimer's disease.
Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors.
Studying synergism of methyl linked cyclohexyl thiophenes with triazole: Synthesis and their cdk5/p25 inhibition activity.
Synthesis and kinase inhibitory activity of novel substituted indigoids.
Targeting MicroRNA-125b Promotes Neurite Outgrowth but Represses Cell Apoptosis and Inflammation via Blocking PTGS2 and CDK5 in a FOXQ1-Dependent Way in Alzheimer Disease.
Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: implications for Alzheimer's disease.
TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice.
The amyloid-beta peptide binds to cyclin B1 and increases human cyclin-dependent kinase-1 activity.
The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism.
The mechanisms regulating cyclin-dependent kinase 5 in hippocampus during systemic inflammatory response: The effect on inflammatory gene expression.
Tolfenamic acid inhibits GSK-3? and PP2A mediated tau hyperphosphorylation in Alzheimer's disease models.
Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing.
Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease.
When good Cdk5 turns bad.
[Cyclin dependent kinases. From molecular biology to pathology]
Ameloblastoma
Detection of cell cycle-related factors in ameloblastomas.
Establishment of human dental epithelial cell lines expressing ameloblastin and enamelin by transfection of hTERT and cdk4 cDNAs.
Amyloidosis
Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice.
Amyotrophic Lateral Sclerosis
Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein.
Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration.
Cyclin-dependent kinase 5 in amyotrophic lateral sclerosis.
Cyclin-dependent kinase 5 in Lewy body-like inclusions in anterior horn cells of a patient with sporadic amyotrophic lateral sclerosis.
Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians.
Cyclin-dependent kinase-5 (CDK5) and amyotrophic lateral sclerosis.
Cyclin-dependent kinase-5 is associated with lipofuscin in motor neurones in amyotrophic lateral sclerosis.
Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors.
p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease.
Phosphoproteome and transcriptome analysis of the neuronal response to a CDK5 inhibitor.
Anemia
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer.
Anemia, Aplastic
Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer.
Anemia, Sickle Cell
Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease.
Aneurysm
Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis.
Angelman Syndrome
Genetic disorders associated with postnatal microcephaly.
Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation.
Angiomyoma
Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors.
Aortic Aneurysm, Abdominal
Upregulation of MicroRNA-15a Contributes to Pathogenesis of Abdominal Aortic Aneurysm (AAA) by Modulating the Expression of Cyclin-Dependent Kinase Inhibitor 2B (CDKN2B).
Arrhythmias, Cardiac
Caregiver's perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients.
Arteriovenous Malformations
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Arthritis
Amelioration of rheumatoid arthritis in a breast cancer patient treated with palbociclib: a case report.
Cyclin-dependent kinase inhibitor p21, via its C-terminal domain, is essential for resolution of murine inflammatory arthritis.
Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis.
Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis.
Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors.
Suppression of arthritis by forced expression of cyclin-dependent kinase inhibitor p21(Cip1) gene into the joints.
Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial.
Treatment of arthritis with cyclin-dependent kinase inhibitor gene.
[Treatment of arthritis with cyclin-dependent kinase inhibitor p 16INK4a gene]
Arthritis, Experimental
Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice.
Amelioration of rheumatoid arthritis in a breast cancer patient treated with palbociclib: a case report.
Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis.
SPACIA1/SAAL1 Deletion Results in a Moderate Delay in Collagen-Induced Arthritis Activity, along with mRNA Decay of Cyclin-dependent Kinase 6 Gene.
Arthritis, Rheumatoid
Amelioration of rheumatoid arthritis in a breast cancer patient treated with palbociclib: a case report.
Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and -independent pathways by cyclin-dependent kinase 4/6.
Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis.
KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy.
p16(INK4a) exerts an anti-inflammatory effect through accelerated IRAK1 degradation in macrophages.
Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors.
Susceptibility of cyclin-dependent kinase inhibitor 1-deficient mice to rheumatoid arthritis arising from interleukin-1?-induced inflammation.
Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial.
The expression of zinc finger 804a (ZNF804a) and cyclin-dependent kinase 1 (CDK1) genes is related to the pathogenesis of rheumatoid arthritis.
[Determination of IgM-RF, IgA-RF, IgG-RF, IL-1RI, CDK2 and ROC evaluation in patients with rheumatoid arthritis]
Arthrogryposis
Congenital dislocation of the knee reduced spontaneously or with minimal treatment.
Asthma
Airway Smooth Muscle Hyperproliferation is Regulated by microRNA-221 in Severe Asthma.
Astrocytoma
Anti-sense oligonucleotide of p21(waf1/cip1) prevents interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells.
Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas.
CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas.
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy.
Cyclin and cyclin-dependent kinase expression in human astrocytoma cell lines.
Glioma biology and molecular markers.
Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human astrocytoma cells by the pyrrolo-1,5-benzoxazepine, PBOX-21.
Low Dose Astaxanthin Treatments Trigger the Hormesis of Human Astroglioma Cells by Up-Regulating the Cyclin-Dependent Kinase and Down-Regulated the Tumor Suppressor Protein P53.
Markers of cellular proliferation are expressed in cortical tubers.
p16(ink4a) and retinoic acid modulate rhoA and GFAP expression during induction of a stellate phenotype in U343 MG-A astrocytoma cells.
Primary and recurrent diffuse astrocytomas: genomic profile comparison reveals acquisition of biologically relevant aberrations.
Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1.
Ataxia
A novel function of HER2/Neu in the activation of G2/M checkpoint in response to ?-irradiation.
Regulation of BRCA1 phosphorylation by interaction with protein phosphatase 1alpha.
The double dealing of cyclin D1.
Tyrosine hydroxylase expression and Cdk5 kinase activity in ataxic cerebellum.
Ataxia Telangiectasia
?-Radiation induces cellular sensitivity and aberrant methylation in human tumor cell lines.
Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-X(L) and survivin.
Cytosine arabinoside induces phosphorylation of histone H2AX in hippocampal neurons via a noncanonical pathway.
Domain within the helicase subunit Mcm4 integrates multiple kinase signals to control DNA replication initiation and fork progression.
Genomic instability--an evolving hallmark of cancer.
GPR68 Contributes to Persistent Acidosis-Induced Activation of AGC Kinases and Tyrosine Phosphorylation in Organotypic Hippocampal Slices.
Hepatitis B virus X protein activates the ATM-Chk2 pathway and delays cell cycle progression.
HiNF-P is a bifunctional regulator of cell cycle controlled histone H4 gene transcription.
Prognostic significance of G2/M arrest signaling pathway proteins in advanced non-small cell lung cancer patients.
RAC1 GTPase plays an important role in ?-irradiation induced G2/M checkpoint activation.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection.
Screening of gene mutations associated with bone metastasis in nonsmall cell lung cancer.
Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications.
The Crucial Role of Cyclin-Dependent Kinase-5-Ataxia-Telangiectasia Mutated Axis in ICH-Induced Neuronal Injury of Rat Model.
Tumor suppressor function of miR-483-3p on breast cancer via targeting of the cyclin E1 gene.
Werner Syndrome Protein and DNA Replication.
Atherosclerosis
Atherosclerosis and Cell Cycle: Put the Brakes On! Critical Role for Cyclin-Dependent Kinase Inhibitors.
Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease.
CDKN2B methylation is associated with carotid artery calcification in ischemic stroke patients.
Coordinate control of proliferation and migration by the p27Kip1/cyclin-dependent kinase/retinoblastoma pathway in vascular smooth muscle cells and fibroblasts.
Cyclin-dependent kinase 5-mediated hyperphosphorylation of sirtuin-1 contributes to the development of endothelial senescence and atherosclerosis.
Cyclin-dependent kinase 9 may as a novel target in downregulating the atherosclerosis inflammation (Review).
Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis.
Deficiency of cyclin-dependent kinase inhibitors p21(Cip1) and p27(Kip1) accelerates atherogenesis in apolipoprotein E-deficient mice.
Disease onset and aging in the world of circular RNAs.
Expression of cyclin-dependent kinase inhibitors in vascular disease.
Expression of the cyclin-dependent kinase inhibitor, p21Waf-1/Cip-1/Sdi-1, in human vascular smooth muscle cells in the proliferating state.
Inhibition of CDK9 attenuates atherosclerosis by inhibiting inflammation and phenotypic switching of vascular smooth muscle cells.
Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression.
p27(Kip1) inhibits tissue factor expression.
The Severity of Internal Carotid Artery Stenosis is Associated with the Cyclin-Dependent Kinase Inhibitor 2A Gene Expression.
[Methylation profile of INK4B-ARF-INK4A locus in atherosclerosis].
Atrial Fibrillation
Cyclin Dependent Kinase 1 (CDK1) Activates Cardiac Fibroblasts via Directly Phosphorylating Paxillin at Ser244.
Atypical Squamous Cells of the Cervix
p16(INK4a) immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities : A systematic review and meta-analysis.
Autoimmune Diseases
Posterior Reversible Encephalopathy Occurring During Treatment With Palbociclib.
Azoospermia
microRNAs in the pathogenesis of non-obstructive azoospermia: the underlying mechanisms and therapeutic potentials.
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Babesiosis
Cyclin-dependent kinase inhibitors block erythrocyte invasion and intraerythrocytic development of Babesia bovis in vitro.
Bacterial Infections
Differential patterns of apoptosis in resolving and nonresolving bacterial pneumonia.
Barrett Esophagus
Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
Beckwith-Wiedemann Syndrome
Cancer Risk in Beckwith-Wiedemann Syndrome: A Systematic Review and Meta-Analysis Outlining a Novel (Epi)Genotype Specific Histotype Targeted Screening Protocol.
CDKN1C mutations: two sides of the same coin.
Functional Versatility of the CDK Inhibitor p57Kip2.
Methylation of KvDMR1 involved in regulating the imprinting of CDKN1C gene in cattle.
MicroRNA-21 inhibits p57Kip2 expression in prostate cancer.
p57K1P2 is expressed in Wilms' tumor with LOH of 11p15.5.
p57Kip2 is an unrecognized DNA damage response effector molecule that functions in tumor suppression and chemoresistance.
Bicuspid Aortic Valve Disease
Correction: Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13.
Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13.
Biliary Tract Neoplasms
CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells.
CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene.
Blast Crisis
Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
Blister
Cell cycle regulation and apoptotic cell death in experimental colon carcinogenesis: intervening with cyclooxygenase-2 inhibitors.
Identification of CDK- and cyclin-like proteins in the eye of Bulla gouldiana.
The cyclin-dependent kinase (cdk) inhibitors, olomoucine and roscovitine, alter the expression of a molluscan circadian pacemaker.
Bloom Syndrome
Identification of cancer stem cell-related biomarkers in lung adenocarcinoma by stemness index and weighted correlation network analysis.
The Bloom syndrome helicase is a substrate of the mitotic Cdc2 kinase.
Brain Diseases
A GABAB receptor antagonist rescues functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder.
A girl with early-onset epileptic encephalopathy associated with microdeletion involving CDKL5.
A male case with CDKL5-associated encephalopathy manifesting transient methylmalonic acidemia.
A maternally inherited frameshift CDKL5 variant in a male with global developmental delay and late-onset generalized epilepsy.
A new cause of developmental and epileptic encephalopathy with continuous spike-and-wave during sleep: CDKL5 disorder.
A novel CDKL5 mutation in a 47,XXY boy with the early-onset seizure variant of Rett syndrome.
A novel p.Arg970X mutation in the last exon of the CDKL5 gene resulting in late-onset seizure disorder.
Aminoglycoside drugs induce efficient read-through of CDKL5 nonsense mutations, slightly restoring its kinase activity.
Association of cyclin-dependent kinase 5 and neuronal activators p35 and p39 complex in early-onset Alzheimer's disease.
CDKL5 alterations lead to early epileptic encephalopathy in both genders.
CDKL5 and Shootin1 Interact and Concur in Regulating Neuronal Polarization.
CDKL5 deficiency disorder in males: Five new variants and review of the literature.
CDKL5 Deficiency Disorder-A Complex Epileptic Encephalopathy.
CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.
CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.
CDKL5 Encephalopathy: A Rare Cause of Infantile Epileptic Encephalopathy.
CDKL5 gene status in female patients with epilepsy and Rett-like features: two new mutations in the catalytic domain.
CDKL5 Gene-Related Epileptic Encephalopathy in Estonia: Four Cases, One Novel Mutation Causing Severe Phenotype in a Boy, and Overview of the Literature.
CDKL5 gene-related epileptic encephalopathy: electroclinical findings in the first year of life.
CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery.
CDKL5 Mutations as a Cause of Severe Epilepsy in Infancy: Clinical and Electroencephalographic Long-term Course in 4 Patients.
CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy.
CDKL5 variant in a boy with infantile epileptic encephalopathy: case report.
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.
CDKL5-Related Disorders: From Clinical Description to Molecular Genetics.
Cell cloning-based transcriptome analysis in cyclin-dependent kinase-like 5 mutation patients with severe epileptic encephalopathy.
Clinical features and gene mutational spectrum of CDKL5-related diseases in a cohort of Chinese patients.
Clinical features of early myoclonic encephalopathy caused by a CDKL5 mutation.
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants.
Comparing Parental Well-Being and Its Determinants Across Three Different Genetic Disorders Causing Intellectual Disability.
Complex mosaic CDKL5 deletion with two distinct mutant alleles in a 4-year-old girl.
Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Screening in Rett Syndrome and Related Disorders.
Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.
Diagnostic Approach to Genetic Causes of Early-Onset Epileptic Encephalopathy.
Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
Early-Onset Developmental and Epileptic Encephalopathies of Infancy: An Overview of the Genetic Basis and Clinical Features.
Encephalopathy and bilateral cataract in a boy with an interstitial deletion of Xp22 comprising the CDKL5 and NHS genes.
Epilepsy caused by CDKL5 mutations.
Epileptic encephalopathy and atypical Rett syndrome with mutations in CDKL5: clinical and molecular characterization of two Brazilian patients.
Epileptic encephalopathy in a girl with an interstitial deletion of Xp22 comprising promoter and exon 1 of the CDKL5 gene.
Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder.
Extrasynaptic NMDA receptor stimulation induces CDKL5 cytoplasmic translocation and proteasomal degradation.
Functional and Structural Impairments in the Perirhinal Cortex of a Mouse Model of CDKL5 Deficiency Disorder Are Rescued by a TrkB Agonist.
Generation and characterization of human induced pluripotent stem cells (iPSCs) from three male and three female patients with CDKL5 Deficiency Disorder (CDD).
Genes of early-onset epileptic encephalopathies: from genotype to phenotype.
High prevalence of genetic alterations in early-onset epileptic encephalopathies associated with infantile movement disorders.
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Historic, clinical, and prognostic features of epileptic encephalopathies caused by CDKL5 mutations.
Impairment of CDKL5 nuclear localisation as a cause for severe infantile encephalopathy.
In vivo magnetic resonance spectroscopy in the brain of Cdkl5 null mice reveals a metabolic profile indicative of mitochondrial dysfunctions.
Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons.
iPS cells to model CDKL5-related disorders.
Key clinical features to identify girls with CDKL5 mutations.
Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice.
Mapping pathological phenotypes in a mouse model of CDKL5 disorder.
Microtubules: A Key to Understand and Correct Neuronal Defects in CDKL5 Deficiency Disorder?
Molecular and genetic insights into an infantile epileptic encephalopathy - CDKL5 disorder.
Molecular and Synaptic Bases of CDKL5 Disorder.
Molecular characterization of a cohort of 73 patients with infantile spasms syndrome.
Mutation in an alternative transcript of CDKL5 in a boy with early onset seizures.
Mutation of Ser172 in Yeast ? Tubulin Induces Defects in Microtubule Dynamics and Cell Division.
Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.
Mutations in the C-terminus of CDKL5: proceed with caution.
Myoclonic encephalopathy in the CDKL5 gene mutation.
Neurobehavioral phenotype in cyclin-dependent kinase-like 5 syndrome: Case report and review of literature.
New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy.
Novel CDKL5 Mutations in Czech Patients with Phenotypes of Atypical Rett Syndrome and Early-Onset Epileptic Encephalopathy.
Novel CDKL5 mutations were found in patients in China: retrospective investigation in cases of CDKL5-related disorders.
Novel STXBP1 Mutations in 2 Patients With Early Infantile Epileptic Encephalopathy.
Optimizing the molecular diagnosis of CDKL5 gene-related epileptic encephalopathy in boys.
Pathogenic role of the X-linked cyclin-dependent kinase-like 5 and aristaless-related homeobox genes in epileptic encephalopathy of unknown etiology with onset in the first year of life.
Phenotypic manifestations between male and female children with CDKL5 mutations.
Re: CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy.
Recurrent mutations in the CDKL5 gene: genotype-phenotype relationships.
Recurrent occurrences of CDKL5 mutations in patients with epileptic encephalopathy.
Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy.
Rett Syndrome and CDKL5 Deficiency Disorder: From Bench to Clinic.
Revisiting the phenotype associated with FOXG1 mutations: two novel cases of congenital Rett variant.
Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies.
Somatic mosaicism for a CDKL5 mutation as an epileptic encephalopathy in males.
Somatic mosaicism of a CDKL5 mutation identified by next-generation sequencing.
Synaptic Synthesis, Dephosphorylation, and Degradation: A NOVEL PARADIGM FOR AN ACTIVITY-DEPENDENT NEURONAL CONTROL OF CDKL5.
The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy.
The Efficacy of Ketogenic Diet for Specific Genetic Mutation in Developmental and Epileptic Encephalopathy.
The neuropathological consequences of CDKL5 mutation.
The three stages of epilepsy in patients with CDKL5 mutations.
Turkish cases of early infantile epileptic encephalopathy: two novel mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene.
Two Novel Variants Affecting CDKL5 Transcript Associated with Epileptic Encephalopathy.
Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients.
Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder.
Validation of high-resolution DNA melting analysis for mutation scanning of the CDKL5 gene: identification of novel mutations.
What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy.
X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder.
Xp22.3 Genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy.
[Clinical usefulness of serial EEG examinations in the diagnostic of hereditary epileptic encephalopathies case of severe epileptic encephalopathy type 2].
[Early-onset epileptic encephalopathy caused by CDKL5 mutation.]
Brain Injuries, Traumatic
Comparing effects of CDK inhibition and E2F1/2 ablation on neuronal cell death pathways in vitro and after traumatic brain injury.
CR8, a novel inhibitor of CDK, limits microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury.
CR8, a Selective and Potent CDK Inhibitor, Provides Neuroprotection in Experimental Traumatic Brain Injury.
Involvement of aberrant Cdk5/p25 activity in experimental traumatic brain injury.
p53-independent transient p21(WAF1/CIP1) mRNA induction in the rat brain following experimental traumatic injury.
Selective CDK inhibitor limits neuroinflammation and progressive neurodegeneration after brain trauma.
Selective CDK inhibitors: promising candidates for future clinical traumatic brain injury trials.
Brain Ischemia
CDK5 inhibition protects against OGDR induced mitochondrial fragmentation and apoptosis through regulation of Drp1S616 phosphorylation.
Cellular and Molecular Mechanisms of R/S-Roscovitine and CDKs Related Inhibition under Both Focal and Global Cerebral Ischemia: A Focus on Neurovascular Unit and Immune Cells.
Expression of cyclin-dependent kinase 5 mRNA and protein in the human brain following acute ischemic stroke.
Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death.
p27Kip1 constrains proliferation of neural progenitor cells in adult brain under homeostatic and ischemic conditions.
Rat focal cerebral ischemia induced astrocyte proliferation and delayed neuronal death are attenuated by cyclin-dependent kinase inhibition.
[Novel actions of HMG-CoA reductase inhibitors(statins)--vascular and cerebral protection through inhibition of small GTPase Rho]
Brain Neoplasms
A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042).
Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain.
Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas.
CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.
Common alternative gene alterations in adult malignant astrocytomas, but not in childhood primitive neuroectodermal tumors: P 16ink4 homozygous deletions and CDK4 gene amplifications.
Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin.
Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Patients with Primary Brain Tumors.
Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
Gene amplification as a prognostic factor in primary brain tumors.
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.
Infrequent mutation of Waf1/p21 gene, a CDK inhibitor gene, in brain tumors.
Targeted Therapies for Breast Cancer Brain Metastases.
Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1.
Breast Neoplasms
"Nutritional and chemopreventive anti-cancer agents up-regulate expression of p27Kip1, a cyclin-dependent kinase inhibitor, in mouse JB6 epidermal and human MCF7, MDA-MB-321 and AU565 breast cancer cells".
123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1/Cip-1).
4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells.
?-Thujaplicin inhibits basal-like mammary tumor growth by regulating glycogen synthase kinase-3?/?-catenin signaling.
?-Thujaplicin modulates estrogen receptor signaling and inhibits proliferation of human breast cancer cells.
?EF1 upregulates CDK4 transcription via the E2-box element on the CDK4 promoter.
A clinical evaluation of treatments that target cell cycle machinery in breast cancer.
A cmap-enabled gene expression signature-matching approach identifies small-molecule inducers of accelerated cell senescence.
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
A genomic approach to predict synergistic combinations for breast cancer treatment.
A Long Non-coding RNA Lnc712 Regulates Breast Cancer Cell Proliferation.
A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer Medicine.
A microfluidic approach to parallelized transcriptional profiling of single cells.
A mixed-methods study of cyclin-dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers.
A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2- metastatic breast cancer.
A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines.
A novel cytoplasmic substrate for cdk4 and cdk6 in normal and malignant epithelial derived cells.
A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation.
A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention.
A p18 mutant defective in CDK6 binding in human breast cancer cells.
A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors.
A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer.
A Phase 1 Study of Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Japanese Patients.
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.
A Phase I/Ib Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer After Trastuzumab and Taxane Therapy.
A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers.
A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status.
A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients.
A Splice Site Variant of CDK12 and Breast Cancer in Three Eurasian Populations.
Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.
Abemaciclib induces apoptosis in cardiomyocytes by activating the Hippo signaling pathway.
Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer.
Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Activation of CDK4 gene expression in human breast cancer cells by the Brn-3b POU family transcription factor.
Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells.
Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells.
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.
Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer.
Adenoviral expression of the cyclin-dependent kinase inhibitor p27Kip1: a strategy for breast cancer gene therapy.
Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials.
Adjuvant cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive breast cancer: One Monarch to rule them all?
Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma.
Advances in Oral Oncolytic Agents for Breast Cancer and Recommendations for Promoting Adherence.
Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors.
Akt-dependent T198 phosphorylation of cyclin-dependent kinase inhibitor p27kip1 in breast cancer.
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations.
Alpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity.
Amelioration of rheumatoid arthritis in a breast cancer patient treated with palbociclib: a case report.
An available strategy based on accurate mass by ultra high performance liquid chromatography coupled to Fourier transform ion cyclotron resonance mass spectrometry technology to characterization of metabolic profile of palbociclib in rat urine, feces and bile.
An evaluation of palbociclib as a breast cancer treatment option: a current update.
Analysis of cell growth inhibitory effects of catechin through MAPK in human breast cancer cell line T47D.
Analysis of phosphorylation of pRB and its regulatory proteins in breast cancer.
Analysis of the resveratrol-binding protein using phage-displayed random peptide library.
Anti-Cancer Effect of IN-2001 in T47D Human Breast Cancer.
Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges.
Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21.
Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells.
Antitumor activity of IFIX, a novel interferon-inducible HIN-200 gene, in breast cancer.
AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity.
AP4 encodes a c-MYC-inducible repressor of p21.
ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Aryl hydrocarbon receptor regulates cell cycle progression in human breast cancer cells via a functional interaction with cyclin-dependent kinase 4.
ASCO 2016: highlights in breast cancer.
Association of cyclin-dependent kinase inhibitor 2A/B with increased risk of developing breast cancer.
Association of cyclin-dependent kinase inhibitor 2B antisense RNA 1 gene expression and rs2383207 variant with breast cancer risk and survival.
Association of germline variation in CCNE1 and CDK2 with breast cancer risk, progression and survival among Chinese Han women.
Berberine enhances posttranslational protein stability of p21/cip1 in breast cancer cells via down-regulation of Akt.
Binding sites for adeno-associated virus Rep proteins within the human genome.
Biological effects of G1 phase arrest compound, sesquicillin, in human breast cancer cell lines.
Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1).
Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy.
Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.
Both p62/SQSTM1-HDAC6-dependent autophagy and the aggresome pathway mediate CDK1 degradation in human breast cancer.
Breast Cancer Special Feature: Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins.
Breast cancer: updates and advances in 2016.
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Bullous Skin Rash: A Rare Case of Palbociclib-Induced Dermatological Toxicity.
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report.
Cardiac arrhythmia considerations of hormone cancer therapies.
Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy.
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment.
CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions.
CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer.
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
Cdk inhibitor p27Kip1 and hormone dependence in breast cancer.
CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis.
CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease.
CDK inhibitors in cancer therapy, an overview of recent development.
CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer.
CDK1 in Breast Cancer: Implications for Theranostic Potential.
CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells.
CDK10 is not a target for aberrant DNA methylation in breast cancer.
CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome.
CDK11p58 inhibits ER?-positive breast cancer invasion by targeting integrin ?3 via the repression of ER? signaling.
CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/? -catenin Signaling.
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion.
Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis.
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open-Cancer Horizons pro and con discussion.
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease.
CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge.
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.
CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?
CDK7-dependent transcriptional addiction in triple-negative breast cancer.
CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy.
CDKN2A/P16INK4A variants association with breast cancer and their in-silico analysis.
Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.
Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Cell cycle control in breast cancer cells.
Cell Cycle Regulation in Treatment of Breast Cancer.
Cell cycle regulators and their abnormalities in breast cancer.
Cell cycle-based therapies move forward.
Cell-proliferation imaging for monitoring response to CDK4/6 inhibition combined with endocrine-therapy in breast cancer: Comparison of [18F]FLT and [18F]ISO-1 PET/CT.
Cellular senescence: from anti-cancer weapon to anti-aging target.
Cellular Uptake and Efflux of Palbociclib In Vitro in Single Cell and Spheroid Models.
CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer.
Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response.
Chemotherapy patient with Stevens-Johnson Syndrome presents to the Emergency Department: A case report.
Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer.
Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy.
Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Clinical Outcomes in Breast Cancer: Innovations and Ideas Commentary on "Expression of CDK13 was Associated with Clinical Outcomes and Expression of HIF-1 and Beclin1 in Breast Cancer Patients".
Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Combination of palbociclib and radiotherapy for glioblastoma.
Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer.
Combined endocrine and targeted therapy in luminal breast cancer.
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.
Combined Luteolin and Indole-3-Carbinol Synergistically Constrains ER?-Positive Breast Cancer by Dual Inhibiting Estrogen Receptor Alpha and Cyclin-Dependent Kinase 4/6 Pathway in Cultured Cells and Xenograft Mice.
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.
Constitutive CCND1/CDK2 activity substitutes for p53 loss, or MYC or oncogenic RAS expression in the transformation of human mammary epithelial cells.
Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect?
Correlation of p27 protein expression with HER-2/neu expression in breast cancer.
Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience.
Critical role of CDK11(p58) in human breast cancer growth and angiogenesis.
Crosstalk of Cyclin-dependent kinase inhibitor 1A (CDKN1A) gene polymorphism with p53 and CCND1 polymorphism in breast cancer.
Curcumin as an Adjuvant to Breast Cancer Treatment.
Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer.
Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience.
Cyclin d1 induces chromosomal instability.
Cyclin D1 promotes secretion of pro-oncogenic immuno-miRNAs and piRNAs.
Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy.
Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors.
Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth.
Cyclin-dependent kinase 15 upregulation is correlated with poor prognosis for patients with breast cancer.
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Cyclin-dependent kinase 4-mediated phosphorylation inhibits smad3 activity in cyclin d-overexpressing breast cancer cells.
Cyclin-dependent kinase 4/6 inhibition in the treatment of hormone receptor-positive breast cancer.
Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer.
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer.
Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy.
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches.
Cyclin-dependent kinase 4/6 inhibitors: what have we learnt across studies, therapy situations and substances.
Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future.
Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor-positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?
Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Cyclin?dependent kinase 4/6 inhibitors in combination with fulvestrant for previously treated metastatic hormone receptor?positive breast cancer patients: A systematic review and meta?analysis of randomized clinical trials.
Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer.
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report.
Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.
Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: Correlation with Jab1 stability and PI3K/Akt pathway.
Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2- Advanced Breast Cancer: A Nationwide Real-World Experience.
Depletion of ?-glutamylcyclotransferase inhibits breast cancer cell growth via cellular senescence induction mediated by CDK inhibitor upregulation.
Depletion of gamma-glutamylcyclotransferase inhibits cancer cell growth by activating the AMPK-FOXO3a-p21 axis.
Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.
Designed Tetrapeptide Interacts with Tubulin and Microtubule.
Dietary phenethyl isothiocyanate alters gene expression in human breast cancer cells.
Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications.
Dinaciclib for the treatment of breast cancer.
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
Doenjang hexane fraction-induced G1 arrest is associated with the inhibition of pRB phosphorylation and induction of Cdk inhibitor p21 in human breast carcinoma MCF-7 cells.
Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer.
Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.
Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA).
Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ER.
Effect of distinct anticancer drugs on the phosphorylation of p53 protein at serine 46 in human MCF-7 breast cancer cells.
Effect of NUCKS-1 overexpression on cytokine profiling in obese women with breast cancer.
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Effects of 60-Hz fields, estradiol and xenoestrogens on human breast cancer cells.
Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel.
Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis.
Efficacy and Safety of CDK4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER-2- ABC Patients: A Systematic Review and Meta-Analysis.
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study.
Ellagic Acid Controls Cell Proliferation and Induces Apoptosis in Breast Cancer Cells via Inhibition of Cyclin-Dependent Kinase 6.
Elucidation of gene function using C-5 propyne antisense oligonucleotides.
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.
Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer.
Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer.
Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review.
Endogenous control of cell cycle progression by autocrine transforming growth factor beta in breast cancer cells.
Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: A case report.
Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.
Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway.
ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
ERINA is an estrogen-responsive lncRNA that drives breast cancer through the E2F1/RB1 pathway.
Establishment of an analytical method for simultaneous quantitation of CDK4/6 inhibitors, aromatase inhibitors, and an estrogen receptor antagonist in human plasma using LC-ESI-MS/MS.
Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells.
Estrogenic and DNA-damaging activity of Red No. 3 in human breast cancer cells.
Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects.
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.
Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Expression and prognostic value of transcription-associated cyclin-dependent kinases in human breast cancer.
Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma.
Expression of CDK inhibitor genes in immortalized and carcinoma derived breast cell lines.
Expression of CDK13 Was Associated with Prognosis and Expression of HIF-1? and beclin1 in Breast Cancer Patients.
Expression of p16 and cyclin-dependent kinase 4 proteins in primary breast carcinomas.
Expression of p27KIP1, p21WAF1 and p53 does not correlate with prognosis in node-negative invasive ductal carcinoma of the breast.
Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.
Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer.
Expression of the G2-M checkpoint regulators cyclin B1 and P34CDC2 in breast cancer: a correlation with cellular kinetics.
Expression of the HER family mRNA in breast cancer tissue and association with cell cycle inhibitors p21(waf1) and p27(kip1).
Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting.
Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
Fatty acid synthase regulates estrogen receptor-? signaling in breast cancer cells.
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
First-line treatment disruption among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta.
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.
Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives.
G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells.
Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis.
Gene delivery of cyclin-dependent kinase inhibitors p21 ( Waf1 ) and p27 ( Kip1 ) suppresses proliferation of MCF-7 breast cancer cells in vitro.
Genetic Association of rs2237572 Cyclin-Dependent Kinase 6 Gene with Breast Cancer in Iraq.
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity.
Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.
Growth inhibitory efficacy and anti-aromatase activity of Tabebuia avellanedae in a model for post-menopausal Luminal A breast cancer.
Heat shock protein B8, a cyclin-dependent kinase-independent cyclin D1 target gene, contributes to its effects on radiation sensitivity.
Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.
Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas: relation to E-cadherin alterations, proliferative activity, and ploidy of the tumors.
Highlights in breast cancer from ASCO 2016.
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Histone deacetylase inhibitor, Trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells.
HIV-1 Tat Peptide Immunoconjugates Differentially Sensitize Breast Cancer Cells to Selected Antiproliferative Agents That Induce the Cyclin-Dependent Kinase Inhibitor p21(WAF-1/CIP-1).
Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm.
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
How selective are clinical CDK4/6 inhibitors?
HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of action, Clinical Activity, and Safety Profiles.
Hyperuricemia in 2 Patients Receiving Palbociclib for Breast Cancer.
Identification of Breast Cancer Peptide Epitopes Presented by HLA-A*0201.
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
Identification of CDKN2A variants in breast cancer patients in Pakistan.
Identification of key genes in glioblastoma-associated stromal cells using bioinformatics analysis.
Immunohistochemical study of nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 in invasive breast carcinoma of no special type.
In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy.
Indole-3-carbinol (I3C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and subcellular localization of the CDK2 protein complex.
Indole-3-carbinol and 3-3'-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions.
Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter.
Induction of G1 arrest and apoptosis in human jurkat T cells by pentagalloylglucose through inhibiting proteasome activity and elevating p27Kip1, p21Cip1/WAF1, and Bax proteins.
Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip).
Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin.
Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.
Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate.
Inhibition of farnesyl protein transferase sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle arrest.
Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2.
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma.
Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein.
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review.
Inhibitory effect of mimosine on proliferation of human lung cancer cells is mediated by multiple mechanisms.
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis.
Insulin-like growth factor binding protein-3 induces G1 cell cycle arrest with inhibition of cyclin-dependent kinase 2 and 4 in MCF-7 human breast cancer cells.
Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
Interference with ER-? enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology.
Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
Involvement of Sphingosine Kinase 2 in p53-Independent Induction of p21 by the Chemotherapeutic Drug Doxorubicin.
Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells.
Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
Isolation and Structural Elucidation of Palbociclib's Eight Process-Related Impurities: Two Identified as New Compounds.
Jasmonates induce Arabidopsis bioactivities selectively inhibiting the growth of breast cancer cells through CDC6 and mTOR.
Keratin 19 regulates cell cycle pathway and sensitivity of breast cancer cells to CDK inhibitors.
Knockdown of FLOT1 Impairs Cell Proliferation and Tumorigenicity in Breast Cancer through Upregulation of FOXO3a.
Knockdown of flotillin-2 impairs the proliferation of breast cancer cells through modulation of Akt/FOXO signaling.
Lack of association between cyclin-dependent kinase inhibitor 1B rs2066827 polymorphism and breast cancer susceptibility.
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis.
Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer.
Malignant pleural mesothelioma: recent developments.
Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors.
Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer.
Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
Markers for Sebaceoma Show a Spectrum of Cell Cycle Regulators, Tumor Suppressor Genes, and Oncogenes.
Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review.
Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer.
Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies.
Metastatic hormone receptor-positive breast cancer in CDK 4/6 era: An outcome audit.
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment.
miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/E2F1 signal activation.
miR-125a-3p inhibits ER? transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer.
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial.
Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Monitoring of long-term effects of resveratrol on cell cycle progression of human HeLa cells after administration of a single dose.
Monocillin II inhibits human breast cancer growth partially by inhibiting MAPK pathways and CDK2 Thr160 phosphorylation.
Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas.
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells.
Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient.
Nuclear exclusion of p53 controls DNA-synthesis through reduction in the expression of p21 inhibitor of cyclin-dependent kinase-2.
Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy.
Okadaic acid-mediated induction of the c-fos gene in estrogen receptor-negative human breast carcinoma cells utilized, in part, posttranscriptional mechanisms involving adenosine-uridine-rich elements.
Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.
On the Rise of Cyclin-Dependent Kinase Inhibitors in Breast Cancer: Progress & Ongoing Challenges.
Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis.
Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Optimizing Palbociclib Therapy Across the Age Spectrum: Hypothetical, Illustrative Case Scenarios in HR+, HER2-Metastatic Breast Cancer.
Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting.
Oral adverse effects of CDK4/6 inhibitors among breast cancer patients: a systematic review and meta-analysis.
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells.
Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase.
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer.
p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up.
p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and c-erbB-2 expression.
p53-GSDME Elevation: A Path for CDK7 Inhibition to Suppress Breast Cancer Cell Survival.
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series.
Palbociclib and beyond for the treatment of HR?+?HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer.
Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response.
Palbociclib for the treatment of postmenopausal breast cancer - an update.
Palbociclib in breast cancer neoadjuvant setting.
Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
Palbociclib in metastatic breast cancer: current evidence and real-life data.
Palbociclib induces DNA damage and inhibits DNA repair to induce cellular senescence and apoptosis in oral squamous cell carcinoma.
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series.
Palbociclib: A new hope in the treatment of breast cancer.
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer.
Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.
Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells.
Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells.
Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment.
Penta-O-galloyl-?-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of P21 cyclin-dependent kinase inhibitor 1A, P27 cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple-negative xenograft growth.
PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion.
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).
Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells.
Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer.
Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer.
Physalis angulata induced G2/M phase arrest in human breast cancer cells.
POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer.
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
Population Pharmacokinetics of Palbociclib in aReal-World Situation.
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.
Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer.
Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.
Preclinical discovery and development of abemaciclib used to treat breast cancer.
Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer.
Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review.
Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer.
Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells.
Prevention of p53 degradation in human MCF-7 cells by proteasome inhibitors does not mimic the action of roscovitine.
Profile of palbociclib in the treatment of metastatic breast cancer.
Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1 gene.
Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300.
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer.
Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.
Progress in targeted therapy for breast cancer.
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer.
Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report and literature overview.
Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells.
Pulchranin A: First report of isolation from an endophytic fungus and its inhibitory activity on cyclin dependent kinases.
Radiological and pathological assessment of response to neoadjuvant CDK4/6 inhibitor and endocrine treatments in a real-life setting-initial results.
Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer.
Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer.
Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation.
Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol.
Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions.
Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group.
Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors.
Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer.
Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
Real-World Palbociclib Use in HR+/HER2- Advanced Breast Cancer in Canada: The IRIS Study.
Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Rebound lymphocytosis in a patient with chronic lymphocytic leukemia after cessation of a CDK 4/6 inhibitor for concomitant breast cancer.
Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.
Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.
Regression of a nonfunctioning pituitary macroadenoma on the CDK4/6 inhibitor palbociclib: case report.
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
Removal of Cdk inhibitors through both sequestration and downregulation in zearalenone-treated MCF-7 breast cancer cells.
RENATA study-Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer-real-world use.
Reproductive and developmental toxicity assessment of palbociclib, a CDK4/6 inhibitor, in Sprague-Dawley rats and New Zealand White rabbits.
Requirement for CDK4 kinase function in breast cancer.
Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Response evaluation with 18F-FDG PET/CT in metastatic breast cancer patients treated with Palbociclib: first experience in clinical practice.
Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.
Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer.
Retrospective assessment of cyclin-dependent kinase 5 mRNA and protein expression and its association with patient survival in breast cancer.
Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer.
Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.
Rhomboid domain-containing protein 1 promotes breast cancer progression by regulating the p-Akt and CDK2 levels.
Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Metastatic Breast Cancer.
Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms.
Ribociclib plus fulvestrant in the treatment of breast cancer.
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.
Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.
Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)-Like Pigmentation in a Metastatic Breast Cancer Patient.
Ribociclib-Induced Pneumonitis: A Case Report.
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
RNAi-mediated downregulation of CDKL1 inhibits growth and colony-formation ability, promotes apoptosis of human melanoma cells.
RNF115/BCA2 E3 Ubiquitin Ligase Promotes Breast Cancer Cell Proliferation through Targeting p21(Waf1/Cip1) for Ubiquitin-Mediated Degradation.
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Role of extracellular signal-regulated kinase pathway in RRR-alpha-tocopheryl succinate-induced differentiation of human MDA-MB-435 breast cancer cells.
Role of p21 in prostaglandin A2-mediated cellular arrest and death.
Role of the Cdc25A phosphatase in human breast cancer.
Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice.
Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice.
Role of the cyclin-dependent kinase inhibitor p27(Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation.
Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-? in human ER-positive breast cancer cells.
Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells.
Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia.
Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination.
Safety of palbociclib concurrent with palliative pelvic radiotherapy: discussion of a case of increased toxicity and brief review of literature.
Sam68 up-regulation correlates with, and its down-regulation inhibits, proliferation and tumourigenicity of breast cancer cells.
SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors.
Secretome analysis of breast cancer-associated adipose tissue to identify paracrine regulators of breast cancer growth.
Selective oestrogen receptor degraders in breast cancer: a review and perspectives.
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.
Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells.
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications.
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy.
Severe hypoglycaemia under abemaciclib administration in a patient with breast cancer: A case report.
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.
Side effects of CDK4/6 inhibitors in the treatment of HR+/HER2- advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines.
Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC-MS/MS.
Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC.
Some molecular and clinical aspects of genetic predisposition to malignant melanoma and tumours of various site of origin.
SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer.
Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR).
Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors.
Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options.
Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer.
Structure-based discovery of cyclin-dependent protein kinase inhibitors.
Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21.
Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer.
T-loop deletion of CDC2 from breast cancer tissues eliminates binding to cyclin B1 and cyclin-dependent kinase inhibitor p21.
Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells.
Targeted Therapies for Brain Metastases from Breast Cancer.
Targeted Therapies for Breast Cancer Brain Metastases.
Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.
Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances.
Targeting Breast Cancer with CDK Inhibitors.
Targeting CDK 4/6 in ER+ Breast cancer.
Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma.
Targeting low molecular weight cyclin E (LMW-E) in breast cancer.
Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells.
Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells.
Telomerase activity in relation to p53 status and clinico-pathological parameters in breast cancer.
The application and prospect of CDK4/6 inhibitors in malignant solid tumors.
The awakening of the CDK10/Cyclin M protein kinase.
The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.
The cell cycle in breast cancer.
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
The cyclin-dependent kinase inhibitor p21CIP/WAF is a positive regulator of insulin-like growth factor I-induced cell proliferation in MCF-7 human breast cancer cells.
The cyclin-dependent kinase inhibitor p21WAF1/Cip1 is an antiestrogen-regulated inhibitor of Cdk4 in human breast cancer cells.
The cyclin-dependent kinase inhibitor p27 (Kip1) regulates both DNA synthesis and apoptosis in mammary epithelium but is not required for its functional development during pregnancy.
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast cancers.
The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo.
The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway.
The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer.
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.
The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part II: Metastatic Disease.
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry.
The Indole-3-carbinol cyclic tetrameric derivative CTet synergizes with cisplatin and doxorubicin in triple-negative breast cancer cell lines.
The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time.
The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells.
The novel isocoumarin 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid (NM-3) induces lethality of human carcinoma cells by generation of reactive oxygen species.
The Open Issues Regarding Cyclin-Dependent Kinase 4/6 Inhibitors in the Management of Advanced Breast Cancer.
The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer.
The PISSLRE gene: structure, exon skipping, and exclusion as tumor suppressor in breast cancer.
The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response.
The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment.
The Role of CDK4/6 Inhibition in Breast Cancer.
The role of CDK4/6 inhibitors in early breast cancer.
The role of CDK6 in cancer.
The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters.
Therapeutic innovations in breast cancer.
Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Trends in the early investigational drug development and areas for improvement.
UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation.
Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy.
Unliganded estrogen receptor alpha inhibits breast cancer cell growth through interaction with a cyclin-dependent kinase inhibitor (p21(WAF1)).
Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization.
Unraveling the complexity of endocrine resistance in breast cancer by functional genomics.
Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a.
Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate.
Updates on managing advanced breast cancer with palbociclib combination therapy.
Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer.
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper.
Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer.
Using the appropriate formula for QT measurement can save lives.
Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients.
Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus.
Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors.
Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials.
Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells.
Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value.
[Consensus recommendations for the clinical application of CDK4/6 inhibitors in patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer].
[Effect of CDK2-AP1 gene over-expression on proliferation and cell cycle regulation of breast cancer cell line MCF-7].
[Prognostic significance of cyclin-dependent kinase inhibitor p27kip1 expression in human breast cancer]
[Progression and future of CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer].
[Subcellular re-distribution of F-actin in MCF7 cells upon inducible expression of CDKN2A/p16(INK4a)].
Breast Neoplasms, Male
Male patient with metastatic stage IV breast cancer achieves complete remission on second line Abemaciclib, Fulvestrant and Leuprolide: A case report.
Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report and literature overview.
The Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Relapsed Ectopic Male Breast Cancer.
Bronchopulmonary Dysplasia
The effect of neonatal hyperoxia on the lung of p21Waf1/Cip1/Sdi1-deficient mice.
Burkitt Lymphoma
A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma.
Type I interferon induction of the Cdk-inhibitor p21WAF1 is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line.
Candidiasis
Markers of potential malignancy in chronic hyperplastic candidiasis.
Carcinogenesis
3'-Hydroxypterostilbene Inhibits 7,12-Dimethylbenz[a]anthracene (DMBA)/12-O-Tetradecanoylphorbol-13-Acetate (TPA)-Induced Mouse Skin Carcinogenesis.
A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis.
Absence of High-Risk Human Papillomavirus (HPV) Detection in Endocervical Adenocarcinoma with Gastric Morphology and Phenotype.
Alteration of p16 (CDKN2) gene is associated with interleukin-2-induced tumor cell growth in adult T-cell leukemia.
Alterations in cyclin-dependent kinase 2 function during differentiation of primary human keratinocytes.
Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma.
Altered expression of cyclin D1 and cyclin-dependent kinase 4 in azoxymethane-induced mouse colon tumorigenesis.
Analysis of location and integrity of the human PITSLRE (p58(cdc2L1)) genes in neuroblastoma cell genomes.
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.
c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice.
c-Jun NH2-Terminal Kinase 1 Plays a Critical Role in Intestinal Homeostasis and Tumor Suppression.
c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression.
CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis.
CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis.
CDK1-mediated mitotic phosphorylation of PBK is involved in cytokinesis and inhibits its oncogenic activity.
CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/? -catenin Signaling.
CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/?-catenin pathway.
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion.
CDK12: a potential therapeutic target in cancer.
CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p/miR-449a and E2F5 contributes to prostate carcinogenesis.
CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis.
CDK5 Knockdown inhibits proliferation and induces apoptosis and Cell Cycle Arrest in Human Glioblastoma.
CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis.
CDK9 is dispensable for YAP-driven hepatoblastoma development.
Cell cycle regulators and human hepatocarcinogenesis.
Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma.
Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers.
Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice.
Chemical transformation of mouse liver cells results in altered cyclin D-CDK protein complexes.
Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032.
ChIP-Seq analysis identifies p27(Kip1)-target genes involved in cell adhesion and cell signalling in mouse embryonic fibroblasts.
Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development.
Cleavage of PITSLRE kinases by ICE/CASP-1 and CPP32/CASP-3 during apoptosis induced by tumor necrosis factor.
Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review.
Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Combined cyclin D1 overexpression and zinc deficiency disrupts cell cycle and accelerates mouse forestomach carcinogenesis.
Combined loss of p21(waf1/cip1) and p27(kip1) enhances tumorigenesis in mice.
Crystal structure of the homolog of the oncoprotein gankyrin, an interactor of Rb and CDK4/6.
Current understanding of the biology of advanced bladder cancer.
Cyclin D1 Overexpression, p16 Loss, and pRb Inactivation Play a Key Role in Pulmonary Carcinogenesis and have a Prognostic Implication for the Long-term Survival in Non-small Cell Lung Carcinoma Patients.
Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy.
Cyclin K regulates prereplicative complex assembly to promote mammalian cell proliferation.
Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth.
Cyclin-dependent kinase 2-associated protein 1 suppresses growth and tumorigenesis of lung cancer.
Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis.
Cyclin-Dependent Kinase 5 (CDK5)-Mediated Phosphorylation of Upstream Stimulatory Factor 2 (USF2) Contributes to Carcinogenesis.
Cyclin-dependent kinase 5 decreases in gastric cancer and its nuclear accumulation suppresses gastric tumorigenesis.
Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer.
Cyclin-Dependent Kinase Inhibitor 3 Promoted Cell Proliferation by Driving Cell Cycle from G1 to S Phase in Esophageal Squamous Cell Carcinoma.
Cyclin-dependent kinase inhibitor 3 promotes cancer cell proliferation and tumorigenesis in nasopharyngeal carcinoma by targeting P27.
Cyclin-dependent kinase inhibitor p21(Waf1): contemporary view on its role in senescence and oncogenesis.
Cyclin-dependent kinase inhibitors in restriction point control, genomic stability, and tumorigenesis.
Cyclin-dependent kinases regulate the antiproliferative function of Smads.
Decreased expression of the CDK inhibitor p27Kip1 and increased oxidative DNA damage in the multistep process of cervical carcinogenesis.
Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors.
Differential expressions of cyclin-dependent kinase inhibitors (p27 and p21) and their relation to p53 and Ki-67 in oral squamous tumorigenesis.
Discovery and Development of Cyclin-Dependent Kinase 8 Inhibitors.
DNA methyltransferase 3A promotes cell proliferation by silencing CDK inhibitor p18INK4C in gastric carcinogenesis.
Down-regulation of p27Kip1 expression is correlated with increased cell proliferation but not expression of p21waf1 and p53, and human papillomavirus infection in benign and malignant tumours of sinonasal regions.
Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.
Downregulation of beta1,4-galactosyltransferase 1 inhibits CDK11(p58)-mediated apoptosis induced by cycloheximide.
Downregulation of PFTK1 Inhibits Migration and Invasion of Non-Small Cell Lung Cancer.
Dual effects of Ral-activated pathways on p27 localization and TGF-? signaling.
Dysregulation of CDK Inhibitors and p53 in HPV-negative Endocervical Adenocarcinoma.
Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia.
EIF4A3-induced circular RNA MMP9 (circMMP9) acts as a sponge of miR-124 and promotes glioblastoma multiforme cell tumorigenesis.
Environment-gene interactions in intestinal cancer.
Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas.
Expression and biological-clinical significance of hTR, hTERT and CKS2 in washing fluids of patients with bladder cancer.
Expression and mutational analysis of Cip/Kip family in early glottic cancer.
Expression of p16(INK4A) in cervical precancerous lesions is unlikely to be preventable by human papillomavirus vaccines.
Expression of p27Kip1, cyclin E and E2F-1 in primary and metastatic tumors of gastric carcinoma.
Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors.
Expression of TBX2 promotes anchorage-independent growth and survival in the p53-negative SW13 adrenocortical carcinoma.
Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer.
FBXL16 is a novel E2F1-regulated gene commonly upregulated in p16INK4A- and p14ARF-silenced HeLa cells.
FoxF1 and FoxF2 transcription factors synergistically promote rhabdomyosarcoma carcinogenesis by repressing transcription of p21(Cip1) CDK inhibitor.
Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas.
Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation.
Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice.
HBP1-mediated Regulation of p21 Protein through the Mdm2/p53 and TCF4/EZH2 Pathways and Its Impact on Cell Senescence and Tumorigenesis.
High expression of DEK is associated with poor prognosis in hepatocellular carcinoma.
Hiwi mediated tumorigenesis is associated with DNA hypermethylation.
Hypoxia-inducible factor 1 alpha is essential for hypoxic p27 induction in endometrioid endometrial carcinoma.
Icariside II inhibits tumorigenesis via inhibiting AKT/Cyclin E/ CDK 2 pathway and activating mitochondria-dependent pathway.
ICK1, a cyclin-dependent protein kinase inhibitor from Arabidopsis thaliana interacts with both Cdc2a and CycD3, and its expression is induced by abscisic acid.
Immunohistochemical analysis for cell regulatory proteins in bladder carcinogenesis induced by N-methyl-N-nitrosourea-terephthalic acid.
Immunohistochemical localization of p21(WAF1/CIP1) in normal, hyperplastic, and neoplastic uterine tissues.
Inactivation of p21WAF1/cip1 enhances intestinal tumor formation in Muc2-/- mice.
Increased expression of the INK4a/ARF locus in polycythemia vera.
Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene.
Inhibition of Smad antiproliferative function by CDK phosphorylation.
Interactions between polymorphisms in the 3'untranslated region of the cyclin dependent kinase 6 gene and the human papillomavirus infection, and risk of cervical precancerous lesions.
Involvement of p21cip1/waf1 in the anti-proliferative effects of polyethylene glycol in colon carcinogenesis.
Iron and carcinogenesis: from Fenton reaction to target genes.
JAB1-STAT3 activation loop is associated with recurrence following 5-fluorouracil-based adjuvant chemotherapy in human colorectal cancer.
Knockdown of Cyclin-Dependent Kinase Inhibitor 3 Inhibits Proliferation and Invasion in Human Gastric Cancer Cells.
Knockdown of FLOT1 Impairs Cell Proliferation and Tumorigenicity in Breast Cancer through Upregulation of FOXO3a.
Lack of association between cyclin-dependent kinase inhibitor 1B rs2066827 polymorphism and breast cancer susceptibility.
Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
Long noncoding RNA DLEU2 affects the proliferative and invasive ability of colorectal cancer cells.
Loss of anchorage in checkpoint-deficient cells increases genomic instability and promotes oncogenic transformation.
Loss of expression of tumor suppressor p16(INK4) protein in human primary gastric cancer is related to the grade of differentiation.
Loss of miR-1258 contributes to carcinogenesis and progression of liver cancer through targeting CDC28 protein kinase regulatory subunit 1B.
Loss of p27Kip1 enhances tumor progression in chronic hepatocyte injury-induced liver tumorigenesis with widely ranging effects on Cdk2 or Cdc2 activation.
Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia.
Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells.
MicroRNA miR-24 promotes cell proliferation by targeting the CDKs inhibitors p27Kip1 and p16INK4a.
MicroRNA-372 Is Down-regulated and Targets Cyclin-dependent Kinase 2 (CDK2) and Cyclin A1 in Human Cervical Cancer, Which May Contribute to Tumorigenesis.
MicroRNA-452 promotes tumorigenesis in hepatocellular carcinoma by targeting cyclin-dependent kinase inhibitor 1B.
MicroRNAs 221 and 222 target p27Kip1 in Marek's disease virus-transformed tumour cell line MSB-1.
Minireview: Cyclin D1: normal and abnormal functions.
miR-152-3p Modulates hepatic carcinogenesis by targeting cyclin-dependent kinase 8.
Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors.
Molecular analysis of p21 and p27 genes in human pituitary adenomas.
Molecular pathology of pituitary adenomas.
Molecular-cloning of the human cycg1 gene encoding a g-type cyclin - overexpression in human osteosarcoma cells.
Mouse mammary hyperplasias and neoplasias exhibit different patterns of cyclins D1 and D2 binding to cdk4.
NUCKS nuclear elevated expression indicates progression and prognosis of ovarian cancer.
NUCKS1 overexpression is a novel biomarker for recurrence-free survival in cervical squamous cell carcinoma.
Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis.
Overexpression of CDK7 is associated with unfavourable prognosis in oral squamous cell carcinoma.
p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells.
P21 and p27: roles in carcinogenesis and drug resistance.
p21 is associated with cyclin D1, p16INK4a and pRb expression in resectable non-small cell lung cancer.
p21WAF1 and tumourigenesis: 20 years after.
p27 expression and proliferation in gastrointestinal stromal tumors.
p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis.
Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling.
PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.
Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.
Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression.
Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor.
Promoter hypermethylation of p16 and APC in gastrointestinal cancer patients.
Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis.
Reduced expression of the CDK inhibitor p27(KIP1) in rat two-stage bladder carcinogenesis and its association with expression profiles of p21(WAF1/Cip1) and p53.
Rho GTPases as key transducers of proliferative signals in g1 cell cycle regulation.
RLIM suppresses hepatocellular carcinogenesis by up-regulating p15 and p21.
RNAi-mediated downregulation of cyclin Y to attenuate human breast cancer cell growth.
Role and therapeutic potential of CDK12 in human cancers.
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
Role of cyclinT/Cdk9 complex in basal and regulated transcription (review).
Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice.
Roles of cyclin-dependent kinase 8 and ?-catenin in the oncogenesis and progression of gastric adenocarcinoma.
Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5.
Sequential and progressive cyclin expression in human osteosarcoma cells - diagnostic and therapeutic implications.
Serine 123 Phosphorylation Modulates p21 Protein Stability and Activity by Suppressing Ubiquitin-Independent Proteasomal Degradation.
Significance of p57(Kip2) down-regulation in oncogenesis of bladder carcinoma: an immunohistochemical study.
Smad3 phosphorylation by cyclin-dependent kinases.
Steady state expression of cell-cycle regulatory genes in prostate carcinoma cell lines.
Sulforaphane: a naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization.
Supernumerary ring chromosomes derived from the long arm of chromosome 12 as the primary cytogenetic anomaly in a rare soft tissue chondroma.
Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma.
Targeting CDK12 for cancer therapy: function, mechanism, and drug discovery.
Targeting p38? to inhibit human colorectal cancer cell progression.
The emerging roles of CDK12 in tumorigenesis.
The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors.
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.
The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance.
The Loss of p16 Expression Worsens the Prognosis of OSCC.
The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
The p34cdc2-related cyclin-dependent kinase 11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis.
The p53-targeting human phosphatase hCdc14A interacts with the Cdk1/cyclin B complex and is differentially expressed in human cancers.
The phosphorylation of survivin Thr34 by p34cdc2 in carcinogenesis of oral submucous fibrosis.
The PISSLRE gene: structure, exon skipping, and exclusion as tumor suppressor in breast cancer.
The PITSLRE protein kinase family.
The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer.
Transcriptional activation of CBF? by CDK11p110 is necessary to promote osteosarcoma cell proliferation.
Transgenesis-mediated reproductive dysfunction and tumorigenesis: effects of immunological neutralization.
Unexpected reduction of skin tumorigenesis on expression of cyclin-dependent kinase 6 in mouse epidermis.
Carcinoid Tumor
Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1.
Carcinoma
1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors.
2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells.
A new cancer diagnostic system based on a CDK profiling technology.
Aberrant methylation in promoter regions of cyclin-dependent kinase inhibitor genes in adenoid cystic carcinoma of the salivary gland.
Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas.
Absence of High-Risk Human Papillomavirus (HPV) Detection in Endocervical Adenocarcinoma with Gastric Morphology and Phenotype.
Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells.
Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas.
Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance.
Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma.
Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus.
An automated image capture and quantitation approach to identify proteins affecting tumor cell proliferation.
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.
Aneuploid CTC and CEC.
Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
CDC28 protein kinase regulatory subunit 1B (CKS1B) expression and genetic status analysis in oral squamous cell carcinoma.
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
CDK11p110 plays a critical role in the tumorigenicity of esophageal squamous cell carcinoma cells and is a potential drug target.
CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression.
CDK5 neutralizes the tumor suppressing effect of BIN1 via mediating phosphorylation of c-MYC at Ser-62 site in NSCLC.
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.
CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppression.
Cell cycle regulation and its aberrations in human lung carcinoma.
Cell cycle regulators in testicular cancer: loss of p18INK4C marks progression from carcinoma in situ to invasive germ cell tumours.
Cell cycle suppressor proteins are not related to HPV status or clinical outcome in patients with vulvar carcinoma.
Cell cycle-related gene abnormalities and product expression in esophageal carcinoma.
Cell shape change precedes staurosporine-induced stabilization and accumulation of p27kip1.
Characteristics of antitumor activity of mutant type p27Kip1 gene in an oral cancer cell line.
Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoter.
Chemopreventive effects of green tea polyphenols correlate with reversible induction of p57 expression.
Clinical and biological impact of cyclin-dependent kinase subunit 2 in esophageal squamous cell carcinoma.
Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis.
Clinical significance of overexpressed cyclin-dependent kinase subunits 1 and 2 in esophageal carcinoma.
Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review.
Cohypermethylation of p14 in combination with CADM1 or DCC as a recurrence-related prognostic indicator in stage I esophageal squamous cell carcinoma.
Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma.
Comparison of mitotic cyclins and cyclin-dependent kinase expression in keratoacanthoma and squamous cell carcinoma.
Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells.
Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma.
Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.
Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells.
Cyclin D1 Overexpression, p16 Loss, and pRb Inactivation Play a Key Role in Pulmonary Carcinogenesis and have a Prognostic Implication for the Long-term Survival in Non-small Cell Lung Carcinoma Patients.
Cyclin-dependent kinase 1 gene expression is associated with poor prognosis in gastric carcinoma.
Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells.
Cyclin-dependent Kinase 2 (CDK-2) Expression in Nonmelanocytic Human Cutaneous Lesions.
Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells.
Cyclin-dependent kinase 5 acts as a promising biomarker in clear cell Renal Cell Carcinoma.
Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells.
Cyclin-Dependent Kinase Inhibitor 3 Promoted Cell Proliferation by Driving Cell Cycle from G1 to S Phase in Esophageal Squamous Cell Carcinoma.
Cyclin-dependent kinase inhibitor p27 is related to cell proliferation and prognosis in laryngeal squamous cell carcinomas.
Cyclin-dependent kinase inhibitor p27(Kip1) expression in transitional cell carcinoma of renal pelvis and ureter.
Cyclin-dependent kinase inhibitor P27(KIP1) is expressed preferentially in early stages of urothelial carcinoma.
Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma.
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Depletion of the cdk inhibitor p16INK4a differentially affects proliferation of established cervical carcinoma cells.
Deregulation of the cyclin D1/Cdk4 retinoblastoma pathway in rat mammary gland carcinomas induced by the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix.
Diagnostic value of cyclin-dependent kinase/cyclin-dependent kinase inhibitor expression ratios as biomarkers of locoregional and hematogenous dissemination risks in oral squamous cell carcinoma.
Differential expression of degradome components in cutaneous squamous cell carcinomas.
Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21waf-1 in human cutaneous squamous cell carcinoma.
Down-regulation of Cdk inhibitor p27 in oral squamous cell carcinoma.
Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells.
Effect of energy restriction on cell cycle machinery in 1-methyl-1-nitrosourea-induced mammary carcinomas in rats.
Effects of marine sponge extracts on mitogen-activated protein kinase (MAPK/ERK(1,2)) activity in SW-13 human adrenal carcinoma cells.
Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells.
Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas.
Elevated activity of cyclin-dependent kinase 6 in human squamous cell carcinoma lines.
Enhanced sensitivity to cis-diamminedichloroplatinum(II) of a human carcinoma cell line with mutated p53 gene by cyclin-dependent kinase inhibitor p21(WAF1) expression.
Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Expression and tissue distribution of human X-linked armadillo repeat containing-6.
Expression of CDK inhibitor genes in immortalized and carcinoma derived breast cell lines.
Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis.
Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity.
Expression of cyclin-dependent kinase 2-associated protein 1 confers an independent prognosticator in nasopharyngeal carcinoma: a cohort study.
Expression of cyclin-dependent kinase inhibitor 2A 16, tumour protein 53 and epidermal growth factor receptor in salivary gland carcinomas is not associated with oncogenic virus infection.
Expression of Cyclin-dependent Kinase Inhibitor p21(WAF1/CIP1) in Non-small Cell Lung Carcinomas: Relationship with p53 Status and Proliferative Activity.
Expression of G1 cell cycle markers and the effect of adenovirus-mediated overexpression of p21Waf-1 in squamous cell carcinoma of the esophagus.
Expression of G1/S-cyclins and cyclin-dependent kinase inhibitors in actinic keratosis and squamous cell carcinoma.
Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression.
Expression of p27Kip1, cyclin E and E2F-1 in primary and metastatic tumors of gastric carcinoma.
Expression of p34cdc2 protein kinase and p53 in supraglottic carcinomas.
Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy.
Expression of p53 and p21CIP1/WAF1 proteins in oral epithelial dysplasias and squamous cell carcinomas.
Expression of Skp2 and p27(kip1) proteins in hypopharyngeal squamous cell carcinoma and its clinical significance.
Expression of the CDK inhibitor p27kip1 and oxidative DNA damage in non-neoplastic and neoplastic vulvar epithelial lesions.
Expression of the cyclin dependent kinase inhibitor p21WAF1/CIP1 in oesophageal squamous cell carcinomas.
Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
Fibronectin stimulates human lung carcinoma cell proliferation by suppressing p21 gene expression via signals involving Erk and Rho kinase.
Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma.
Gene expression reveals two distinct groups of anal carcinomas with clinical implications.
Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma.
Genetic alterations of chromosome band 9p21-22 in head and neck cancer are not restricted to p16INK4a.
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Genetic status and expression of the cyclin-dependent kinase inhibitors in human gastric carcinoma cell lines.
Growth inhibitory effect of interferon-beta is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1 in a human gastric carcinoma cell line.
H(2)O(2) scavenging inhibits G1/S transition by increasing nuclear levels of p27(KIP1).
High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas.
Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia.
Hypermethylation of Promoter Region of LATS1 - a CDK Interacting Protein in Oral Squamous Cell Carcinomas - a Pilot Study in India.
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours.
Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients with non-early stage gastric carcinoma.
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
In vitro effects of 2-methoxyestradiol on cell morphology and Cdc2 kinase activity in SNO oesophageal carcinoma cells.
Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in squamous cell carcinoma of the larynx.
Increased cdc2 and cdk2 kinase activity by retinoid X receptor gamma-mediated transcriptional down-regulation of the cyclin-dependent kinase inhibitor p21Cip1/WAF1 correlates with terminal differentiation of squamous cell carcinoma lines.
Increased expression of p34cdc2 and its kinase activity in human gastric and colonic carcinomas.
Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer.
Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27(Kip1).
Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells.
Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-? signaling.
Influence of 2-methoxyestradiol on cell morphology and cdc2 kinase activity in WHCO3 esophageal carcinoma cells.
Influence of the G2 cell cycle block abrogator pentoxifylline on the expression and subcellular location of cyclin B1 and p34cdc2 in HeLa cervical carcinoma cells.
Inhibition of polyamine oxidase prevented cyclin-dependent kinase inhibitor-induced apoptosis in HCT 116 colon carcinoma cells.
Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression.
Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression.
Inverse correlation between expression levels of p27 and the ubiquitin ligase subunit Skp2 in early esophageal squamous cell carcinoma.
Investigating DNA methylation as a potential mediator between pigmentation genes, pigmentary traits and skin cancer.
Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis.
Involvement of glycogen synthase kinase-3beta signaling and aberrant nucleocytoplasmic localization of retinoblastoma protein in tumor promotion in a rat two-stage thyroid carcinogenesis model.
Lack of evidence for CDK12 as an ovarian cancer predisposing gene.
LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice.
LINE-1 Methylation Level and Patient Prognosis in a Database of 208 Hepatocellular Carcinomas.
Long non-coding RNA CCAT1 is a prognostic biomarker for the progression of oral squamous cell carcinoma via miR-181a-mediated Wnt/?-catenin signaling pathway.
Long noncoding RNA MACC1-AS1 is a potential sponge of microRNA-34a in cervical squamous cell carcinoma and upregulates cyclin-dependent kinase 6.
Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck squamous cell carcinoma.
Low Expression of CDK10 Correlates with Adverse Prognosis in Gastric Carcinoma.
Low Expression of CyclinH and Cyclin-Dependent Kinase 7 Can Decrease the Proliferation of Human Esophageal Squamous Cell Carcinoma.
Mechanisms by which energy restriction inhibits rat mammary carcinogenesis: in vivo effects of corticosterone on cell cycle machinery in mammary carcinomas.
microRNA-365-targeted nuclear factor I/B transcriptionally represses cyclin-dependent kinase 6 and 4 to inhibit the progression of cutaneous squamous cell carcinoma.
miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
miR-145 downregulates the expression of cyclin-dependent kinase 6 in human cervical carcinoma cells.
miR-204 enhances p27 mRNA stability by targeting Brd4 in head and neck squamous cell carcinoma.
miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2.
MiR-31-5p acts as a tumor suppressor in renal cell carcinoma by targeting cyclin-dependent kinase 1 (CDK1).
miR-449a and CDK6 in gastric carcinoma.
miR-9 induces cell arrest and apoptosis of oral squamous cell carcinoma via CDK 4/6 pathway.
Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines.
Molecular cloning of PISSLRE, a novel putative member of the cdk family of protein serine/threonine kinases.
Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells.
Morphologic and Immunohistochemical Appraisal of Primary Gastric Carcinomas.
Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis.
Nitric oxide-induced apoptosis in human pancreatic carcinoma cell lines is associated with a G1-arrest and an increase of the cyclin-dependent kinase inhibitor p21WAF1/CIP1.
On the concentrations of cyclins and cyclin-dependent kinases in extracts of cultured human cells.
Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27.
Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.
Overexpression of p34cdc2 protein kinase in epithelial ovarian carcinoma.
Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma.
p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours.
p16 as a prognostic factor for the response to induction chemotherapy in advanced hypopharyngeal squamous cell carcinoma.
P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
p27/Kip1 mediates retinoic acid-induced suppression of ovarian carcinoma cell growth.
p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and c-erbB-2 expression.
p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma.
p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma.
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma.
Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck.
Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.
Phosphorylation of casein kinase II by p34cdc2 in vitro and at mitosis.
Physalis angulata induced G2/M phase arrest in human breast cancer cells.
Possible associations among expression of p14(ARF), p16(INK4a), p21(WAF1/CIP1), p27(KIP1), and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas.
Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells.
Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.
Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck.
Preferential cytoplasmic localization of p34cdc2 in recurrent human squamous cell carcinoma after radiotherapy.
Prognostic implications of cyclin B1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer.
Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx.
Prognostic significance of p34cdc2 expression in tongue squamous cell carcinoma.
Prognostic value of human papillomavirus infection and p53, p16, epidermal growth factor receptor and p34cdc2 expression in patients with salivary adenoid cystic carcinoma.
Promoter hypermethylation of the cyclin-dependent kinase inhibitor (CDKI) gene p21WAF1/CIP1/SDI1 is rare in various lymphomas and carcinomas.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Rapid induction of p21WAF1 but delayed down-regulation of Cdc25A in the TGF-beta-induced cell cycle arrest of gastric carcinoma cells.
Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is an indicator of malignant behavior in oral squamous cell carcinoma.
Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas.
Reduced expression of p27(Kip1) protein in relation to salivary adenoid cystic carcinoma metastasis.
Relationship between intracellular localization of p34cdc2 protein and differentiation of esophageal squamous cell carcinoma.
Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells.
Retinoic acid receptor beta induces terminal differentiation of squamous cell carcinoma lines in the absence of cyclin-dependent kinase inhibitor expression.
Role and therapeutic potential of CDK12 in human cancers.
Roles and Mechanisms of the Long Noncoding RNAs in Cervical Cancer.
Roles of cyclin-dependent kinase 8 and ?-catenin in the oncogenesis and progression of gastric adenocarcinoma.
S10 phosphorylation of p27 mediates atRA induced growth arrest in ovarian carcinoma cell lines.
Significance of p57(Kip2) down-regulation in oncogenesis of bladder carcinoma: an immunohistochemical study.
Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells.
SIRT1 knockdown up-regulates p53 and p21/Cip1 expression in renal adenocarcinoma cells but not in normal renal-derived cells in a deacetylase-independent manner.
SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells.
Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer.
Sulforaphane Increases Cyclin-Dependent Kinase Inhibitor, p21 Protein in Human Oral Carcinoma Cells and Nude Mouse Animal Model to Induce G(2)/M Cell Cycle Arrest.
Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.
Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21.
Suppression of survival in human SKBR3 breast carcinoma in response to metal-chelator complexes is preferential for copper-dithiocarbamate.
Targeted Transferrin-Modified Polymeric Micelles: Enhanced Efficacy in Vitro and in Vivo in Ovarian Carcinoma.
Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells.
The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein.
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
The clinical significance of CDK1 expression in oral squamous cell carcinoma.
The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1beta-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells.
The cyclin-dependent kinase inhibitor p21(cip1/waf1) enhances the cytotoxicity of ganciclovir in HSV-tk transfected ovarian carcinoma cells.
The effect of dual ligand-targeted micelles on the delivery and efficacy of poorly soluble drug for cancer therapy.
The emerging roles of CDK12 in tumorigenesis.
The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells-A Systematic Analysis.
The localization of p34cdc2 in the cells of normal, hyperplastic, and malignant epithelial and lymphoid tissues of the oral cavity.
The overexpression of cyclin-dependent kinase (CDK) 2 in laryngeal squamous cell carcinomas.
The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells.
The physiology of p16(INK4A)-mediated G1 proliferative arrest.
The role of cyclin-dependent kinase inhibitor p27 in squamous cell carcinoma of the esophagus.
The role of protein p16INK4a in non-oropharyngeal head and neck squamous cell carcinoma in Southern China.
The ubiquitous transcription factor NF-Y positively regulates the transcription of human p27Kip1 through a CCAAT box located in the 5-upstream region of the p27Kip1 gene.
The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
Transfection of p27(Kip1) threonine residue 187 mutant type gene, which is not influenced by ubiquitin-mediated degradation, induces cell cycle arrest in oral squamous cell carcinoma cells.
TSC-box is essential for the nuclear localization and antiproliferative effect of XTSC-22.
Ultraviolet radiation down-regulates expression of the cell-cycle inhibitor p21WAF1/CIP1 in human cancer cells independently of p53.
Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma.
Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas.
Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization.
Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells.
[Expression of key cell cycle markers in squamous cell carcinoma of the cervix positive in human papillomavirus: a comparative study between Chinese and Australian populations]
[Expression of miR-145 in transfected HeLa cells and its effect on the targeted inhibition of CDK6].
[Expression of P27(kip1) in renal cell carcinoma and its clinical significance.]
[Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma]
Carcinoma, Adenoid Cystic
Aberrant methylation in promoter regions of cyclin-dependent kinase inhibitor genes in adenoid cystic carcinoma of the salivary gland.
Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells.
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours.
Prognostic value of human papillomavirus infection and p53, p16, epidermal growth factor receptor and p34cdc2 expression in patients with salivary adenoid cystic carcinoma.
Carcinoma, Basal Cell
Cyclin-dependent Kinase 2 (CDK-2) Expression in Nonmelanocytic Human Cutaneous Lesions.
Investigating DNA methylation as a potential mediator between pigmentation genes, pigmentary traits and skin cancer.
Carcinoma, Ductal
Expression of the G2-M checkpoint regulators cyclin B1 and P34CDC2 in breast cancer: a correlation with cellular kinetics.
Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence.
Carcinoma, Ehrlich Tumor
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Carcinoma, Embryonal
Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.
Expression and role of p27(kip1) in neuronal differentiation of embryonal carcinoma cells.
Human testis phosphoproteome reveals kinases as potential targets in spermatogenesis and testicular cancer.
Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation.
Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors.
Regulation of expression and activity of distinct pRB, E2F, D-type cyclin, and CKI family members during terminal differentiation of P19 cells.
Carcinoma, Hepatocellular
6-[(1-naphthylmethyl)sulfanyl]-9H-purine induces G2/M phase arrest and apoptosis in human hepatocellular carcinoma HepG2 cells.
A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility.
A Novel Tetranucleotide Repeat Polymorphism Within KCNQ1OT1 Confers Risk for Hepatocellular Carcinoma.
A role for both Ets and C/EBP transcription factors and mRNA stabilization in the MAPK-dependent increase in p21 (Cip-1/WAF1/mda6) protein levels in primary hepatocytes.
Activation of protein kinase C alpha is required for TPA-triggered ERK (MAPK) signaling and growth inhibition of human hepatoma cell HepG2.
Caspase 3-mediated cleavage of p21WAF1/CIP1 associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells.
CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene.
CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.
CDK13 RNA Over-Editing Mediated by ADAR1 Associates with Poor Prognosis of Hepatocellular Carcinoma Patients.
CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma.
CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis.
Cell cycle regulators and human hepatocarcinogenesis.
Circular RNA circSP3 promotes hepatocellular carcinoma growth by sponging microRNA-198 and upregulating cyclin-dependent kinase 4.
Clinical and biological significance of Cdk10 in hepatocellular carcinoma.
Clinical role and biological function of CDK5 in hepatocellular carcinoma: A study based on immunohistochemistry, RNA-seq and
Coupling function of cyclin-dependent kinase 2 and Septin2 in the promotion of hepatocellular carcinoma.
Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma.
Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
Cyclin-dependent kinase 1 inhibitor RO3306 promotes mitotic slippage in paclitaxel-treated HepG2 cells.
Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1?: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma.
Cyclin-dependent kinase inhibitor 2B gene is associated with the sensitivity of hepatoma cells to Sorafenib.
Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation.
Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation.
Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.
Decorin interferes with platelet-derived growth factor receptor signaling in experimental hepatocarcinogenesis.
Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.
Effect of dibutyryl cyclic AMP on the cyclin-dependent kinase inhibitor p27Kip1 in the human hepatoma cells PLC/PRF/5.
Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer.
Effect of survivin regulation of transcription level by p21waf1 overexpression in HepG2 hepatocellular carcinoma cells.
Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl-XL downregulation, and Cdc2 kinase activity.
Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma.
Expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27Kip1 in hepatocellular carcinoma.
Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma.
Expression and Significance of LncRNA-MINCR and CDK2 mRNA in Primary Hepatocellular Carcinoma.
Farnesoid X receptor knockdown provides significant growth inhibition in hepatocellular carcinoma cells while it does not interfere with the proliferation of primary human hepatocyte-derived cells.
Frequent Amplification of CENPF, GMNN and CDK13 Genes in Hepatocellular Carcinomas.
Genistein arrests hepatoma cells at G2/M phase: involvement of ATM activation and upregulation of p21waf1/cip1 and Wee1.
Glucocorticoids stimulate p21 gene expression by targeting multiple transcriptional elements within a steroid responsive region of the p21waf1/cip1 promoter in rat hepatoma cells.
Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma.
Ibulocydine sensitizes human cancers to radiotherapy by induction of mitochondria-mediated apoptosis.
Ibulocydine, a novel prodrug Cdk inhibitor, effectively induces apoptosis in hepatocellular carcinoma cells.
Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NFkappaB, c-fos/c-jun, and p53 proteins.
Infrequent alterations of the p16INK4A gene in liver cancer.
Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
Integrin beta1 subunit overexpressed in the SMMC-7721 cells regulates the promoter activity of p21(CIP1) and enhances its transcription.
Introduction of G1 phase arrest in Human Hepatocellular carcinoma cells (HHCC) by APMCF1 gene transfection through the down-regulation of TIMP3 and up-regulation of the CDK inhibitors p21.
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model.
Lnc-ATG9B-4 aggravates progress of hepatocellular carcinoma through cell proliferation and migration by upregulating CDK5.
Long non-coding RNA colon cancer-associated transcript 1 functions as a competing endogenous RNA to regulate cyclin-dependent kinase 1 expression by sponging miR-490-3p in hepatocellular carcinoma progression.
Long non-coding RNA LINC00630 facilitates hepatocellular carcinoma progression through recruiting transcription factor E2F1 to up-regulate cyclin-dependent kinase 2 expression.
MAPRE1 promotes cell cycle progression of hepatocellular carcinoma cells by interacting with CDK2.
MicroRNA-1271-5p inhibits cell proliferation and enhances radiosensitivity by targeting CDK1 in hepatocellular carcinoma.
MicroRNA-452 promotes tumorigenesis in hepatocellular carcinoma by targeting cyclin-dependent kinase inhibitor 1B.
Molecular mechanism of cell cycle blockage of hepatoma SK-Hep-1 cells by Epimedin C through suppression of mitogen-activated protein kinase activation and increased expression of CDK inhibitors p21(Cip1) and p27(Kip1).
NUCKS1 Acts as a Promising Novel Biomarker for the Prognosis of Patients with Hepatocellular Carcinoma.
Overexpression of cyclin E and cyclin-dependent kinase 2 is correlated with development of hepatocellular carcinomas.
PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma.
PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion.
Phosphorylation of Caldesmon by PFTAIRE1 kinase promotes actin binding and formation of stress fibers.
Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas.
Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
Quercetin induces cell cycle G1 arrest through elevating Cdk inhibitors p21 and p27 in human hepatoma cell line (HepG2).
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Research progress on proteasome subunits in regulating occurrence and development of hepatocellular carcinoma.
Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway.
Silencing of solute carrier family 13 member 5 disrupts energy homeostasis and inhibits proliferation of human hepatocarcinoma cells.
Suppression of albumin and alpha-fetoprotein gene expression by butyrolactone I, a selective inhibitor of the cdk family, in HuH-7 human hepatoma cells.
TGF-beta1-mediated activations of c-Src and Rac1 modulate levels of cyclins and p27(Kip1) CDK inhibitor in hepatoma cells replated on fibronectin.
The centrosomal protein Tax1 binding protein 2 is a novel tumor suppressor in hepatocellular carcinoma regulated by cyclin-dependent kinase 2.
The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
The effect of R547, a cyclin-dependent kinase inhibitor, on hepatocellular carcinoma cell death.
The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines.
The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells.
Vitamin K3 inhibits growth of human hepatoma HepG2 cells by decreasing activities of both p34cdc2 kinase and phosphatase.
Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
[Correlations of expressions of macrophage migration inhibitor factor and cyclin D1 with tumor size and metastasis of hepatocellular carcinoma]
[Cyclins A and B: redundancy and specificity]
[Effect of acupoint-injection of oxymatrine on experimental hepatic carcinoma and study on the mechanism]
[Effects of simvastatin on the proliferation of HepG2 cells].
[Mitotic cyclins--new possibilities for examining mechanisms of neoplasm growth]
Carcinoma, Lewis Lung
miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2.
Carcinoma, Lobular
Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence.
Carcinoma, Mucoepidermoid
Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours.
Carcinoma, Neuroendocrine
Dramatic response to cyclin D-dependent kinase 4/6 inhibitor in refractory poorly differentiated neuroendocrine carcinoma of the breast.
Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas.
Carcinoma, Non-Small-Cell Lung
A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling.
Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance.
An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
Cell shape change precedes staurosporine-induced stabilization and accumulation of p27kip1.
Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.
Cyclin D1 Overexpression, p16 Loss, and pRb Inactivation Play a Key Role in Pulmonary Carcinogenesis and have a Prognostic Implication for the Long-term Survival in Non-small Cell Lung Carcinoma Patients.
Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer.
Cyclin-dependent kinase 5 controls vasculogenic mimicry formation in non-small cell lung cancer via the FAK-AKT signaling pathway.
Downregulation of PFTK1 Inhibits Migration and Invasion of Non-Small Cell Lung Cancer.
Downregulation of XIAP and Induction of Apoptosis by the Synthetic Cyclin-Dependent Kinase Inhibitor GW8510 in Non-Small Cell Lung Cancer Cells.
Ectopic p21sdi1 gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment.
Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.
Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells.
Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells.
Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer.
Involvement of p21Waf1/Cip1 cleavage during roscovitine-induced apoptosis in non-small cell lung cancer cells.
Knockdown of PFTK1 Expression by RNAi Inhibits the Proliferation and Invasion of Human Non-Small Lung Adenocarcinoma Cells.
Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC.
Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer.
miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.
miR-377 inhibited tumorous behaviors of non-small cell lung cancer through directly targeting CDK6.
Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines.
Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells.
Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells.
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.
Protective function of p27(KIP1) against apoptosis in small cell lung cancer cells in unfavorable microenvironments.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer.
RNAi-mediated downregulation of cyclin Y to attenuate human breast cancer cell growth.
Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer.
SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation.
Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163.
The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: its immunohistochemical evaluation using biopsy specimens.
The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells.
Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer.
Carcinoma, Ovarian Epithelial
ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers.
Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer.
Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in epithelial ovarian cancer.
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer.
Overexpression of p34cdc2 protein kinase in epithelial ovarian carcinoma.
PFTK1 regulates cell proliferation, migration and invasion in epithelial ovarian cancer.
Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer.
Upregulated CDK16 Expression in Serous Epithelial Ovarian Cancer Cells.
Carcinoma, Renal Cell
BAI, a novel Cdk inhibitor, enhances farnesyltransferase inhibitor LB42708-mediated apoptosis in renal carcinoma cells through the downregulation of Bcl-2 and c-FLIP (L).
Cyclin-dependent kinase 5 acts as a promising biomarker in clear cell Renal Cell Carcinoma.
Cyclin-Dependent Kinase Inhibitor BMI-1026 Induces Apoptosis by Downregulating Mcl-1 (L) and c-FLIP (L) and Inactivating p-Akt in Human Renal Carcinoma Cells.
MiR-31-5p acts as a tumor suppressor in renal cell carcinoma by targeting cyclin-dependent kinase 1 (CDK1).
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.
[Expression of P27(kip1) in renal cell carcinoma and its clinical significance.]
Carcinoma, Squamous Cell
A Key Role for Early Growth Response-1 and Nuclear Factor-{kappa}B in Mediating and Maintaining GRO/CXCR2 Proliferative Signaling in Esophageal Cancer.
Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus.
Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21.
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1.
Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review.
Comparison of mitotic cyclins and cyclin-dependent kinase expression in keratoacanthoma and squamous cell carcinoma.
Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells.
Cyclin-dependent Kinase 2 (CDK-2) Expression in Nonmelanocytic Human Cutaneous Lesions.
Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells.
Cyclin-dependent kinase inhibitor p27 is related to cell proliferation and prognosis in laryngeal squamous cell carcinomas.
Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix.
Differential expression of degradome components in cutaneous squamous cell carcinomas.
Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21waf-1 in human cutaneous squamous cell carcinoma.
Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells.
Elevated activity of cyclin-dependent kinase 6 in human squamous cell carcinoma lines.
Expression of G1 cell cycle markers and the effect of adenovirus-mediated overexpression of p21Waf-1 in squamous cell carcinoma of the esophagus.
Expression of G1/S-cyclins and cyclin-dependent kinase inhibitors in actinic keratosis and squamous cell carcinoma.
Expression of p34cdc2 protein kinase and p53 in supraglottic carcinomas.
Expression of the CDK inhibitor p27kip1 and oxidative DNA damage in non-neoplastic and neoplastic vulvar epithelial lesions.
Expression of the cyclin dependent kinase inhibitor p21WAF1/CIP1 in oesophageal squamous cell carcinomas.
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors.
Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells.
Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma.
Genetic alterations of chromosome band 9p21-22 in head and neck cancer are not restricted to p16INK4a.
Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia.
Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in squamous cell carcinoma of the larynx.
Increased cdc2 and cdk2 kinase activity by retinoid X receptor gamma-mediated transcriptional down-regulation of the cyclin-dependent kinase inhibitor p21Cip1/WAF1 correlates with terminal differentiation of squamous cell carcinoma lines.
Increased expression of the P27KIP1 protein in human esophageal cancer cell lines that over-express cyclin D1.
Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells.
Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-? signaling.
Long noncoding RNA MACC1-AS1 is a potential sponge of microRNA-34a in cervical squamous cell carcinoma and upregulates cyclin-dependent kinase 6.
Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck squamous cell carcinoma.
microRNA-365-targeted nuclear factor I/B transcriptionally represses cyclin-dependent kinase 6 and 4 to inhibit the progression of cutaneous squamous cell carcinoma.
miR-204 enhances p27 mRNA stability by targeting Brd4 in head and neck squamous cell carcinoma.
p21(WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo.
Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest.
Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck.
Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck.
Preferential cytoplasmic localization of p34cdc2 in recurrent human squamous cell carcinoma after radiotherapy.
Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx.
Prognostic significance of p34cdc2 expression in tongue squamous cell carcinoma.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells.
Retinoic acid receptor beta induces terminal differentiation of squamous cell carcinoma lines in the absence of cyclin-dependent kinase inhibitor expression.
Retinoic acid-mediated G1 arrest is associated with induction of p27(Kip1) and inhibition of cyclin-dependent kinase 3 in human lung squamous carcinoma CH27 cells.
Role of p12(CDK2-AP1) in transforming growth factor-beta1-mediated growth suppression.
Roles for basal and stimulated p21(Cip-1/WAF1/MDA6) expression and mitogen-activated protein kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells.
Suppression of DNA methyltransferase 1 levels in head and neck squamous carcinoma cells using small interfering RNA results in growth inhibition and increase in Cdk inhibitor p21.
The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells-A Systematic Analysis.
The overexpression of cyclin-dependent kinase (CDK) 2 in laryngeal squamous cell carcinomas.
The p53 homologue DeltaNp63alpha interacts with the nuclear factor-kappaB pathway to modulate epithelial cell growth.
The role of cyclin-dependent kinase inhibitor p27 in squamous cell carcinoma of the esophagus.
The role of protein p16INK4a in non-oropharyngeal head and neck squamous cell carcinoma in Southern China.
Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57.
[Expression of key cell cycle markers in squamous cell carcinoma of the cervix positive in human papillomavirus: a comparative study between Chinese and Australian populations]
Carcinoma, Transitional Cell
Cyclin-dependent kinase inhibitor p27(Kip1) expression in transitional cell carcinoma of renal pelvis and ureter.
p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours.
Carcinosarcoma
Role of cyclin-dependent kinase p27 in uterine carcinosarcomas.
Cardiomegaly
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Facilitates the Development of Cardiac Hypertrophy.
Essential roles for G1 cyclin-dependent kinase activity in development of cardiomyocyte hypertrophy.
Overexpression of cdk Inhibitor p16INK4a by adenovirus vector inhibits cardiac hypertrophy in vitro and in vivo: a novel strategy for the gene therapy of cardiac hypertrophy.
Senescence as a novel mechanism involved in ?-adrenergic receptor mediated cardiac hypertrophy.
SGK1-Sensitive Regulation of Cyclin-Dependent Kinase Inhibitor 1B (p27) in Cardiomyocyte Hypertrophy.
The protective effect of 1,25(OH)2D3 against cardiac hypertrophy is mediated by the cyclin-dependent kinase inhibitor p21.
Cardiomyopathies
Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy.
Cardiotoxicity
Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes.
Cardiovascular Diseases
Control of vascular smooth muscle cell growth by cyclin-dependent kinase inhibitory proteins and its implication in cardiovascular disease.
Disease onset and aging in the world of circular RNAs.
Effects of CDKN2B-AS1 polymorphisms on the susceptibility to coronary heart disease.
Inhibitory effect of fenofibrate on neointima hyperplasia via G(0)/G(1) arrest of cell proliferation.
Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms.
Single nucleotide polymorphism on chromosome 9p21 and endothelial progenitor cells in a general population cohort.
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Carney Complex
Molecular genetic advances in pituitary tumor development.
Carotid Stenosis
The Severity of Internal Carotid Artery Stenosis is Associated with the Cyclin-Dependent Kinase Inhibitor 2A Gene Expression.
Cataract
Climatic droplet keratopathy in the Argentine Patagonia.
Encephalopathy and bilateral cataract in a boy with an interstitial deletion of Xp22 comprising the CDKL5 and NHS genes.
Phospholipidomic Studies in Human Cornea From Climatic Droplet Keratopathy.
Ultraviolet light and ocular diseases.
[Epidemiology of Bietti's keratopathy. Study of risk factors in Central Africa (Chad)]
Central Nervous System Neoplasms
Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors.
Cerebral Infarction
Localization and expression of cdc2 and cdk4 in Alzheimer brain tissue.
Long noncoding RNA CDKN2B-AS1 interacts with transcription factor BCL11A to regulate progression of cerebral infarction through mediating MAP4K1 transcription.
Protection by D609 Through Cell-Cycle Regulation After Stroke.
Cervical Intraepithelial Neoplasia
Enzyme-linked immunosorbent assay for p16(INK4a) - a new triage test for the detection of cervical intraepithelial neoplasia?
Expression of CK7 and CDKN2 in Cervical Intraepithelial Neoplasia and Correlation with Clinical Outcome.
Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents.
p16(INK4a) immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities : A systematic review and meta-analysis.
The triage of low-grade cytological abnormalities by the immunocytological expression of cyclin-dependent kinase inhibitor p16INK4a versus Human Papillomavirus test: a real possibility to predict cervical intraepithelial neoplasia CIN2 or CIN2+.
Chemical and Drug Induced Liver Injury
Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors.
Cholangiocarcinoma
ADC cut points for chronic kidney disease in pathologically-proven cholangiocarcinoma.
Adenovirus expressing mutant p27kip1 enhanced apoptosis against cholangiocarcinoma than adenovirus-p27kip1 wild type.
Antitumor effects of flavopiridol, a cyclin-dependent kinase inhibitor, on human cholangiocarcinoma in vitro and in an in vivo xenograft model.
Apoptosis-related protein-1 acts as a tumor suppressor in cholangiocarcinoma cells by inducing cell cycle arrest via downregulation of cyclin-dependent kinase subunits.
Cholangiocarcinoma cells express somatostatin receptor subtype 2 and respond to octreotide treatment.
CRM-1 knockdown inhibits extrahepatic cholangiocarcinoma tumor growth by blocking the nuclear export of p27Kip1.
Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
Immunohistochemically detected expression of p27(Kip1) and Skp2 predicts survival in patients with intrahepatic cholangiocarcinomas.
Infrequent alterations of the p16INK4A gene in liver cancer.
The cyclin?dependent kinase pathway involving CDK1 is a potential therapeutic target for cholangiocarcinoma.
Upregulated lncRNA Cyclin-dependent kinase inhibitor 2B antisense RNA 1 induces the proliferation and migration of colorectal cancer by miR-378b/CAPRIN2 axis.
Cholangitis
CRM-1 knockdown inhibits extrahepatic cholangiocarcinoma tumor growth by blocking the nuclear export of p27Kip1.
miRNA-21 ablation protects against liver injury and necroptosis in cholestasis.
Practical value of applying cdc2 kinase shRNA to chronic proliferative cholangitis in treatment of hepatolithiasis.
Cholesteatoma
Expression patterns of p27Kip1 and Ki-67 in cholesteatoma epithelium.
Roles of cytokines and cell cycle regulating substances in proliferation of cholesteatoma epithelium.
Cholesteatoma, Middle Ear
Expression patterns of p27Kip1 and Ki-67 in cholesteatoma epithelium.
Chondrosarcoma
Array-comparative genomic hybridization of central chondrosarcoma: identification of ribosomal protein S6 and cyclin-dependent kinase 4 as candidate target genes for genomic aberrations.
Chondrosarcoma and peroxisome proliferator-activated receptor.
Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Chordoma
Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067.
CDK4 expression in chordoma: A potential therapeutic target.
Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic value.
Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.
Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy.
Small-molecule targeting of brachyury transcription factor addiction in chordoma.
Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity.
Choriocarcinoma
Immunohistochemical expression of cell cycle proteins E2F-1, Cdk-2, Cyclin E, p27(kip1), and Ki-67 in normal placenta and gestational trophoblastic disease.
The expression of Cdk inhibitors p27kip1 and p57kip2 in mouse placenta and human choriocarcinoma JEG-3 cells.
[Effect of F10 gene silencing and over-expression on cell cycle of choriocarcinoma cell line JAR and the mechanisms].
Choroid Plexus Neoplasms
Expression of proline-directed protein kinase, (p34cdc2/p58cyclin A), a novel cell proliferation marker in childhood brain tumors.
Ciliopathies
A homozygous deleterious CDK10 mutation in a patient with agenesis of corpus callosum, retinopathy, and deafness.
DNA replication stress underlies renal phenotypes in CEP290-associated Joubert syndrome.
Nek8 couples renal ciliopathies to DNA damage and checkpoint control.
NEK8 Links the ATR-Regulated Replication Stress Response and S Phase CDK Activity to Renal Ciliopathies.
Classical Lissencephalies and Subcortical Band Heterotopias
A novel neurological mutant mouse, yotari, which exhibits reeler-like phenotype but expresses CR-50 antigen/reelin.
Cleft Palate
Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome.
Clubfoot
Congenital dislocation of the knee reduced spontaneously or with minimal treatment.
Early reduction for congenital dislocation of the knee within twenty-four hours of birth.
Coinfection
Accumulation of human papillomavirus type 16 E7 protein bypasses G1 arrest induced by serum deprivation and by the cell cycle inhibitor p21.
Characterization of the p125 subunit of human DNA polymerase delta and its deletion mutants. Interaction with cyclin-dependent kinase-cyclins.
Colitis
CDK4/6 inhibitor-induced colitis: a case report and review of the literature.
Colonic Neoplasms
5,5'-Dibromo-bis(3'-indolyl)methane induces Kruppel-like factor 4 and p21 in colon cancer cells.
Adiponectin Represses Colon Cancer Cell Proliferation via AdipoR1- and -R2-Mediated AMPK Activation.
Antiproliferative activity of mixed-ligand dien-Cu(II) complexes with thiazole, thiazoline and imidazole derivatives.
Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells.
Antitumor Effects of Fucoidan on Human Colon Cancer Cells via Activation of Akt Signaling.
Bisimidazoacridones induce a potent cytostatic effect in colon tumor cells that sensitizes them to killing by UCN-01.
Butyrate-induced G2/M block in Caco-2 colon cancer cells is associated with decreased p34cdc2 activity.
C-glycosyl flavone from Urginea indica inhibits proliferation & angiogenesis & induces apoptosis via cyclin-dependent kinase 6 in human breast, hepatic & colon cancer cell lines.
Caco-2 intestinal cell differentiation is associated with G1 arrest and suppression of CDK2 and CDK4.
CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival.
Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032.
Common targets for a deadly duo of diabetes mellitus and colon cancer: Catching two fish with one worm.
CSBF/C10orf99, a novel potential cytokine, inhibits colon cancer cell growth through inducing G1 arrest.
Cyclooxygenase-independent induction of p21WAF-1/cip1, apoptosis and differentiation by L-745,337, a selective PGH synthase-2 inhibitor, and salicylate in HT-29 cells.
Differential cyclin-dependent kinase expression and activation in human colon cancer.
Differential roles of p21(Waf1) and p27(Kip1) in modulating chemosensitivity and their possible application in drug discovery studies.
Downregulation of CDK-8 inhibits colon cancer hepatic metastasis by regulating Wnt/?-catenin pathway.
Effects of cyclin-dependent kinase 8 specific siRNA on the proliferation and apoptosis of colon cancer cells.
Fargesin Inhibits EGF-Induced Cell Transformation and Colon Cancer Cell Growth by Suppression of CDK2/Cyclin E Signaling Pathway.
Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.
Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Gene expression network analysis of lymph node involvement in colon cancer identifies AHSA2, CDK10, and CWC22 as possible prognostic markers.
Halogenated diarylacetylenes repress c-myc expression in cancer cells.
HY-1 induces G(2)/M cell cycle arrest in human colon cancer cells through the ATR-Chk1-Cdc25C and Weel pathways.
Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21.
IGFBP-rP1, a potential molecule associated with colon cancer differentiation.
In vitro and in vivo studies of the anticancer action of terbinafine in human cancer cell lines: G0/G1 p53-associated cell cycle arrest.
Increased expression of p34cdc2 and its kinase activity in human gastric and colonic carcinomas.
Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin.
Inhibition of autophagy by 3-MA potentiates purvalanol-induced apoptosis in Bax deficient HCT 116 colon cancer cells.
Inhibition of colon cancer cell proliferation by the dietary compound conjugated linoleic acid is mediated by the CDK inhibitor p21CIP1/WAF1.
Inhibition of mitotic cyclin B and cdc2 kinase activity by selenomethionine in synchronized colon cancer cells.
Knockdown of PFTAIRE Protein Kinase 1 (PFTK1) Inhibits Proliferation, Invasion, and EMT in Colon Cancer Cells.
Lebein, a snake venom disintegrin, suppresses human colon cancer cells proliferation and tumor-induced angiogenesis through cell cycle arrest, apoptosis induction and inhibition of VEGF expression.
Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway.
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/?-catenin signaling pathway.
Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells.
p27 Kip1 nuclear localization and cyclin-dependent kinase inhibitory activity are regulated by glycogen synthase kinase-3 in human colon cancer cells.
Pharmacological Inhibition of CDK8 in Triple-Negative Breast Cancer Cell Line MDA-MB-468 Increases E2F1 Protein, Induces Phosphorylation of STAT3 and Apoptosis.
Purvalanol induces endoplasmic reticulum stress-mediated apoptosis and autophagy in a time-dependent manner in HCT116 colon cancer cells.
Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in human colon cancer.
Role of CDK8 and beta-catenin in colorectal adenocarcinoma.
Silencing of the polyamine catabolic key enzyme SSAT prevents CDK inhibitor-induced apoptosis in Caco-2 colon cancer cells.
Silencing Prion Protein in HT29 Human Colorectal Cancer Cells Enhances Anticancer Response to Fucoidan.
Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer.
SUMO-specific protease 1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CDK inhibitors.
Suppression of cancer cell growth by adenovirus expressing p21(WAF1/CIP1) deficient in PCNA interaction.
Suppression of colonic polyposis by homeoprotein CDX2 through its nontranscriptional function that stabilizes p27Kip1.
Synthesis, characterization, biological evaluation and molecular docking studies of 2-(1H-benzo[d]imidazol-2-ylthio)-N-(substituted 4-oxothiazolidin-3-yl) acetamides.
The anti-tumor effect of miR-539-3p on colon cancer via regulating cell viability, motility, and nude mouse tumorigenicity with CDK14 inhibition.
The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.
The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression).
The Flavonoid Apigenin Downregulates CDK1 by Directly Targeting Ribosomal Protein S9.
Colorectal Neoplasms
A molecular dynamics investigation of CDK8/CycC and ligand binding: conformational flexibility and implication in drug discovery.
A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer.
A survival-stratification model of human colorectal carcinomas with beta-catenin and p27kip1.
Activation of cyclin E-dependent kinase activity in colorectal cancer.
Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma.
Anti-p21 autoantibodies detected in colorectal cancer patients: A proof of concept study.
Antitumor effects of a covalent cyclin-dependent kinase 7 inhibitor in colorectal cancer.
CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells.
CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene.
CDK5 functions as a tumor promoter in human colorectal cancer via modulating the ERK5-AP-1 axis.
CDKN3 regulates cisplatin resistance to colorectal cancer through TIPE1.
Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032.
Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells.
Correlation between the expressions of gastrin, somatostatin and cyclin and cyclin-depend kinase in colorectal cancer.
Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells.
Cyclin-dependent kinase 2 inhibitor SU9516 increases sensitivity of colorectal carcinoma cells Caco-2 but not HT29 to BH3 mimetic ABT-737.
Cyclin-dependent kinase 9 expression and its association with CD8+ T cell infiltration in microsatellite-stable colorectal cancer.
Differences in loss of p16INK4 protein expression by promoter methylation between left- and right-sided primary colorectal carcinomas.
Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
Downregulation of lncRNA NR2F2 Antisense RNA 1 Induces G1 Arrest of Colorectal Cancer Cells by Downregulating Cyclin-Dependent Kinase 6.
Ectopic p21sdi1 gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment.
Effects of epidermal growth factor and its signal transduction inhibitors on apoptosis in human colorectal cancer cells.
Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma.
Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Expressions of cell cycle regulators in human colorectal cancer cell lines.
Frequent Amplification of CENPF, GMNN and CDK13 Genes in Hepatocellular Carcinomas.
High expression of PFTK1 in cancer cells predicts poor prognosis in colorectal cancer.
High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients.
Identification of Phosphorylated Cyclin-Dependent Kinase 1 Associated with Colorectal Cancer Survival Using Label-Free Quantitative Analyses.
Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil.
Inactivation of the kinase domain of CDK10 prevents tumor growth in a preclinical model of colorectal cancer, and is accompanied by downregulation of Bcl-2.
Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.
Involvement of p21(Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate.
Mechanistic Studies of Cyclin-Dependent Kinase Inhibitor 3 (CDKN3) in Colorectal Cancer.
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
MicroRNA-1258 Inhibits the Proliferation and Migration of Human Colorectal Cancer Cells through Suppressing CKS1B Expression.
microRNA-200b and microRNA-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs.
microRNA-769 is downregulated in colorectal cancer and inhibits cancer progression by directly targeting cyclin-dependent kinase 1.
Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells.
Nondysplastic Ulcerative Colitis Has High Levels of the Homologous Recombination Repair Protein NUCKS1 and Low Levels of the DNA Damage Marker Gamma-H2AX.
Notch1-dependent regulation of p27 determines cell fate in colorectal cancer.
p22/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis.
p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.
p34cdc2 expression is an independent indicator for lymph node metastasis in colorectal carcinoma.
p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.
p53-independent inhibition of proliferation and p21(WAF1/Cip1)-modulated induction of cell death by the antioxidants N-acetylcysteine and vitamin E.
Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma.
Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice.
Personalized oncology through integrative high-throughput sequencing: a pilot study.
PI3K p110? Blockade Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells.
Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization.
Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas.
Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells.
Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is an indicator of malignant behavior in oral squamous cell carcinoma.
Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas.
Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer.
Resveratrol, a chemopreventive agent, disrupts the cell cycle control of human SW480 colorectal tumor cells.
Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells.
Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer.
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
Synergistic effects of dexamethasone and genistein on the expression of Cdk inhibitor p21WAF1/CIP1 in human hepatocellular and colorectal carcinoma cells.
Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells.
Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer.
Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients.
Tumorigenesis in p27/p53- and p18/p53-double null mice: functional collaboration between the pRb and p53 pathways.
Upregulated lncRNA Cyclin-dependent kinase inhibitor 2B antisense RNA 1 induces the proliferation and migration of colorectal cancer by miR-378b/CAPRIN2 axis.
Common Cold
p27Kip1-mediated controlled proliferation technology increases constitutive sICAM production in CHO-DUKX adapted for growth in suspension and serum-free media.
Communicable Diseases
Targeting malaria with specific CDK inhibitors.
Congenital Abnormalities
Congenital dislocation of the knee reduced spontaneously or with minimal treatment.
Congenital dislocation of the knee: overview of management options.
Contracture
[Congenital dislocation of the knee (CDK)].
Corneal Diseases
Advanced glycation end product deposits in climatic droplet keratopathy.
Immunohistochemical localization of D-{beta}-aspartic acid-containing proteins in climatic droplet keratopathy.
Tissue Microarray Analysis of Cyclin-Dependent Kinase Inhibitors p21 and p16 in Fuchs Dystrophy.
Corneal Dystrophies, Hereditary
Tissue Microarray Analysis of Cyclin-Dependent Kinase Inhibitors p21 and p16 in Fuchs Dystrophy.
Corneal Perforation
Climatic droplet keratopathy, exfoliation syndrome, and cataract.
Coronary Artery Disease
Association between rs3088440 (G?>?A) polymorphism at 9p21.3 locus with the occurrence and severity of coronary artery disease in an Iranian population.
Evaluation of the role of CDKN2B gene in type 2 diabetes mellitus and hypertension in ethnic Saudi Arabs.
Ex vivo antisense oligonucleotides to proliferating cell nuclear antigen and Cdc2 kinase inhibit graft coronary artery disease.
Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs?
Inhibition of CDK9 attenuates atherosclerosis by inhibiting inflammation and phenotypic switching of vascular smooth muscle cells.
The role of CDKN2B in cardiovascular risk in ethnic Saudi Arabs: A validation study.
Coronary Disease
CDKN2B-AS1 gene rs4977574 A/G polymorphism and coronary heart disease: A meta-analysis of 40,979 subjects.
Increased Risk of CHD in the Presence of rs7865618 (A allele): Tehran Lipid and Glucose Study.
New findings in the roles of Cyclin-dependent Kinase inhibitors 2B Antisense RNA 1 (CDKN2B-AS1) rs1333049 G/C and rs4977574 A/G variants on the risk to coronary heart disease.
Costello Syndrome
Retinoblastoma protein modulates the inverse relationship between cellular proliferation and elastogenesis.
Cough
Role of cyclin-dependent kinase 5 in capsaicin-induced cough.
COVID-19
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience.
Prediction of repurposed drugs for treating lung injury in COVID-19.
The Global Phosphorylation Landscape of SARS-CoV-2 Infection.
Cushing Syndrome
Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
cyclin-dependent kinase deficiency
A framework for understanding quality of life domains in individuals with the CDKL5 deficiency disorder.
A GABAB receptor antagonist rescues functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder.
A novel transcript of cyclin-dependent kinase-like 5 (CDKL5) has an alternative C-terminus and is the predominant transcript in brain.
Aberrant mitochondrial function in patient-derived neural cells from CDKL5 deficiency disorder and Rett Syndrome.
Abnormalities of mitochondrial dynamics and bioenergetics in neuronal cells from CDKL5 deficiency disorder.
Age-Related Cognitive and Motor Decline in a Mouse Model of CDKL5 Deficiency Disorder is Associated with Increased Neuronal Senescence and Death.
Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
Altered network and rescue of human neurons derived from individuals with early-onset genetic epilepsy.
Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.
Alu-specific microhomology-mediated deletions in CDKL5 in females with early-onset seizure disorder.
AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder.
Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder.
Brain morphological abnormalities in children with cyclin-dependent kinase-like 5 deficiency disorder.
Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.
CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer.
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.
CDKL5 deficiency augments inhibitory input into the dentate gyrus that can be reversed by deep brain stimulation.
CDKL5 deficiency disorder in males: Five new variants and review of the literature.
CDKL5 Deficiency Disorder-A Complex Epileptic Encephalopathy.
CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.
CDKL5 deficiency entails sleep apneas in mice.
CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.
Cerebral visual impairment in CDKL5 deficiency disorder: vision as an outcome measure.
Characterisation of Cdkl5 transcript isoforms in rat.
Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
Clinical features of early myoclonic encephalopathy caused by a CDKL5 mutation.
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants.
Comparison of Core Features in Four Developmental Encephalopathies in the Rett Natural History Study.
Comprehensive behavioral analysis of the Cdkl5 knockout mice revealed significant enhancement in anxiety- and fear-related behaviors and impairment in both acquisition and long-term retention of spatial reference memory.
Computational experiments reveal the efficacy of targeting CDK2 and CKIs for significantly lowering cellular senescence bar for potential cancer treatment.
Content Validation of Clinician-Reported Items for a Severity Measure for CDKL5 Deficiency Disorder.
Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder.
Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder.
Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.
Cyclin-dependent-like kinase 5 is required for pain signaling in human sensory neurons and mouse models.
Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder.
Evoked Potentials and EEG Analysis in Rett Syndrome and Related Developmental Encephalopathies: Towards a Biomarker for Translational Research.
Expanding the phenotype of the CDKL5 deficiency disorder: Are seizures mandatory?
Exploring genotype-phenotype relationships in the CDKL5 deficiency disorder using an international dataset.
Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder.
Functional and Structural Impairments in the Perirhinal Cortex of a Mouse Model of CDKL5 Deficiency Disorder Are Rescued by a TrkB Agonist.
Generation and characterization of human induced pluripotent stem cells (iPSCs) from three male and three female patients with CDKL5 Deficiency Disorder (CDD).
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
In vivo magnetic resonance spectroscopy in the brain of Cdkl5 null mice reveals a metabolic profile indicative of mitochondrial dysfunctions.
Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons.
Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.
Loss of CDKL5 in Glutamatergic Neurons Disrupts Hippocampal Microcircuitry and Leads to Memory Impairment in Mice.
Microtubules: A Key to Understand and Correct Neuronal Defects in CDKL5 Deficiency Disorder?
Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder.
Pregnenolone and pregnenolone-methyl-ether rescue neuronal defects caused by dysfunctional CLIP170 in a neuronal model of CDKL5 Deficiency Disorder.
Proof-of-concept for a gene replacement approach to CDKL5 deficiency disorder.
Reflex Seizures in a Patient with CDKL5 Deficiency Disorder.
Reigning in Excitatory Signaling in CDKL5 Deficiency.
Rescue of prepulse inhibition deficit and brain mitochondrial dysfunction by pharmacological stimulation of the central serotonin receptor 7 in a mouse model of CDKL5 Deficiency Disorder.
Rett Syndrome and CDKL5 Deficiency Disorder: From Bench to Clinic.
Seizures in Mouse Models of Rare Neurodevelopmental Disorders.
Severity Assessment in CDKL5 Deficiency Disorder.
Site-specific abnormalities in the visual system of a mouse model of CDKL5 deficiency disorder.
Sodium channel blockers for the treatment of epilepsy in CDKL5 deficiency disorder: Findings from a multicenter cohort.
Structural Bases of Atypical Whisker Responses in a Mouse Model of CDKL5 Deficiency Disorder.
Synaptic Synthesis, Dephosphorylation, and Degradation: A NOVEL PARADIGM FOR AN ACTIVITY-DEPENDENT NEURONAL CONTROL OF CDKL5.
The antidepressant tianeptine reverts synaptic AMPA receptor defects caused by deficiency of CDKL5.
The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo.
The perceived effects of cannabis products in the management of seizures in CDKL5 Deficiency Disorder.
Therapeutic potential of pregnenolone and pregnenolone methyl ether on depressive and CDKL5 deficiency disorders: Focus on microtubule targeting.
Treatment with a GSK-3?/HDAC Dual Inhibitor Restores Neuronal Survival and Maturation in an In Vitro and In Vivo Model of CDKL5 Deficiency Disorder.
Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder.
X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder.
Cystadenoma
Overexpression of p34cdc2 protein kinase in epithelial ovarian carcinoma.
Cystitis
Cyclin-dependent kinase 1 shows to be a potential genetic target for chemical cystitis.
Cystitis, Interstitial
Oncosuppressor protein p53 and cyclin-dependent kinase inhibitor p21 regulate interstitial cystitis associated gene expression.
Cysts
Ascofuranone: A Possible Therapeutic Tool for Autosomal Dominant Polycystic Kidney Disease? - Letter.
Cyclin-Dependent Kinase 1 Activity Is a Driver of Cyst Growth in Polycystic Kidney Disease.
Early Cyst Growth Is Associated with the Increased Nuclear Expression of Cyclin D1/Rb Protein in an Autosomal-Recessive Polycystic Kidney Disease Rat Model.
Functional loss of p21/Waf-1 in a case of benign canine multicentric melanoma.
High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney Disease.
Induction of cdc2a and cyc1At expression in Arabidopsis thaliana during early phases of nematode-induced feeding cell formation.
Next-generation sequencing adds value to the preoperative diagnosis of pancreatic cysts.
Polycystic kidney disease: a case of suppressed autophagy?
Regulation of a Myb transcription factor by cyclin-dependent kinase 2 in Giardia lamblia.
Super-enhancer-driven metabolic reprogramming promotes cystogenesis in autosomal dominant polycystic kidney disease.
Transcription by RNA polymerase II during Acanthamoeba differentiation.
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
[New therapies for ADPKD]
Cytomegalovirus Infections
Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of cdk9 and cdk7.
Deafness
A homozygous deleterious CDK10 mutation in a patient with agenesis of corpus callosum, retinopathy, and deafness.
Dehydration
Regulation of cell cycle components during exposure to anoxia or dehydration stress in the wood frog, Rana sylvatica.
Dementia
CDK5 knockdown prevents hippocampal degeneration and cognitive dysfunction produced by cerebral ischemia.
Cell cycle proteins preceded neuronal death after chronic cerebral hypoperfusion in rats.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Enhanced proteasome-dependent degradation of the CDK inhibitor p27(kip1) in immortalized lymphocytes from Alzheimer's dementia patients.
Targeting CDK5 post-stroke provides long-term neuroprotection and rescues synaptic plasticity.
The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders.
Demyelinating Diseases
Cyclin-dependent kinase inhibitor flavopiridol promotes remyelination in a cuprizone induced demyelination model.
Serine/Threonine-Protein Kinase PFTK1 Modulates Oligodendrocyte Differentiation via PI3K/AKT Pathway.
Dermatitis, Phototoxic
Cellular Phototoxicity Evoked Through the Inhibition of Human ABC Transporter ABCG2 by Cyclin-dependent Kinase Inhibitors In vitro.
Dermatomyositis
T-cell anti-apoptotic mechanisms in inflammatory myopathies.
Developmental Dysplasia of the Hip
Early reduction for congenital dislocation of the knee within twenty-four hours of birth.
Diabetes Mellitus
Angiotensin converting-enzyme inhibitor treatment reduces glomerular p16INK4 and p27Kip1 expression in diabetic BBdp rats.
Association of a cyclin-dependent kinase 5 regulatory subunit-associated protein 1-like 1 (CDKAL1) polymorphism with elevated hemoglobin A?(c) levels and the prevalence of metabolic syndrome in Japanese men: Interaction with dietary energy intake.
CDKAL1 gene rs7756992 A/G polymorphism and type 2 diabetes mellitus: a meta-analysis of 62,567 subjects.
Common variants in TCF7L2 and CDKAL1 genes and risk of type 2 diabetes mellitus in Egyptians.
Cyclin-dependent kinase 5 (Cdk5): a potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus.
Cyclin-Dependent Kinase 5/p35/p39: A Novel and Imminent Therapeutic Target for Diabetes Mellitus.
Evaluation of the role of CDKN2B gene in type 2 diabetes mellitus and hypertension in ethnic Saudi Arabs.
Inflammation and poor response to treatment with erythropoietin in chronic kidney disease.
Studies of variations of the cyclin-dependent kinase inhibitor 1C and the cyclin-dependent kinase 4 genes in relation to type 2 diabetes mellitus and related quantitative traits.
The type 2 diabetes mellitus susceptibility gene CDKAL1 polymorphism is associated with depressive symptom in first-episode drug-naive schizophrenic patients.
Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13.
Diabetes Mellitus, Type 1
Cyclin-dependent kinase 4 hyperactivity promotes autoreactivity in the immune system but protects pancreatic cell mass from autoimmune destruction in the nonobese diabetic mouse model.
Pancreatic islets from cyclin-dependent kinase 4/R24C (Cdk4) knockin mice have significantly increased beta cell mass and are physiologically functional, indicating that Cdk4 is a potential target for pancreatic beta cell mass regeneration in Type 1 diabetes.
Diabetes Mellitus, Type 2
Association between Type 2 Diabetes and CDKN2A/B: a meta-analysis study.
Association of a cyclin-dependent kinase 5 regulatory subunit-associated protein 1-like 1 (CDKAL1) polymorphism with elevated hemoglobin A?(c) levels and the prevalence of metabolic syndrome in Japanese men: Interaction with dietary energy intake.
Cdk5 Inhibitory Peptide (CIP) Inhibits Cdk5/p25 Activity Induced by High Glucose in Pancreatic Beta Cells and Recovers Insulin Secretion from p25 Damage.
CDKAL1 gene rs7756992 A/G polymorphism and type 2 diabetes mellitus: a meta-analysis of 62,567 subjects.
cDNA cloning and mRNA expression of cat and dog Cdkal1.
Common variants in TCF7L2 and CDKAL1 genes and risk of type 2 diabetes mellitus in Egyptians.
Contribution of CDKAL1 rs7756992 and IGF2BP2 rs4402960 polymorphisms in Type 2 diabetes, diabetic complications, obesity risk and hypertension in the Tunisian population.
Cyclin-Dependent Kinase 5 Promotes Pancreatic {beta}-Cell Survival via Fak-Akt Signaling Pathways.
Distinct Hepatic PKA and CDK Signaling Pathways Control Activity-Independent Pyruvate Kinase Phosphorylation and Hepatic Glucose Production.
Evaluation of the role of CDKN2B gene in type 2 diabetes mellitus and hypertension in ethnic Saudi Arabs.
Expression profiling of cell cycle genes in human pancreatic islets with and without type 2 diabetes.
Genetic variants of cyclin-dependent kinase 5 regulatory subunit associated protein 1-like 1 and transcription factor 7-like 2 are not associated with polycystic ovary syndrome in Chinese women.
Pharmacogenomics of Sulfonylureas Response in Relation to rs7754840 Polymorphisms in Cyclin-Dependent Kinase 5 Regulatory Subunit-associated Protein 1-like (CDKAL1) Gene in Iranian Type 2 Diabetes Patients.
Studies of variations of the cyclin-dependent kinase inhibitor 1C and the cyclin-dependent kinase 4 genes in relation to type 2 diabetes mellitus and related quantitative traits.
The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel.
The type 2 diabetes mellitus susceptibility gene CDKAL1 polymorphism is associated with depressive symptom in first-episode drug-naive schizophrenic patients.
Diabetic Nephropathies
CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via erk1/2/ppar? pathway.
Cyclin-dependent kinase 5 contributes to endoplasmic reticulum stress induced podocyte apoptosis via promoting MEKK1 phosphorylation at Ser280 in diabetic nephropathy.
LNCRNA CDKN2B-AS1 regulates mesangial cell proliferation and extracellular matrix accumulation via miR-424-5p/HMGA2 axis.
Long non-coding RNA CDKN2B-AS1 regulates high glucose-induced human mesangial cell injury via regulating the miR-15b-5p/WNT2B axis.
p16ink4a Expression Is Increased through 12-Lipoxygenase in High Glucose-Stimulated Glomerular Mesangial Cells and Type 2 Diabetic Glomeruli.
The Expression of Intermediate Filament Protein Nestin and Its Association with Cyclin-Dependent Kinase 5 in the Glomeruli of Rats With Diabetic Nephropathy.
DiGeorge Syndrome
A Collection of Pre-mRNA Splicing Mutants in Arabidopsis thaliana.
DNA Repair-Deficiency Disorders
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Down Syndrome
Comparing Parental Well-Being and Its Determinants Across Three Different Genetic Disorders Causing Intellectual Disability.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Intellectual disabilities, neuronal posttranscriptional RNA metabolism, and RNA-binding proteins: three actors for a complex scenario.
Drug Eruptions
Severe drug eruption induced by cyclin-dependent kinase 4 and 6 inhibitor.
Drug Resistant Epilepsy
Alu-specific microhomology-mediated deletions in CDKL5 in females with early-onset seizure disorder.
Amelioration of intractable epilepsy by adjunct vagus nerve stimulation therapy in a girl with a CDKL5 mutation.
Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.
CDKL5 and Shootin1 Interact and Concur in Regulating Neuronal Polarization.
CDKL5 controls postsynaptic localization of GluN2B-containing NMDA receptors in the hippocampus and regulates seizure susceptibility.
CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons.
CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy.
Clinical features of early myoclonic encephalopathy caused by a CDKL5 mutation.
Diaper changing-induced reflex seizures in CDKL5-related epilepsy.
Extrasynaptic NMDA receptor stimulation induces CDKL5 cytoplasmic translocation and proteasomal degradation.
Impacts of caring for a child with the CDKL5 disorder on parental wellbeing and family quality of life.
Mutation screening of the CDKL5 gene in cryptogenic infantile intractable epilepsy and review of clinical sensitivity.
Novel CDKL5 Mutations in Czech Patients with Phenotypes of Atypical Rett Syndrome and Early-Onset Epileptic Encephalopathy.
Pathogenic role of the X-linked cyclin-dependent kinase-like 5 and aristaless-related homeobox genes in epileptic encephalopathy of unknown etiology with onset in the first year of life.
Re: CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy.
Recurrent mutations in the CDKL5 gene: genotype-phenotype relationships.
The three stages of epilepsy in patients with CDKL5 mutations.
Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients.
Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder.
What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy.
Xp22.3 Genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy.
Dry Eye Syndromes
Surface alterations, corneal hypoesthesia, and iris atrophy in patients with climatic droplet keratopathy.
Dwarfism
The Mediator kinase module acts as a positive regulator of salicylic acid accumulation and systemic acquired resistance.
Dyskinesias
Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease.
Dysplastic Nevus Syndrome
Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.
Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study.
Encephalitis
Cell cycle inhibitor enhances the resolution of HSV-1-induced proinflammatory response in murine microglial cells.
Isolated spinal cord contusion in rats induces chronic brain neuroinflammation, neurodegeneration, and cognitive impairment. Involvement of cell cycle activation.
Isolated spinal cord contusion in rats induces chronic brain neuroinflammation, neurodegeneration, and cognitive impairment: Involvement of cell cycle activation.
Encephalitis, Herpes Simplex
Cell cycle inhibitor enhances the resolution of HSV-1-induced proinflammatory response in murine microglial cells.
Encephalomyelitis
CDK inhibitors suppress Th17 and promote iTreg differentiation, and ameliorate experimental autoimmune encephalomyelitis in mice.
Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
CDK inhibitors suppress Th17 and promote iTreg differentiation, and ameliorate experimental autoimmune encephalomyelitis in mice.
Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis.
Endometrial Hyperplasia
Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance.
Loss of cables, a cyclin-dependent kinase regulatory protein, is associated with the development of endometrial hyperplasia and endometrial cancer.
The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma.
Endometrial Neoplasms
Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-?B transcriptional signaling.
Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21(Waf1/Cip1) and p27(Kip1).
Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes.
Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers.
Cyclin-dependent kinase 4/6-specific activities as a biomarker for prognosis and chemosensitivity in endometrial cancer.
Cyclin-dependent kinase inhibitor p21 in endometrial carcinoma.
Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.
Effect of cyclin-dependent kinase 7 silencing on cisplatin sensitivity in endometrial carcinoma cells.
Loss of cables, a cyclin-dependent kinase regulatory protein, is associated with the development of endometrial hyperplasia and endometrial cancer.
Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.
Medroxyprogesterone acetate stimulates cdk inhibitors, p21 and p27, in endometrial carcinoma cells transfected with progesterone receptor-B cDNA.
p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein.
Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.
Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
Sox2-dependent inhibition of p21 is associated with poor prognosis of endometrial cancer.
Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?
Targeting histone deacetylases in endometrial cancer: a paradigm-shifting therapeutic strategy?
The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer.
The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma.
Transforming growth factor-beta, estrogen, and progesterone converge on the regulation of p27Kip1 in the normal and malignant endometrium.
Endometriosis
A genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese.
A potential role of cyclin-dependent kinase inhibitor 1 (p21/WAF1) in the pathogenesis of endometriosis: Directions for future research.
Association of CDKN2B-AS and WNT4 genetic polymorphisms in Korean patients with endometriosis.
Comprehensive characterization of endometrial competing endogenous RNA network in infertile women of childbearing age.
Cumulative alterations of p27-related cell-cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
Expression of the cyclin-dependent kinase inhibitor p27Kip1 in eutopic endometrium and peritoneal endometriosis.
[Regulatory mechanism of malignant behavior of endometriosis mediated by puerarin]
Endotoxemia
Cyclin-Dependent Kinase 9 Inhibition Suppresses Necroptosis and Pyroptosis in the Progress of Endotoxemia.
Ependymoma
Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
Immunohistochemical markers for prognosis of ependymal neoplasms.
Epilepsies, Myoclonic
Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder.
CDKL5 and ARX mutations are not responsible for early onset severe myoclonic epilepsy in infancy.
Clinical features of early myoclonic encephalopathy caused by a CDKL5 mutation.
Genotype-phenotype correlates of infantile-onset developmental & epileptic encephalopathy syndromes in South India: A single centre experience.
Myoclonic encephalopathy in the CDKL5 gene mutation.
Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
Rodent genetic models of neurodevelopmental disorders and epilepsy.
Seizures in Mouse Models of Rare Neurodevelopmental Disorders.
Epilepsies, Partial
[Autism, epilepsy and genetics]
Epilepsy
A case of CDKL5 disorder: improved ADL by simple treatment strategy for intractable epileptic seizures.
A GABAB receptor antagonist rescues functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder.
A novel mutation in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene associated with a severe Rett phenotype.
A novel p.Arg970X mutation in the last exon of the CDKL5 gene resulting in late-onset seizure disorder.
Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.
Alu-specific microhomology-mediated deletions in CDKL5 in females with early-onset seizure disorder.
Analysis of Hungarian patients with Rett syndrome phenotype for MECP2, CDKL5 and FOXG1 gene mutations.
Artificial escape from XCI by DNA methylation editing of the CDKL5 gene.
Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder.
Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.
Caregiver's perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients.
CDKL5 and ARX mutations are not responsible for early onset severe myoclonic epilepsy in infancy.
CDKL5 and ARX mutations in males with early-onset epilepsy.
CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.
CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.
CDKL5 gene status in female patients with epilepsy and Rett-like features: two new mutations in the catalytic domain.
CDKL5 Mutations as a Cause of Severe Epilepsy in Infancy: Clinical and Electroencephalographic Long-term Course in 4 Patients.
CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients.
CDKL5 PROTEIN SUBSTITUTION THERAPY RESCUES NEUROLOGICAL PHENOTYPES OF A MOUSE MODEL OF CDKL5 DISORDER.
CDKL5 variant in a boy with infantile epileptic encephalopathy: case report.
Clinical and electroencephalographic features in patients with CDKL5 mutations: two new Italian cases and review of the literature.
Clinical evolution and epilepsy outcome in three patients with CDKL5-related developmental encephalopathy.
Clinical features of early myoclonic encephalopathy caused by a CDKL5 mutation.
Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants.
Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder.
Detection of a mosaic CDKL5 deletion and inversion by optical genome mapping ends an exhaustive diagnostic odyssey.
Diagnostic Approach to Genetic Causes of Early-Onset Epileptic Encephalopathy.
Diaper changing-induced reflex seizures in CDKL5-related epilepsy.
Early onset seizures and Rett-like features associated with mutations in CDKL5.
Early-onset seizure variant of Rett syndrome: Definition of the clinical diagnostic criteria.
Epilepsy and mental retardation limited to females with PCDH19 mutations can present de novo or in single generation families.
Epilepsy caused by CDKL5 mutations.
Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies.
Functional and Structural Impairments in the Perirhinal Cortex of a Mouse Model of CDKL5 Deficiency Disorder Are Rescued by a TrkB Agonist.
Genetic Variants Identified from Epilepsy of Unknown Etiology in Chinese Children by Targeted Exome Sequencing.
Genotype-phenotype correlates of infantile-onset developmental & epileptic encephalopathy syndromes in South India: A single centre experience.
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Historic, clinical, and prognostic features of epileptic encephalopathies caused by CDKL5 mutations.
Identification of De Novo DNMT3A Mutations That Cause West Syndrome by Using Whole-Exome Sequencing.
Impairment of CDKL5 nuclear localisation as a cause for severe infantile encephalopathy.
Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons.
Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.
Key clinical features to identify girls with CDKL5 mutations.
Mapping an X-linked locus that influences heat-induced febrile seizures in mice.
Maternal origin of a novel C-terminal truncation mutation in CDKL5 causing a severe atypical form of Rett syndrome.
Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation.
Myoclonic encephalopathy in the CDKL5 gene mutation.
Network for Therapy in Rare Epilepsies (NETRE): Lessons From the Past 15 Years.
Neuron-Type Specific Loss of CDKL5 Leads to Alterations in mTOR Signaling and Synaptic Markers.
New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy.
Novel CDKL5 mutations were found in patients in China: retrospective investigation in cases of CDKL5-related disorders.
Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes.
Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome.
Reigning in Excitatory Signaling in CDKL5 Deficiency.
Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder.
Severity Assessment in CDKL5 Deficiency Disorder.
Sodium channel blockers for the treatment of epilepsy in CDKL5 deficiency disorder: Findings from a multicenter cohort.
Synaptic roles of cyclin-dependent kinase 5 & its implications in epilepsy.
Targeted gene sequencing in 6994 individuals with neurodevelopmental disorder with epilepsy.
The perceived effects of cannabis products in the management of seizures in CDKL5 Deficiency Disorder.
The three stages of epilepsy in patients with CDKL5 mutations.
Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients.
White Matter Lesions Detected by Magnetic Resonance Imaging in Neonates and Children With Congenital Myotonic Dystrophy.
[Autism, epilepsy and genetics]
[Molecular basis of Rett syndrome: A current look].
Epilepsy, Generalized
A maternally inherited frameshift CDKL5 variant in a male with global developmental delay and late-onset generalized epilepsy.
Epileptic Syndromes
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Network for Therapy in Rare Epilepsies (NETRE): Lessons From the Past 15 Years.
Epstein-Barr Virus Infections
Investigation of differentially expressed genes in nasopharyngeal carcinoma by integrated bioinformatics analysis.
MAGT1 is required for HeLa cell proliferation through regulating p21 expression, S-phase progress, and ERK/p38 MAPK MYC axis.
Proteomics Analysis of Gastric Epithelial AGS Cells Infected with Epstein-Barr Virus.
Erythema Multiforme
Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions.
Esophageal Neoplasms
Adenovirus-mediated p16INK4 gene transfer significantly suppresses human breast cancer growth.
CDKN2B, SLC19A3 and DLEC1 promoter methylation alterations in the bone marrow of patients with acute myeloid leukemia during chemotherapy.
Correlation between microvessel density (MVD) and multi-spiral CT (MSCT) perfusion parameters of esophageal cancer lesions and the diagnostic value of combined CtBP2 and P16INK4A.
Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
Induction of differentiation-dependent apoptosis in human esophageal squamous cell carcinoma by adenovirus-mediated p21sdi1 gene transfer.
Inhibition of pRB Pathway Differentially Modulates Apoptosis in Esophageal Cancer Cells.
Negative regulation of CDK6 expression by microRNA-126-5p and its influence on the proliferation and invasion of esophageal cancer cells.
PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion.
Esophageal Squamous Cell Carcinoma
CDK11p110 plays a critical role in the tumorigenicity of esophageal squamous cell carcinoma cells and is a potential drug target.
Clinical and biological impact of cyclin-dependent kinase subunit 2 in esophageal squamous cell carcinoma.
Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma.
Cyclin-Dependent Kinase Inhibitor 3 Promoted Cell Proliferation by Driving Cell Cycle from G1 to S Phase in Esophageal Squamous Cell Carcinoma.
Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells.
Inverse correlation between expression levels of p27 and the ubiquitin ligase subunit Skp2 in early esophageal squamous cell carcinoma.
LINE-1 Methylation Level and Patient Prognosis in a Database of 208 Hepatocellular Carcinomas.
Low Expression of CyclinH and Cyclin-Dependent Kinase 7 Can Decrease the Proliferation of Human Esophageal Squamous Cell Carcinoma.
Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis.
Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma.
Relationship between intracellular localization of p34cdc2 protein and differentiation of esophageal squamous cell carcinoma.
Exanthema
Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)-Like Pigmentation in a Metastatic Breast Cancer Patient.
Exfoliation Syndrome
Climatic droplet keratopathy, exfoliation syndrome, and cataract.
[Epidemiology of Bietti's keratopathy. Study of risk factors in Central Africa (Chad)]
Exostoses
Variations in the HHEX gene are associated with increased risk of type 2 diabetes in the Japanese population.
Fanconi Anemia
Construction of a high-resolution physical and transcription map of chromosome 16q24.3: a region of frequent loss of heterozygosity in sporadic breast cancer.
Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.
Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor.
The Fanconi anemia polypeptide, FAC, binds to the cyclin-dependent kinase, cdc2.
Fatty Liver
Significant lethality following liver resection in A20 heterozygous knockout mice uncovers a key role for A20 in liver regeneration.
Febrile Neutropenia
Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
Fibroma
Cyclin-dependent Kinase 2 (CDK-2) Expression in Nonmelanocytic Human Cutaneous Lesions.
Fibromatosis, Aggressive
Analysis of p27KIP1 protein and Ki-67 expression in aggressive fibromatosis (desmoid tumor).
The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report.
Fibrosarcoma
Cell cycle control with minimal participation of Cdk2 in a murine fibrosarcoma clone cultured in protein-free medium.
p21Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells.
Fibrous Dysplasia, Polyostotic
Molecular genetic advances in pituitary tumor development.
Fragile X Syndrome
A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders.
Lens GABA receptors are a target of GABA-related agonists that mitigate experimental myopia.
Serotonin 5-HT7 receptors require cyclin-dependent kinase 5 to rescue hippocampal synaptic plasticity in a mouse model of Fragile X Syndrome.
Frontotemporal Dementia
Phosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase 5 complexed with p35, p25, or p39.
Serine-409 phosphorylation and oxidative damage define aggregation of human protein tau in yeast.
Fuchs' Endothelial Dystrophy
Tissue Microarray Analysis of Cyclin-Dependent Kinase Inhibitors p21 and p16 in Fuchs Dystrophy.
Gallbladder Neoplasms
Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma.
miR-433 accelerates acquired chemoresistance of gallbladder cancer cells by targeting cyclin M.
Nanomaterial-Facilitated Cyclin-Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction.
Ganglioglioma
Mutational and expression analysis of the reelin pathway components CDK5 and doublecortin in gangliogliomas.
Gastrointestinal Neoplasms
CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene.
Cyclin-Dependent Kinase Inhibitors and the Treatment of Gastrointestinal Cancers.
Gastrointestinal Stromal Tumors
Cyclin-Dependent Kinase Activity Correlates with the Prognosis of Patients Who Have Gastrointestinal Stromal Tumors.
Genetic Diseases, Inborn
Comparing Parental Well-Being and Its Determinants Across Three Different Genetic Disorders Causing Intellectual Disability.
Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder.
Expression pattern of cdkl5 during zebrafish early development: implications for use as model for atypical Rett syndrome.
Functional Versatility of the CDK Inhibitor p57Kip2.
Impacts of caring for a child with the CDKL5 disorder on parental wellbeing and family quality of life.
Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches.
Gestational Trophoblastic Disease
Differential expression of p57kip2, a maternally imprinted cdk inhibitor, in normal human placenta and gestational trophoblastic disease.
Gigantism
Cyclin-dependent kinase inhibitor gene polymorphisms in pituitary gigantism.
Glaucoma
CDKN2B gene rs1063192 polymorphism decreases the risk of glaucoma.
CDKN2B-AS1 genotype-glaucoma feature correlations in primary open-angle glaucoma patients from the United States.
Elevation of p-NR2A(S1232) by Cdk5/p35 contributes to retinal ganglion cell apoptosis in a rat experimental glaucoma model.
Overexpression of CDKN1B inhibits fibroblast proliferation in a rabbit model of experimental glaucoma filtration surgery.
Glaucoma, Open-Angle
Analysis of Cyclin-Dependent Kinase Inhibitor-2B rs1063192 Polymorphism in Saudi Patients with Primary Open-Angle Glaucoma.
Association of polymorphisms in APOE, p53, and p21 with primary open-angle glaucoma in Turkish patients.
CDKN2B-AS1 genotype-glaucoma feature correlations in primary open-angle glaucoma patients from the United States.
[Epidemiology of Bietti's keratopathy. Study of risk factors in Central Africa (Chad)]
Glioblastoma
Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
Alkylaminophenol Induces G1/S Phase Cell Cycle Arrest in Glioblastoma Cells Through p53 and Cyclin-Dependent Kinase Signaling Pathway.
Alternative splicing of the p15 cdk inhibitor in glioblastoma multiforme.
Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme.
CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas.
Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma.
Chromosomal abnormalities in human glioblastomas: gain in chromosome 7p correlating with loss in chromosome 10q.
Co-amplification of phosphoinositide 3-kinase enhancer A and cyclin-dependent kinase 4 triggers glioblastoma progression.
Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation.
Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma.
Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture models.
Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?
Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas.
Fluorescent Biosensor of CDK5 Kinase Activity in Glioblastoma Cell Extracts and Living Cells.
G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells.
Gap Junctions Enhance the Antiproliferative Effect of MicroRNA-124-3p in Glioblastoma Cells.
Glioma biology and molecular markers.
Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase.
Identification of Quinazolinone Analogs Targeting CDK5 Kinase Activity and Glioblastoma Cell Proliferation.
Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma.
Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
Inhibition of glioma growth by flavokawain B is mediated through endoplasmic reticulum stress induced autophagy.
Interferon-? sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02.
Involvement of Phosphatase and Tensin Homolog in Cyclin-Dependent Kinase 4/6 Inhibitor-Induced Blockade of Glioblastoma.
Karenitecin (bnp1350) and flavopridol as radiosensitizers in malignant glioma.
MGMT-inhibitor in combination with TGF-?RI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6.
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.
Molecular genetics of human glioma.
Molecular response of human glioblastoma multiforme cells to ionizing radiation: cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors, and autophagy.
Multiple forms of protein kinase from normal human brain and glioblastoma.
N-(4-Hydroxyphenyl)retinamide induced differentiation with repression of telomerase and cell cycle to increase interferon-gamma sensitivity for apoptosis in human glioblastoma cells.
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway.
p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis.
Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.
Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition.
Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Restoration of growth arrest by p16INK4, p21WAF1, pRB, and p53 is dependent on the integrity of the endogenous cell-cycle control pathways in human glioblastoma cell lines.
Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme.
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans.
SOX5/6/21 Prevent Oncogene-Driven Transformation of Brain Stem Cells.
Targeting CDK9 for the Treatment of Glioblastoma.
TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma.
Glioma
Alkylaminophenol Induces G1/S Phase Cell Cycle Arrest in Glioblastoma Cells Through p53 and Cyclin-Dependent Kinase Signaling Pathway.
Anti-proliferative effect of Zea mays L. cob extract on rat C6 glioma cells through regulation of glycolysis, mitochondrial ROS, and apoptosis.
Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors.
Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells.
Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
Bioinformatical analysis of gene expression signatures of different glioma subtypes.
CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells.
CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
CDKL5 promotes proliferation, migration, and chemotherapeutic drug resistance of glioma cells via activation of the PI3K/AKT signaling pathway.
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma.
Cell surface aggregation of elastin receptor molecules caused by suramin amplified signals leading to proliferation of human glioma cells.
Chronic treatment with ginsenoside Rg3 induces Akt-dependent senescence in human glioma cells.
CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Clinical and biological significance of forkhead class box O 3a expression in glioma: mediation of glioma malignancy by transcriptional regulation of p27(kip1).
Common alternative gene alterations in adult malignant astrocytomas, but not in childhood primitive neuroectodermal tumors: P 16ink4 homozygous deletions and CDK4 gene amplifications.
Coordinate up-regulation of cyclin-dependent kinase 4 and its inhibitor p16(INK4) in human glioma cells following chloroethylnitrosourea-induced DNA damage.
Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA.
Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma.
Cyclin-dependent kinase activating kinase/Cdk7 co-localizes with PKC-iota in human glioma cells.
Cyclin?dependent kinase 10 prevents glioma metastasis via modulation of Snail expression.
Deletions and rearrangements inactivate the p16INK4 gene in human glioma cells.
Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.
Disrupting the PIKE-A/Akt interaction inhibits glioblastoma cell survival, migration, invasion and colony formation.
DNA methylation and leukemia susceptibility in China: Evidence from an updated meta-analysis.
Effect of glutamine or glucose deprivation on the expression of cyclin and cyclin-dependent kinase genes in glioma cell line U87 and its subline with suppressed activity of signaling enzyme of endoplasmic reticulum-nuclei-1.
Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells.
Expression and localization of cyclin-dependent kinase 5 in apoptotic human glioma cells.
Expression of cyclin-dependent kinase 6, but not cyclin-dependent kinase 4, alters morphology of cultured mouse astrocytes.
Expression of the p16 and p15 cyclin-dependent kinase inhibitors in lymphocyte activation and neuronal differentiation.
Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas.
Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway.
Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas.
Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation.
Glioma biology and molecular markers.
Glioma-specific cation conductance regulates migration and cell cycle progression.
Glucose metabolism and proliferation in glia: role of astrocytic gap junctions.
Histone deacetylase HDAC4 promotes the proliferation and invasion of glioma cells.
Histone demethylase KDM6B regulates 1,25-dihydroxyvitamin D3-induced senescence in glioma cells.
Human glioma PKC-iota and PKC-betaII phosphorylate cyclin-dependent kinase activating kinase during the cell cycle.
Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis.
Inhibition of cell cycle progression by penta-acetyl geniposide in rat C6 glioma cells.
Inhibition of DNA synthesis in human gliomas by roscovitine.
Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study.
Interaction of transforming growth factor-beta (TGF-beta) and epidermal growth factor (EGF) in human glioma cells.
Interferon-? sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02.
Knockdown of PFTK1 Inhibits the Migration of Glioma Cells.
Long noncoding RNA FOXD2-AS1 promotes glioma cell cycle progression and proliferation through the FOXD2-AS1/miR-31/CDK1 pathway.
Magnolol and honokiol exert a synergistic anti-tumor effect through autophagy and apoptosis in human glioblastomas.
MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6.
MicroRNA-613 impedes the proliferation and invasion of glioma cells by targeting cyclin-dependent kinase 14.
miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma.
Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.
Oroxyloside inhibits human glioma progression by suppressing proliferation, metastasis and inducing apoptosis related pathways.
Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.
Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas.
Proliferation arrest and induction of CDK inhibitors p21 and p27 by depleting the calcium store in cultured C6 glioma cells.
Protein kinase translocation following beta-adrenergic receptor activation in C6 glioma cells.
Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis.
Sirtuin 7 promotes glioma proliferation and invasion through activation of the ERK/STAT3 signaling pathway.
Staurosporine-induced Growth Inhibition of Glioma Cells is Accompanied by Altered Expression of Cyclins, CDKs and CDK Inhibitors.
Staurosporine-induced growth inhibition of glioma cells is accompanied by altered expression of cyclins, CDKs and CDK inhibitors.
The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.
The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells.
Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.
Tyrosine phosphorylation of the p21 cyclin-dependent kinase inhibitor facilitates the development of proneural glioma.
[Expression of cyclin-dependent kinase CDC2 and its significance in malignant progression of gliomas]
Glomerulonephritis
CYC-202 Cyclacel.
Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus.
Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist.
R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury.
The cyclin-dependent kinase inhibitor p21 limits murine mesangial proliferative glomerulonephritis.
The map kinase ERK regulates renal activity of cyclin-dependent kinase 2 in experimental glomerulonephritis.
Treatment with a cyclin-dependent kinase inhibitor, seliciclib, is effective in reducing glomerular macrophage numbers and the severity of established experimental glomerulonephritis.
[Nephroprotective role of early correction of impaired nutritional status in patients with chronic disease of the kidneys at a predialysis stage]
Glomerulonephritis, IGA
Role of differential and cell type-specific expression of cell cycle regulatory proteins in mediating progressive glomerular injury in human IgA nephropathy.
Glomerulonephritis, Membranous
Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation.
Glomerulosclerosis, Focal Segmental
Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation.
Phenotypic characteristics and cyclin-dependent kinase inhibitors repression in hyperplastic epithelial pathology in idiopathic focal segmental glomerulosclerosis.
Graft vs Host Disease
p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes.
Granulosa Cell Tumor
Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors.
Graves Disease
p27kip1 expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma.
Growth Hormone-Secreting Pituitary Adenoma
CDKN2A (p16INK4A) affects the anti?tumor effect of CDK inhibitor in somatotroph adenomas.
Head and Neck Neoplasms
Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor.
BAI, a novel cyclin-dependent kinase inhibitor induces apoptosis in A549 cells through activation of caspases and inactivation of Akt.
Basic investigation on the development of molecular targeting therapy against cyclin-dependent kinase inhibitor p27Kip1 in head and neck cancer cells.
Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?
Cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors and their role in head and neck cancer.
Double Edge: CDK2AP1 in Cell-cycle Regulation and Epigenetic Regulation.
E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1.
Expression of cyclin-dependent kinase 2-associated protein 1 confers an independent prognosticator in nasopharyngeal carcinoma: a cohort study.
Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA.
Selective antitumor activity of roscovitine in head and neck cancer.
The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells-A Systematic Analysis.
Hearing Loss
Inactivation of Cyclin-Dependent Kinase 5 in Hair Cells Causes Hearing Loss in Mice.
p19(Ink4d) and p21(Cip1) collaborate to maintain the postmitotic state of auditory hair cells, their codeletion leading to DNA damage and p53-mediated apoptosis.
Progressive hearing loss in mice lacking the cyclin-dependent kinase inhibitor Ink4d.
Rescue from early-onset hearing loss in a mouse model lacking the cyclin-dependent kinase inhibitor p19(Ink4d).
Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13.
Hearing Loss, Noise-Induced
CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss.
Heart Defects, Congenital
A set of consensus mammalian mediator subunits identified by multidimensional protein identification technology.
De novo variants in CDK13 associated with syndromic ID/DD; molecular and clinical delineation of 15 individuals and a further review.
Mouse Model of Congenital Heart Defects, Dysmorphic Facial Features and Intellectual Developmental Disorders as a Result of Non-functional CDK13.
Phenotypic and molecular characterisation of CDK13-related congenital heart defects, dysmorphic facial features and intellectual developmental disorders.
Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13.
Heart Diseases
Redefining the phenotypic spectrum of de novo heterozygous CDK13 variants: Three patients without cardiac defects.
Heart Failure
Activation of cyclins and cyclin-dependent kinases, DNA synthesis, and myocyte mitotic division in pacing-induced heart failure in dogs.
Cyclin-Dependent Kinase Inhibitor 2b Controls Fibrosis and Functional Changes in Ischemia-Induced Heart Failure via the BMI1-p15-Rb Signalling Pathway.
Cyclin-dependent kinase inhibitor expression in human heart failure. A comparison with fetal development.
The protective effect of 1,25(OH)2D3 against cardiac hypertrophy is mediated by the cyclin-dependent kinase inhibitor p21.
Hemangioma
[Expression and clinical significance of cyclin H and CDK7 in human hemangiomas]
Hematologic Neoplasms
A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies.
Cdk6: At the interface of Rb and p53.
CDKN2 Gene Deletion as Poor Prognosis Predictor Involved in the Progression of Adult B-Lineage Acute Lymphoblastic Leukemia Patients.
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
Cyclin-dependent kinase inhibitors (CKIs) and hematological malignancies.
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
Discovery of N-(4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)quinazolin-7-amine as a Novel, Potent, and Oral Cyclin-Dependent Kinase Inhibitor against Haematological Malignancies.
Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia.
Hitting the target in MCL.
Hypermethylation of the cell cycle inhibitor p15INK4b 3'-untranslated region interferes with its transcriptional regulation in primary lymphomas.
Kinases as drug discovery targets in hematologic malignancies.
Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.
Metabolomic Applications to the Characterization of the Mode-of-Action of CDK Inhibitors.
Methylation status of cyclin-dependent kinase inhibitor genes within the transforming growth factor beta pathway in human T-cell lymphoblastic lymphoma/leukemia.
Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia.
p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing.
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias.
Suppression of cyclin D1 but not cdk4 or cyclin A with induction of melanoma terminal differentiation.
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
The role of CDK6 in cancer.
Hepatitis
Functionally active cyclin-dependent kinase 9 is essential for porcine reproductive and respiratory syndrome virus subgenomic RNA synthesis.
Hepatitis B
Cooperative repression of cyclin-dependent kinase inhibitor p21 gene expression by hepatitis B virus X protein and hepatitis C virus core protein.
Hepatitis B virus HBx protein activation of cyclin A-cyclin-dependent kinase 2 complexes and G1 transit via a Src kinase pathway.
Hepatitis B Virus Pre-S2 Mutant Surface Antigen Induces Degradation of Cyclin-Dependent Kinase Inhibitor p27Kip1 through c-Jun Activation Domain-Binding Protein 1.
Natural variants of hepatitis B virus X protein have differential effects on the expression of cyclin-dependent kinase inhibitor p21 gene.
Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCs.
Requirement of cyclin-dependent kinase function for hepatitis B virus cccDNA synthesis as measured by digital PCR.
[Cyclins A and B: redundancy and specificity]
[Mitotic cyclins--new possibilities for examining mechanisms of neoplasm growth]
Hepatitis C
Cooperative repression of cyclin-dependent kinase inhibitor p21 gene expression by hepatitis B virus X protein and hepatitis C virus core protein.
Dual effects of hepatitis C virus Core protein on the transcription of cyclin-dependent kinase inhibitor p21 gene.
Hepatitis C virus core protein expression leads to biphasic regulation of the p21 cdk inhibitor and modulation of hepatocyte cell cycle.
Hepatitis C virus core protein represses the p21 promoter through inhibition of a TGF-beta pathway.
Hepatitis C Virus NS5B Protein Delays S Phase Progression in Human Hepatocyte-derived Cells by Relocalizing Cyclin-dependent Kinase 2-interacting Protein (CINP).
Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors.
Hepatitis, Chronic
Hepatocellular carcinoma cell cycle: study of Long-Evans cinnamon rats.
Hepatoblastoma
Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma.
Herpes Simplex
Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection.
cdc2 cyclin-dependent kinase binds and phosphorylates herpes simplex virus 1 U(L)42 DNA synthesis processivity factor.
Cellular proteins (cyclin dependent kinases) as potential targets for antiviral drugs.
Establishment and use of a cell line expressing HSV-1 thymidine kinase to characterize viral thymidine kinase-dependent drug-resistance.
Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs.
Functionally active cyclin-dependent kinase 9 is essential for porcine reproductive and respiratory syndrome virus subgenomic RNA synthesis.
Gene and other biological therapies for vascular diseases.
Herpes Simplex Virus 1 (HSV-1) ICP22 protein directly interacts with cyclin-dependent kinase (CDK)9 to inhibit RNA polymerase II transcription elongation.
Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions.
Identification of homeodomain proteins, PBX1 and PREP1, involved in the transcription of murine leukemia virus.
Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins.
Role of a cdk5-associated protein, p35, in herpes simplex virus type 1 replication in vivo.
Selective inhibition of HIV-1 replication by the CDK9 inhibitor FIT-039.
The Cyclin-Dependent Kinase 5 Inhibitor Peptide Inhibits Herpes Simplex Virus Type 1 Replication.
The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters the posttranslational modification of herpes simplex virus type 1 ICP0.
The differential requirement for cyclin-dependent kinase activities distinguishes two functions of herpes simplex virus type 1 ICP0.
The role of cdc2 in the expression of herpes simplex virus genes.
Virtual screening identified compounds that bind to cyclin dependent kinase 2 and prevent herpes simplex virus type 1 replication and reactivation in neurons.
[The role of cyclin-dependent protein kinase 2 in the replication of herpes simplex virus]
Herpes Zoster
Are Atlantic cod in Store Lungegårdsvann, a seawater recipient in Bergen, affected by environmental contaminants? A qRT-PCR survey.
Cellular and Molecular Impact of Vitrification Versus Slow Freezing on Ovarian Tissue.
HIV Infections
p16INK4a Expression and Immunologic Aging in Chronic HIV Infection.
Hodgkin Disease
Apoptosis of malignant cells in Hodgkin's disease is related to expression of the cdk inhibitor p27KIP1.
Effects of adenovirus-mediated expression of p27Kip1, p21Waf1 and p16INK4A in cell lines derived from t(2;5) anaplastic large cell lymphoma and Hodgkin's disease.
Huntington Disease
Cyclin-Dependent Kinase 5 Dysfunction Contributes to Depressive-like Behaviors in Huntington's Disease by Altering the DARPP-32 Phosphorylation Status in the Nucleus Accumbens.
Hydatidiform Mole
Characteristics of hydatidiform moles: analysis of a prospective series with p57 immunohistochemistry and molecular genotyping.
[The expressions of p16, CDK4 and PCNA proteins in trophoblastic tumors]
Hyperalgesia
Activation of cyclin-dependent kinase 5 (Cdk5) in primary sensory and dorsal horn neurons by peripheral inflammation contributes to heat hyperalgesia.
Activation of cyclin-dependent kinase 5 mediates orofacial mechanical hyperalgesia.
Cdk5 contributes to inflammation-induced thermal hyperalgesia mediated by the p38 MAPK pathway in microglia.
Cdk5-Dependent Phosphorylation of CaV3.2 T-Type Channels: Possible Role in Nerve Ligation-Induced Neuropathic Allodynia and the Compound Action Potential in Primary Afferent C Fibers.
Hypothalamic GPR40 signaling activated by free long chain fatty acids suppresses CFA-induced inflammatory chronic pain.
Increased synaptophysin is involved in inflammation-induced heat hyperalgesia mediated by cyclin-dependent kinase 5 in rats.
Phosphorylation of TRPV1 by cyclin-dependent kinase 5 promotes TRPV1 surface localization, leading to inflammatory thermal hyperalgesia.
The BDNF/TrkB Signaling Pathway Is Involved in Heat Hyperalgesia Mediated by Cdk5 in Rats.
VGLUT2/Cdk5/p25 Signaling Pathway Contributed to Inflammatory Pain by Complete Freund's Adjuvant.
Hypercalcemia
Multiple Endocrine Neoplasia Type 1 (MEN1) Phenocopy Due to a Cell Cycle Division 73 (CDC73) Variant.
Hyperparathyroidism
Mutational analysis of CDKN1B, a candidate tumor-suppressor gene, in refractory secondary/tertiary hyperparathyroidism.
Hyperparathyroidism, Primary
Caspase 8 and menin expressions are not correlated in human parathyroid tumors.
Hyperparathyroidism, Secondary
Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor and cyclin-dependent kinase inhibitors, p21 and p27.
Hypersensitivity
A novel WEE1 pathway for replication stress responses.
ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
Ethanol-hypersensitive and ethanol-dependent cdc- mutants in Schizosaccharomyces pombe.
Maintenance of open chromatin and selective genomic occupancy at the cell cycle-regulated histone H4 promoter during differentiation of HL-60 promyelocytic leukemia cells.
Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
p21 promotes error-free replication-coupled DNA double-strand break repair.
Protein phosphatase 5 and the tumor suppressor P53 down-regulate each other's activities in mice.
TORC1 kinase and the S-phase cyclin Clb5 collaborate to promote mitotic spindle assembly and DNA replication in S. cerevisiae.
Hypertension
Evaluation of the role of CDKN2B gene in type 2 diabetes mellitus and hypertension in ethnic Saudi Arabs.
Inflammation and poor response to treatment with erythropoietin in chronic kidney disease.
Posterior Reversible Encephalopathy Occurring During Treatment With Palbociclib.
The genetics of hypertension modifies the renal cell replication response induced by experimental diabetes.
Hypertension, Pulmonary
Cyclin-dependent kinase inhibitor p27Kip1, but not p21WAF1/Cip1, is required for inhibition of hypoxia-induced pulmonary hypertension and remodeling by heparin in mice.
Gene expression of cyclin-dependent kinase inhibitors and effect of heparin on their expression in mice with hypoxia-induced pulmonary hypertension.
Hyperthyroidism
Thyroid status affects rat liver regeneration after partial hepatectomy by regulating cell cycle and apoptosis.
Hypertrophy, Left Ventricular
Downregulation of cyclin-dependent kinase inhibitors p21 and p27 in pressure-overload hypertrophy.
Hypopituitarism
A GRFa2/Prop1/stem (GPS) cell niche in the pituitary.
Hypothyroidism
Thyroid status affects rat liver regeneration after partial hepatectomy by regulating cell cycle and apoptosis.
Hypoxia, Brain
Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.
Infarction, Middle Cerebral Artery
Cell cycle-related gene expression in the adult rat brain: selective induction of cyclin G1 and p21WAF1/CIP1 in neurons following focal cerebral ischemia.
Expression of cyclin-dependent kinase 5 and its activator p35 in rat brain after middle cerebral artery occlusion.
Targeting CDK5 post-stroke provides long-term neuroprotection and rescues synaptic plasticity.
Infections
A protein encoded by the latency-related gene of bovine herpesvirus 1 is expressed in trigeminal ganglionic neurons of latently infected cattle and interacts with cyclin-dependent kinase 2 during productive infection.
Accumulation of human papillomavirus type 16 E7 protein bypasses G1 arrest induced by serum deprivation and by the cell cycle inhibitor p21.
Activation of human cyclin-dependent kinases in vitro.
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
Adenovirus E1B 55-Kilodalton Protein Targets SMARCAL1 for Degradation during Infection and Modulates Cellular DNA Replication.
AG490 inhibits G1-S traverse in BALB/c-3T3 cells following either mitogenic stimulation or exogenous expression of E2F-1.
Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection.
Antagonistic Relationship between Human Cytomegalovirus pUL27 and pUL97 Activities during Infection.
BRD4 Couples NF-?B/RelA with Airway Inflammation and the IRF-RIG-I Amplification Loop in Respiratory Syncytial Virus Infection.
CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21.
cdc2 cyclin-dependent kinase binds and phosphorylates herpes simplex virus 1 U(L)42 DNA synthesis processivity factor.
CDK6 inhibits lymphoid cell infiltration and represents a prognostic marker in HPV+ squamous cell carcinoma of head and neck.
CDK9-dependent transcriptional elongation in the innate interferon-stimulated gene response to respiratory syncytial virus infection in airway epithelial cells.
Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells.
Cell cycle suppressor proteins are not related to HPV status or clinical outcome in patients with vulvar carcinoma.
Classical swine fever virus Shimen infection increases p53 signaling to promote cell cycle arrest in porcine alveolar macrophages.
Climatic droplet keratopathy in leprosy.
Cyclin-dependent kinase activity controls the onset of the HCMV lytic cycle.
Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles.
Cyclin-Dependent Kinase CRK9, Required for Spliced Leader trans Splicing of Pre-mRNA in Trypanosomes, Functions in a Complex with a New L-Type Cyclin and a Kinetoplastid-Specific Protein.
Cyclin-dependent kinases as therapeutic targets for HIV-1 infection.
Disease and Carrier Isolates of Neisseria meningitidis Cause G1 Cell Cycle Arrest in Human Epithelial Cells.
Distinct cell cycle regulation during saprophytic and pathogenic growth in fungal pathogens.
Early life infection alters adult BALB/c hippocampal gene expression in a sex specific manner.
Ectopic p21sdi1 gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment.
Epstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment.
FgCDC14 regulates cytokinesis, morphogenesis, and pathogenesis in Fusarium graminearum.
Hepatitis C virus core protein expression leads to biphasic regulation of the p21 cdk inhibitor and modulation of hepatocyte cell cycle.
Herpes simplex virus type 1 infection imposes a G(1)/S block in asynchronously growing cells and prevents G(1) entry in quiescent cells.
Host CDK-1 and formin mediate microvillar effacement induced by enterohemorrhagic Escherichia coli.
HSV-1 upregulates p35, alters CDK-5 localization, and stimulates CDK-5 kinase activity during acute infection in neurons.
Human cytomegalovirus (HCMV) IE1 plays role in resistance to apoptosis with etoposide in cancer cell line by Cdk2 accumulation.
Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation.
Human T-cell lymphotropic virus type 1 infection of CD34+ hematopoietic progenitor cells induces cell cycle arrest by modulation of p21(cip1/waf1) and survivin.
Impact of clean delivery-kit use on newborn umbilical cord and maternal puerperal infections in Egypt.
In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug.
In vivo and in vitro phosphorylation of DNA-dependent RNA polymerase of Escherichia coli by bacteriophage-T7-induced protein kinase.
Increased expression of p27Kip1 arrests neuroblastoma cell growth.
Loss of Cyclin-Dependent Kinase Inhibitor Alters Oncolytic Adenovirus Replication and Promotes More Efficient Virus Production.
Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib.
Murine coronavirus replication induces cell cycle arrest in G0/G1 phase.
Nuclear export of the human cytomegalovirus tegument protein pp65 requires cyclin-dependent kinase activity and the Crm1 exporter.
Oct-1 is posttranslationally modified and exhibits reduced capacity to bind cognate sites at late times after infection with herpes simplex virus 1.
p21WAF1/CIP1 RNA Expression in Highly HIV-1 Exposed, Uninfected Individuals.
Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss.
Phosphoproteomics to characterize host response during influenza A virus infection of human macrophages.
Primitive hematopoietic cells resist HIV-1 infection via p21.
Prognostic value of human papillomavirus infection and p53, p16, epidermal growth factor receptor and p34cdc2 expression in patients with salivary adenoid cystic carcinoma.
Prolonged activation of the mitogen-activated protein kinase pathway promotes DNA synthesis in primary hepatocytes from p21Cip-1/WAF1-null mice, but not in hepatocytes from p16INK4a-null mice.
Protein kinase of bacteriophage T7. 1. Purification.
Recruitment of cdk9 to the immediate-early viral transcriptosomes during human cytomegalovirus infection requires efficient binding to cyclin T1, a threshold level of IE2 86, and active transcription.
Regulation of Hepatitis B Virus Replication by Cyclin Docking Motifs in Core Protein.
RGNNV-induced cell cycle arrest at G1/S phase enhanced viral replication via p53-dependent pathway in GS cells.
Rotavirus infection induces G1 to S phase transition in MA104 cells via Ca(+2)/Calmodulin pathway.
The CDK inhibitor p21Cip1/WAF1 is induced by Fc{gamma}R activation and restricts the replication of HIV-1 and related primate lentiviruses in human macrophages.
The cyclin dependent kinase subunit Cks1 is required for infection-associated development of the rice blast fungus Magnaporthe oryzae.
The cytotoxic effect of E1B 55-kDa mutant adenovirus on human hepatocellular carcinoma cell lines.
The latency-related gene of bovine herpesvirus 1 inhibits programmed cell death.
The local environment orchestrates mucosal decidual macrophage differentiation and substantially inhibits HIV-1 replication.
The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic.
The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase.
Two Cdc2 Kinase Genes with Distinct Functions in Vegetative and Infectious Hyphae in Fusarium graminearum.
Ubiquitin-dependent proteolysis of cyclin D1 is associated with coxsackievirus-induced cell growth arrest.
Vaccinia virus regulates expression of p21WAF1/Cip1 in A431 cells.
[Voriconazole compromises renal function in an elderly CDK patient with Candida albicans infection]
Infertility, Male
Cyclin-Dependent Kinase Inhibitor Gene TaICK1 acts as a Potential Contributor to Wheat Male Sterility induced by a Chemical Hybridizing Agent.
Inflammatory Bowel Diseases
Immunohistochemical expression of cyclin D1, cyclin E, p21/waf1 and p27/kip1 in inflammatory bowel disease: correlation with other cell-cycle-related proteins (Rb, p53, ki-67 and PCNA) and clinicopathological features.
Inflammatory Breast Neoplasms
Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer.
Influenza, Human
Kinase inhibitor roscovitine as a PB2 cap-binding inhibitor against influenza a virus replication.
Phosphoproteomics to characterize host response during influenza A virus infection of human macrophages.
Insulin Resistance
A novel non-agonist peroxisome proliferator-activated receptor ? (PPAR?) ligand UHC1 blocks PPAR? phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
Cyclin-dependent kinase inhibitor, p21WAF1/CIP1, is involved in adipocyte differentiation and hypertrophy, linking to obesity, and insulin resistance.
Distinct Hepatic PKA and CDK Signaling Pathways Control Activity-Independent Pyruvate Kinase Phosphorylation and Hepatic Glucose Production.
Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) ? activators and pan-PPAR partial agonists.
Molecular Recognition of PPAR? by Kinase Cdk5/p25: Insights from a Combination of Protein-Protein Docking and Adaptive Biasing Force Simulations.
Thrap3 docks on phosphoserine 273 of PPAR? and controls diabetic gene programming.
Insulinoma
Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours.
Intellectual Disability
A GABAB receptor antagonist rescues functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder.
A maternally inherited frameshift CDKL5 variant in a male with global developmental delay and late-onset generalized epilepsy.
Aberrant mitochondrial function in patient-derived neural cells from CDKL5 deficiency disorder and Rett Syndrome.
Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.
Aminoglycoside drugs induce efficient read-through of CDKL5 nonsense mutations, slightly restoring its kinase activity.
AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder.
Caregiver's perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients.
CDK13-related disorder.
CDKL5 deficiency augments inhibitory input into the dentate gyrus that can be reversed by deep brain stimulation.
CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.
CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons.
CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail.
CDKL5 Gene-Related Epileptic Encephalopathy in Estonia: Four Cases, One Novel Mutation Causing Severe Phenotype in a Boy, and Overview of the Literature.
CDKL5 localizes at the centrosome and midbody and is required for faithful cell division.
CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients.
CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy.
CDKL5 PROTEIN SUBSTITUTION THERAPY RESCUES NEUROLOGICAL PHENOTYPES OF A MOUSE MODEL OF CDKL5 DISORDER.
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.
CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders.
Characterization of interstitial Xp duplications in two families by tiling path array CGH.
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Comparing Parental Well-Being and Its Determinants Across Three Different Genetic Disorders Causing Intellectual Disability.
Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Screening in Rett Syndrome and Related Disorders.
De novo variants in CDK13 associated with syndromic ID/DD; molecular and clinical delineation of 15 individuals and a further review.
Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
Early onset seizures and Rett-like features associated with mutations in CDKL5.
Epilepsy and mental retardation limited to females with PCDH19 mutations can present de novo or in single generation families.
Epilepsy caused by CDKL5 mutations.
Expression pattern of cdkl5 during zebrafish early development: implications for use as model for atypical Rett syndrome.
Functional characterization of CDK5 and CDK5R1 mutations identified in patients with non-syndromic intellectual disability.
Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation.
HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder.
Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder.
Identification of a novel CDKL5 exon and pathogenic mutations in patients with severe mental retardation, early-onset seizures and Rett-like features.
In vivo magnetic resonance spectroscopy in the brain of Cdkl5 null mice reveals a metabolic profile indicative of mitochondrial dysfunctions.
Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons.
Inhibition of GSK3? rescues hippocampal development and learning in a mouse model of CDKL5 disorder.
Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.
Lens GABA receptors are a target of GABA-related agonists that mitigate experimental myopia.
Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3? signaling.
Loss of CDKL5 in Glutamatergic Neurons Disrupts Hippocampal Microcircuitry and Leads to Memory Impairment in Mice.
Molecular and genetic insights into an infantile epileptic encephalopathy - CDKL5 disorder.
Molecular and Synaptic Bases of CDKL5 Disorder.
Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression.
Mutations in the C-terminus of CDKL5: proceed with caution.
Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation.
Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation.
Novel Mutations in Cyclin-Dependent Kinase-Like 5 (CDKL5) Gene in Indian Cases of Rett Syndrome.
Pathogenic role of the X-linked cyclin-dependent kinase-like 5 and aristaless-related homeobox genes in epileptic encephalopathy of unknown etiology with onset in the first year of life.
Pregnenolone and pregnenolone-methyl-ether rescue neuronal defects caused by dysfunctional CLIP170 in a neuronal model of CDKL5 Deficiency Disorder.
Redefining the phenotypic spectrum of de novo heterozygous CDK13 variants: Three patients without cardiac defects.
Reigning in Excitatory Signaling in CDKL5 Deficiency.
Sequential Elution Interactome Analysis of the Mind Bomb 1 Ubiquitin Ligase Reveals a Novel Role in Dendritic Spine Outgrowth.
Splicing Mutations Impairing CDKL5 Expression and Activity Can be Efficiently Rescued by U1snRNA-Based Therapy.
Structural Bases of Atypical Whisker Responses in a Mouse Model of CDKL5 Deficiency Disorder.
The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo.
The neurobiology of x-linked intellectual disability.
Treatment with the GSK3-beta inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, Cdkl5 knockout mice.
X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder.
Xp22.33p22.12 Duplication in a Patient with Intellectual Disability and Dysmorphic Facial Features.
Intervertebral Disc Degeneration
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Atuveciclib Suppresses Intervertebral Disk Degeneration via the Inhibition of the NF-?B Signaling Pathway.
Intracranial Aneurysm
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Epidemiology and genetics of intracranial aneurysms.
Intracranial Hemorrhages
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Ischemic Attack, Transient
Down-regulation of cyclin-dependent kinase 5 attenuates p53-dependent apoptosis of hippocampal CA1 pyramidal neurons following transient cerebral ischemia.
Ischemic Stroke
Cellular and Molecular Mechanisms of R/S-Roscovitine and CDKs Related Inhibition under Both Focal and Global Cerebral Ischemia: A Focus on Neurovascular Unit and Immune Cells.
Cyclin-dependent kinase inhibition with roscovitine: neuroprotection in acute ischemic stroke.
Cyclin-dependent kinase-5 targeting for ischaemic stroke.
Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors.
Expression of cyclin-dependent kinase 5 mRNA and protein in the human brain following acute ischemic stroke.
Genetic variants on chromosome 9p21 and ischemic stroke in Chinese.
Hypothermia treatment ameliorated cyclin-dependent kinase 5-mediated inflammation in ischemic stroke and improved outcomes in ischemic stroke patients.
Hypothermia treatment reduced cyclin-dependent kinase 5-mediated inflammation in ischemic stroke and improved outcomes in ischemic stroke patients.
Neuronal expression of cell cycle-related proteins after brain ischaemia in man.
Keloid
Effects of the circ_101238/miR-138-5p/CDK6 axis on proliferation and apoptosis keloid fibroblasts.
Effects of the cyclin-dependent kinase 10 (CDK10) on the tamoxifen sensitivity of keloid samples.
Keratitis
Immunohistochemical localization of D-{beta}-aspartic acid-containing proteins in climatic droplet keratopathy.
Infectious keratitis in climatic droplet keratopathy.
Phototherapeutic keratectomy for climatic droplet keratopathy, KKESH Excimer Laser Study Group. King Khaled Eye Specialist Hospital.
Keratoacanthoma
Comparison of mitotic cyclins and cyclin-dependent kinase expression in keratoacanthoma and squamous cell carcinoma.
Expression of the cyclin-dependent kinase inhibitor p27 in keratoacanthoma.
Keratosis, Actinic
Expression of G1/S-cyclins and cyclin-dependent kinase inhibitors in actinic keratosis and squamous cell carcinoma.
Kidney Diseases
CDK inhibitor shows promise for inflammatory kidney disease.
Novel Substituted 1,6-Naphthyridines as CDK 5 Inhibitors for Treating Kidney Diseases.
Podocytes as target of vitamin D.
Kidney Diseases, Cystic
Role of cyclin-dependent kinase 2 in the progression of mouse juvenile cystic kidney disease.
Kidney Failure, Chronic
Association between Nrf2 and CDKN2A expression in patients with end-stage renal disease: a pilot study.
Construction and Validation of Predictive Model to Identify Critical Genes Associated with Advanced Kidney Disease.
Somatopsychic correlates and quality of life of the dialyzed patient: a cross-sectional study.
The aftermath of acute kidney injury: a narrative review of long-term mortality and renal function.
The lack of a functional p21(WAF1/CIP1) gene ameliorates progression to chronic renal failure.
Kidney Neoplasms
Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells.
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.
Kyphosis
An algorithmic strategy of surgical intervention for cervical degenerative kyphosis.
Language Development Disorders
Neurodevelopmental and neurobehavioral characteristics in males and females with CDKL5 duplications.
Laryngeal Neoplasms
Expression of cyclin-dependent kinase inhibitor p21(WAF1) and p53 tumour suppressor gene in laryngeal cancer.
Leiomyoma
An essential role of p27 down-regulation in Fenvalerate-induced cell growth in human uterine leiomyoma and smooth muscle cells.
CDK-inhibitors-associated kinase activity: a possible determinant of malignant potential in smooth muscle tumors of the external soft tissue.
Cyclin-dependent kinase inhibitor p27Kip1 controls growth and cell cycle progression in human uterine leiomyoma.
Human Chorionic Gonadotrophin as a Possible Mediator of Leiomyoma Growth during Pregnancy: Molecular Mechanisms.
Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors.
Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
Leiomyosarcoma
CDK-inhibitors-associated kinase activity: a possible determinant of malignant potential in smooth muscle tumors of the external soft tissue.
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.
Cyclin-dependent kinase subunit 2 overexpression promotes tumor progression and predicts poor prognosis in uterine leiomyosarcoma.
Expression of cyclin-dependent kinase subunit 2 in uterine leiomyosarcoma cells.
Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors.
Leishmaniasis, Visceral
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis.
Lennox Gastaut Syndrome
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Leprosy, Lepromatous
Climatic droplet keratopathy in leprosy.
Leukemia
7,8-dihydroxyflavone induces G1 arrest of the cell cycle in U937 human monocytic leukemia cells via induction of the Cdk inhibitor p27 and downregulation of pRB phosphorylation.
A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest.
A new aspect on glutathione-associated biological function of MRP/GS-X pump and its gene expression.
A novel, extraneuronal role for cyclin-dependent protein kinase 5 (CDK5): modulation of cAMP-induced apoptosis in rat leukemia cells.
Acetylation at lysine 346 controls the transforming activity of the HTLV-1 Tax oncoprotein in the Rat-1 fibroblast model.
Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells.
AKT1 induces caspase-mediated cleavage of the CDK inhibitor p27Kip1 during cell cycle progression in leukemia cells transformed by FLT3-ITD.
Alterations of cyclin-dependent kinase 4 inhibitor (p16INK4A/MTS1) gene structure and expression in acute lymphoblastic leukemias.
Ampelopsin Inhibits Cell Proliferation and Induces Apoptosis in HL60 and K562 Leukemia Cells by Downregulating AKT and NF-?B Signaling Pathways.
Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines.
Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1(high) leukemia cells.
Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.
Binary and ternary solid dispersions of an anticancer preclinical lead, IIIM-290: In vitro and in vivo studies.
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
c-JUN prevents methylation of p16(INK4a) (and Cdk6): the villain turned bodyguard.
Cancer stem cells: potential target for bioactive food components.
CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia.
CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.
Cell cycle-based therapies move forward.
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.
Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc.
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Conversion of drug-induced differentiation to apoptosis by pharmacologic cyclin-dependent kinase inhibitors.
Cyclin-dependent kinase antagonizes promyelocytic leukemia zinc-finger through phosphorylation.
Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism.
DNA methylation and leukemia susceptibility in China: Evidence from an updated meta-analysis.
Downregulation of Mcl-1 has anti-inflammatory pro-resolution effects and enhances bacterial clearance from the lung.
Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis.
E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
Effect of Xpcl1 Activation and p27 Loss on Gene Expression in Murine Lymphoma.
Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells.
Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine.
Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937).
Expression of the p16 and p15 cyclin-dependent kinase inhibitors in lymphocyte activation and neuronal differentiation.
Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.
Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
Ganoderic acid A exerts antitumor activity against MDA-MB-231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Gene expression of growth signaling pathways is up-regulated in CD133-positive medulloblastoma cells.
Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Guided myeloid leukemia cell differentiation by blocking a specific cell cycle stage.
Hes6 controls cell proliferation via interaction with cAMP-response element-binding protein-binding protein in the promyelocytic leukemia nuclear body.
High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia.
Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome.
Homozygous deletions of cyclin-dependent kinase inhibitor genes, p16(INK4A) and p18, in childhood T cell lineage acute lymphoblastic leukemias.
Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias.
Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease.
Inactivation of cyclin-dependent kinase inhibitor genes and development of human acute leukemias.
Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer.
Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors.
Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes.
Isolation, identification and screening of microorganisms for cytotoxic activities from deep sea sediments at different pacific stations
KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy.
KLF2 inhibits Jurkat T leukemia cell growth via upregulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1.
Linalool preferentially induces robust apoptosis of a variety of leukemia cells via upregulating p53 and cyclin-dependent kinase inhibitors.
Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis.
Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
Meeting Report:The 7th ESPE Growth Plate Working Group Symposium - EUROGROP June 27th 2007, Helsinki, Finland.
Methylation of the INK4A/ARF locus in blood mononuclear cells.
Mitotic slippage: an old tale with a new twist.
MJ-29 inhibits tubulin polymerization, induces mitotic arrest, and triggers apoptosis via cyclin-dependent kinase 1-mediated Bcl-2 phosphorylation in human leukemia U937 cells.
Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias.
Momilactone B induces apoptosis and G1 arrest of the cell cycle in human monocytic leukemia U937 cells through downregulation of pRB phosphorylation and induction of the cyclin-dependent kinase inhibitor p21Waf1/Cip1.
Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4).
Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest.
p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia.
p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.
PDX1, a cellular homeoprotein, binds to and regulates the activity of human cytomegalovirus immediate early promoter.
Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms.
Promyelocytic leukemia zinc finger-retinoic acid receptor ? (PLZF-RAR?), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes.
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine.
Recent progress in molecular mechanisms of leukemogenesis: the cyclin-dependent kinase 4-inhibitor gene in human leukemias.
Repression of CDKN2C caused by PML/RAR? binding promotes the proliferation and differentiation block in acute promyelocytic leukemia.
Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma.
Role of promyelocytic leukemia zinc finger (PLZF) in cell proliferation and cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) gene repression.
Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma.
Roscovitine enhances All-trans retinoic acid (ATRA)-induced leukemia cell differentiation: Novel effects on signaling molecules for a putative Cdk2 inhibitor.
Screening biomarkers of bladder cancer using combined miRNA and mRNA microarray analysis.
Selection of a Water-Soluble Salt Form of a Preclinical Candidate, IIIM-290: Multiwell-Plate Salt Screening and Characterization.
Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias.
Specific association of increased cyclin-dependent kinase 5 expression with monocytic lineage of differentiation of human leukemia HL60 cells.
Specific nuclear binding of anti-cdc2 on p34cdc2 positive autonomously grown human leukemia cells induces differentiation.
Suppression of U937 human monocytic leukemia cell growth by dideoxypetrosynol A, a polyacetylene from the sponge Petrosia sp., via induction of Cdk inhibitor p16 and down-regulation of pRB phosphorylation.
Synergistic Anti Leukemia Effect of a Novel Hsp90 and a Pan Cyclin Dependent Kinase Inhibitors.
Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.
Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma.
The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway.
The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells.
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression.
The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression.
The prognostic potential of coilin in association with p27 expression in pediatric acute lymphoblastic leukemia for disease relapse.
The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase.
The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21(WAF1/Cip1) by STAT5.
TLS-ERG leukemia fusion protein deregulates cyclin-dependent kinase 1 and blocks terminal differentiation of myeloid progenitor cells.
TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner.
Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer.
Tyrosine phosphorylation modulates binding preference to cyclin-dependent kinases and subcellular localization of p27Kip1 in the acute promyelocytic leukemia cell line NB4.
Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Up-regulation of Egr1 by 1,25-dihydroxyvitamin D3 contributes to increased expression of p35 activator of cyclin-dependent kinase 5 and consequent onset of the terminal phase of HL60 cell differentiation.
Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
[Effect of MLL-AF9 fusion gene silence of acute monocytic leukemia cell line THP-1 on cyclin-dependent kinase inhibitor p27 expression]
[Expression of cyclin-dependent kinase inhibitors in leukemia]
[SCP Phosphatases and Oncogenesis].
Leukemia, B-Cell
PDX1, a cellular homeoprotein, binds to and regulates the activity of human cytomegalovirus immediate early promoter.
Leukemia, Erythroblastic, Acute
CDK6 blocks differentiation: coupling cell proliferation to the block to differentiation in leukemic cells.
Changes in p34cdc2 kinase activity and cyclin A during induced differentiation of murine erythroleukemia cells.
Differential modulation of G1-S-phase cyclin-dependent kinase 2/cyclin complexes occurs during the acquisition of a polyploid DNA content.
GATA-1 directly regulates p21 gene expression during erythroid differentiation.
Manipulating the onset of cell cycle withdrawal in differentiated erythroid cells with cyclin-dependent kinases and inhibitors.
Modulation of MDM2/p53 and cyclin-activating kinase during the megakaryocyte differentiation of human erythroleukemia cells.
Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.
Ability to downregulate the level of cyclin-dependent kinase inhibitor p27(Kip1) after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway.
Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia.
Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia.
Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
CDK9 Inhibitor Induces the Apoptosis of B-Cell Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolytic Metabolism.
Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27.
Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.
Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.
Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma.
Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Emerging Drug Profile: Cyclin-Dependent Kinase Inhibitors.
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
Flavopiridol-induced iNOS downregulation during apoptosis of chronic lymphocytic leukemia cells is caspase-dependent.
High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease.
Inhibition of NF-?B-mediated signaling by the CDK inhibitor CR8 overcomes pro-survival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Mutational and methylation analysis of the cyclin-dependent kinase 4 inhibitor (p16) gene in chronic lymphocytic leukemia.
Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.
Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms.
Rebound lymphocytosis in a patient with chronic lymphocytic leukemia after cessation of a CDK 4/6 inhibitor for concomitant breast cancer.
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells.
The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines.
Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Leukemia, Lymphoid
Inhibitor of Cyclin-dependent Kinase (CDK) Interacting with Cyclin A1 (INCA1) Regulates Proliferation and Is Repressed by Oncogenic Signaling.
Kinases as drug discovery targets in hematologic malignancies.
Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias.
Leukemia, Monocytic, Acute
[Effect of MLL-AF9 fusion gene silence of acute monocytic leukemia cell line THP-1 on cyclin-dependent kinase inhibitor p27 expression]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity.
Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines.
Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
Flow cytometric evaluation of cell cycle regulators (cyclins and cyclin-dependent kinase inhibitors) expressed on bone marrow cells in patients with chronic myeloid leukemia and multiple myeloma.
Gene therapy for BCR-ABL(+) human CML with dual phosphorylation resistant p27(Kip1) and stable RNA interference using an EBV vector.
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
Leukemia, Myeloid
1-beta-D-arabinofuranosylcytosine activates tyrosine phosphorylation of p34cdc2 and its association with the Src-like p56/p53lyn kinase in human myeloid leukemia cells.
Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.
CDK2 destabilizes tumor suppressor C/EBP? expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia.
Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine.
Kinases as drug discovery targets in hematologic malignancies.
Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol.
Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways.
The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor.
Leukemia, Myeloid, Acute
"Amyloid-beta accumulation cycle" as a prevention and/or therapy target for Alzheimer's disease.
CDK Blockade Using AT7519 Suppresses Acute Myeloid Leukemia Cell Survival through the Inhibition of Autophagy and Intensifies the Anti-leukemic Effect of Arsenic Trioxide.
CDK9 Inhibitor Induces the Apoptosis of B-Cell Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolytic Metabolism.
CDKN1B encoding the cyclin-dependent kinase inhibitor 1B (p27) is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.
Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy.
Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia.
FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27(Kip1) in acute myeloid leukemia.
Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia.
miR-148a-3p suppresses the progression of acute myeloid leukemia via targeting cyclin-dependent kinase 6 (CDK6).
Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias.
Prognostic significance of the cell cycle inhibitor p27Kip1 in acute myeloid leukemia.
Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors.
Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression.
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia.
Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
[Apoptosis of acute myeloid leukemia HL-60 cells induced by CDK inhibitor SNS-032 and its molecular mechanisms].
[Expression of cyclin-dependent kinase inhibitors in leukemia]
[Methylation of the genes in the 9P21 region in children with acute myeloid leukemia].
Leukemia, Plasma Cell
Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma.
Leukemia, Promyelocytic, Acute
Repression of CDKN2C caused by PML/RAR? binding promotes the proliferation and differentiation block in acute promyelocytic leukemia.
Tyrosine phosphorylation modulates binding preference to cyclin-dependent kinases and subcellular localization of p27Kip1 in the acute promyelocytic leukemia cell line NB4.
Leukemia, T-Cell
A cooperative interaction of human T-cell leukemia virus type 1 Tax with the p21 cyclin-dependent kinase inhibitor activates the human immunodeficiency virus type 1 enhancer.
Acetylation at lysine 346 controls the transforming activity of the HTLV-1 Tax oncoprotein in the Rat-1 fibroblast model.
Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells.
Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia.
Human T-cell leukemia virus type 1 Tax activates cyclin-dependent kinase inhibitor p21/Waf1/Cip1 expression through a p53-independent mechanism: Inhibition of cdk2.
Inhibition of cyclin-dependent kinase 5 but not of glycogen synthase kinase 3-? prevents neurite retraction and tau hyperphosphorylation caused by secretable products of human T-cell leukemia virus type I-infected lymphocytes.
p21WAF1 modulates NF-kappaB signaling and induces anti-apoptotic protein Bcl-2 in Tax-expressing rat fibroblast.
Physical interaction of human T-cell leukemia virus type 1 Tax with cyclin-dependent kinase 4 stimulates the phosphorylation of retinoblastoma protein.
PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo.
Transcriptional up-regulation of the cyclin D2 gene and acquisition of new cyclin-dependent kinase partners in human T-cell leukemia virus type 1-infected cells.
Leukemia-Lymphoma, Adult T-Cell
Alteration of p16 (CDKN2) gene is associated with interleukin-2-induced tumor cell growth in adult T-cell leukemia.
Altered Expression of Cell Cycle Regulators in Adult T-Cell Leukemia/ Lymphoma Patients.
Leukoencephalopathies
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Leukopenia
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Leukoplakia
Expression of apoptotic signaling proteins in leukoplakia and oral lichen planus: quantitative and topographical studies.
Lewy Body Disease
Cyclin-dependent kinase 5 (Cdk5) associated with Lewy bodies in diffuse Lewy body disease.
Lichen Planus, Oral
Study of P21 Expression in Oral Lichen Planus and Oral Squamous Cell Carcinoma by Immunohistochemical Technique.
Lichen Sclerosus et Atrophicus
Expression of the CDK inhibitor p27kip1 and oxidative DNA damage in non-neoplastic and neoplastic vulvar epithelial lesions.
Lipoma
Cyclin-dependent kinase inhibitor 2A (p16) distinguishes well-differentiated liposarcoma from lipoma.
Nuclear expression of MDM2 in hibernoma: a potential diagnostic pitfall.
Liposarcoma
Application of molecular biology to individualize therapy for patients with liposarcoma.
Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells.
Cyclin-dependent kinase inhibitor 2A (p16) distinguishes well-differentiated liposarcoma from lipoma.
Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Managing Liposarcomas: Cutting Through the Fat.
Retroperitoneal liposarcoma with colonic involvement: a case report.
Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.
The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers.
Liver Cirrhosis
Modulations of cell cycle checkpoints during HCV associated disease.
Proliferative capability of hepatocytes and expression of G1-related cell cycle molecules in the development of liver cirrhosis in rats.
Liver Cirrhosis, Biliary
miRNA-21 ablation protects against liver injury and necroptosis in cholestasis.
Liver Diseases
Cyclin and cyclin-dependent kinase 1 mRNA expression in models of regenerating liver and human liver diseases.
Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma.
Liver Diseases, Alcoholic
Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCs.
Liver Neoplasms
A cyclin-dependent kinase inhibitor (p21(WAF1/CIP1)) affects thymidine incorporation in human liver cancer cells.
A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility.
Alterations in specific gene expression and focal neoplastic growth during spontaneous hepatocarcinogenesis in albumin-SV40 T antigen transgenic rats.
Aryl hydrocarbon receptor gene silencing with small inhibitory RNA differentially modulates Ah-responsiveness in MCF-7 and HepG2 cancer cells.
Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation.
Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer.
Infrequent alterations of the p16INK4A gene in liver cancer.
Kaempferol induces autophagy through AMPK and AKT signaling molecules and causes G2/M arrest via downregulation of CDK1/cyclin B in SK-HEP-1 human hepatic cancer cells.
Loss of miR-1258 contributes to carcinogenesis and progression of liver cancer through targeting CDC28 protein kinase regulatory subunit 1B.
Loss of p27Kip1 enhances tumor progression in chronic hepatocyte injury-induced liver tumorigenesis with widely ranging effects on Cdk2 or Cdc2 activation.
miR372 Promotes Progression of Liver Cancer Cells by Upregulating erbB-2 through Enhancement of YB-1.
Molecular mechanisms underlying anticancer effects of myricetin.
Overexpression of CMTM7 inhibits cell growth and migration in liver cancer.
[The effect of p21 on transcription of survivin in hepatocellular carcinoma HepG2 cells and its regulation mechanism]
Liver Neoplasms, Experimental
Maturation-promoting factor and the regulation of the cell cycle.
Lung Diseases, Interstitial
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
Lung Injury
CDK 4/6 inhibitor induced lung injury: a case report and review of literature.
Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis.
Ifenprodil and Flavopiridol Identified by Genomewide RNA Interference Screening as Effective Drugs To Ameliorate Murine Acute Lung Injury after Influenza A H5N1 Virus Infection.
Induction of A- and D-type cyclins and cdc2 kinase activity during recovery from short-term hyperoxic lung injury.
Long non-coding RNA CDKN2B-AS1 enhances LPS-induced apoptotic and inflammatory damages in human lung epithelial cells via regulating the miR-140-5p/TGFBR2/Smad3 signal network.
Prediction of repurposed drugs for treating lung injury in COVID-19.
Ribociclib-Induced Pneumonitis: A Case Report.
Serial analysis of gene expression in mice with lipopolysaccharide-induced acute lung injury.
The cyclin-dependent kinase inhibitor p21 protects the lung from oxidative stress.
Lung Neoplasms
?-Cyclodextrin Interacts Close to Vinblastine Site of Tubulin and Delivers Curcumin Preferentially to the Tubulin Surface of Cancer Cell.
A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
A two kinase-gene signature model using CDK2 and PAK4 expression predicts poor outcome in non-small cell lung cancers.
Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling.
An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis.
Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells.
Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.
Cell cycle control and cancer: lessons from lung cancer.
Cell cycle inhibitors for the treatment of NSCLC.
Circular RNA circDLGAP4 is involved in lung cancer development through modulating microRNA-143/CDK1 axis.
Cis-diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung-cancer cells.
CKS2 Promotes the Growth in Non-Small-Cell Lung Cancer by Downregulating Cyclin-Dependent Kinase Inhibitor.
Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.
Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer.
Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer.
Cyclin-dependent kinase 2-associated protein 1 suppresses growth and tumorigenesis of lung cancer.
Cyclin-dependent kinase 5 controls vasculogenic mimicry formation in non-small cell lung cancer via the FAK-AKT signaling pathway.
Cyclin-dependent kinase 5 regulates the proliferation, motility and invasiveness of lung cancer cells through its effects on cytoskeletal remodeling.
Cyclin-dependent kinase inhibitors for the treatment of lung cancer.
Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?
Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin Dependent Kinases 1 and 2.
Distinct Molecular Mechanisms Analysis of Three Lung Cancer Subtypes Based on Gene Expression Profiles.
DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdi1).
Downregulation of PFTK1 Inhibits Migration and Invasion of Non-Small Cell Lung Cancer.
Downregulation of XIAP and Induction of Apoptosis by the Synthetic Cyclin-Dependent Kinase Inhibitor GW8510 in Non-Small Cell Lung Cancer Cells.
Ectopic p21sdi1 gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment.
Effect of suramin on p34cdc2 kinase in vitro and in extracts from human H69 cells: evidence for a double mechanism of action.
Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.
Elevated expression of CDK4 in lung cancer.
Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells.
Enolase 1 differentially contributes to cell transformation in lung cancer but not in esophageal cancer.
Establishment of two data mining models of lung cancer screening based on three gene promoter methylations combined with telomere damage.
Expression of cell cycle regulating factor mRNA in small cell lung cancer xenografts.
Fibronectin stimulates human lung carcinoma cell proliferation by suppressing p21 gene expression via signals involving Erk and Rho kinase.
Flavopiridol (Hoechst AG).
Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells.
Genome-wide cDNA microarray screening of genes related to survival in patients after curative resection of non-small cell lung cancer.
Hot spots for molecular genetic alterations in lung cancer.
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins.
Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era.
In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers.
Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer.
Induction of apoptosis by a novel indirubin-5-nitro-3'-monoxime, a CDK inhibitor, in human lung cancer cells.
Inhibition of PI-3K restores nuclear p27(Kip1) expression in a mouse model of Kras-driven lung cancer.
Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells.
Integrated Analysis of lncRNAs and mRNAs Identifies a Potential Driver lncRNA FENDRR in Lung Cancer in Xuanwei, China.
Involvement of p21Waf1/Cip1 cleavage during roscovitine-induced apoptosis in non-small cell lung cancer cells.
Knockdown of PFTK1 Expression by RNAi Inhibits the Proliferation and Invasion of Human Non-Small Lung Adenocarcinoma Cells.
Low levels of p27 in association with deregulated p53-pRb protein status enhance tumor proliferation and chromosomal instability in non-small cell lung carcinomas.
Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC.
Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer.
Mechanistic insight of cyclin-dependent kinase 5 in modulating lung cancer growth.
Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study.
miR-377 inhibited tumorous behaviors of non-small cell lung cancer through directly targeting CDK6.
Mitotic cell death caused by follistatin-like 1 inhibition is associated with up-regulated Bim by inactivated Erk1/2 in human lung cancer cells.
Modulation of cell cycle regulatory protein expression and suppression of tumor growth by mimosine in nude mice.
Molecular analysis of a family of cyclin-dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non-small cell lung cancers.
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.
Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
p53 regulates cellular responses to environmental carcinogen benzo[a]pyrene-7,8-diol-9,10-epoxide in human lung cancer cells.
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells.
Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells.
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.
Protective function of p27(KIP1) against apoptosis in small cell lung cancer cells in unfavorable microenvironments.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer.
RNA silencing of Cks1 induced G2/M arrest and apoptosis in human lung cancer cells.
RNAi-mediated downregulation of cyclin Y to attenuate human breast cancer cell growth.
Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer.
Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study.
Screening of gene mutations associated with bone metastasis in nonsmall cell lung cancer.
SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation.
Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163.
Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth.
Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.
Targeting cyclin-dependent kinase 6 by vanillin inhibits proliferation of breast and lung cancer cells: Combined computational and biochemical studies.
The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: its immunohistochemical evaluation using biopsy specimens.
The exogenous wild-type p14ARF gene induces growth arrest and promotes radiosensitivity in human lung cancer cell lines.
The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells.
The tumor-growth inhibitory activity of flavanone and 2'-OH flavanone in vitro and in vivo through induction of cell cycle arrest and suppression of cyclins and CDKs.
Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer.
Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer.
TRIGGERING ANAPHASE CATASTROPHE TO COMBAT ANEUPLOID CANCERS.
Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro.
[Antimitotic agents]
Lupus Erythematosus, Systemic
Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus.
Identification of Cyclin-dependent Kinase 1 as a Novel Regulator of Type 1 Interferon Signaling in Systemic Lupus Erythematosus.
Lupus susceptibility region containing CDKN1B rs34330 mechanistically influences expression and function of multiple target genes, also linked to proliferation and apoptosis.
Lymphadenopathy
New agents in chronic lymphocytic leukemia.
Update in the management of chronic lymphocytic leukemia.
Lymphatic Metastasis
Cyclin Y regulates the proliferation, migration, and invasion of ovarian cancer cells via Wnt signaling pathway.
Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report.
Downregulated CDK10 expression in gastric cancer: Association with tumor progression and poor prognosis.
Expression of CDK13 Was Associated with Prognosis and Expression of HIF-1? and beclin1 in Breast Cancer Patients.
p34cdc2 expression is an independent indicator for lymph node metastasis in colorectal carcinoma.
Prognostic significance of p34cdc2 expression in tongue squamous cell carcinoma.
Lymphedema
Transcriptome analysis and functional identification of adipose-derived mesenchymal stem cells in secondary lymphedema.
Lymphocytosis
Rebound lymphocytosis in a patient with chronic lymphocytic leukemia after cessation of a CDK 4/6 inhibitor for concomitant breast cancer.
Lymphoma
3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
53BP1 inhibits the migration and regulates the chemotherapy resistance of ovarian cancer cells.
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and Lymphomas.
A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Altered regulation of cyclic AMP-dependent protein kinase in a mouse lymphoma cell line.
Analysis of the novel cyclin-dependent kinase 4 and 6 inhibitor gene p18 in lymphoma and leukemia cell lines.
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Cdc2 expression in primary thyroid lymphoma: its relationship with biological aggressiveness and G2 cyclins.
Cellular kinetic differences between Hodgkin's and anaplastic large cell lymphomas: relation to the expression of p34cdc2 and cyclin B-1.
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Cyclamin, a natural 13,28-epoxy triterpenoid saponin, synergistically enhances the cytotoxicity of chemotherapeutic drugs in human liver cancer cells but not non-neoplastic liver cells.
Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma.
Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas.
Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas.
Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma.
Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Effect of Xpcl1 Activation and p27 Loss on Gene Expression in Murine Lymphoma.
Effects of adenovirus-mediated expression of p27Kip1, p21Waf1 and p16INK4A in cell lines derived from t(2;5) anaplastic large cell lymphoma and Hodgkin's disease.
Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma.
Expression and subcellular localization of cyclin-dependent kinase inhibitor p27 does not correlate with proliferation pattern of mantle lymphoma cells.
Expression of cyclin-dependent kinase 6 (cdk6) and frequent loss of CD44 in nasal-nasopharyngeal NK/T-cell lymphomas: comparison with CD56-negative peripheral T-cell lymphomas.
Expression of cyclin-dependent kinase inhibitor p27(Kip1) in AIDS-related diffuse large-cell lymphomas is associated with Epstein-Barr virus-encoded latent membrane protein 1.
Expression of cyclin-dependent kinase inhibitor p27kip1 in malignant lymphomas.
Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas.
Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory Non-Hodgkin's Lymphoma.
Flavopiridol Strongly Sensitizes Canine Lymphoma Cells to TRAIL-induced Apoptosis.
Growth regulation by p27Kip1 is abrogated by multiple mechanisms in aggressive malignant lymphomas.
Hitting the target in MCL.
Human non-Hodgkin's lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21.
Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
Investigation of the cytotoxic effect of flavopiridol in canine lymphoma cell lines.
Isolation, identification and screening of microorganisms for cytotoxic activities from deep sea sediments at different pacific stations
Kinase Inhibitor Indole Derivatives as Anticancer Agents: A Patent Review.
Kinases as drug discovery targets in hematologic malignancies.
Long-term arsenite exposure induces premature senescence in B cell lymphoma A20 cells.
Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.
Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor.
Methylation analysis of cyclin-dependent kinase inhibitor genes in primary gastrointestinal lymphomas.
Methylation of the INK4A/ARF locus in blood mononuclear cells.
Mutation analysis of the pRb pathway in 2',3'-dideoxycytidine- and 1, 3-butadiene-induced mouse lymphomas.
MYC-driven tumorigenesis is inhibited by WRN syndrome gene deficiency.
Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.
Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future.
P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease.
Prognostic implications of p27 and cyclin E protein contents in malignant lymphomas.
Promoter hypermethylation of the cyclin-dependent kinase inhibitor (CDKI) gene p21WAF1/CIP1/SDI1 is rare in various lymphomas and carcinomas.
Protein expression of cell cycle regulator, p27Kip1, correlates with histopathological grade of non-Hodgkin's lymphoma.
Reciprocal control of Forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels.
Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 in feline lymphoma.
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma.
Roles of the tumor suppressor p53 and the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in receptor-mediated apoptosis of WEHI 231 B lymphoma cells.
Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study.
Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma.
Steroid- and retinoid-mediated growth arrest and apoptosis in WEHI-231 cells: role of NF-kappaB, c-Myc and CKI p27(Kip1).
Study on the role of G1 cyclins in Epstein-Barr virus-associated human lymphomas maintained in severe combined immune deficiency (SCID) mice.
Subunit interaction in cyclic AMP-dependent protein kinase of mutant lymphoma cells.
Successful combination chemotherapy for metastatic inflammatory myofibroblastic tumor: A case report.
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
The double dealing of cyclin D1.
The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.
The localization of p34cdc2 in the cells of normal, hyperplastic, and malignant epithelial and lymphoid tissues of the oral cavity.
Thyroid status modulates T lymphoma growth via cell cycle regulatory proteins and angiogenesis.
Treatment of T-cell non-Hodgkin's lymphoma.
Lymphoma, B-Cell
53BP1 inhibits the migration and regulates the chemotherapy resistance of ovarian cancer cells.
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
A Sterol from Soft Coral Induces Apoptosis and Autophagy in MCF-7 Breast Cancer Cells.
Anti-Condyloma acuminata mechanism of microRNAs-375 modulates HPV in cervical cancer cells via the UBE3A and IGF-1R pathway.
Are Atlantic cod in Store Lungegårdsvann, a seawater recipient in Bergen, affected by environmental contaminants? A qRT-PCR survey.
Atypical uterine leiomyoma: a case report and review of the literature.
CCT020312 Inhibits Triple-Negative Breast Cancer Through PERK Pathway-Mediated G1 Phase Cell Cycle Arrest and Apoptosis.
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.
Dietary supplementation with essential amino acids boosts the beneficial effects of rosuvastatin on mouse kidney.
Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells.
Effect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line.
EPO Mediates Neurotrophic, Neuroprotective, Anti-Oxidant, and Anti-Apoptotic Effects via Downregulation of miR-451 and miR-885-5p in SH-SY5Y Neuron-Like Cells.
Expressions of the CIP/KIP family of CDK inhibitor proteins in primary intestinal large B-cell lymphomas: correlation with clinical outcomes.
EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma.
Herbal Extracts Induce Dermal Papilla Cell Proliferation of Human Hair Follicles.
Hsp90 inhibitor SY-016 induces G2/M arrest and apoptosis in paclitaxel-resistant human ovarian cancer cells.
Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.
In silico and in vitro investigation of anticancer effect of newly synthesized nonivamide-s-allyl cysteine ester.
Increased expression of S100A6 promotes cell proliferation in gastric cancer cells.
Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas.
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model.
LncRNA THUMPD3-AS1 enhances the proliferation and inflammatory response of chondrocytes in osteoarthritis.
Loss of mitofusin 2 links beta-amyloid-mediated mitochondrial fragmentation and Cdk5-induced oxidative stress in neuron cells.
Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas.
Magnolin Inhibits Proliferation and Invasion of Breast Cancer MDA-MB-231 Cells by Targeting the ERK1/2 Signaling Pathway.
MicroRNA-491 regulates the proliferation and apoptosis of CD8(+) T cells.
miR-636 represses cell survival by targeting CDK6/Bcl-2 in cervical cancer.
Molecular docking and dynamics simulation study of bioactive compounds from Ficus carica L. with important anticancer drug targets.
Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future.
Promising therapies for the treatment of chronic lymphocytic leukemia.
Radiosensitization of human glioma cells by tamoxifen is associated with the inhibition of PKC-? activity in vitro.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.
Stat1 stimulates cap-independent mRNA translation to inhibit cell proliferation and promote survival in response to antitumor drugs.
Strong Anti-tumorous Potential of Nardostachys jatamansi Rhizome Extract on Glioblastoma and In Silico Analysis of its Molecular Drug Targets.
Synthesis and Evaluation of Novel Cholestanoheterocyclic Steroids as Anticancer Agents.
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
The transcription factor FOXA1 induces epithelial ovarian cancer tumorigenesis and progression.
Lymphoma, Follicular
The effect of TGFbeta1 on the expression and phosphorylation of key cell-cycle regulators in malignant B cells.
Lymphoma, Large B-Cell, Diffuse
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Expression of cyclin-dependent kinase inhibitor p27(Kip1) in AIDS-related diffuse large-cell lymphomas is associated with Epstein-Barr virus-encoded latent membrane protein 1.
EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma.
G1 arrest of U937 cells by onconase is associated with suppression of cyclin D3 expression, induction of p16INK4A, p21WAF1/CIP1 and p27KIP and decreased pRb phosphorylation.
Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
Lymphoma, Large-Cell, Anaplastic
The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.
Lymphoma, Mantle-Cell
A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia.
Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma.
Hitting the target in MCL.
Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.
Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.
P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
The double dealing of cyclin D1.
Lymphoma, Non-Hodgkin
Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: independent prognostic value of p27Kip1.
Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma.
Expression of p16/INK4a in posttransplantation lymphoproliferative disorders.
Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27.
The effect of TGFbeta1 on the expression and phosphorylation of key cell-cycle regulators in malignant B cells.
Lymphoma, T-Cell
Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma.
Cyclin D1 expression in peripheral T-cell lymphomas.
Inactivation of the cyclin-dependent kinase inhibitor p15INK4b by deletion and de novo methylation with independence of p16INK4a alterations in murine primary T-cell lymphomas.
Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma.
Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma.
Lymphoma, T-Cell, Peripheral
Expression of cyclin-dependent kinase 6 (cdk6) and frequent loss of CD44 in nasal-nasopharyngeal NK/T-cell lymphomas: comparison with CD56-negative peripheral T-cell lymphomas.
Lymphoproliferative Disorders
Antitumor activity of cyclin-dependent kinase inhibitor alsterpaullone in Epstein-Barr virus-associated lymphoproliferative disorders.
Malaria
Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk.
In silico three-dimensional pharmacophores for aiding the discovery of the Pfmrk (Plasmodium cyclin-dependent protein kinases) specific inhibitors for the therapeutic treatment of malaria.
Pfmrk, a MO15-related protein kinase from Plasmodium falciparum. Gene cloning, sequence, stage-specific expression and chromosome localization.
Structural model of the Plasmodium CDK, Pfmrk, a novel target for malaria therapeutics.
Targeting malaria with specific CDK inhibitors.
Malformations of Cortical Development
The potential role of cyclin-dependent kinase 5 in focal cortical dysplasia.
Medulloblastoma
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity.
Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin.
DiSCoVERing innovative therapies for rare tumors: combining genetically accurate disease models with in silico analysis to identify novel therapeutic targets.
Expression of p27kip1 and p53 in medulloblastoma: relationship with cell proliferation and survival.
Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma.
Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models.
Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells.
p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.
Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells.
Prognostic value and functional consequences of cell cycle inhibitor p27Kip1 loss in medulloblastoma.
Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
The CDK Inhibitor p18(Ink4c) is a Tumor Suppressor in Medulloblastoma.
VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells.
Melanoma
12-O-tetradecanoylphorbol-13-acetate induces transient cell cycle arrest in G1 and G2 in metastatic melanoma cells: inhibition of phosphorylation of p34cdc2.
A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors.
Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma.
Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma.
An automated image capture and quantitation approach to identify proteins affecting tumor cell proliferation.
Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.
Array comparative genome hybridization for tumor classification and gene discovery in mouse models of malignant melanoma.
Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.
Binding patterns and structure-activity relationship of CDK8 inhibitors.
CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells.
CDK4/6 inhibition in cancer: the cell cycle splicing connection.
CDKN2A germline mutations in individuals with cutaneous malignant melanoma.
CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds.
Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation.
Cell cycle control as a promising target in melanoma.
Cell cycle transitions and Cdk inhibition in melanoma therapy: Cyclin' through the options.
Changes in Tumor Morphology and Cyclin-Dependent Kinase Inhibitor Expression in Metastatic Melanoma Treated With Selective Second-Generation BRAF Inhibitor.
Characterization of the CDKN2A and ARF genes in UV-induced melanocytic hyperplasias and melanomas of an opossum (Monodelphis domestica).
Clinical characteristics of malignant melanoma.
Clinical genetic testing for familial melanoma in Italy: A cooperative study.
Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma.
Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model.
Conditional ablation of Ikkb inhibits melanoma tumor development in mice.
Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions.
Cyclin-dependent kinase 2 expression in human melanomas and benign melanocytic skin lesions.
Cyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spread-Identification of a Promising Novel therapeutic target.
Cyclin-dependent kinase 5 regulates proliferation, migration, tyrosinase activity, and melanin production in B16-F10 melanoma cells via the essential regulator p-CREB.
Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors.
Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors. Mouriaux F,*(1) Maurage CA, Labalette P, Sablonniere B, Malecaze F, Darbon JM. Inv Ophthalmol Vis Sci 2000;41:2837-2843.
Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Cyclin-dependent kinases as therapeutic targets in melanoma.
Death-signal-induced relocalization of cyclin-dependent kinase 11 to mitochondria.
Deregulated E2F transcriptional activity in autonomously growing melanoma cells.
Dermal fibroblasts induce cell cycle arrest and block epithelial-mesenchymal transition to inhibit the early stage melanoma development.
Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.
Differential expression of G1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes.
Distinct sets of genetic alterations in melanoma.
Does the PITSLRE gene complex contribute to the pathogenesis of malignant melanoma of the skin? A study of patient-derived tumor samples?
Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.
Drug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicine.
Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
Ectopic Tbx2 expression results in polyploidy and cisplatin resistance.
Effect of melphalan and hyperthermia on p34cdc2 kinase activity in human melanoma cells.
Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin.
Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma.
Expression of cell cycle regulators in human cutaneous malignant melanoma.
Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins.
Expression of p16 protein in acral lentiginous melanoma.
Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
Familial Melanoma-Associated Mutations in p16 Uncouple its Tumor-Suppressor Functions.
Familial melanoma: Clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
Fas-induced apoptosis in human malignant melanoma cell lines is associated with the activation of the p34(cdc2)-related PITSLRE protein kinases.
First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo.
Fluorescent Peptide Biosensor for Probing CDK6 Kinase Activity in Lung Cancer Cell Extracts.
Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.
Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
Generation of knockout mouse models of cyclin-dependent kinase inhibitors by engineered nuclease-mediated genome editing.
Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion.
Genetics in melanoma.
Genetics of cutaneous melanoma and nevi.
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.
Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families.
Gossypin as a Novel Selective Dual Inhibitor of v-raf Murine Sarcoma Viral Oncogene Homolog B1 and Cyclin-Dependent Kinase 4 for Melanoma.
Growth factors and melanomas.
High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas.
High- and low-penetrance cutaneous melanoma susceptibility genes.
Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient.
Human melanocyte senescence and melanoma susceptibility genes.
Human polynucleotide phosphorylase selectively and preferentially degrades microRNA-221 in human melanoma cells.
Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27.
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Identification of new fisetin analogs as kinase inhibitors: Data on synthesis and anti-skin cancer activities evaluation.
Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations.
In vitro behavior and UV response of melanocytes derived from carriers of CDKN2A mutations and MC1R variants.
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Induction of apoptosis and regression of spontaneous dog melanoma following in vivo application of synthetic cyclin-dependent kinase inhibitor olomoucine.
Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor.
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
Interferon regulates expression of mda-6/WAF1/CIP1 and cyclin-dependent kinases independently from p53 in B16 murine melanoma cells.
Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1.
Interleukin-6-resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity.
Investigating DNA methylation as a potential mediator between pigmentation genes, pigmentary traits and skin cancer.
Lack of p21waf1 and p27kip1 protein induction by interferon-alpha2a in human melanoma cell lines.
Lanthanide-based peptide biosensor to monitor CDK4/cyclin D kinase activity.
Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.
Lycorine hydrochloride inhibits melanoma cell proliferation, migration and invasion via down-regulating p21Cip1/WAF1.
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.
Melanocyte development and malignant melanoma.
Melanoma and genetics.
Melanoma cell autonomous growth: the Rb/E2F pathway.
Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma.
Melanoma susceptibility and cell cycle genes in Xiphophorus hybrids.
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth.
Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny.
Modulation of cdk2, cyclin D1, p16INK4a, p21WAF and p27Kip1 expression in endothelial cells by TNF/IFN gamma.
Molecular pathogenesis of malignant melanoma: A different perspective from the studies of melanocytic nevus and acral melanoma.
Multiple neurofibromas as the presenting feature of familial atypical multiple malignant melanoma (FAMMM) syndrome.
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells.
Mutation testing in melanoma families: INK4A, CDK4 and INK4D.
New established melanoma cell lines: genetic and biochemical characterization of cell division cycle.
Normal repair of ultraviolet radiation-induced DNA damage in familial melanoma without CDKN2A or CDK4 gene mutation.
Novel CDKN2A mutation detected in Spanish melanoma pedigree.
Novel CDKN2A mutations detected in western Swedish families with hereditary malignant melanoma.
NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation.
Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
Overexpression of a fish CDKN2 gene in a hereditary melanoma model.
Overexpression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in human cutaneous malignant melanoma.
p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes.
p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression.
Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.
Pancreatic carcinoma surveillance in patients with familial melanoma.
Pediatric Melanoma in Melanoma-Prone Families.
Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism.
Population-Based Prevalence of CDKN2A Mutations in Utah Melanoma Families.
Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.
Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.
Promoter methylation as biomarkers for diagnosis of melanoma: A systematic review and meta-analysis.
Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival.
Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-?B Pathways.
Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation.
Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.
Rb/E2F: a two-edged sword in the melanocytic system.
Reduced expression of SRY-box containing gene 17 correlates with an unfavorable melanoma patient survival.
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
Regulation of stability of cyclin-dependent kinase CDK11p110 and a caspase-processed form, CDK11p46, by Hsp90.
Regulation of the cell cycle at the G2/M boundary in metastatic melanoma cells by 12-O-tetradecanoyl phorbol-13-acetate (TPA) by blocking p34cdc2 kinase activity.
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Role of the cyclin-dependent kinase inhibitor CDKN2A in familial melanoma.
Roscovitine inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma.
RTL1 promotes melanoma proliferation by regulating Wnt/?-catenin signalling.
Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study.
Selection criteria for genetic assessment of patients with familial melanoma.
Sensitization of Melanoma Cells for Death Ligand TRAIL Is Based on Cell Cycle Arrest, ROS Production, and Activation of Proapoptotic Bcl-2 Proteins.
Silencing of astrocyte elevated gene-1 inhibits proliferation and migration of melanoma cells and induces apoptosis.
SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors.
Some molecular and clinical aspects of genetic predisposition to malignant melanoma and tumours of various site of origin.
SOX9 is a dose-dependent metastatic fate determinant in melanoma.
Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.
Structural organization, mapping, characterization and evolutionary relationships of CDKN2 gene family members in Xiphophorus fishes.
Suppression of cyclin D1 but not cdk4 or cyclin A with induction of melanoma terminal differentiation.
Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers.
Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth.
Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma.
Targeting human melanoma neoantigens by T cell receptor gene therapy.
Targeting the cyclin-dependent kinase 5 in metastatic melanoma.
The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling.
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
The cyclin-dependent kinase inhibitors p15INK4B and p21CIP1 are critical regulators of fibrillar collagen-induced tumor cell cycle arrest.
The genetics of hereditary melanoma and nevi. 1998 update.
The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells.
The p16(INK4A) tumor suppressor regulates cellular oxidative stress.
The physiology of p16(INK4A)-mediated G1 proliferative arrest.
The role of CDK6 in cancer.
Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
Translational pathophysiology: a novel molecular mechanism of human disease.
Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition.
Update in genetic susceptibility in melanoma.
Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells.
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
WD repeat and SOCS box containing protein 2 in the proliferation, cycle progression, and migration of melanoma cells.
[Cyclin-dependent kinase inhibitory proteins in normal and transformed choroidal melanocytes]
[p16(INK4A)/CDKN2--the "melanoma gene"? Status of research and outlook]
Melanoma, Experimental
Cyclin-dependent kinase 2 and cyclin A interaction with E2F are targets for tyrosine induction of B16 melanoma terminal differentiation.
G1 phase-specific suppression of the Cdk2 activity by ginsenoside Rh2 in cultured murine cells.
Memory Disorders
Cyclin-dependent kinase inhibitor flavopiridol promotes remyelination in a cuprizone induced demyelination model.
Loss of CDKL5 in Glutamatergic Neurons Disrupts Hippocampal Microcircuitry and Leads to Memory Impairment in Mice.
Tolfenamic acid inhibits GSK-3? and PP2A mediated tau hyperphosphorylation in Alzheimer's disease models.
Meningioma
Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02.
Mental Retardation, X-Linked
Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Screening in Rett Syndrome and Related Disorders.
Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation.
Mesothelioma
Diagnostic mesothelioma biomarkers in effusion cytology.
Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.
Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma.
Fluorescent Peptide Biosensor for Probing CDK6 Kinase Activity in Lung Cancer Cell Extracts.
Hippo/YAP pathway for targeted therapy.
Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells.
Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Mesothelioma, Malignant
Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.
Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma.
Hippo/YAP pathway for targeted therapy.
Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma.
The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Metabolic Syndrome
Association of a cyclin-dependent kinase 5 regulatory subunit-associated protein 1-like 1 (CDKAL1) polymorphism with elevated hemoglobin A?(c) levels and the prevalence of metabolic syndrome in Japanese men: Interaction with dietary energy intake.
Invited commentary: Gene x lifestyle interactions and complex disease traits--inferring cause and effect from observational data, sine qua non.
Microcephaly
CDK5RAP2 Expression During Murine and Human Brain Development Correlates with Pathology in Primary Autosomal Recessive Microcephaly.
Congenital microcephaly-linked CDK5RAP2 affects eye development.
Many roads lead to primary autosomal recessive microcephaly.
Revisiting the phenotype associated with FOXG1 mutations: two novel cases of congenital Rett variant.
What primary microcephaly can tell us about brain growth.
Microphthalmos
Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
Motor Neuron Disease
Alterations in cyclin-dependent protein kinase 5 (CDK5) protein levels, activity and immunocytochemistry in canine motor neuron disease.
Mouth Neoplasms
Abrogation of the retinoblastoma tumor suppressor checkpoint during keratinocyte immortalization is not sufficient for induction of centrosome-mediated genomic instability.
Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer.
CDK2AP1/DOC-1 is a bona fide subunit of the Mi-2/NuRD complex.
Cell cycle dysregulation in oral cancer.
Helioxanthin suppresses the cross talk of COX-2/PGE2 and EGFR/ERK pathway to inhibit Arecoline-induced Oral Cancer Cell (T28) proliferation and blocks tumor growth in xenografted nude mice.
Molecular concept in human oral cancer.
Molecular docking analysis of piperine with CDK2,CDK4,Cyclin D and Cyclin T proteins.
p21(WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo.
p21{Waf1/CIP1} is a poor diagnostic and prognostic marker for OSCC although its expression increases in patients with N1 regional metastasis.
Role of p21WAF1 in green tea polyphenol-induced growth arrest and apoptosis of oral carcinoma cells.
The curcumin analog (PAC) suppressed cell survival and induced apoptosis and autophagy in oral cancer cells.
The Loss of p16 Expression Worsens the Prognosis of OSCC.
[Effect of long chain non-coding RNA H19 on the migration and invasion of oral cancer cells and its molecular mechanism].
Movement Disorders
Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder.
Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies.
Mucositis
Ribociclib-Induced Pneumonitis: A Case Report.
Multicystic Dysplastic Kidney
Novel CDK10 variants with multicystic dysplastic kidney, left ventricular non-compaction, and a solitary median maxillary central incisor.
Multiple Endocrine Neoplasia
Deficiency of the Cyclin-Dependent Kinase Inhibitor, CDKN1B, Results in Overgrowth and Neurodevelopmental Delay.
Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours.
Functional characterization of a CDKN1B mutation in a Sardinian kindred with multiple endocrine neoplasia type 4 (MEN4).
Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype.
Germline and Somatic Mutations in Cyclin-Dependent Kinase Inhibitor Genes CDKN1A, CDKN2B, and CDKN2C in Sporadic Parathyroid Adenomas.
Molecular genetic advances in pituitary tumor development.
Mutational analysis of CDKN1B, a candidate tumor-suppressor gene, in refractory secondary/tertiary hyperparathyroidism.
p18Ink4c collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers.
p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors.
Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.
Somatic and germline mutations in the pathogenesis of pituitary adenomas.
Multiple Endocrine Neoplasia Type 1
Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours.
Germline and Somatic Mutations in Cyclin-Dependent Kinase Inhibitor Genes CDKN1A, CDKN2B, and CDKN2C in Sporadic Parathyroid Adenomas.
Molecular genetic advances in pituitary tumor development.
Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.
Multiple Endocrine Neoplasia Type 2a
Multiple endocrine neoplasia (MEN) syndromes.
Multiple Endocrine Neoplasia Type 2b
Multiple endocrine neoplasia (MEN) syndromes.
Multiple Myeloma
A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.
Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma.
Arylazopyrazole AAP1742 Inhibits CDKs and Induces Apoptosis in Multiple Myeloma Cells via Mcl-1 Downregulation.
Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.
Cyclin D1 Overexpression Increases the Susceptibility of Human U266 Myeloma Cells to CDK Inhibitors Through a Process Involving p130-, p107- and E2F-Dependent S Phase Entry.
Cyclin D1 targets hexokinase 2 to control aerobic glycolysis in myeloma cells.
Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.
EphA4 promotes cell proliferation and cell adhesion-mediated drug resistance via the AKT pathway in multiple myeloma.
Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.
Flow cytometric evaluation of cell cycle regulators (cyclins and cyclin-dependent kinase inhibitors) expressed on bone marrow cells in patients with chronic myeloid leukemia and multiple myeloma.
Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis.
Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.
Infrequent epigenetic dysregulation of CIP/KIP family of cyclin-dependent kinase inhibitors in multiple myeloma.
Methylation of the INK4A/ARF locus in blood mononuclear cells.
MicroRNA-26a inhibits multiple myeloma cell growth by suppressing cyclin-dependent kinase 6 expression.
MicroRNA-338-3p inhibits proliferation and promotes apoptosis of multiple myeloma cells through targeting Cyclin-dependent kinase 4.
Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms.
Roscovitine, a small molecule CDK inhibitor induces apoptosis in multidrug-resistant human multiple myeloma cells.
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells.
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
The molecular determinants of R-roscovitine block of hERG channels.
The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
Multiple System Atrophy
Cyclin-dependent kinase 5 and mitogen-activated protein kinase in glial cytoplasmic inclusions in multiple system atrophy.
Muscle Hypotonia
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Impairment of CDKL5 nuclear localisation as a cause for severe infantile encephalopathy.
Key clinical features to identify girls with CDKL5 mutations.
Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.
What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy.
Muscular Atrophy
Androgen depletion alters the diurnal patterns to signals that regulate autophagy in the limb skeletal muscle.
Spinal motor neuron loss occurs through a p53-and-p21-independent mechanism in the Smn2B/- mouse model of spinal muscular atrophy.
Muscular Atrophy, Spinal
Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy.
Muscular Dystrophies
CDK inhibitors for muscle stem cell differentiation and self-renewal.
Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies.
Muscular Dystrophy, Duchenne
Antisense oligonucleotides and short interfering RNAs silencing the cyclin-dependent kinase inhibitor p21 improve proliferation of Duchenne muscular dystrophy patients' primary skeletal myoblasts.
Mycoses
IP7-SPX Domain Interaction Controls Fungal Virulence by Stabilizing Phosphate Signaling Machinery.
Mycosis Fungoides
MicroRNA-106b Regulates Expression of the Tumour Suppressors p21 and TXNIP and Promotes Tumour Cell Proliferation in Mycosis Fungoides.
Myelodysplastic Syndromes
Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors.
Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15, p16, p18 and p19 in the myelodysplastic syndromes.
Role of p15(INK4B) Methylation in Patients With Myelodysplastic Syndromes: A Systematic Meta-Analysis.
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
Myeloproliferative Disorders
Kinases as drug discovery targets in hematologic malignancies.
Myocardial Infarction
Higher frequency of rs4977574 (the G Allele) on chromosome 9p21.3 in patients with myocardial infarction as revealed by PCR-RFLP analysis.
MTAP and CDKN2B genes are associated with myocardial infarction in Chinese Hans.
New findings in the roles of Cyclin-dependent Kinase inhibitors 2B Antisense RNA 1 (CDKN2B-AS1) rs1333049 G/C and rs4977574 A/G variants on the risk to coronary heart disease.
Myocarditis
Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy.
Myoepithelioma
Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours.
Myositis
Aberrant expression of cyclin-dependent kinase 5 in inclusion body myositis.
Cyclin-dependent kinase 5 colocalizes with phosphorylated tau in human inclusion-body myositis paired-helical filaments and may play a role in tau phosphorylation.
T-cell anti-apoptotic mechanisms in inflammatory myopathies.
Myositis, Inclusion Body
Aberrant expression of cyclin-dependent kinase 5 in inclusion body myositis.
T-cell anti-apoptotic mechanisms in inflammatory myopathies.
Myotonic Dystrophy
CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model.
Reliable and versatile immortal muscle cell models from healthy and myotonic dystrophy type 1 primary human myoblasts.
Nasopharyngeal Carcinoma
CDK4 and miR-15a comprise an abnormal automodulatory feedback loop stimulating the pathogenesis and inducing chemotherapy resistance in nasopharyngeal carcinoma.
Cyclin-dependent kinase 4 overexpression is mostly independent of gene amplification and constitutes an independent prognosticator for nasopharyngeal carcinoma.
Cyclin-dependent kinase inhibitor 3 promotes cancer cell proliferation and tumorigenesis in nasopharyngeal carcinoma by targeting P27.
Decreased P27 protein expression is correlated with the progression and poor prognosis of nasopharyngeal carcinoma.
EBV-encoded LMP1 regulates Op18/stathmin signaling pathway by cdc2 mediation in nasopharyngeal carcinoma cells.
Expression of cyclin-dependent kinase 2-associated protein 1 confers an independent prognosticator in nasopharyngeal carcinoma: a cohort study.
Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
miR-539 induces cell cycle arrest in nasopharyngeal carcinoma by targeting cyclin-dependent kinase 4.
Nuclear expression of CDK4 correlates with disease progression and poor prognosis in human nasopharyngeal carcinoma.
Nuclear p27 expression confers a favorable outcome for nasopharyngeal carcinoma patients.
Overexpression of CDC28 protein kinase regulatory subunit 1B confers an independent prognostic factor in nasopharyngeal carcinoma.
Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer.
Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.
Nematode Infections
Induction of cdc2a and cyc1At expression in Arabidopsis thaliana during early phases of nematode-induced feeding cell formation.
The Armadillo BTB Protein ABAP1 Is a Crucial Player in DNA Replication and Transcription of Nematode-Induced Galls.
Neoplasm Metastasis
A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility.
Anti-metastasis effect of fucoidan from Undaria pinnatifida sporophylls in mouse hepatocarcinoma Hca-F cells.
CDK inhibitors reduce cell proliferation and reverse hypoxia-induced metastasis of neuroblastoma tumours in a chick embryo model.
CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/? -catenin Signaling.
CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/?-catenin pathway.
CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade.
Characterization of a Candidate Tumor Suppressor Gene Uroplakin 1A in Esophageal Squamous Cell Carcinoma.
Chfr is linked to tumour metastasis through the downregulation of HDAC1.
Clinical development of 17-allylamino, 17-demethoxygeldanamycin.
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Codelivery of HIF-1? siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression.
Curcumin as an Adjuvant to Breast Cancer Treatment.
Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer.
Cyclin Y regulates the proliferation, migration, and invasion of ovarian cancer cells via Wnt signaling pathway.
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.
Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser727 on STAT3 in prostate cancer cells.
Cyclin-dependent kinase 7 inhibitors in cancer therapy.
Cyclin?dependent kinase 10 prevents glioma metastasis via modulation of Snail expression.
Cytochrome b5 reductase 2 suppresses tumor formation in nasopharyngeal carcinoma by attenuating angiogenesis.
Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report.
Downregulated CDK10 expression in gastric cancer: Association with tumor progression and poor prognosis.
Downregulation of CDK-8 inhibits colon cancer hepatic metastasis by regulating Wnt/?-catenin pathway.
Downregulation of PFTK1 Inhibits Migration and Invasion of Non-Small Cell Lung Cancer.
Epigenetic inactivation of T-box transcription factor 5, a novel tumor suppressor gene, is associated with colon cancer.
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma.
Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma.
Expression of CDK13 Was Associated with Prognosis and Expression of HIF-1? and beclin1 in Breast Cancer Patients.
Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis.
Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma.
Expression of p27Kip1, cyclin E and E2F-1 in primary and metastatic tumors of gastric carcinoma.
Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
High expression of PFTK1 in cancer cells predicts poor prognosis in colorectal cancer.
Identification and characterization of a novel phosphoregulatory site on cyclin-dependent kinase 5.
Identification of hub genes associated with esophageal cancer progression using bioinformatics analysis.
Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling.
Inhibitor of growth 4 suppresses colorectal cancer growth and invasion by inducing G1 arrest, inhibiting tumor angiogenesis and reversing epithelial-mesenchymal transition.
Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform Cancer Therapy.
Long noncoding RNA gastric cancer-related lncRNA1 mediates gastric malignancy through miRNA-885-3p and cyclin-dependent kinase 4.
Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis.
Low expression of CDK12 in gastric cancer is correlated with advanced stage and poor outcome.
MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, CDK6.
Minireview: Cyclin D1: normal and abnormal functions.
Mutational characteristics of bone metastasis of lung cancer.
N-myc Downstream Regulated 1 (NDRG1) Is Regulated by Eukaryotic Initiation Factor 3a (eIF3a) during Cellular Stress Caused by Iron Depletion.
p16 inhibits matrix metalloproteinase-2 expression via suppression of Sp1-mediated gene transcription.
p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
p21WAF1/CIP1 protein expression in primary ovarian cancer.
p34cdc2 expression is an independent indicator for lymph node metastasis in colorectal carcinoma.
Palbociclib in breast cancer neoadjuvant setting.
Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling.
Polyketides from the marine-derived fungus Aspergillus falconensis: In silico and in vitro cytotoxicity studies.
Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.
Prognostic significance of p34cdc2 expression in tongue squamous cell carcinoma.
Promoter-associated endogenous and exogenous small RNAs suppress human bladder cancer cell metastasis by activating p21 (CIP1/WAF1) expression.
Risk factors of metastasis in oral squamous cell carcinomas.
Selective oestrogen receptor degraders in breast cancer: a review and perspectives.
Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression.
Talin phosphorylation by Cdk5 regulates Smurf1-mediated talin head ubiquitylation and cell migration.
Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma.
Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer.
The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells.
The hallmarks of CDKN1C (p57, KIP2) in cancer.
The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma.
Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis.
Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma.
Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors.
Up-regulated p27Kip1 reduces matrix metalloproteinase-9 and inhibits invasion of human breast cancer cells.
Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer.
Neoplasm, Residual
Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.
p21WAF1/CIP1 protein expression in primary ovarian cancer.
Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.
The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.
Neoplasms
"Hedgehog pathway": a potential target of itraconazole in the treatment of cancer.
2,4-bis (p-hydroxyphenyl)-2-butenal (HPB242) induces apoptosis via modulating E7 expression and inhibition of PI3K/Akt pathway in SiHa human cervical cancer cells.
2-Aminoquinazoline inhibitors of cyclin-dependent kinases.
2-methoxyestradiol Prevents LNCaP Tumor Development in Nude Mice: Potential Role of G2/M Regulatory Proteins.
3'-Hydroxypterostilbene Inhibits 7,12-Dimethylbenz[a]anthracene (DMBA)/12-O-Tetradecanoylphorbol-13-Acetate (TPA)-Induced Mouse Skin Carcinogenesis.
3D Microenvironment Stiffness Regulates Tumor Spheroid Growth and Mechanics via p21 and ROCK.
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
?-Cyclodextrin Interacts Close to Vinblastine Site of Tubulin and Delivers Curcumin Preferentially to the Tubulin Surface of Cancer Cell.
A Bead-Based Microfluidic Approach to Integrated Single-Cell Gene Expression Analysis by Quantitative RT-PCR.
A biomimetic assay platform for the interrogation of antigen-dependent anti-tumor T-cell function.
A CDK2 activity signature predicts outcome in CDK2-low cancers.
A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence.
A cell cycle regulator potentially involved in genesis of many tumor types.
A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia.
A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
A conditional mouse mutant in the tumor suppressor SdhD gene unveils a link between p21(WAF1/Cip1) induction and mitochondrial dysfunction.
A consensus cAMP-dependent protein kinase (PK-A) site in place of the CcN motif casein kinase II site simian virus 40 large T-antigen confers PK-A-mediated regulation of nuclear import.
A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts.
A Dual-Targeting Delivery System for Effective Genome Editing and In Situ Detecting Related Protein Expression in Edited Cells.
A Fast and Efficient Approach to Obtaining High-Purity Glioma Stem Cell Culture.
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.
A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers.
A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors.
A genomic approach to predict synergistic combinations for breast cancer treatment.
A human tumour-derived mutant p53 protein induces a p34cdc2 reversible growth arrest in fission yeast.
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis.
A Mechanism Misregulating p27 in Tumors Discovered in a Functional Genomic Screen.
A methoxyflavanone derivative from the Asian medicinal herb (Perilla frutescens) induces p53-mediated G2/M cell cycle arrest and apoptosis in A549 human lung adenocarcinoma.
A microRNA profile of pediatric glioblastoma: The role of NUCKS1 upregulation.
A minimum folding unit in the ankyrin repeat protein p16(INK4).
A naturally occurring mixture of tocotrienols inhibits the growth of human prostate tumor, associated with epigenetic modifications of cyclin-dependent kinase inhibitors p21 and p27.
A new cancer diagnostic system based on a CDK profiling technology.
A new method for determining the status of p53 in tumor cell lines of different origin.
A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2.
A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism.
A novel compound, ferulic acid-bound resveratrol, induces the tumor suppressor gene p15 and inhibits the three-dimensional proliferation of colorectal cancer cells.
A novel cyclin-dependent kinase inhibitor down-regulates tumor necrosis factor-alpha (TNF-alpha)-induced expression of cell adhesion molecules by inhibition of NF-kappaB activation in human pulmonary epithelial cells.
A novel cytoplasmic substrate for cdk4 and cdk6 in normal and malignant epithelial derived cells.
A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor.
A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype.
A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility.
A novel miRNA-mediated STOP sign in lung cancer: miR-340 inhibits the proliferation of lung cancer cells through p27(KIP1).
A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype.
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
A Novel Tetranucleotide Repeat Polymorphism Within KCNQ1OT1 Confers Risk for Hepatocellular Carcinoma.
A p53-independent pathway for induction of p21waf1cip1 and concomitant G1 arrest in UV-irradiated human skin fibroblasts.
A p53-Responsive miRNA Network Promotes Cancer Cell Quiescence.
A Pan-Cancer Compendium of Genes Deregulated by Somatic Genomic Rearrangement across More Than 1,400 Cases.
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.
A Phase 1 Study of Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Japanese Patients.
A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers.
A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers.
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.
A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and Lymphomas.
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor.
A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma.
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors.
A precisely positioned MED12 activation helix stimulates CDK8 kinase activity.
A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis.
A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer.
A simple stochastic model for the feedback circuit between p16INK4a and p53 mediated by p38MAPK: implications for senescence and apoptosis.
A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo.
A Strategy for Direct Chemical Activation of the Retinoblastoma Protein.
A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
A UNIQUE CDK4/6 INHIBITOR: CURRENT AND FUTURE THERAPEUTIC STRATEGIES OF ABEMACICLIB.
A variable fork rate affects timing of origin firing and S phase dynamics in Saccharomyces cerevisiae.
A versatile modular vector system for rapid combinatorial mammalian genetics.
Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067.
Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype.
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia.
Aberrant methylation in promoter regions of cyclin-dependent kinase inhibitor genes in adenoid cystic carcinoma of the salivary gland.
Aberrant methylation of hypermethylated-in-cancer-1 and exocyclic DNA adducts in tobacco smokers.
Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China.
Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas.
Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation.
Aberrant Splicing of Cables Gene, A CDK Regulator, in Human Cancers.
Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines.
Ablation of p21waf1cip1 expression enhances the capacity of p53-deficient human tumor cells to repair UVB-induced DNA damage.
Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis.
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification.
Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours.
Absence of p16 and p27 gene rearrangements and mutations in de novo myelodysplastic syndromes.
Absolute quantification of somatic DNA alterations in human cancer.
Accumulation of cytoplasmic CDC25A in cutaneous squamous cell carcinoma leads to a dependency on CDC25A for cancer cell survival and tumor growth.
Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.
Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway.
Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells.
Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours.
Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells.
Activation of p53 by roscovitine-mediated suppression of MDM2 expression.
Activation of protein kinase C alpha is required for TPA-triggered ERK (MAPK) signaling and growth inhibition of human hepatoma cell HepG2.
Activation of protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c).
Activation of RB/E2F signaling pathway is required for the modulation of hepatitis C virus core protein-induced cell growth in liver and non-liver cells.
Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1.
Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene.
Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
Activation of the mammalian target of rapamycin signalling pathway in epidermal tumours and its correlation with cyclin-dependent kinase 2.
Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.
Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms.
Activin effects on neoplastic proliferation of human pituitary tumors.
Activity of roniciclib in medullary thyroid cancer.
ACTL6A suppresses p21Cip1 expression to enhance the epidermal squamous cell carcinoma phenotype.
Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma.
Adenovirus expressing p27(Kip1) induces growth arrest of lung cancer cell lines and suppresses the growth of established lung cancer xenografts.
Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.
Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
Adenovirus-mediated p16INK4 gene transfer significantly suppresses human breast cancer growth.
Adjuvant cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive breast cancer: One Monarch to rule them all?
Advances in the biology of oral cancer.
Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia.
Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain.
Akt, FoxO and regulation of apoptosis.
Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization.
Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile.
Alginate oligosaccharide alleviates enterotoxigenic Escherichia coli-induced intestinal mucosal disruption in weaned pigs.
All-trans retinoic acid induces DU145 cell cycle arrest through Cdk5 activation.
Allelic deletion at 9p21-22 in primary cutaneous CD30(+) large cell lymphoma.
Alteration of cell cycle in cervical tumor associated with human papillomavirus: cyclin-dependent kinase inhibitors.
Alteration of cell cycle-related genes in hepatocarcinogenesis.
Alteration of G1 cell-cycle protein expression and induction of p53 but not p21/waf1 by the DNA-modifying carcinogen 2-acetylaminofluorene in growth-stimulated hepatocytes in vitro.
Alteration of p16 and p15 genes in human uterine tumours.
Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling.
Alterations in cell cycle regulation in mouse skin tumors.
Alterations in cytokine/antioncogene expression in skin lesions caused by "low-risk" types of human papillomaviruses.
Alterations in Promoter Methylation Status of Tumor Suppressor HIC1, SFRP2, and DAPK1 Genes in Prostate Carcinomas.
Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma.
Alterations of CDKN2 (p16) in non-small cell lung cancer.
Alterations of cyclin-dependent kinase 4 inhibitor (p16INK4A/MTS1) gene structure and expression in acute lymphoblastic leukemias.
Alterations of p16INK4A and p15INK4B genes in gastric carcinomas.
Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies.
Alterations of the putative tumor suppressor gene p16/MTS1 in human hematological malignancies.
Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma.
Altered expression of cyclin D1 and cyclin-dependent kinase 4 in azoxymethane-induced mouse colon tumorigenesis.
Altered expression of GADD45 genes during the development of chemical-mediated liver hypertrophy and liver tumor promotion in rats.
Altered expression of Skp2, c-Myc and p27 proteins but not mRNA after H. pylori eradication in chronic gastritis.
Alternative pathway of transcriptional induction of p21WAF1/Cip1 by cyclosporine A in p53-deficient human glioblastoma cells.
Amniotic Membrane-Derived Cells Inhibit Proliferation of Cancer Cell Lines by Inducing Cell Cycle Arrest.
An AC-repeat adjacent to mouse Cdkn2B allows the detection of specific allelic losses in the p15INK4b and p16INK4a tumor suppressor genes.
An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks.
An Antitumor 2-Hydroxyarylidene-4-cyclopentene-1,3-Dione as a Protein Tyrosine Kinase Inhibitor: Interaction Between TX-1123 Derivatives and Src Kinase.
An automated image capture and quantitation approach to identify proteins affecting tumor cell proliferation.
An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence.
An evaluation of palbociclib as a breast cancer treatment option: a current update.
An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
An Indirubin Derivative, Indirubin-3'-Monoxime Suppresses Oral Cancer Tumorigenesis through the Downregulation of Survivin.
An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpes viridae.
An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
An insight into the risk factors of brain tumors and their therapeutic interventions.
An integrated chemical biology approach provides insight into cdk2 functional redundancy and inhibitor sensitivity.
An opposite effect of the CDK inhibitor, p18(INK4c) on embryonic stem cells compared with tumor and adult stem cells.
An RB insensitive to CDK regulation.
Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas.
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Analysis of location and integrity of the human PITSLRE (p58(cdc2L1)) genes in neuroblastoma cell genomes.
Analysis of p16 gene mutations and deletions in childhood acute lymphoblastic leukemias.
Analysis of p18INK4C in adult T-cell leukaemia and non-Hodgkin's lymphoma.
Analysis of p27KIP1 protein and Ki-67 expression in aggressive fibromatosis (desmoid tumor).
Analysis of phosphorylation of pRB and its regulatory proteins in breast cancer.
Analysis of promoter hypermethylation of death-associated protein kinase and p16 tumor suppressor genes in actinic keratoses and squamous cell carcinomas of the skin.
Analysis of site-specific phosphorylation of the retinoblastoma protein during cell cycle progression.
Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.
Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.
Andrographolide induces degradation of mutant p53 via activation of Hsp70.
Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata.
Aneuploid CTC and CEC.
Annulus cells from more degenerated human discs show modified gene expression in 3D culture compared with expression in cells from healthier discs.
Anomalous overexpression of p27(Kip1) in sporadic pancreatic endocrine tumors.
Anti-angiogenic effects of novel cyclin-dependent kinase inhibitors with a pyrazolo[4,3-d]pyrimidine scaffold.
Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer.
Anti-Condyloma acuminata mechanism of microRNAs-375 modulates HPV in cervical cancer cells via the UBE3A and IGF-1R pathway.
Anti-proliferative effect of polysaccharides from Salicornia herbacea on induction of G2/M arrest and apoptosis in human colon cancer cells.
Anti-tumor activity of noble indirubin derivatives in human solid tumor models in vitro.
Anticancer Activity of Ramalin, a Secondary Metabolite from the Antarctic Lichen Ramalina terebrata, against Colorectal Cancer Cells.
Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS?032, on cervical cancer.
Anticancer bioactive peptide (ACBP) inhibits gastric cancer cells by upregulating growth arrest and DNA damage-inducible gene 45A (GADD45A).
Anticancer potential of emodin.
Anticancer potential of silymarin: from bench to bed side.
Anticancer therapeutic strategies based on CDK inhibitors.
Antineoplastic Activities, Apoptotic Mechanism of Action and Structural Properties of a Novel Silver(I) Chelate.
Antiproliferative effect of resveratrol in human prostate carcinoma cells.
Antiproliferative strategies for the treatment of vascular proliferative disease.
Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors.
Antitumor Activity of Ohmyungsamycin A through the Regulation of the Skp2-p27 Axis and MCM4 in Human Colorectal Cancer Cells.
Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.
Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo.
Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells.
AP4 directly downregulates p16 and p21 to suppress senescence and mediate transformation.
Apoptosis and melanoma: molecular mechanisms.
Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor.
Apoptosis oxidative damage-mediated and antiproliferative effect of selenylated imidazo[1,2-a]pyridines on hepatocellular carcinoma HepG2 cells and in vivo.
Apoptosis-related protein-1 acts as a tumor suppressor in cholangiocarcinoma cells by inducing cell cycle arrest via downregulation of cyclin-dependent kinase subunits.
AR, the cell cycle, and prostate cancer.
Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses.
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.
Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-X(L) and survivin.
Arsenic trioxide inhibits DNA methyltransferase and restores expression of methylation-silenced CDKN2B/CDKN2A genes in human hematologic malignant cells.
Artemis interacts with the Cul4A-DDB1DDB2 ubiquitin E3 ligase and regulates degradation of the CDK inhibitor p27.
Assessment of biomarkers in paired primary and recurrent colorectal adenocarcinomas.
Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene.
Association between variations in cell cycle genes and idiopathic pulmonary fibrosis.
Association of bone loss with the upregulation of survival-related genes and concomitant downregulation of Mammalian target of rapamycin and osteoblast differentiation-related genes in the peripheral blood of late postmenopausal osteoporotic women.
Association of breast cancer risk loci with breast cancer survival.
Association of polymorphisms in APOE, p53, and p21 with primary open-angle glaucoma in Turkish patients.
Atherosclerosis and cancer: common molecular pathways of disease development and progression.
ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers.
ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor.
ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
ATP-site directed inhibitors of cyclin-dependent kinases.
Attenuation of Aluminum Chloride-Induced Neuroinflammation and Caspase Activation Through the AKT/GSK-3? Pathway by Hesperidin in Wistar Rats.
Atypical uterine leiomyoma: a case report and review of the literature.
AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells.
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.
AZD5438, an Inhibitor of Cdk1, 2, and 9, Enhances the Radiosensitivity of Non-Small Cell Lung Carcinoma Cells.
Baffled by bafilomycin: an anticancer agent that induces hypoxia-inducible factor-1alpha expression.
BAI, a novel Cdk inhibitor, enhances farnesyltransferase inhibitor LB42708-mediated apoptosis in renal carcinoma cells through the downregulation of Bcl-2 and c-FLIP (L).
Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT.
Baohuoside-1 inhibits activated T cell proliferation at G(1)-S phase transition.
Basic investigation on the development of molecular targeting therapy against cyclin-dependent kinase inhibitor p27Kip1 in head and neck cancer cells.
Basic Pan-Cancer Analysis of the Carcinogenic Effects of Cyclin-Dependent Kinase 4 (CDK4) in Human Surface Tumors.
Bauerenol, a triterpenoid from Indian Suregada angustifolia: Induces reactive oxygen species-mediated P38MAPK activation and apoptosis in human hepatocellular carcinoma (HepG2) cells.
Bax-mediated cell death by the Gax homeoprotein requires mitogen activation but is independent of cell cycle activity.
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.
Bear Bile Powder Inhibits Growth of Hepatocellular Carcinoma via Suppressing STAT3 Signaling Pathway in Mice.
Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.
Biliary cancer: Utility of next-generation sequencing for clinical management.
Binary and ternary solid dispersions of an anticancer preclinical lead, IIIM-290: In vitro and in vivo studies.
Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells.
Biological correlates of p27 compartmental expression in prostate cancer.
Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer.
Bitter Melon (Momordica charantia) Extract Suppresses Adrenocortical Cancer Cell Proliferation Through Modulation of the Apoptotic Pathway, Steroidogenesis, and Insulin-Like Growth Factor Type 1 Receptor/RAC-? Serine/Threonine-Protein Kinase Signaling.
Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer.
Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy.
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer.
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
Brca1 inactivation induces p27(Kip1)-dependent cell cycle arrest and delayed development in the mouse mammary gland.
BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.
BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.
Breast Cancer Special Feature: Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins.
c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition.
Cables1 controls p21/Cip1 protein stability by antagonizing proteasome subunit alpha type 3.
CAMK1 Phosphoinositide Signal-Mediated Protein Sorting and Transport Network in Human Hepatocellular Carcinoma (HCC) by Biocomputation.
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.
Cancer dormancy: role of cyclin-dependent kinase inhibitors in induction of cell cycle arrest mediated via membrane IgM.
Cancer epigenomics: implications of DNA methylation in personalized cancer therapy.
Cancer Risk in Beckwith-Wiedemann Syndrome: A Systematic Review and Meta-Analysis Outlining a Novel (Epi)Genotype Specific Histotype Targeted Screening Protocol.
Candidate gene polymorphisms and risk of psoriasis: A pilot study.
Canine Mammary Carcinomas: A Comparative Analysis of Altered Gene Expression.
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.
Caspase 8 and menin expressions are not correlated in human parathyroid tumors.
CCRK is a novel signalling hub exploitable in cancer immunotherapy.
Cdc14 phosphatase: warning, no delay allowed for chromosome segregation!
Cdc2-cyclin E complexes regulate the G1/S phase transition.
cdc2-like kinase from rat spinal cord specifically phosphorylates KSPXK motifs in neurofilament proteins: isolation and characterization.
CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability.
Cdc6 knockdown inhibits human neuroblastoma cell proliferation.
CDCA5 regulates proliferation in hepatocellular carcinoma and has potential as a negative prognostic marker.
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors.
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
CDK Blockade Using AT7519 Suppresses Acute Myeloid Leukemia Cell Survival through the Inhibition of Autophagy and Intensifies the Anti-leukemic Effect of Arsenic Trioxide.
CDK inhibition and cancer therapy.
Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response.
CDK Inhibitor Targets: a Hit or Miss Proposition?: Cyclin-Dependent Kinase Inhibitors Kill Tumor Cells by Downregulation of Anti-apoptotic Proteins.
CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis.
CDK inhibitors in cancer therapy, an overview of recent development.
CDK inhibitors in cancer therapy: what is next?
CDK inhibitors in clinical development for the treatment of cancer.
Cdk inhibitors in development and cancer.
CDK inhibitors reduce cell proliferation and reverse hypoxia-induced metastasis of neuroblastoma tumours in a chick embryo model.
Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.
CDK inhibitors: from the bench to clinical trials.
Cdk inhibitory nucleoside analogs prevent transcription from viral genomes.
CDK phosphorylation of the discs large tumour suppressor controls its localisation and stability.
CDK redundancy guarantees cell cycle progression in Rb-negative tumor cells independently of their p16 status.
CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
CDK-inhibitors-associated kinase activity: a possible determinant of malignant potential in smooth muscle tumors of the external soft tissue.
CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer.
CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner.
CDK1 inhibitors antagonize the immediate apoptosis triggered by spindle disruption but promote apoptosis following the subsequent rereplication and abnormal mitosis.
CDK1 stabilizes HIF-1? via direct phosphorylation of Ser668 to promote tumor growth.
CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
Cdk1/P34Cdc2 and P21waf expression in colorectal adenomas and carcinomas.
CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells.
CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene.
CDK11 is required for transcription of replication-dependent histone genes.
CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells.
CDK11p110 plays a critical role in the tumorigenicity of esophageal squamous cell carcinoma cells and is a potential drug target.
CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression.
CDK12 and PAK2 as novel therapeutic targets for human gastric cancer.
CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes.
CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
CDK12 inactivation across solid tumors: an actionable genetic subtype.
CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation.
CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability.
CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/? -catenin Signaling.
CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration.
CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/?-catenin pathway.
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion.
CDK12 regulates DNA repair genes by suppressing intronic polyadenylation.
CDK12: A Potent Target and Biomarker for Human Cancer Therapy.
CDK12: a potential therapeutic target in cancer.
CDK12: an emerging therapeutic target for cancer.
CDK12: cellular functions and therapeutic potential of versatile player in cancer.
CDK13 RNA Over-Editing Mediated by ADAR1 Associates with Poor Prognosis of Hepatocellular Carcinoma Patients.
CDK13, a Kinase Involved in Pre-mRNA Splicing, Is a Component of the Perinucleolar Compartment.
CDK16 overexpressed in non-small cell lung cancer and regulates cancer cell growth and apoptosis via a p27-dependent mechanism.
Cdk2 is required for breast cancer mediated by the low molecular weight isoform of cyclin E.
CDK2 knockdown enhances head and neck cancer cell radiosensitivity.
CDK2-AP1 inhibits growth of breast cancer cells by regulating cell cycle and increasing docetaxel sensitivity in vivo and in vitro.
CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons.
CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer.
CDK4 regulates lysosomal function and mTORC1 activation to promote cancer cell survival.
CDK4-6 inhibitors in breast cancer: current status and future development.
CDK4/6 blockade in breast cancer: current experience and future perspectives.
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
CDK4/6 inhibition in cancer: the cell cycle splicing connection.
CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAFV600 Melanoma via a p53 Dependent Pathway.
CDK4/6 inhibitor PD 0332991 sensitizes acute myeloid leukemia to cytarabine-mediated cytotoxicity.
CDK4/6 inhibitors in breast cancer.
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease.
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity.
CDK5 functions as a tumor promoter in human colorectal cancer via modulating the ERK5-AP-1 axis.
CDK5 in oncology: recent advances and future prospects.
CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.
Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity.
CDK5RAP3 Inhibits the Translocation of MCM6 to Influence the Prognosis in Gastric Cancer.
CDK6 inhibits lymphoid cell infiltration and represents a prognostic marker in HPV+ squamous cell carcinoma of head and neck.
Cdk6: At the interface of Rb and p53.
CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway.
CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition.
CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38?/MYC/PD-L1 signaling in non-small cell lung cancer.
CDK7 Inhibitor THZ1 Induces the Cell Apoptosis of B-Cell Acute Lymphocytic Leukemia by Perturbing Cellular Metabolism.
CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery.
CDK8 kinase--An emerging target in targeted cancer therapy.
CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells.
CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation.
CDK9 Inhibitor FIT-039 Suppresses Viral Oncogenes E6 and E7 and Has a Therapeutic Effect on HPV-Induced Neoplasia.
CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.
CDKN1B encoding the cyclin-dependent kinase inhibitor 1B (p27) is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.
CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells.
CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner.
CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma.
CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer.
CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia.
CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
Cdkn2a encodes functional variation of p16INK4a but not p19ARF, which confers selection in mouse lung tumorigenesis.
CDKN2A, CDK1, and CCNE1 overexpression in sebaceous gland carcinoma of eyelid.
CDKN2A/P16INK4A variants association with breast cancer and their in-silico analysis.
CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1-Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion.
CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer.
CDKN3 knockdown reduces cell proliferation, invasion and promotes apoptosis in human ovarian cancer.
CDKN3 promotes cell proliferation, invasion and migration by activating the AKT signaling pathway in esophageal squamous cell carcinoma.
CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets.
Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway.
Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.
Cell cycle arrest mediated by a pyridopyrimidine is not abrogated by over-expression of Bcl-2 and cyclin D1.
Cell cycle checkpoints, genetic instability and cancer.
Cell cycle control and cancer: lessons from lung cancer.
Cell cycle control as a basis for cancer chemoprevention through dietary agents.
Cell cycle control in breast cancer cells.
Cell cycle dysregulation in oral cancer.
Cell cycle gene regulation in reversibly differentiated new human hepatoma cell lines.
Cell cycle inhibitor p21/ WAF1/ CIP1 as a cofactor of MITF expression in melanoma cells.
Cell cycle molecular targets in novel anticancer drug discovery.
Cell Cycle Regulating Kinase Cdk4 as a Potential Target for Tumor Cell Treatment and Tumor Imaging.
Cell cycle regulation and anticancer drug discovery.
Cell cycle regulation and its aberrations in human lung carcinoma.
Cell cycle regulation by bevacizumab in ARPE-19 human retinal pigment epithelial cells.
Cell cycle regulators in testicular cancer: loss of p18INK4C marks progression from carcinoma in situ to invasive germ cell tumours.
Cell cycle regulators in the keratinocyte (cyclin-cdk).
Cell cycle regulatory proteins in the liver in murine Trypanosoma cruzi infection.
Cell cycle, CDKs and cancer: a changing paradigm.
Cell cycle-based therapies move forward.
Cell cycle-dependent translation of p27 involves a responsive element in its 5'-UTR that overlaps with a uORF.
Cell cyclins and cyclin-dependent kinase activities in mouse mammary tumor development.
Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor.
Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes.
Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers.
Cell-cycle targeted therapies.
Cell-specific responses to loss of cyclin-dependent kinases.
Cellular and molecular advances in elucidating p53 function.
Cellular and molecular evidence for malignancy-inhibitory functions of p15RS.
Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix.
Cellular Response upon Stress: p57 Contribution to the Final Outcome.
Cellular senescence and chromatin structure.
Centrosome aberrations and cancer.
Centrosome replication, genomic instability and cancer.
Changes in Tumor Morphology and Cyclin-Dependent Kinase Inhibitor Expression in Metastatic Melanoma Treated With Selective Second-Generation BRAF Inhibitor.
Characteristics of antitumor activity of mutant type p27Kip1 gene in an oral cancer cell line.
Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations.
Characterization of protein tyrosine kinase activity in murine Leydig tumor cells.
Characterization of regulatory elements on the promoter region of p16(INK4a) that contribute to overexpression of p16 in senescent fibroblasts.
Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.
Characterizing CDK12-Mutated Prostate Cancers.
Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors.
Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells.
Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.
Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets.
Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response.
Chemoproteomic Profiling Uncovers CDK4-Mediated Phosphorylation of the Translational Suppressor 4E-BP1.
Chfr is linked to tumour metastasis through the downregulation of HDAC1.
Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner.
ChIP-Seq analysis identifies p27(Kip1)-target genes involved in cell adhesion and cell signalling in mouse embryonic fibroblasts.
Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer.
Chromosome condensation induced by fostriecin does not require p34cdc2 kinase activity and histone H1 hyperphosphorylation, but is associated with enhanced histone H2A and H3 phosphorylation.
Chromothripsis in human breast cancer.
Cidofovir in the treatment of HPV-associated lesions.
Circular RNA CircCCNB1 sponges micro RNA-449a to inhibit cellular senescence by targeting CCNE2.
Circulating and Tissue Expression Profile of MicroRNAs in Primary Hyperparathyroidism Caused by Sporadic Parathyroid Adenomas.
Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer.
Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway.
Cisplatin's potential for type 2 diabetes repositioning by inhibiting CDKN1A, FAS, and SESN1.
Cisplatin-induced inhibition of p34cdc2 is abolished by 5-fluorouracil.
CKS protein overexpression renders tumors susceptible to a chemotherapeutic strategy that protects normal tissues.
Cks1 is a critical regulator of hematopoietic stem cell quiescence and cycling, operating upstream of Cdk inhibitors.
CKS1BP7, a Pseudogene of CKS1B, is Co-Amplified with IGF1R in Breast Cancers.
CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Classical anticytokinins do not interact with cytokinin receptors but inhibit cyclin-dependent kinases.
Cleavage of PITSLRE kinases by ICE/CASP-1 and CPP32/CASP-3 during apoptosis induced by tumor necrosis factor.
Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
Clinical and biological significance of Cdk10 in hepatocellular carcinoma.
Clinical and biological significance of forkhead class box O 3a expression in glioma: mediation of glioma malignancy by transcriptional regulation of p27(kip1).
Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis.
Clinical development of 17-allylamino, 17-demethoxygeldanamycin.
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Clinical significance of cell cycle inhibitors in hepatocellular carcinoma.
Clinicopathological features of atypical lipomatous tumors of the laryngopharynx.
Clinicopathological significance and potential drug target of p15INK4B in multiple myeloma.
Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica.
Co-purification of p34cdc2/p58cyclin A proline-directed protein kinase and the retinoblastoma tumor susceptibility gene product: interaction of an oncogenic serine/threonine protein kinase with a tumor-suppressor protein.
Codelivery of HIF-1? siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression.
Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer.
Combinatorial drug therapy in cancer - New insights.
Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.
Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.
Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity.
Combining flavopiridol with various signal transduction inhibitors.
Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification.
Coming full circle: cyclin-dependent kinases as anti-cancer drug targets.
Commentary on "A new cancer diagnostic system based on a CDK profiling technology" [Biochim. Biophys. Acta Molecular Basis of Disease 1741 (2005) 226-233].
Common alternative gene alterations in adult malignant astrocytomas, but not in childhood primitive neuroectodermal tumors: P 16ink4 homozygous deletions and CDK4 gene amplifications.
Comparative proteomic analysis of colon cancer cells in response to Oxaliplatin treatment.
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma.
Comparison of p16INK4A and Hybrid Capture 2 human papillomavirus testing as adjunctive tests in liquid-based gynecologic SurePath preparations.
Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model.
Comprehensive bioinformatics analysis of the TP53 signaling pathway in Wilms' tumor.
Computational experiments reveal the efficacy of targeting CDK2 and CKIs for significantly lowering cellular senescence bar for potential cancer treatment.
Computational study to evaluate the potency of phytochemicals in Boerhavia diffusa and the impact of point mutation on cyclin-dependent kinase 2-associated protein 1.
Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients.
Conditional ablation of Ikkb inhibits melanoma tumor development in mice.
Consequences of p53 gene expression by adenovirus vector on cell cycle arrest and apoptosis in human aortic vascular smooth muscle cells.
Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc.
Constitutive CCND1/CDK2 activity substitutes for p53 loss, or MYC or oncogenic RAS expression in the transformation of human mammary epithelial cells.
Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53.
Contrasting behavior of the p18INK4c and p16INK4a tumor suppressors in both replicative and oncogene-induced senescence.
Contribution of the dual coding capacity of the p16INK4a/MTS1/CDKN2 locus to human malignancies.
Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells.
Control of cell cycle progression by c-Jun is p53 dependent.
Control of G1 progression by D-type cyclins: key event for cell proliferation.
Control of the G1/S transition.
Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity.
Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma.
Cooperative role between p21cip1/waf1 and p27kip1 in premature senescence in glandular proliferative lesions in mice.
Correction: Combined Depletion of Cell Cycle and Transcriptional Cyclin-Dependent Kinase Activities Induces Apoptosis in Cancer Cells.
Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma.
Correlation between TGF-beta1 and p21 (WAF1/CIP1) expression and prognosis in resectable invasive ductal carcinoma of the pancreas.
Correlation of constitutive photomorphogenic 1 (COP1) and p27 tumor suppressor protein expression in ovarian cancer.
Correlation of p16 immunohistochemistry in FNA biopsies with corresponding tissue specimens in HPV-related squamous cell carcinomas of the oropharynx.
Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas.
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience.
CREB activation induced by mitochondrial dysfunction is a new signaling pathway that impairs cell proliferation.
CRL4B(DCAF11) E3 ligase targets p21 for degradation to control cell cycle progression in human osteosarcoma cells.
CRM-1 knockdown inhibits extrahepatic cholangiocarcinoma tumor growth by blocking the nuclear export of p27Kip1.
CRMP2 Phosphorylation Drives Glioblastoma Cell Proliferation.
Crystal structure of the homolog of the oncoprotein gankyrin, an interactor of Rb and CDK4/6.
Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines.
Current concepts in neuro-oncology: the cell cycle--a review.
Current medical treatment of estrogen receptor-positive breast cancer.
Current understanding and management of nasopharyngeal carcinoma.
CYC-202 Cyclacel.
Cyclin A2 and CDK2 as Novel Targets of Aspirin and Salicylic Acid: A Potential Role in Cancer Prevention.
Cyclin D-CDK4/6 functions in cancer.
Cyclin D-dependent kinases, INK4 inhibitors and cancer.
Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity.
Cyclin D1 overexpression in mouse epidermis increases cyclin-dependent kinase activity and cell proliferation in vivo but does not affect skin tumor development.
Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases.
Cyclin D3 deficiency inhibits skin tumor development, but does not affect normal keratinocyte proliferation.
Cyclin Dependent Kinase 2 Inhibitors in Cancer Therapy: an Update.
Cyclin dependent kinase inhibitors.
Cyclin dependent kinases in cancer: Potential for therapeutic intervention.
Cyclin E dysregulation and chromosomal instability in endometrial cancer.
Cyclin E overexpression impairs progression through mitosis by inhibiting APC(Cdh1).
Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.
Cyclin E: a potential treatment target to reverse cancer chemoresistance by regulating the cell cycle.
Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions.
Cyclin Y regulates the proliferation, migration, and invasion of ovarian cancer cells via Wnt signaling pathway.
Cyclin-binding motifs are essential for the function of p21CIP1.
Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials.
Cyclin-dependent kinase (cdk6) and p16 in pancreatic endocrine neoplasms.
Cyclin-dependent kinase 1 disruption inhibits angiogenesis by inducing cell cycle arrest and apoptosis.
Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML.
Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.
Cyclin-Dependent Kinase 14 Promotes Cell Proliferation, Migration and Invasion in Ovarian Cancer by Inhibiting Wnt Signaling Pathway.
Cyclin-Dependent Kinase 2 Functions in Normal DNA Repair and Is a Therapeutic Target in BRCA1-Deficient Cancers.
Cyclin-Dependent Kinase 2 in Cellular Senescence and Cancer. A Structural and Functional Review.
Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.
Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma.
Cyclin-dependent kinase 2-associated protein 1 suppresses growth and tumorigenesis of lung cancer.
Cyclin-dependent kinase 2/cyclin E complex is involved in p120 catenin (p120ctn)-dependent cell growth control: a new role for p120ctn in cancer.
Cyclin-dependent kinase 4 (CDK4) expression in pancreatic endocrine tumors.
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines.
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines.
Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging.
Cyclin-dependent kinase 4/6 inhibition in cancer therapy.
Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 - 2019).
Cyclin-dependent kinase 4/6 inhibitors: what have we learnt across studies, therapy situations and substances.
Cyclin-Dependent Kinase 5 (CDK5)-Mediated Phosphorylation of Upstream Stimulatory Factor 2 (USF2) Contributes to Carcinogenesis.
Cyclin-dependent kinase 5 activates guanine nucleotide exchange factor GIV/Girdin to orchestrate migration-proliferation dichotomy.
Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA.
Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma.
Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells.
Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy.
Cyclin-dependent kinase 7 inhibitors in cancer therapy.
Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Atuveciclib Suppresses Intervertebral Disk Degeneration via the Inhibition of the NF-?B Signaling Pathway.
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.
Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer.
Cyclin-dependent kinase 9 expression and its association with CD8+ T cell infiltration in microsatellite-stable colorectal cancer.
Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells.
Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway.
Cyclin-Dependent Kinase Activity Correlates with the Prognosis of Patients Who Have Gastrointestinal Stromal Tumors.
Cyclin-Dependent Kinase and Antioxidant Gene Expression in Cancers with Poor Therapeutic Response.
Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1.
Cyclin-Dependent Kinase Inhibitor 2b Controls Fibrosis and Functional Changes in Ischemia-Induced Heart Failure via the BMI1-p15-Rb Signalling Pathway.
Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation.
Cyclin-dependent kinase inhibitor 3 (CDKN3) plays a critical role in prostate cancer via regulating cell cycle and DNA replication signaling.
Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation.
Cyclin-dependent kinase inhibitor 3 promotes cancer cell proliferation and tumorigenesis in nasopharyngeal carcinoma by targeting P27.
Cyclin-dependent kinase inhibitor expression in pulmonary Clara cells transformed with SV40 large T antigen in transgenic mice.
Cyclin-dependent kinase inhibitor p27 as a prognostic biomarker and potential cancer therapeutic target.
Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors.
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing's family tumor cells.
Cyclin-dependent kinase inhibitors (CDKIs) and the DNA damage response: The link between signaling pathways and cancer.
Cyclin-dependent kinase inhibitors and human cancer.
Cyclin-dependent kinase inhibitors as anticancer drugs.
Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.
Cyclin-dependent kinase inhibitors as potential targeted anticancer agents.
Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Cyclin-dependent kinase inhibitors for the treatment of lung cancer.
Cyclin-dependent kinase inhibitors for treating cancer.
Cyclin-Dependent Kinase Inhibitors in Cancer Therapeutics.
Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?
Cyclin-dependent kinase inhibitors in human neoplasms.
Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cyclin-dependent kinase inhibitors uncouple cell cycle progression from mitochondrial apoptotic functions in DNA-damaged cancer cells.
Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians.
Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors.
Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors. Mouriaux F,*(1) Maurage CA, Labalette P, Sablonniere B, Malecaze F, Darbon JM. Inv Ophthalmol Vis Sci 2000;41:2837-2843.
Cyclin-dependent kinase like 3 promotes triple-negative breast cancer progression via inhibiting the p53 signaling pathway.
Cyclin-Dependent Kinase Modulators and Cancer Therapy.
Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
Cyclin-Dependent Kinase Pathway Aberrations in Diverse Malignancies: Clinical and Molecular Characteristics.
Cyclin-dependent kinase pathways as targets for cancer treatment.
Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Cyclin-dependent kinase regulation of the replication functions of polyomavirus large T antigen.
Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.
Cyclin-dependent kinase site-regulated signal-dependent nuclear localization of the SW15 yeast transcription factor in mammalian cells.
Cyclin-dependent kinase subunit 2 overexpression promotes tumor progression and predicts poor prognosis in uterine leiomyosarcoma.
Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents.
Cyclin-dependent kinase-like function is shared by the beta- and gamma- subset of the conserved herpesvirus protein kinases.
Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.
Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors.
Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies.
Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers.
Cyclin-dependent kinases and P53 pathways are activated independently and mediate Bax activation in neurons after DNA damage.
Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage.
Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics.
Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
Cyclin-dependent kinases as targets for cancer therapy.
Cyclin-dependent kinases regulate the antiproliferative function of Smads.
Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target.
Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis.
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.
Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer.
Cyclooxygenase-2 overexpression inhibits platelet-derived growth factor-induced mesangial cell proliferation through induction of the tumor suppressor gene p53 and the cyclin-dependent kinase inhibitors p21waf-1/cip-1 and p27kip-1.
Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.
Cytoplasmic p21 is responsible for paclitaxel resistance in ovarian cancer A2780 cells.
Cytoplasmic p27Kip1 promotes tumorigenesis via suppression of RhoB activity.
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.
Cytotoxic Effect of Portulaca Oleracea Extract on the Regulation of CDK1 and P53 Gene Expression in Pancreatic Cancer Cell Line.
Cytotoxic Effects of Fascaplysin against Small Cell Lung Cancer Cell Lines.
Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFN?-dependent cell-cycle arrest.
Deciphering the retinoblastoma protein phosphorylation code.
Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.
Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report.
Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin.
Decreased expression and rare somatic mutation of the CIP1/WAF1 gene in human hepatocellular carcinoma.
Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma.
Decreased expression of the INK4 family of cyclin-dependent kinase inhibitors in Wilms tumor.
Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block.
Decreasing CNPY2 Expression Diminishes Colorectal Tumor Growth and Development through Activation of p53 Pathway.
Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.
Defective DNA double-strand break repair underlies enhanced tumorigenesis and chromosomal instability in p27-deficient mice with growth factor-induced oligodendrogliomas.
Deficiency of the Cyclin-Dependent Kinase Inhibitor, CDKN1B, Results in Overgrowth and Neurodevelopmental Delay.
Definition of smad3 phosphorylation events that affect malignant and metastatic behaviors in breast cancer cells.
Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer.
Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors.
Deletion mapping of a putative tumor suppressor gene on chromosome 4 in mouse lung tumors.
Deletion of 1p36 in childhood endodermal sinus tumors by two-color fluorescence in situ hybridization: a pediatric oncology group study.
Deletions of the p16 gene in pediatric leukemia and corresponding cell lines.
Delta-like 4/Notch signaling promotes Apc
Dephosphorylation of Rb (Thr-821) in response to cell stress.
Dephosphorylation of threonine-821 of the retinoblastoma tumor suppressor protein (Rb) is required for apoptosis induced by UV and Cdk inhibition.
Depletion of the cdk inhibitor p16INK4a differentially affects proliferation of established cervical carcinoma cells.
Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin.
Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein.
Deregulation of the cell cycle in cancer.
Deregulation of the G1/S-phase control in human testicular germ cell tumours.
Deregulation of the RB pathway in human testicular germ cell tumours.
Dermal fibroblasts induce cell cycle arrest and block epithelial-mesenchymal transition to inhibit the early stage melanoma development.
Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
Design and screening of FAK, CDK 4/6 dual inhibitors by pharmacophore model, molecular docking, and molecular dynamics simulation.
Design and Synthesis of New CDK2 Inhibitors Containing Thiazolone and Thiazolthione Scafold with Apoptotic Activity.
Design of Fluorescent Coumarin-Hydroxamic Acid Derivatives as Inhibitors of HDACs: Synthesis, Anti-Proliferative Evaluation and Docking Studies.
Design, Synthesis and Anticancer Activity of New Thiazole-Tetrazole or Triazole Hybrid Glycosides Targeting CDK-2 via Structure-Based Virtual Screening.
Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.
Design, Synthesis and Biological Evaluation of Novel Pyrimido[4,5-d]pyrimidine CDK2 Inhibitors as Anti-Tumor Agents.
Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors.
Design, synthesis, and primary activity assays of baicalein derivatives as cyclin-dependent kinase 1 inhibitors.
Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes.
Design, Synthesis, Molecular Modeling, Anticancer Studies, and Density Functional Theory Calculations of 4-(1,2,4-Triazol-3-ylsulfanylmethyl)-1,2,3-triazole Derivatives.
Design, synthesis, structure-activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones.
Designed Tetrapeptide Interacts with Tubulin and Microtubule.
Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features.
Detection of human papillomavirus type 16 in oropharyngeal squamous cell carcinoma using droplet digital polymerase chain reaction.
Detection of p16 gene alteration in cervical cancer using tissue microdissection and LOH study.
Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry.
Developing structure-activity relationships from an HTS hit for inhibition of the Cks1-Skp2 protein-protein interaction.
Development and validation of an LC-MS/MS method for the quantitative analysis of milciclib in human and mouse plasma, mouse tissue homogenates and tissue culture medium.
Development of a CDK10/CycM in vitro Kinase Screening Assay and Identification of First Small-Molecule Inhibitors.
Development of bioartificial renal tubule devices with lifespan-extended human renal proximal tubular epithelial cells.
Development of CDK2 and CDK5 Dual Degrader TMX-2172.
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.
Diagnostic approach using the expression profiling of the P53 tumor suppressor gene and its related proteins in ovarian epithelial tumors.
Dietary fat increases solid tumor growth and metastasis of 4T1 murine mammary carcinoma cells, and mortality in obesity-resistant BALB/c mice.
Dietary Mixed Cereal Grains Ameliorate the Azoxymethane and Dextran Sodium Sulfate-Induced Colonic Carcinogenesis in C57BL/6J Mice.
Dietary phenethyl isothiocyanate alters gene expression in human breast cancer cells.
Difference of cell cycle arrests induced by lidamycin in human breast cancer cells.
Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Differential activities of E2F family members: unique functions in regulating transcription.
Differential Akt signalling in non-seminomatous testicular germ cell tumors.
Differential cyclin-dependent kinase expression and activation in human colon cancer.
Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesis.
Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia.
Differential expression of forkhead box M1 and its downstream cyclin-dependent kinase inhibitors p27(kip1) and p21(waf1/cip1) in the diagnosis of pulmonary neuroendocrine tumours.
Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping.
Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
Differential gene expression of p27Kip1 and Rb knockout pituitary tumors associated with altered growth and angiogenesis.
Differential modulation of G1-S-phase cyclin-dependent kinase 2/cyclin complexes occurs during the acquisition of a polyploid DNA content.
Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.
Differential regulation of cyclin-dependent kinase inhibitors in neuroblastoma cells.
Differential regulation of p27kip1 levels and CDK activities by hypertrophic and hyperplastic agents in vascular smooth muscle cells.
Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo.
Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types.
Differentiation-associated expression and intracellular localization of cyclin-dependent kinase inhibitor p27KIP1 and c-Jun co-activator JAB1 in neuroblastoma.
Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21waf-1 in human cutaneous squamous cell carcinoma.
Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma.
Dinaciclib for the treatment of breast cancer.
Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin Dependent Kinases 1 and 2.
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.
Dinaciclib prolongs survival in the LSL-KrasG12D/+ ; LSL-Trp53R172H/+ ; Pdx-1-Cre (KPC) transgenic murine models of pancreatic ductal adenocarcinoma.
Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
Direct association of the HPV16 E7 oncoprotein with cyclin A/CDK2 and cyclin E/CDK2 complexes.
Direct current electrical fields induce apoptosis in oral mucosa cancer cells by NADPH oxidase-derived reactive oxygen species.
Direct evidence for the role of centrosomally localized p53 in the regulation of centrosome duplication.
Direct evidence from siRNA-directed "knock down" that p16(INK4a) is required for human fibroblast senescence and for limiting ras-induced epithelial cell proliferation.
Direct interaction of p21 cyclin-dependent kinase inhibitor with the retinoblastoma tumor suppressor protein.
Discordant hepatic expression of the cell division control enzyme p34cdc2 kinase, proliferating cell nuclear antigen, p53 tumor suppressor protein, and p21Waf1 cyclin-dependent kinase inhibitory protein after WY14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid) dosing to rats.
Discovery and characterization of a novel inhibitor of CDC25B, LGH00045.
Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors.
Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
Discovery and resistance mechanism of a selective CDK12 degrader.
Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation.
Discovery of N-(4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)quinazolin-7-amine as a Novel, Potent, and Oral Cyclin-Dependent Kinase Inhibitor against Haematological Malignancies.
Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer.
Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2.
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer.
Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Disrupting the PIKE-A/Akt interaction inhibits glioblastoma cell survival, migration, invasion and colony formation.
Disruption of G1-phase phospholipid turnover by inhibition of Ca2+-independent phospholipase A2 induces a p53-dependent cell-cycle arrest in G1 phase.
Dissecting the contribution of p16(INK4A) and the Rb family to the Ras transformed phenotype.
Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors.
Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies.
Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development.
Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors.
DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression.
DNA hypermethylation profiles in squamous cell carcinoma of the vulva.
DNA loop sequence as the determinant for chiral supramolecular compound G-quadruplex selectivity.
DNA Methylation and Uveal Melanoma.
DNA methylation markers and early recurrence in stage I lung cancer.
DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdi1).
DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications.
Doenjang hexane fraction-induced G1 arrest is associated with the inhibition of pRB phosphorylation and induction of Cdk inhibitor p21 in human breast carcinoma MCF-7 cells.
Does the PITSLRE gene complex contribute to the pathogenesis of malignant melanoma of the skin? A study of patient-derived tumor samples?
Double identity of SCAPER: A substrate and regulator of cyclin A/Cdk2.
Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species.
Down-regulation of p21Waf-1 protein facilitates IR- and UV-induced apoptosis in human squamous carcinoma cells.
Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases.
Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades.
Down-regulation of p27Kip1 expression is correlated with increased cell proliferation but not expression of p21waf1 and p53, and human papillomavirus infection in benign and malignant tumours of sinonasal regions.
Down-regulation of S-phase kinase associated protein 2 (Skp2) induces apoptosis in oral cancer cells.
Down-regulation of telomerase activity in malignant glioma cells by p27KIP1.
Downregulated CDK10 expression in gastric cancer: Association with tumor progression and poor prognosis.
Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
Downregulation of MSP58 inhibits growth of human colorectal cancer cells via regulation of the cyclin D1-cyclin-dependent kinase 4-p21 pathway.
Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories.
Downregulation of p57(kip2) promotes cell invasion via LIMK/cofilin pathway in human nasopharyngeal carcinoma cells.
Downregulation of PFTK1 Inhibits Migration and Invasion of Non-Small Cell Lung Cancer.
DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation.
Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Dual association by TFAP2A during activation of the p21cip/CDKN1A promoter.
Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.
Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
Dynamic Bcl-xL (S49) and (S62) Phosphorylation/Dephosphorylation during Mitosis Prevents Chromosome Instability and Aneuploidy in Normal Human Diploid Fibroblasts.
Dynamic expression of the vertebrate-specific protein Nucks during rodent embryonic development.
Dysregulation of CDK8 and Cyclin C in tumorigenesis.
Dysregulation of the Urothelial Cancer Associated 1 Long Noncoding RNA Promotes Proliferation of Vascular Smooth Muscle Cells by Modulating Expression of P27KIP1/CDK2.
E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis.
Early development of cyclin dependent kinase modulators.
Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
Ectopic expression of human Cdk2 and its yeast homolog, Ime2, is deleterious to Saccharomyces cerevisiae.
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells.
Effect of NUCKS-1 overexpression on cytokine profiling in obese women with breast cancer.
Effect of p27Kip1 on the ability of invasion and metastasis of an oral cancer cell line.
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer.
Effect of tumor suppressor gene cyclin-dependent kinase inhibitor 2A wild-type and A148T mutant on the cell cycle of human ovarian cancer cells.
Effect of tumor suppressors on cell cycle-regulatory genes: RB suppresses p34cdc2 expression and normal p53 suppresses cyclin A expression.
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Effects of ALA-PDT on HPV16-immortalized cervical epithelial cell.
Effects of Beclin 1 overexpression on aggressive phenotypes of colon cancer cells.
Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells.
Effects of exogenous p16INK4a on growth of cells with various status of cell-cycle regulators.
Effects of Ferroportin-Mediated Iron Depletion in Cells Representative of Different Histological Subtypes of Prostate Cancer.
Effects of ionizing radiation and caffeine treatment on cyclin dependent kinase complexes in V79 hamster cells.
Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication.
Effects of quercetin on CDK4 mRNA and protein expression in A549 cells infected by H1N1.
Effects of roniciclib in preclinical models of anaplastic thyroid cancer.
Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl-XL downregulation, and Cdc2 kinase activity.
Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
Electro-hyperthermia up-regulates tumour suppressor Septin 4 to induce apoptotic cell death in hepatocellular carcinoma.
Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas.
Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study.
Elevated expression of SAG/ROC2/Rbx2/Hrt2 in human colon carcinomas: SAG does not induce neoplastic transformation, but antisense SAG transfection inhibits tumor cell growth.
Elevated nuclear CDK6 is associated with an unfavorable prognosis in lung adenocarcinoma patients.
Ellagic Acid Controls Cell Proliferation and Induces Apoptosis in Breast Cancer Cells via Inhibition of Cyclin-Dependent Kinase 6.
Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers.
Embryo arrest and reactivation: potential candidates controlling embryonic diapause in the tammar wallaby and mink1.
Emerging Drug Profile: Cyclin-Dependent Kinase Inhibitors.
Endothelial cells from umbilical cord of women affected by gestational diabetes: A suitable in vitro model to study mechanisms of early vascular senescence in diabetes.
Endothelial p21(WAF1/CiP1) cell cycle inhibitor is down-regulated in breast cancer.
Endpoint of cancer treatment: targeted therapies.
Engineering an analog-sensitive CDK12 cell line using CRISPR/Cas.
Enhanced sensitivity to cis-diamminedichloroplatinum(II) of a human carcinoma cell line with mutated p53 gene by cyclin-dependent kinase inhibitor p21(WAF1) expression.
Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides.
Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.
Environment-gene interactions in intestinal cancer.
Enzyme-linked immunosorbent assay for p16(INK4a) - a new triage test for the detection of cervical intraepithelial neoplasia?
Epidermal growth factor and transforming growth factor-alpha-associated overexpression of cyclin D1, Cdk4, and c-Myc during hepatocarcinogenesis in Helicobacter hepaticus-infected A/JCr mice.
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.
Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours.
Epigallocatechin-3-gallate and trichostatin A synergistically inhibit human lymphoma cell proliferation through epigenetic modification of p16INK4a.
Epigenetic inactivation of T-box transcription factor 5, a novel tumor suppressor gene, is associated with colon cancer.
Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma.
Epigenetic regulation of miRNA-124 and multiple downstream targets is associated with treatment response in myeloid malignancies.
Epigenetic Targeting of TERT-Associated Gene Expression Signature in Human Neuroblastoma with TERT Overexpression.
Epigenetic targets in hematopoietic malignancies.
Epigenome-Wide Analysis of Methylation Changes in the Sequence of Gallstone Disease, Dysplasia, and Gallbladder Cancer.
ERpS294 is a biomarker of ligand or mutational ER? activation and a breast cancer target for CDK2 inhibition.
Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation.
Establishment of an immortal chicken embryo liver-derived cell line.
Estrogen regulated expression of the p21 Waf1/Cip1 gene in estrogen receptor positive human breast cancer cells.
Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours.
Evaluation of cyclin-dependent kinase-like 1 expression in breast cancer tissues and its regulation in cancer cell growth.
Evaluation of the cyclin-dependent kinase inhibitor p21Cip1 in epithelial ovarian tumors of low malignant potential and adenocarcinomas.
Evaluation of the two polymorphisms rs1801133 in MTHFR and rs10811661 in CDKN2A/B in breast cancer.
Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma.
Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors.
EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.
Exploiting structural principles to design cyclin-dependent kinase inhibitors.
Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach.
Expression and alternative splicing of the cyclin-dependent kinase inhibitor-3 gene in human cancer.
Expression and Prognostic Significance of CDK8 and ?-Catenin in Hepatocellular Carcinoma.
Expression and prognostic significance of cyclin-dependent kinase inhibitor 1A in patients with resected gastric adenocarcinoma.
Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma.
Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.
Expression of a novel form of p21Cip1/Waf1 in UV-irradiated and transformed cells.
Expression of apoptotic signaling proteins in leukoplakia and oral lichen planus: quantitative and topographical studies.
Expression of CDK13 Was Associated with Prognosis and Expression of HIF-1? and beclin1 in Breast Cancer Patients.
Expression of cell cycle inhibitor p27Kip1 and its inactivator Jab1 in melanocytic lesions.
Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.
Expression of CK7 and CDKN2 in Cervical Intraepithelial Neoplasia and Correlation with Clinical Outcome.
Expression of Concern: MicroRNA-505-5p functions as a tumor suppressor by targeting Cyclin-Dependent Kinase 5 in cervical cancer.
Expression of cyclin E and p27(KIP1) in cervical carcinoma.
Expression of cyclin kinase inhibitor p27(Kip1) in skin tumours of dogs.
Expression of cyclin-dependent kinase 2-associated protein 1 confers an independent prognosticator in nasopharyngeal carcinoma: a cohort study.
Expression of cyclin-dependent kinase 6, but not cyclin-dependent kinase 4, alters morphology of cultured mouse astrocytes.
Expression of cyclin-dependent kinase inhibitor 2A 16, tumour protein 53 and epidermal growth factor receptor in salivary gland carcinomas is not associated with oncogenic virus infection.
Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation.
Expression of cyclin-dependent kinase inhibitor p21(WAF1) and p53 tumour suppressor gene in laryngeal cancer.
Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity.
Expression of cyclin-dependent kinase inhibitor p27/Kip1 and AP-1 coactivator p38/Jab1 correlates with differentiation of embryonal rhabdomyosarcoma.
Expression of cyclins D1, D3 and p27 in thymic epithelial tumors.
Expression of p15INK?b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.
Expression of p16 and cyclin D1 in bladder cancer and correlation in cancer progression.
Expression of p16 protein in gallbladder carcinoma and its precancerous conditions.
Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma.
Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity.
Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
Expression of p18(INK4C) is Down-regulated in Human Pituitary Adenomas.
Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme.
Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression.
Expression of p27kip1 and p53 in medulloblastoma: relationship with cell proliferation and survival.
Expression of p27kip1 in breast cancer and its prognostic significance.
Expression of p27kip1 in prostatic adenocarcinoma.
Expression of p27Kip1, cyclin E and E2F-1 in primary and metastatic tumors of gastric carcinoma.
Expression of p34cdc2 protein kinase and p53 in supraglottic carcinomas.
Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy.
Expression of p53 and p21CIP1/WAF1 proteins in oral epithelial dysplasias and squamous cell carcinomas.
Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival.
Expression of p57-Kip2 in monocytes and macrophages.
Expression of proline-directed protein kinase, (p34cdc2/p58cyclin A), a novel cell proliferation marker in childhood brain tumors.
Expression of Rb, E2F1, cdc2, and D, and B cyclins in developing spinal cord.
Expression of the CDK inhibitor p27kip1 and oxidative DNA damage in non-neoplastic and neoplastic vulvar epithelial lesions.
Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: is it a good predictor for tumor behavior?
Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression.
Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate.
Expression of the HPV E7 oncoprotein mimics but does not evoke a p53-dependent cellular DNA damage response pathway.
Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer.
Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression.
Expression Pattern of Cdkn2b and Its Regulators in Canine Mammary Tumors.
Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors.
Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Expression profiles of a human pancreatic cancer cell line upon induction of apoptosis search for modulators in cancer therapy.
Expression, Purification, and Identification of Associated Proteins of the Full-length hCDK12/CyclinK Complex.
Expressions and clinical significance of factors related to giant cell tumor of bone.
Extensive analysis of the retinoblastoma gene in adult T cell leukemia/lymphoma (ATL).
Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib.
Extrapolating the effect of deleterious nsSNPs in the binding adaptability of flavopiridol with CDK7 protein: a molecular dynamics approach.
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Familial head and neck cancer: molecular analysis of a new clinical entity.
Fascaplysin Exerts Anti-Cancer Effects through the Downregulation of Survivin and HIF-1? and Inhibition of VEGFR2 and TRKA.
Fasting-mimicking diet and hormone therapy induce breast cancer regression.
FBXL16 is a novel E2F1-regulated gene commonly upregulated in p16INK4A- and p14ARF-silenced HeLa cells.
Feasibility of immunocytochemical detection of tumor markers (XIAP, phosphohistone H1 and p63) in FNA cellblock samples from head and neck squamous cell carcinoma.
Features of replicative senescence induced by direct addition of antennapedia-p16INK4A fusion protein to human diploid fibroblasts.
Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa B.
Fighting tubulin-targeting anticancer drug toxicity and resistance.
Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX-1 in apoE-/- mice.
Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy.
Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci.
Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo.
Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.
Flavopiridol inhibits lipopolysaccharide-induced TNF-? production through inactivation of nuclear factor-?B and mitogen-activated protein kinases in the MyD88-dependent pathway.
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication.
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.
Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids.
Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
Folate-functionalized human serum albumin carrier for anticancer copper(II) complexes derived from natural plumbagin.
Folic acid inhibits COLO-205 colon cancer cell proliferation through activating the FR?/c-SRC/ERK1/2/NF?B/TP53 pathway: in vitro and in vivo studies.
Fragment-Based De Novo Design of Cyclin-Dependent Kinase 2 Inhibitors.
Francisella tularensis Modulates a Distinct Subset of Regulatory Factors and Sustains Mitochondrial Integrity to Impair Human Neutrophil Apoptosis.
Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors.
Frequent Amplification of CENPF, GMNN and CDK13 Genes in Hepatocellular Carcinomas.
Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy.
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.
Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
Frequent genetic defects in the p16/INK4A tumor suppressor in canine cell models of breast cancer and melanoma.
Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer.
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27(Kip1) in estrogen-related Endometrial adenocarcinomas.
Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood.
Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas.
Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors.
Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer.
Frogs and estivation: transcriptional insights into metabolism and cell survival in a natural model of extended muscle disuse.
From simple to complex patterns of oscillatory behavior in a model for the mammalian cell cycle containing multiple oscillatory circuits.
Functional Ablation of pRb Activates Cdk2 and Causes Antiestrogen Resistance in Human Breast Cancer Cells.
Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway.
Functional characterization of a CDKN1B mutation in a Sardinian kindred with multiple endocrine neoplasia type 4 (MEN4).
Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype.
Functional characterization of human PFTK1 as a cyclin-dependent kinase.
Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity.
Functional conservation of the cell cycle-regulating transcription factor DRTF1/E2F and its pathway of control in Drosophila melanogaster.
Functional Genetic Single-Nucleotide Polymorphisms (SNPs) in Cyclin-Dependent Kinase Inhibitor 2A/B (CDKN2A/B) Locus Are Associated with Risk and Prognosis of Osteosarcoma in Chinese Populations.
Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
Functional inactivation of Rb sensitizes cancer cells to TSC2 inactivation induced cell death.
G0/G1 growth arrest mediated by a region encompassing the basic leucine zipper (bZIP) domain of the Epstein-Barr virus transactivator Zta.
G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation.
G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer.
Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11p110.
Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells.
Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity.
Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation.
Gene expression of cyclin-dependent kinase subunit Cks2 is repressed by the tumor suppressor p53 but not by the related proteins p63 or p73.
Gene expression profiling analysis of ovarian cancer.
Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays.
Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation.
Generation of knockout mouse models of cyclin-dependent kinase inhibitors by engineered nuclease-mediated genome editing.
Genesis, a Winged Helix transcriptional repressor, has embryonic expression limited to the neural crest, and stimulates proliferation in vitro in a neural development model.
Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
Genetic alterations of chromosome band 9p21-22 in head and neck cancer are not restricted to p16INK4a.
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer.
Genetic and epigenetic alterations in multistep carcinogenesis of the stomach.
Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion.
Genetic association between the cyclin-dependent kinase inhibitor gene p27/Kip1 polymorphism (rs34330) and cancer susceptibility: a meta-analysis.
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy.
Genetic dissection of cell growth arrest functions mediated by the Epstein-Barr virus lytic gene product, Zta.
Genetic variants of p21 and p27 and hepatocellular cancer risk in a Chinese Han population: a case-control study.
Genetic variants of p21 and p27 and pancreatic cancer risk in non-Hispanic Whites: a case-control study.
Genetics of parathyroid tumours.
Genome-wide cDNA microarray screening of genes related to survival in patients after curative resection of non-small cell lung cancer.
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report.
Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation.
Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites.
Genomic instability--an evolving hallmark of cancer.
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.
Genomic Profiling of Prostate Cancers from Men with African and European Ancestry.
Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer.
Genomic Sequencing of Cancer-related Genes in Sinonasal Squamous Cell Carcinoma and Coexisting Inverted Papilloma.
Germline and Somatic Mutations in Cyclin-Dependent Kinase Inhibitor Genes CDKN1A, CDKN2B, and CDKN2C in Sporadic Parathyroid Adenomas.
Global Trend in Research and Development of CDK4/6 Inhibitors for Clinical Cancer Therapy: A Bibliometric Analysis.
Green tea polyphenol epigallocatechin-3 gallate induces apoptosis of proliferating vascular smooth muscle cells via activation of p53.
Growth arrest of immortalized human keratinocytes and suppression of telomerase activity by p21WAF1 gene expression.
Growth induction of rat primary hepatocytes using antisense oligonucleotides.
Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines.
Growth inhibition of the pulmonary metastatic tumors by systemic delivery of the p27(kip1) gene using lyophilized lipid-polycation-DNA complexes.
Growth stimulation versus induction of cell quiescence by hydrogen peroxide in prostate tumor spheroids is encoded by the duration of the Ca(2+) response.
Guilu Erxian Glue () Inhibits Chemotherapy-Induced Bone Marrow Hematopoietic Stem Cell Senescence in Mice May via p16INK4a-Rb Signaling Pathway.
Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice.
Helicobacter pylori increases proteasome-mediated degradation of p27(kip1) in gastric epithelial cells.
Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
Hematopoiesis specific loss of Cdk2 and Cdk4 results in increased erythrocyte size and delayed platelet recovery following stress.
Heme controls the expression of cell cycle regulators and cell growth in HeLa cells.
Heparin regulates colon cancer cell growth through p38 mitogen-activated protein kinase signalling.
Hepatitis B Virus Pre-S2 Mutant Surface Antigen Induces Degradation of Cyclin-Dependent Kinase Inhibitor p27Kip1 through c-Jun Activation Domain-Binding Protein 1.
Hepatitis B virus X protein differentially regulates cell cycle progression in X-transforming versus nontransforming hepatocyte (AML12) cell lines.
Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions.
Heterogeneous EGFR, CDK4, MDM4, and PDGFRA Gene Expression Profiles in Primary GBM: No Association with Patient Survival.
High expression of Cks1 in human non-small cell lung carcinomas.
High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors.
High expression of PFTK1 in cancer cells predicts poor prognosis in colorectal cancer.
High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers.
High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas.
High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci.
High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers.
High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients.
High-throughput screening for inhibitors of the cks1-skp2 interaction.
High-throughput screening for the identification of small-molecule inhibitors of retinoblastoma protein phosphorylation in cells.
High-throughput sequencing-based analysis of gene expression of hepatitis B virus infection-associated human hepatocellular carcinoma.
Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.
Hinokitiol Exhibits Antitumor Properties through Induction of ROS-Mediated Apoptosis and p53-Driven Cell-Cycle Arrest in Endometrial Cancer Cell Lines (Ishikawa, HEC-1A, KLE).
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Histone acetylation-mediated regulation of genes in leukaemic cells.
Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts.
Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter.
Histone Deacetylase Inhibitors Reverse CpG Methylation by Regulating DNMT1 through ERK Signaling.
Hitting the target in MCL.
HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.
Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome.
Homozygous deletions and loss of expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors.
Hot spots for molecular genetic alterations in lung cancer.
How selective are clinical CDK4/6 inhibitors?
Huanglian, A chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells.
Human CDK12 and CDK13, multi-tasking CTD kinases for the new millennium.
Human cytomegalovirus (HCMV) IE1 plays role in resistance to apoptosis with etoposide in cancer cell line by Cdk2 accumulation.
Human cytomegalovirus-encoded viral cyclin-dependent kinase (v-CDK) UL97 phosphorylates and inactivates the retinoblastoma protein-related p107 and p130 proteins.
Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways.
Human papillomavirus and overexpression of P16INK4a in nonmelanoma skin cancer.
Human papillomavirus dysregulates the cellular apparatus controlling the methylation status of H3K27 in different human cancers to consistently alter gene expression regardless of tissue of origin.
Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents.
Human papillomavirus type 16 E7 oncoprotein associates with the centrosomal component gamma-tubulin.
Human tumor antigens recognized by T lymphocytes: implications for cancer therapy.
Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
HuR knockdown changes the oncogenic potential of oral cancer cells.
Hypermethylation of CpG islands in the promoter region of the p15INK4B gene in childhood acute leukaemia.
Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia.
Hypermethylation of the cell cycle inhibitor p15INK4b 3'-untranslated region interferes with its transcriptional regulation in primary lymphomas.
Hypermethylation of the p15INK4B gene in myelodysplastic syndromes.
Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas.
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B.
Hypoxia regulates human lung fibroblast proliferation via p53-dependent and -independent pathways.
Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice.
Identification and characterization of a novel phosphoregulatory site on cyclin-dependent kinase 5.
Identification and Functional Characterization of FMN2, a Regulator of the Cyclin-Dependent Kinase Inhibitor p21.
Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors.
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
Identification of dysregulated microRNAs in canine malignant melanoma.
Identification of dysregulated pathways associated with pancreatic cancer by survival analysis.
Identification of key candidate genes for colorectal cancer by bioinformatics analysis.
Identification of new biomarkers for clinical trials of Hsp90 inhibitors.
Identification of novel CDK2 inhibitors by a multistage virtual screening method based on SVM, pharmacophore and docking model.
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Identification of NUCKS1 as a putative oncogene and immunodiagnostic marker of hepatocellular carcinoma.
Identification of oncogenes collaborating with p27Kip1 loss by insertional mutagenesis and high-throughput insertion site analysis.
Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein.
Identification of PFTAIRE protein kinase 1, a novel cell division cycle-2 related gene, in the motile phenotype of hepatocellular carcinoma cells.
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Identification of Quinazolinone Analogs Targeting CDK5 Kinase Activity and Glioblastoma Cell Proliferation.
Identification of selective cyclin-dependent kinase 2 inhibitor from the library of pyrrolone-fused benzosuberene compounds: an in silico exploration.
Identification of YPL014W (Cip1) as a novel negative regulator of cyclin-dependent kinase in Saccharomyces cerevisiae.
IFNgamma induction of p21WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential.
IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours.
Imidazo[1,2-a]pyridines: promising drug candidate for antitumor therapy.
Immunohistochemical analysis of p18INK4C and p14ARF protein expression in 117 oligodendrogliomas: correlation with tumor grade and clinical outcome.
Immunohistochemical analysis of p53 and p21 in human primary glioblastomas in relation to proliferative potential and apoptosis.
Immunohistochemical analysis of the D-type cyclin-dependent kinases Cdk4 and Cdk6, using a series of monoclonal antibodies.
Immunohistochemical characterization of p57KIP2 expression in human esophageal squamous cell carcinoma.
Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma.
Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.
Immunohistochemical determination of the P15 protein expression in cutaneous squamous cell carcinoma.
Immunohistochemical evaluation of p27 (kip1) in pleomorphic adenomas and adenoid cystic carcinomas of the minor salivary glands.
Immunohistochemical Expression of p16 and p21 in Pituitary Tissue Adjacent to Pituitary Adenoma versus Pituitary Tissue Obtained at Autopsy: Is There a Difference?
Immunohistochemical investigation of F344/N rat islet cell tumors from national toxicology program studies.
Immunolocalization of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human breast carcinoma.
Immunomodulation by anticancer cell cycle inhibitors.
Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication.
Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.
Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents.
Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients with non-early stage gastric carcinoma.
Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents.
Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations.
Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma.
Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction.
Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.
In Search of Novel CDK8 Inhibitors by Virtual Screening.
In silico and in vitro investigation of anticancer effect of newly synthesized nonivamide-s-allyl cysteine ester.
In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug.
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
In vitro and in vivo antitumor effects of vitamin K5 on hepatocellular carcinoma.
In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer.
In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug.
In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin.
In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers.
In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer.
In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2.
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Inactivation of INK4a and ARF induces myocardial proliferation and improves cardiac repair following ischemia?reperfusion.
Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies.
Inactivation of p21WAF1/cip1 enhances intestinal tumor formation in Muc2-/- mice.
Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors.
Inactivation of TGF-? signaling and loss of PTEN cooperate to induce colon cancer in vivo.
Inactivation of the kinase domain of CDK10 prevents tumor growth in a preclinical model of colorectal cancer, and is accompanied by downregulation of Bcl-2.
Inadequate formalin fixation decreases reliability of p27 immunohistochemical staining: probing optimal fixation time using high-density tissue microarrays.
Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function.
Increased cyclin-dependent kinase 6 expression in bladder cancer.
Increased epithelial stem cell traits in advanced endometrial endometrioid carcinoma.
Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer.
Increased expression of cyclin D1, cyclin E and p21(Cip1) associated with decreased expression of p27(Kip1) in chemically induced rat mammary carcinogenesis.
Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis.
Increased Expression of NPM1 Suppresses p27Kip1 Function in Cancer Cells.
Increased expression of p34cdc2 and its kinase activity in human gastric and colonic carcinomas.
Increased G1 cyclin/cdk activity in cells overexpressing the candidate oncogene, MCT-1.
Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin-induced diabetes mellitus: role in the development of diabetic glomerular disease.
Increased proteasome activator 28 gamma (PA28?) levels are unspecific but correlate with disease activity in rheumatoid arthritis.
Independent prognostic role of p16 expression in lung cancer.
Indirubin 3'-Oxime Inhibits Migration, Invasion, and Metastasis InVivo in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT, and SAPK/JNK Pathways.
Indirubin-3'-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer.
Indole-3-carbinol as a chemopreventive and anti-cancer agent.
Induced expression of p16 and p21 proteins in UVB-irradiated human epidermis and cultured keratinocytes.
Induced G2/M arrest and apoptosis in human epidermoid carcinoma cell lines by semisynthetic drug Ukrain.
Inducible p27(Kip1) expression inhibits proliferation of K562 cells and protects against apoptosis induction by proteasome inhibitors.
Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells.
Induction of apoptosis by flavopiridol in human neuroblastoma cells is enhanced under hypoxia and associated with N-myc proto-oncogene down-regulation.
Induction of apoptosis in p16INK4A mutant cell lines by adenovirus-mediated overexpression of p16INK4A protein.
Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27(Kip1).
Induction of cyclin-dependent kinase inhibitor, p21WAF1, by treatment with 3,4-dihydro-6-[4-(3,4)-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinoline (vesnarinone) in a human salivary cancer cell line with mutant p53 gene.
Induction of G0/G1 phase arrest and apoptosis by CRISPR/Cas9-mediated knockout of CDK2 in A375 melanocytes.
Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner.
Induction of transcriptionally active Jun proteins regulates drug-induced senescence.
Infrequent alterations of the p16 (MTS-1) gene in human gastric cancer.
Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene.
Inhibin and p27 interact to regulate gonadal tumorigenesis.
Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.
Inhibiting CDK inhibitors: new lessons from DNA tumor viruses.
Inhibiting CDK6 Activity by Quercetin Is an Attractive Strategy for Cancer Therapy.
Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling.
Inhibition of Ca2+-independent phospholipase A2 decreases prostate cancer cell growth by p53-dependent and independent mechanisms.
Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.
Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer.
Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ER? expression in high-grade serous ovarian carcinoma.
Inhibition of CDK2/CyclinE1 by xanthones from the mangosteen (Garcinia mangostana): a structure-activity relationship study.
Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss.
Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models.
Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells.
Inhibition of cell growth by transforming growth factor beta 1 is associated with p53-independent induction of p21 in gastric carcinoma cells.
Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1.
Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells.
Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product.
Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.
Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
Inhibition of cyclin-dependent kinase activity and induction of apoptosis by preussin in human tumor cells.
Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas.
Inhibition of cyclin-dependent kinases - a review of the recent patent literature.
Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer.
Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
Inhibition of extracellular signal-regulated kinase potentiates the apoptotic and antimetastatic effects of cyclin-dependent kinase inhibitors on metastatic DU145 and PC3 prostate cancer cells.
Inhibition of F-Box protein p45(SKP2) expression and stabilization of cyclin-dependent kinase inhibitor p27(KIP1) in vitamin D analog-treated cancer cells.
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Inhibition of mitotic cyclin B and cdc2 kinase activity by selenomethionine in synchronized colon cancer cells.
Inhibition of NF-?B-mediated signaling by the CDK inhibitor CR8 overcomes pro-survival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
Inhibition of ornithine decarboxylase alters the roscovitine-induced mitochondrial-mediated apoptosis in MCF-7 breast cancer cells.
Inhibition of PI-3K restores nuclear p27(Kip1) expression in a mouse model of Kras-driven lung cancer.
Inhibition of polyamine oxidase prevented cyclin-dependent kinase inhibitor-induced apoptosis in HCT 116 colon carcinoma cells.
Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.
Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.
Inhibition of Smad antiproliferative function by CDK phosphorylation.
Inhibition of tumor cell growth by p21WAF1 adenoviral gene transfer in lung cancer.
Inhibition of UBE2N-dependent CDK6 protein degradation by miR-934 promotes human bladder cancer cell growth.
Inhibitor of growth 4 suppresses colorectal cancer growth and invasion by inducing G1 arrest, inhibiting tumor angiogenesis and reversing epithelial-mesenchymal transition.
Inhibitors of cyclin-dependent kinase and cancer.
Inhibitors of cyclin-dependent kinase modulators for cancer therapy.
Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action.
Inhibitors of SCF-Skp2/Cks1 E3ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
Inhibitory effect of glycolic acid on ultraviolet-induced skin tumorigenesis in SKH-1 hairless mice and its mechanism of action.
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis.
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.
Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes.
Insight into the mechanisms of action of estrogen receptor beta.
Insufficient effect of p27(KIP1) to inhibit cyclin D1 in human esophageal cancer in vitro.
Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
Integrated genomic analyses of ovarian carcinoma.
Integrating Old and New Paradigms of G1/S Control.
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
Interaction of Nkx3.1 and p27kip1 in prostate tumor initiation.
Interactions of the human papillomavirus E7 protein with cell cycle regulators.
Interferon Regulatory Factor 1 (IRF-1) induces p21(WAF1/CIP1) dependent cell cycle arrest and p21(WAF1/CIP1) independent modulation of survivin in cancer cells.
Interleukin-1alpha regulates G1 cell cycle progression and arrest in thyroid carcinoma cell lines NIM1 and NPA.
Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression.
Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells.
Interplay between p53 and Ink4c in spermatogenesis and fertility.
Interplay Between the p53 Tumor Suppressor Protein Family and Cdk5: Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases Using Selective Cdk Inhibitors.
Intratumoral Heterogeneity of Chromosome 9 Loss and CDKN2A (p16) Protein Expression in a Morphologically Challenging Spitzoid Melanoma.
Inverse correlation between expression levels of p27 and the ubiquitin ligase subunit Skp2 in early esophageal squamous cell carcinoma.
Investigating the Mechanism of Scutellariae barbata Herba in the Treatment of Colorectal Cancer by Network Pharmacology and Molecular Docking.
Investigation of the cytotoxic effect of flavopiridol in canine lymphoma cell lines.
Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Involvement of cyclin-dependent kinases in doxorubicin-induced apoptosis in human tumor cells.
Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors.
Involvement of PKR in the regulation of myogenesis.
Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia.
Iron and carcinogenesis: from Fenton reaction to target genes.
Ironing out the role of the cyclin-dependent kinase inhibitor, p21 in cancer: Novel iron chelating agents to target p21 expression and activity.
Isolation and characterization of adult mammary stem cells from breast cancer-adjacent tissues.
iTRAQ-based quantitative proteomic analysis provides insight for molecular mechanism of neuroticism.
JAB1-STAT3 activation loop is associated with recurrence following 5-fluorouracil-based adjuvant chemotherapy in human colorectal cancer.
Jinfukang induces cellular apoptosis through activation of Fas and DR4 in A549 cells.
JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells.
K252a induces cell cycle arrest and apoptosis by inhibiting Cdc2 and Cdc25c.
Karyopherin subunit-? 2 expression accelerates cell cycle progression by upregulating CCNB2 and CDK1 in hepatocellular carcinoma.
Karyotypically abnormal human ESCs are sensitive to HDAC inhibitors and show altered regulation of genes linked to cancers and neurological diseases.
Ketoconazole potentiates the antitumor effects of nocodazole: In vivo therapy for human tumor xenografts in nude mice.
KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner.
Killing cells by targeting mitosis.
Kinase-independent function of E-type cyclins in liver cancer.
KLF2 (kruppel like factor 2 [lung]) regulates osteoclastogenesis by modulating autophagy.
Knockdown of CDK2AP1 by RNA interference inhibits cell growth and tumorigenesis of human glioma.
Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis.
Knockdown of PFTAIRE Protein Kinase 1 (PFTK1) Inhibits Proliferation, Invasion, and EMT in Colon Cancer Cells.
Knockdown of PFTK1 Inhibits the Migration of Glioma Cells.
Knockdown of PFTK1 inhibits tumor cell proliferation, invasion and epithelial-to-mesenchymal transition in pancreatic cancer.
Korean Scutellaria baicalensis water extract inhibits cell cycle G1/S transition by suppressing cyclin D1 expression and matrix-metalloproteinase-2 activity in human lung cancer cells.
Kurarinone from Sophora Flavescens Roots Triggers ATF4 Activation and Cytostatic Effects Through PERK Phosphorylation.
Lack of imprinting of three human cyclin-dependent kinase inhibitor genes.
Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study.
Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
Lack of p19INK4d in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis.
Lactacystin, a specific inhibitor of the proteasome, induces apoptosis and activates caspase-3 in cultured cerebellar granule cells.
Lebein, a snake venom disintegrin, suppresses human colon cancer cells proliferation and tumor-induced angiogenesis through cell cycle arrest, apoptosis induction and inhibition of VEGF expression.
Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21(WAF1/CIP1).
Let-7a Functions as a Tumor Suppressor in Ewing's Sarcoma Cell Lines Partly by Targeting Cyclin-Dependent Kinase 6.
Leydig-cell tumour in children: variable clinical presentation, diagnostic features, follow-up and genetic analysis of four cases.
Lin-28 homologue A (LIN28A) promotes cell cycle progression via regulation of cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell division cycle 25 homolog A (CDC25A) expression in cancer.
LINE-1 Methylation Level and Patient Prognosis in a Database of 208 Hepatocellular Carcinomas.
Lipid-Based Liquid Crystalline Nanoparticles Facilitate Cytosolic Delivery of siRNA via Structural Transformation.
Lipophilic Grape Seed Proanthocyanidin Exert Anti-Proliferative and Pro-apoptotic Effects on PC3 Human Prostate Cancer Cells and Suppresses PC3 Xenograft Tumor Growth in Vivo.
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model.
LncRNA H19/miR-194/PFTK1 axis modulates the cell proliferation and migration of pancreatic cancer.
LncRNA KTN1-AS1 promotes the progression of non-small cell lung cancer via sponging of miR-130a-5p and activation of PDPK1.
LncRNA THUMPD3-AS1 enhances the proliferation and inflammatory response of chondrocytes in osteoarthritis.
Localization and expression of p27KIP1 in multistage colorectal carcinogenesis.
Localization of the CDKN4/p27Kip1 gene to human chromosome 12p12.3.
Long non-coding RNA H19 regulates viability and metastasis, and is upregulated in retinoblastoma.
Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
Long noncoding RNA gastric cancer-related lncRNA1 mediates gastric malignancy through miRNA-885-3p and cyclin-dependent kinase 4.
Long Noncoding RNA GATA3-AS1 Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma by Suppression of PTEN, CDKN1A, and TP53.
Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Loss of anchorage in checkpoint-deficient cells increases genomic instability and promotes oncogenic transformation.
Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis.
Loss of heterozygosity on the short arm of chromosome 9 without p16 gene mutation in gastric carcinomas.
Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer.
Loss of p16INK4a results in increased glucocorticoid receptor activity during fibrosarcoma development.
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.
Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers.
Loss of p27Kip1 expression is a strong independent prognostic factor of reduced survival in N0 gastric carcinomas.
Loss of p27Kip1 leads to expansion of CD4+ effector memory T cells and accelerates colitis-associated colon cancer in mice with a T cell lineage restricted deletion of Smad4.
Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.
Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.
Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack.
Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade.
Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion.
Low Dose Astaxanthin Treatments Trigger the Hormesis of Human Astroglioma Cells by Up-Regulating the Cyclin-Dependent Kinase and Down-Regulated the Tumor Suppressor Protein P53.
Low dose dinaciclib enhances doxorubicin-induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways.
Low Expression of CDK10 Correlates with Adverse Prognosis in Gastric Carcinoma.
Low expression of CDK12 in gastric cancer is correlated with advanced stage and poor outcome.
Low Expression of CyclinH and Cyclin-Dependent Kinase 7 Can Decrease the Proliferation of Human Esophageal Squamous Cell Carcinoma.
Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia.
Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas.
Low expression of p27(Kip1), a cyclin-dependent kinase inhibitor, is a marker of poor prognosis in synovial sarcoma.
Low incidence of genetic alterations of the p16CDKN2a in clear cell chondrosarcoma.
Low levels of p27 in association with deregulated p53-pRb protein status enhance tumor proliferation and chromosomal instability in non-small cell lung carcinomas.
Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer.
Low-grade central osteosarcoma of the metatarsal bone: a clinicopathological, immunohistochemical, cytogenetic and molecular cytogenetic analysis.
Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway.
MAGT1 is required for HeLa cell proliferation through regulating p21 expression, S-phase progress, and ERK/p38 MAPK MYC axis.
Malignant transformation of biliary adenofibroma: a rare biliary cystic tumor.
Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer.
Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor.
MAPKAPK2 plays a crucial role in the progression of head and neck squamous cell carcinoma by regulating transcript stability.
Mapping the Synthetic Dosage Lethality Network of CDK1/CDC28.
Marine guanidine alkaloids crambescidins inhibit tumor growth and activate intrinsic apoptotic signaling inducing tumor regression in a colorectal carcinoma zebrafish xenograft model.
Markers for Sebaceoma Show a Spectrum of Cell Cycle Regulators, Tumor Suppressor Genes, and Oncogenes.
Markers of potential malignancy in chronic hyperplastic candidiasis.
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review.
Mechanisms of TGF-beta-induced cell cycle arrest.
Mechanisms of transforming growth factor-beta 1-induced cell cycle arrest.
Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association.
Melanomas, from the cell cycle point of view (Review).
MEN-4 and other multiple endocrine neoplasias due to cyclin-dependent kinase inhibitors (p27(Kip1) and p18(INK4C)) mutations.
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors.
Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c.
Meta-analysis of the relationship between p21 Ser31Arg polymorphism and lung cancer susceptibility.
Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.
Methylation analysis of cell cycle control genes in adult T-cell leukemia/lymphoma.
Methylation analysis of cyclin-dependent kinase inhibitor genes in primary gastrointestinal lymphomas.
Methylation of cyclin-dependent kinase inhibitors, XAF1, JUNB, CDH13 and soluble Wnt inhibitors in essential thrombocythaemia.
Methylation of KvDMR1 involved in regulating the imprinting of CDKN1C gene in cattle.
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Methylation status of p16 (INK4A) tumor suppressor gene in Iranian patients with sporadic breast cancer.
Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity.
Mg2+/Mn2+-dependent phosphatase 1A is involved in regulating pregnane X receptor-mediated cytochrome p450 3A4 gene expression.
Mice lacking a CDK inhibitor, p57Kip2, exhibit skeletal abnormalities and growth retardation.
Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control.
Microdissection-based allelotyping: a novel technique to determine the temporal sequence and biological aggressiveness of colorectal cancer.
Microglia-derived IL-1? triggers p53-mediated cell cycle arrest and apoptosis in neural precursor cells.
MicroRNA miR-24 promotes cell proliferation by targeting the CDKs inhibitors p27Kip1 and p16INK4a.
MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.
MicroRNA-106b Regulates Expression of the Tumour Suppressors p21 and TXNIP and Promotes Tumour Cell Proliferation in Mycosis Fungoides.
MicroRNA-1258 Inhibits the Proliferation and Migration of Human Colorectal Cancer Cells through Suppressing CKS1B Expression.
MicroRNA-137 inhibits tumor growth and sensitizes chemosensitivity to paclitaxel and cisplatin in lung cancer.
MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, CDK6.
microRNA-200b and microRNA-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs.
MicroRNA-21 inhibits p57Kip2 expression in prostate cancer.
MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
MicroRNA-372 inhibits endometrial carcinoma development by targeting the expression of the Ras homolog gene family member C (RhoC).
microRNA-377 suppresses the proliferation of human osteosarcoma MG-63 cells by targeting CDK6.
MicroRNA-505-5p functions as a tumor suppressor by targeting cyclin-dependent kinase 5 in cervical cancer.
MicroRNA-7 inhibits proliferation, migration and invasion of thyroid papillary cancer cells via targeting CKS2.
microRNA-769 is downregulated in colorectal cancer and inhibits cancer progression by directly targeting cyclin-dependent kinase 1.
MicroRNA-96 expression induced by low-dose cisplatin or doxorubicin regulates chemosensitivity, cell death and proliferation in gastric cancer SGC7901 cells by targeting FOXO1.
MicroRNAs 221 and 222 target p27Kip1 in Marek's disease virus-transformed tumour cell line MSB-1.
microRNAs in the pathogenesis of non-obstructive azoospermia: the underlying mechanisms and therapeutic potentials.
MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability.
Milk Oligosaccharides From Different Cattle Breeds Influence Growth-Related Characteristics of Intestinal Cells.
miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells.
miR-125a-3p inhibits ER? transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer.
MiR-142-3p targeting NUCKS1 inhibits proliferation and invasion of pancreatic cancer cells.
miR-152-3p Modulates hepatic carcinogenesis by targeting cyclin-dependent kinase 8.
miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9.
miR-221 overexpression contributes to liver tumorigenesis.
miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer.
miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2.
MiR-31-5p acts as a tumor suppressor in renal cell carcinoma by targeting cyclin-dependent kinase 1 (CDK1).
Mirk regulates the exit of colon cancer cells from quiescence.
miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression.
Mitochondrial control by DRP1 in brain tumor initiating cells.
Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence.
Mitoinhibitory effects of the tumor promoter 2-acetylaminofluorene in rat liver: loss of E2F-1 and E2F-3 expression and cdk 2 kinase activity in late G1.
Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress.
Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions.
Mitotic slippage: an old tale with a new twist.
Modification of p27 with O-linked N-acetylglucosamine regulates cell proliferation in hepatocellular carcinoma.
Modified p27 Kip1 is efficient in suppressing HER2-mediated tumorigenicity.
Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.
Modulating cell cycle: current applications and prospects for future drug development.
Modulation of drug resistance by artificial transcription factors.
Modulation of glucocorticoid receptor transcriptional activation, phosphorylation, and growth inhibition by p27Kip1.
Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors.
Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis.
Modulation of p53 in 7,12-dimethylbenz[a]anthracene-induced skin tumors by diallyl sulfide in Swiss albino mice.
Modulatory Effect of Indoles on the Expression of miRNAs Regulating G1/S Cell Cycle Phase in Breast Cancer Cells.
Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors.
Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias.
Molecular analysis of H2O2-induced senescent-like growth arrest in normal human fibroblasts: p53 and Rb control G1 arrest but not cell replication.
Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies.
Molecular analysis of the cyclin-dependent kinase inhibitor genes p15INK4b/MTS2, p16INK4/MTS1, p18 and p19 in human cancer cell lines.
Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15, p16, p18 and p19 in the myelodysplastic syndromes.
Molecular biology of laryngeal squamous cell carcinoma.
Molecular characterization of the cyclin-dependent protein kinase 6 in whitefish (Coregonus lavaretus) and its potential interplay with miR-34a.
Molecular concept in human oral cancer.
Molecular Determinants for the Inactivation of the Retinoblastoma Tumor Suppressor by the Viral Cyclin-dependent Kinase UL97.
Molecular genetic advances in pituitary tumor development.
Molecular markers in dysplasia of the larynx: expression of cyclin-dependent kinase inhibitors p21, p27 and p53 tumour suppressor gene in predicting cancer risk.
Molecular mechanisms of anti-tumor properties of P276-00 in head and neck squamous cell carcinoma.
Molecular mechanisms of cellular transformation by HTLV-1 Tax.
Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
Molecular pathogenesis of malignant mesothelioma.
Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network.
Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
Molecular systems biology of Sic1 in yeast cell cycle regulation through multiscale modeling.
Monoclonal antibody specific for histone H1 phosphorylated by cyclin-dependent kinases: a novel immunohistochemical probe of proliferation and neoplasia.
Mouse mammary hyperplasias and neoplasias exhibit different patterns of cyclins D1 and D2 binding to cdk4.
MPT0B169, a New Tubulin Inhibitor, Inhibits Cell Growth and Induces G2/M Arrest in Nonresistant and Paclitaxel-Resistant Cancer Cells.
MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Multifaceted p21 in carcinogenesis, stemness of tumor and tumor therapy.
Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells.
Multiple Endocrine Neoplasia Type 1 (MEN1) Phenocopy Due to a Cell Cycle Division 73 (CDC73) Variant.
Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells.
Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.
Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region.
Multiple neurofibromas as the presenting feature of familial atypical multiple malignant melanoma (FAMMM) syndrome.
Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy.
Murine coronavirus nonstructural protein p28 arrests cell cycle in G0/G1 phase.
Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.
Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells.
Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors.
Mutation of the HEXIM1 gene results in defects during heart and vascular development partly through downregulation of vascular endothelial growth factor.
Mutational alterations of the p16CDKN2A tumor suppressor gene have low incidence in mesenchymal chondrosarcoma.
Mutational analysis of CDKN1B, a candidate tumor-suppressor gene, in refractory secondary/tertiary hyperparathyroidism.
Mutational analysis of p27 (CDKN1B) and p18 (CDKN2C) in sporadic pancreatic endocrine tumors argues against tumor-suppressor function.
Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors.
Mutational analysis of the P16-binding domain of cyclin-dependent kinase 4 in tumors in the head region of the pancreas.
Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men.
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3.
Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis.
MYC up-regulation confers resistance to everolimus and establishes vulnerability to cyclin dependent kinase inhibitors in pancreatic neuroendocrine neoplasms cells.
Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.
Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
Nanobiosensor Reports on CDK1 Kinase Activity in Tumor Xenografts in Mice.
Natural product (-)-gossypol inhibits colon cancer cell growth by targeting RNA-binding protein Musashi-1.
NDR family of AGC kinases--essential regulators of the cell cycle and morphogenesis.
Negative regulators of cyclin-dependent kinases and their roles in cancers.
Neisseria gonorrhoeae infection causes DNA damage and affects the expression of p21, p27 and p53 in non-tumor epithelial cells.
Network Pharmacological Analysis through a Bioinformatics Approach of Novel NSC765600 and NSC765691 Compounds as Potential Inhibitors of CCND1/CDK4/PLK1/CD44 in Cancer Types.
New agents in chronic lymphocytic leukemia.
New concepts regarding focal adhesion kinase promotion of cell migration and proliferation.
New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy.
New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer.
New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?
Next-generation sequencing adds value to the preoperative diagnosis of pancreatic cysts.
Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.
Nicotinic receptor-induced apoptotic cell death of hippocampal progenitor cells.
Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway.
Nitrative and oxidative DNA damage in cervical intraepithelial neoplasia associated with human papilloma virus infection.
Nitric Oxide Donor DETA/NO Inhibits the Growth of Endometrial Cancer Cells by Upregulating the Expression of RASSF1 and CDKN1A.
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.
Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells.
No driver behind the wheel? Targeting transcription in cancer.
No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.
Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells.
Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells.
Novel Cdk inhibitors restore TGF-beta sensitivity in cdk4 overexpressing epithelial cells.
Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.
Novel Chemically Defined Approach To Produce Multipotent Cells from Terminally Differentiated Tissue Syncytia.
Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Novel expression of cyclin-dependent kinase inhibitors in human B-cell precursors.
Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling.
Novel p53/p130 axis in bladder tumors.
Novel potent pharmacological cyclin-dependent kinase inhibitors.
Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
Novel therapeutic targets for multiple myeloma.
Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.
NUCKS nuclear elevated expression indicates progression and prognosis of ovarian cancer.
NUCKS1 Acts as a Promising Novel Biomarker for the Prognosis of Patients with Hepatocellular Carcinoma.
NUCKS1 overexpression is a novel biomarker for recurrence-free survival in cervical squamous cell carcinoma.
NUCKS1 promotes gastric cancer cell aggressiveness by upregulating IGF-1R and subsequently activating the PI3K/Akt/mTOR signaling pathway.
Nucleocytoplasmic shuttling of the retinoblastoma tumor suppressor protein via Cdk phosphorylation-dependent nuclear export.
Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity.
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials.
Oleic Acid and Insulin as Key Characteristics of T2D Promote Colorectal Cancer Deterioration in Xenograft Mice Revealed by Functional Metabolomics.
Oligosaccharides from human milk induce growth arrest via G2/M by influencing growth-related cell cycle genes in intestinal epithelial cells.
Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone.
Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1).
Oncogene-induced DNA damage: cyclic AMP steps into the ring.
Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer.
Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis.
Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III.
One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element.
Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
Optimization of luminescent assay for screening of cyclin-dependent kinase 2 inhibitors.
Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice.
Organometallic 3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines as potential anticancer agents.
Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy.
Orphan nuclear receptor TLX recruits histone deacetylases to repress transcription and regulate neural stem cell proliferation.
Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine.
Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.
Over-expression of CDKIs p15INK4b, p16INK4a and p21CIP1/WAF1 genes mediate growth arrest in human osteosarcoma cell lines.
Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27.
Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors.
Overcoming Hypoxia-Induced Apoptotic Resistance through Combinatorial Inhibition of GSK-3{beta} and CDK1.
Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a meta-analysis and systemic review of randomized clinical trials.
Overexpression of a fish CDKN2 gene in a hereditary melanoma model.
Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells.
Overexpression of CDC25B overrides radiation-induced G2-M arrest and results in increased apoptosis in esophageal cancer cells.
Overexpression of CDC28 protein kinase regulatory subunit 1B confers an independent prognostic factor in nasopharyngeal carcinoma.
Overexpression of cdk4/cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma.
Overexpression of endoplasmic reticulum protein 29 regulates mesenchymal-epithelial transition and suppresses xenograft tumor growth of invasive breast cancer cells.
Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability.
Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features.
Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma.
Overexpression of p27 protein in human breast cancer correlates with in vitro resistance to doxorubicin and mitomycin C.
Overexpression of p27kip1 in urinary bladder urothelial carcinoma.
Overexpression of p34cdc2 protein kinase in epithelial ovarian carcinoma.
Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma.
Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients.
Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer.
Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present.
Oxidized low density lipoprotein induces the cyclin-dependent kinase inhibitor p21(waf1) and the tumor suppressor Rb.
p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck.
p15(INK4b) in HDAC inhibitor-induced growth arrest.
p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis.
p16 Controls p53 Protein Expression Through miR-dependent Destabilization of MDM2.
p16 expression in relation to human papillomavirus in anogenital lesions.
p16 inhibits matrix metalloproteinase-2 expression via suppression of Sp1-mediated gene transcription.
p16 promotes proliferation in cervical carcinoma cells through CDK6-HuR-IL1A axis.
P16 promotes the growth and mobility potential of breast cancer both in vitro and in vivo: the key role of the activation of IL-6/JAK2/STAT3 signaling.
p16 proteins from melanoma-prone families are deficient in binding to Cdk4.
p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes.
p16(INK4a) -mediated suppression of telomerase in normal and malignant human breast cells.
p16(INK4a) immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities : A systematic review and meta-analysis.
p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways.
p16INK4 gene mutations are relatively frequent in ampullary carcinomas.
p16INK4a expression and clinicopathologic parameters in renal cell carcinoma.
p16INK4A participates in a G1 arrest checkpoint in response to DNA damage.
P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control.
p185(HER-2/neu) and p21(CIP1/WAF1) expression in primary tumors and lymph node metastases in non-small cell lung cancer.
p18Ink4c collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers.
p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors.
p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma.
p21 and p27 immunoexpression in gastric well differentiated endocrine tumors (ECL-cell carcinoids).
P21 and p27 Immunoexpression in Upper Urinary Tract Urothelial Carcinomas.
P21 and p27: roles in carcinogenesis and drug resistance.
p21 induction plays a dual role in anti-cancer activity of ursolic acid.
p21 promotes sustained liver regeneration and hepatocarcinogenesis in chronic cholestatic liver injury.
p21 Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression.
p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1.
p21(WAF1/CIP1) and cancer: a shifting paradigm?
p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA.
p21(WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo.
p21: A Two-Faced Genome Guardian.
p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo.
p21CIP1 controls the squamous differentiation response to replication stress.
p21cip1/waf1 Coordinate Autophagy, Proliferation and Apoptosis in Response to Metabolic Stress.
p21WAF1 protein expression determined by quantitative immunoassay in relation to non-small-cell lung cancer aggressiveness.
p21WAF1 regulates anchorage-independent growth of HCT116 colon carcinoma cells via E-cadherin expression.
p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer.
P21Waf1/Cip1 dysfunction in neuroblastoma: a novel mechanism of attenuating G0-G1 cell cycle arrest.
p21WAF1/CIP1 mutants deficient in inhibiting cyclin-dependent kinases (CDKs) can promote assembly of active cyclin D/CDK4(6) complexes in human tumor cells.
p21WAF1/CIP1 protein expression in primary ovarian cancer.
p21WAF1/CIP1/SDI1 is elevated through a p53-independent pathway by mimosine.
p21Waf1/Cip1: its paradoxical effect in the regulation of breast cancer.
p27 as a Transcriptional Regulator: New Roles in Development and Cancer.
p27 inhibits CDK6/CCND1 complex formation resulting in cell cycle arrest and inhibition of cell proliferation.
p27 Kip1 expression is reduced in pancreatic carcinoma but has limited prognostic value.
p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis.
p27 Labeling index and proliferation in gastrointestinal stromal tumors: correlations with clinicopathologic factors and recurrence.
p27 modulates tropism of mesenchymal stem cells toward brain tumors.
p27 Protein and cancers of the gastrointestinal tract and liver: an overview.
p27 suppresses cyclooxygenase-2 expression by inhibiting p38? and p38?-mediated CREB phosphorylation upon arsenite exposure.
p27(kip1) and Other Cell-Cycle Protein Expression in Normal and Neoplastic Endocrine Tissues.
p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up.
p27(Kip1) loss does not predict survival in patients with advanced gastric carcinoma.
p27(kip1) protein expression correlates with survival in myxoid and round-cell liposarcoma.
p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase.
p27/Kip1 mutation found in breast cancer.
p27Kip1 and p21Cip1 collaborate in the regulation of transcription by recruiting cyclin-Cdk complexes on the promoters of target genes.
p27kip1 deficiency confers susceptibility to gastric carcinogenesis in Helicobacter pylori-infected mice.
p27kip1 deficiency impairs G2/M arrest in response to DNA damage, leading to an increase in genetic instability.
P27Kip1 expression and survival in NO gastric carcinoma.
p27kip1 expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma.
p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis.
p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis.
p27kip1 expression is inversely related to the grade of gastric MALT lymphoma.
p27kip1 expression limits H-Ras-driven transformation and tumorigenesis by both canonical and non-canonical mechanisms.
p27kip1 in intestinal tumorigenesis and chemoprevention in the mouse.
p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells.
p27Kip1 is inactivated in human colorectal cancer by cytoplasmic localization associated with activation of Akt/PKB.
p27Kip1 localizes to detergent-insoluble microdomains within lymphocyte membranes.
p27Kip1 Repression of ErbB2-Induced Mammary Tumor Growth in Transgenic Mice Involves Skp2 and Wnt/{beta}-Catenin Signaling.
p27Kip1  - p(RhoB)lematic in lung cancer.
p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers.
p27kip1: A New Multiple Endocrine Neoplasia Gene?
P300 plays a role in p16(INK4a) expression and cell cycle arrest.
p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and c-erbB-2 expression.
p34cdc2 kinase activity is maintained upon activation of the replication checkpoint in Schizosaccharomyces pombe.
p38? is essential for cell cycle progression and liver tumorigenesis.
P53 and p21 (Waf1/Cip1) mRNA expression associated with DNA damage and repair in acute immune complex alveolitis in mice.
p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.
p53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells.
p53 Is Preferentially Recruited to the Promoters of Growth Arrest Genes p21 and GADD45 during Replicative Senescence of Normal Human Fibroblasts.
P53 pathways involving G2 checkpoint regulators and the role of their subcellular localisation.
p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein.
p53, cyclin-dependent kinase and abnormal amplification of centrosomes.
p53, mdm-2, and p21 waf-1 in the porokeratoses.
p53-dependent induction of p21(Cip1/WAF1/Sdi1) protects against oxygen-induced toxicity.
p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma.
p53-independent expression of p21(CIP1/WAF1) in plasmacytic cells during G(2) cell cycle arrest induced by Actinobacillus actinomycetemcomitans cytolethal distending toxin.
p53-independent inhibition of proliferation and p21(WAF1/Cip1)-modulated induction of cell death by the antioxidants N-acetylcysteine and vitamin E.
p53-induced p21 controls DNA replication.
p53-mediated accumulation of hypophosphorylated pRb after the G1 restriction point fails to halt cell cycle progression.
p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21.
p53-mediated regulation of proliferating cell nuclear antigen expression in cells exposed to ionizing radiation.
p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells.
p57(KIP2) control of actin cytoskeleton dynamics is responsible for its mitochondrial pro-apoptotic effect.
p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19.
p57(Kip2) regulates the proper development of labyrinthine and spongiotrophoblasts.
p57: A multifunctional protein in cancer (Review).
p57K1P2 is expressed in Wilms' tumor with LOH of 11p15.5.
p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.
Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
Palbociclib has anti-tumor effects on Pten deficient endometrial neoplasias.
Palbociclib induces cell senescence and apoptosis of gastric cancer cells by inhibiting the Notch pathway.
Palbociclib: A breakthrough in breast carcinoma in women.
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.
Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors.
Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models.
Parathyroid tumor suppressor on 1p: analysis of the p18 cyclin-dependent kinase inhibitor gene as a candidate.
Patient-derived xenografts: a promising resource for preclinical cancer research.
PATZ1 (MAZR) Co-occupies Genomic Sites With p53 and Inhibits Liver Cancer Cell Proliferation via Regulating p27.
Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity.
PCTAIRE1 phosphorylates p27 and regulates mitosis in cancer cells.
PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis.
Pectenotoxin-2 induces G1 arrest of the cell cycle in synovial fibroblasts of patients with rheumatoid arthritis.
Pediatric adrenocortical neoplasms: immunohistochemical expression of p57 identifies loss of heterozygosity and abnormal imprinting of the 11p15.5.
PEP-1-p18 prevents neuronal cell death by inhibiting oxidative stress and Bax expression.
PEP8-TAT2, a membrane-permeable peptide, inhibits cyclin-Cdk2 activity in HeLa cells.
Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.
Performance of in silico tools for the evaluation of p16INK4a (CDKN2A) variants in CAGI.
Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors.
Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence.
Perspectives on cancer therapy: cell cycle blockers and perturbators.
PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion.
PFTK1 regulates cell proliferation, migration and invasion in epithelial ovarian cancer.
Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer.
Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells.
Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia.
Pharmacological inhibition of CDK7 by THZ1 impairs tumor growth in p53-mutated HNSCC.
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.
Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors.
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells.
Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer.
Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells.
Phosphorylated Platelet-Derived Growth Factor Receptor-Positive Cells With Anti-apoptotic Properties Accumulate in the Synovium of Patients With Rheumatoid Arthritis.
Phosphorylation of adenovirus E1A proteins by the p34cdc2 protein kinase.
Phosphorylation of human DNMT1: implication of cyclin-dependent kinases.
Phosphorylation of OGFOD1 by Cell Cycle-Dependent Kinase 7/9 Enhances the Transcriptional Activity of RNA Polymerase II in Breast Cancer Cells.
Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function.
Phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) by the cyclin-dependent kinase p34.
Phosphorylation: Implications in Cancer.
Physalin B inhibits cell proliferation and induces apoptosis in undifferentiated human gastric cancer HGC-27 cells.
Phytoestrogens and breast cancer: In vitro anticancer activities of isoflavones, lignans, coumestans, stilbenes and their analogs and derivatives.
Phytoestrogens and prevention of breast cancer: The contentious debate.
PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer.
Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.
PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.
Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs).
Plant cytokinin analogues with inhibitory activity on cyclin-dependent kinases exert their antiproliferative effect through induction of apoptosis initiated by the mitochondrial pathway: determination by a multiparametric flow cytometric analysis.
Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells.
Pleurotus ostreatus inhibits proliferation of human breast and colon cancer cells through p53-dependent as well as p53-independent pathway.
Polyamine depletion enhances the roscovitine-induced apoptosis through the activation of mitochondria in HCT116 colon carcinoma cells.
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
Polycomb protein Ezh2 regulates pancreatic beta-cell Ink4a/Arf expression and regeneration in diabetes mellitus.
Polyketides from the marine-derived fungus Aspergillus falconensis: In silico and in vitro cytotoxicity studies.
Polymorphisms of p21 cyclin-dependent kinase inhibitor and malignant skin tumors.
Positive tetracycline control of expression of p15INK4B from an Epstein-Barr autonomous plasmid in a human melanoma cell line.
Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol.
Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor.
Post-translational regulation of the tumor suppressor p27(KIP1).
Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer.
Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens.
Potential mechanisms underlying CDK5 related Osteosarcoma progression.
Potential of Cyclin-Dependent Kinase Inhibitors as Cancer Therapy.
Potential therapeutic effect of targeting glycogen synthase kinase 3? in esophageal squamous cell carcinoma.
Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics.
PP2A Counterbalances Phosphorylation of pRB and Mitotic Proteins by Multiple CDKs: Potential Implications for PP2A Disruption in Cancer.
PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a.
Preclinical and clinical development of cyclin-dependent kinase modulators.
Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.
Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Predicting the regrowth of clinically non-functioning pituitary adenoma with a statistical model.
Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells.
Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review.
Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis.
Preferential cytoplasmic localization of p34cdc2 in recurrent human squamous cell carcinoma after radiotherapy.
Preliminary findings of chromosomal alterations and expression of cell cycle genes in head an neck tumors.
Preparation and biological activity of 6-benzylaminopurine derivatives in plants and human cancer cells.
Preparation and evaluation of 99mTc-labeled HYNIC-palbociclib analogs for cyclin-dependent kinase 4/6-positive tumor imaging.
Presenilin 1 overexpressions in Chinese hamster ovary (CHO) cells decreases the phosphorylation of retinoblastoma protein: relevance for neurodegeneration.
PRMT4-mediated arginine methylation negatively regulates retinoblastoma tumor suppressor protein and promotes E2F-1 dissociation.
PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.
Pro-IL-16 regulation in activated murine CD4+ lymphocytes.
Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
Probing protein structure using biochemical and biophysical methods. Proteolysis, matrix-assisted laser desorption/ionization mass spectrometry, high-performance liquid chromatography and size-exclusion chromatography of p21Waf1/Cip1/Sdi1.
Progesterone is Primary Regulator of Cdk2ap1 Gene Expression and Tissue-specific Expression in the Uterus.
Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas.
Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor.
Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1.
Prognostic implications of p27 and cyclin E protein contents in malignant lymphomas.
Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.
Prognostic role of p27(Kip1) expression in oral squamous cell carcinoma in Taiwan.
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.
Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.
Prognostic significance of cyclin a expression in meningiomas.
Prognostic significance of p16INK4a alterations and 9p21 loss of heterozygosity in locally advanced laryngeal squamous cell carcinoma.
Prognostic significance of p21 and p53 expression in gastric cancer.
Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer.
Prognostic significance of p27 and Ki-67 expression in mucoepidermoid carcinoma of the intraoral minor salivary gland.
Prognostic significance of p27(kip-1) expression in colorectal adenocarcinomas is associated with tumor stage.
Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization.
Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.
Prognostic significance of p34cdc2 expression in tongue squamous cell carcinoma.
Prognostic value and functional consequences of cell cycle inhibitor p27Kip1 loss in medulloblastoma.
Prognostic value of p16 expression and alcohol consumption in Japanese patients with oropharyngeal squamous cell carcinoma.
Prognostic value of p27 expression in adenocarcinoma of the pancreatic head region.
Prognostic Value of p27 in Follicular Thyroid Carcinoma and its Relation to Radioactive Iodine Response: Does it Aid in the Modification of Risk Stratification?
Prognostic value of p27Kip1 expression in Basaloid Squamous Cell Carcinoma of the larynx.
Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1).
Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
Proliferative and androgenic effects of indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic concentrations.
Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Prolonged progestin treatment induces the promoter of CDK inhibitor p21 Cip1,Waf1 through activation of p53 in human breast and endometrial tumor cells.
Prolyl oligopeptidase inhibition-induced growth arrest of human gastric cancer cells.
Prolyl oligopeptidase participates in cell cycle progression in a human neuroblastoma cell line.
Promoter and histone methylation and p16(INK4A) gene expression in colon cancer.
Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas.
Promoter Hypermethylation of LATS1 Gene in Oral Squamous Cell Carcinoma (OSCC) among North Indian Population.
Promoter hypermethylation of p16 and APC in gastrointestinal cancer patients.
Promoter-associated endogenous and exogenous small RNAs suppress human bladder cancer cell metastasis by activating p21 (CIP1/WAF1) expression.
Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms.
Promyelocytic leukemia zinc finger-retinoic acid receptor ? (PLZF-RAR?), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes.
Prostate cancer and inositol hexaphosphate: efficacy and mechanisms.
Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells.
Proteasome: an emerging target for cancer therapy.
Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells.
Protective function of p27(KIP1) against apoptosis in small cell lung cancer cells in unfavorable microenvironments.
Protein deep sequencing applied to biobank samples from patients with pancreatic cancer.
Protein destruction: adapting roles for Cks proteins.
Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival.
Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
Protein Phosphatase 1H, Cyclin-Dependent Kinase Inhibitor p27, and Cyclin-Dependent Kinase 2 in Paclitaxel Resistance for Triple Negative Breast Cancers.
Protein phosphatase 2A-B55? enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.
Protein phosphatase 5 and the tumor suppressor P53 down-regulate each other's activities in mice.
Protein-protein interactions involved in the recognition of p27 by E3 ubiquitin ligase.
Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
PTEN/FOXO3/AKT pathway regulates cell death and mediates morphogenetic differentiation of Colorectal Cancer Cells under Simulated Microgravity.
PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells.
Pumilio directs deadenylation-associated translational repression of the cyclin-dependent kinase 1 activator RGC-32.
Purine analogs as CDK enzyme inhibitory agents: a survey and QSAR analysis.
Purvalanol A enhances cell killing by inhibiting up-regulation of CDC2 kinase activity in tumor cells irradiated with high doses of X rays.
Purvalanol A is a strong apoptotic inducer via activating polyamine catabolic pathway in MCF-7 estrogen receptor positive breast cancer cells.
Purvalanol induces endoplasmic reticulum stress-mediated apoptosis and autophagy in a time-dependent manner in HCT116 colon cancer cells.
Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine: Evaluation of a Novel Selective Inhibitor of Cyclin-Dependent Kinases with Antiproliferative Activity.
Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI.
Quantitative analysis of PD 0332991 in xenograft mouse tumor tissue by a 96-well supported liquid extraction format and liquid chromatography/mass spectrometry.
Quantitative Assessment the Relationship between p21 rs1059234 Polymorphism and Cancer Risk.
Quantitative Phosphoproteomic Analysis Reveals Key Mechanisms of Cellular Proliferation in Liver Cancer Cells.
Quercetin induces cell cycle G1 arrest through elevating Cdk inhibitors p21 and p27 in human hepatoma cell line (HepG2).
RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4/6 inhibitors.
RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Radiosensitizing Effect of Novel Phenylpyrimidine Derivatives on Human Lung Cancer Cells via Cell Cycle Perturbation.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Radiosynthesis and radiopharmacological evaluation of cyclin-dependent kinase 4 (Cdk4) inhibitors.
Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest.
Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes.
Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation.
Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.
Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.
RASSF1A Methylation is Predictive of Poor Prognosis in Female Breast Cancer in a Background of Overall Low Methylation Frequency.
Rb and p16INK4a expression in resected non-small cell lung tumors.
RB stabilizes XPC and promotes cellular NER.
RB2/p130 gene-enhanced expression down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in vivo.
Reactivation of lytic replication from B cells latently infected with Epstein-Barr virus occurs with high S-phase cyclin-dependent kinase activity while inhibiting cellular DNA replication.
Recent advances in CDK inhibitors for cancer therapy.
Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future.
Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
Recent advances in the molecular genetics of malignant melanoma.
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Recent patents on cell cycle regulatory proteins.
Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.
Recent researches for dual Aurora target inhibitors in antitumor field.
Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents.
Redox regulation of P-glycoprotein-mediated multidrug resistance in multicellular prostate tumor spheroids.
Reduced expression of cyclin-dependent kinase inhibitor p27(Kip1) in oral malignant tumors.
Reduced expression of p16 and p27 proteins in nasopharyngeal carcinoma.
Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer.
Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity.
Reduction of plasma angiopoietin-like 2 after cardiac surgery is related to tissue inflammation and senescence status of patients.
Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5.
Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin.
Regulation of CBP and Tip60 coordinates histone acetylation at local and global levels during Ras-induced transformation.
Regulation of CDKN2A/B and Retinoblastoma genes in Xiphophorus melanoma.
Regulation of cell proliferation by induction of p21/WAF1 in rat bladder carcinoma cells using the Cre--loxP system.
Regulation of cyclin-dependent kinase 5 and p53 by ERK1/2 pathway in the DNA damage-induced neuronal death.
Regulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1 by protein kinase Cdelta-mediated phosphorylation.
Regulation of p27 by ubiquitin ligases and its pathological significance in human lung carcinomas.
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
Regulation of protein transport to the nucleus: central role of phosphorylation.
Regulation of RB transcription in vivo by RB family members.
Regulation of stability of cyclin-dependent kinase CDK11p110 and a caspase-processed form, CDK11p46, by Hsp90.
Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor.
Regulation of the cdk inhibitor p27 and its deregulation in cancer.
Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer.
Regulation of V(D)J recombination activator protein RAG-2 by phosphorylation.
Regulatory mechanisms of fluvastatin and lovastatin for the p21 induction in human cervical cancer HeLa cells.
Relationship between intracellular localization of p34cdc2 protein and differentiation of esophageal squamous cell carcinoma.
Renal cell carcinoma: current status and future directions.
Replacement of the p16/CDKN2 gene suppresses human glioma cell growth.
Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation.
Reshaping tumor immune microenvironment through acidity-responsive nanoparticles featured with CRISPR/Cas9-mediated PD-L1 attenuation and chemotherapeutics-induced immunogenic cell death.
Responses of hela and chinese-hamster ovary p34(cdc2)/cyclin-B kinase in relation to cell-cycle perturbations induced by Etoposide.
Restoration of p16INK4A protein induces myogenic differentiation in RD rhabdomyosarcoma cells.
Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Resveratrol addiction: to die or not to die.
Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells.
Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21(WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2.
RET Regulates Human Medullary Thyroid Cancer Cell Proliferation through CDK5 and STAT3 Activation.
Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase.
Retinoblastoma protein expression and its predictors in triple-negative breast cancer.
Retinoblastoma protein function and p16INK4a expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16INK4a expression and infiltrative behavior.
Retinoblastoma protein in human renal cell carcinoma in relation to alterations in G1/S regulatory proteins.
Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase.
Retinoblastoma tumor-suppressor protein phosphorylation and inactivation depend on direct interaction with Pin1.
Retinoic acid negatively regulates p34cdc2 expression during human neuroblastoma differentiation.
Retraction notice to "Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines" [Biochem. Pharmacol. 73 (2007) 1024-1032].
Retraction notice to “Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines” [Biochem. Pharmacol. 73 (2007) 1024–1032].
Retraction: MicroRNA-505-5p functions as a tumor suppressor by targeting Cyclin-Dependent Kinase 5 in cervical cancer.
Retroperitoneal lipomatous angiomyolipoma associated with amyloid deposition masquerading as well-differentiated liposarcoma.
Retroperitoneal liposarcoma with colonic involvement: a case report.
Revealing the molecular mechanism of gastric cancer marker annexin a4 in cancer cell proliferation using exon arrays.
Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.
Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.
Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics.
Rho GTPases as key transducers of proliferative signals in g1 cell cycle regulation.
Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
Ribociclib: First Global Approval.
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
RLIM suppresses hepatocellular carcinogenesis by up-regulating p15 and p21.
RNA-Binding Protein FXR1 Regulates p21 and TERC RNA to Bypass p53-Mediated Cellular Senescence in OSCC.
RNAi-mediated downregulation of CDKL1 inhibits growth and colony-formation ability, promotes apoptosis of human melanoma cells.
Role and therapeutic potential of CDK12 in human cancers.
Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas.
Role of cell cycle regulators in tumor formation in transgenic mice expressing the human neurotropic virus, JCV, early protein.
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity.
Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development.
Role of human papillomavirus and tumor suppressor genes in oral cancer.
Role of p15(INK4B) Methylation in Patients With Myelodysplastic Syndromes: A Systematic Meta-Analysis.
Role of p21WAF1 in green tea polyphenol-induced growth arrest and apoptosis of oral carcinoma cells.
Role of the cyclin-dependent kinase inhibitors in the development of cancer.
Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL).
Role of tumor suppressor protein p16 in patients with oral lichen planus.
Roles of CDK/Cyclin complexes in transcription and pre-mRNA splicing: Cyclins L and CDK11 at the cross-roads of cell cycle and regulation of gene expression.
Roles of cyclin-dependent kinase 8 and ?-catenin in the oncogenesis and progression of gastric adenocarcinoma.
Roles of estrogen receptor and p21WAF1 in bortezomib-induced growth inhibition in human breast cancer cells.
Roles of the tumor suppressor p53 and the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in receptor-mediated apoptosis of WEHI 231 B lymphoma cells.
Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9.
Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.
Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study.
Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons.
Roscovitine-treated HeLa cells finalize autophagy later than apoptosis by downregulating Bcl?2.
RRS1 silencing suppresses colorectal cancer cell proliferation and tumorigenesis by inhibiting G2/M progression and angiogenesis.
RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD.
S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase.
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer.
Salivary High-Risk Human Papillomavirus (HPV) DNA as a Biomarker for HPV-Driven Head and Neck Cancers.
SCFFbl12 Increases p21Waf1/Cip1 Expression Level through Atypical Ubiquitin Chain Synthesis.
Screening for differentially expressed genes between left- and right-sided colon carcinoma by microarray analysis.
Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study.
Screening the active constituents of Chinese medicinal herbs as potent inhibitors of Cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2 kinase.
Searching for selective cyclin-dependent kinase inhibitors to target the retinoblastoma/p16 cancer gene pathway.
Selection of a Water-Soluble Salt Form of a Preclinical Candidate, IIIM-290: Multiwell-Plate Salt Screening and Characterization.
Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.
Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth.
Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.
Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5.
Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase.
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.
Seliciclib in malignancies.
Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.
Senescence and Telomere Homeostasis Might Be Involved in Placenta Percreta-Preliminary Investigation.
Senescence delay of human diploid fibroblast induced by anti-sense p16INK4a expression.
Senescence research from historical theory to future clinical application.
Senescence-like changes induced by hydroxyurea in human diploid fibroblasts.
Senescence: a new weapon for cancer therapy.
Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors.
Sensitization of Cancers Resistant to HER2 Antibodies.
Sequestration of E12/E47 and suppression of p27KIP1 play a role in Id2-induced proliferation and tumorigenesis.
Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1.
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth.
Short Term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor Positive Breast Cancers.
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans.
Siah2 control of T-regulatory cells limits anti-tumor immunity.
Signaling pathways and intracellular targets of sulforaphane mediating cell cycle arrest and apoptosis.
Signatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer.
Significance of immunohistochemical expression of p27 and involucrin as the marker of cellular differentiation of squamous cell carcinoma of the esophagus.
Significance of p57(Kip2) down-regulation in oncogenesis of bladder carcinoma: an immunohistochemical study.
Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines.
Silencing of circular RNA_0000326 inhibits cervical cancer cell proliferation, migration and invasion by boosting microRNA-338-3p-dependent down-regulation of CDK4.
Silencing of the polyamine catabolic key enzyme SSAT prevents CDK inhibitor-induced apoptosis in Caco-2 colon cancer cells.
Silencing P12CDK²AP¹ with a lentivirus promotes HaCaT cell proliferation.
Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling.
Simulation of Different Truncated p16 Forms and In Silico Study of Interaction with Cdk4.
Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis.
Simultaneous evaluation of p53 and p21 expression level for early cancer diagnosis using SERS technique.
Simultaneous Inactivation of the p16, p15 and p14 Genes Encoding Cyclin-Dependent Kinase Inhibitors in Canine T-Lymphoid Tumor Cells.
Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells.
Single chain antibodies as tools to study TGF-? regulated SMAD proteins in proximity ligation-based pharmacological screens.
Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy.
siRNA-mediated silencing of CDK8 inhibits proliferation and growth in breast cancer cells.
Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis.
Skp2 is an independent prognosticator of gallbladder carcinoma among p27(Kip1)-interacting cell cycle regulators: an immunohistochemical study of 62 cases by tissue microarray.
Skp2 is oncogenic and overexpressed in human cancers.
Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas.
Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163.
Smad3 phosphorylation by cyclin-dependent kinases.
Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.
Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.
Small molecule modulators of cyclin-dependent kinases for cancer therapy.
Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression.
Small-molecule targeting of brachyury transcription factor addiction in chordoma.
Snail associates with EGR-1 and SP-1 to upregulate transcriptional activation of p15INK4b.
SNP rs1059234 in CDKN1A Gene Correlates with Prognosis in Resected Gastric Adenocarcinoma.
SOCS1 blocks G1-S transition in hepatocellular carcinoma by reducing the stability of the CyclinD1/CDK4 complex in the nucleus.
Solid pseudopapillary neoplasms of the pancreas show an interruption of the Wnt-signaling pathway and express gene products of 11q.
Solution structure of p21(Waf1/Cip1/Sdi1) C-terminal domain bound to Cdk4.
Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tumors.
Somatic and germline mutations in the pathogenesis of pituitary adenomas.
Somatic Mutation and Germline Sequence Abnormalities in CDKN1B, Encoding p27Kip1, in Sporadic Parathyroid Adenomas.
Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts.
Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in The Biology of Cancer Progression.
Soy extract inhibits mammary adenocarcinoma growth in a syngeneic mouse model.
Sp1 phosphorylation by cyclin-dependent kinase 1/cyclin B1 represses its DNA-binding activity during mitosis in cancer cells.
Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein.
Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor.
Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer.
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance.
Split Cyclin-Dependent Kinase 4/6-Retinoblastoma 1 Axis in Pancreatic Cancer.
SRSF2 is required for sodium butyrate-mediated p21(WAF1) induction and premature senescence in human lung carcinoma cell lines.
Stabilization of Cyclin-Dependent Kinase 4 by Methionyl-tRNA Synthetase in p16INK4a-Negative Cancer.
Stabilization of the retinoblastoma protein by A-type nuclear lamins is required for INK4A-mediated cell cycle arrest.
Statin-induced depletion of geranylgeranyl pyrophosphate inhibits cell proliferation by a novel pathway of Skp2 degradation.
Staurosporine resistance accompanies DNA tumor virus-induced immortalization and is independent of the expression and activities of ERK1, ERK2, cyclin A, cyclin-dependent kinase (cdk) 2, and cdk4.
Stimulation of c-Jun/AP-1-Activity by the Cell Cycle Inhibitor p57Kip2.
Stress-Induced, p53-Mediated Tumor Growth Inhibition of Melanoma by Modulated Electrohyperthermia in Mouse Models without Major Immunogenic Effects.
Stressing the cell cycle in senescence and aging.
Structural and binding studies of cyclin-dependent kinase 2 with NU6140 inhibitor.
Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design.
Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a.
Structural basis of divergent cyclin-dependent kinase activation by Spy1/RINGO proteins.
Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors.
Structural characterization of As-MIF and hJAB1 during the inhibition of cell-cycle regulation.
Structural consequences of tumor-derived mutations in p16INK4a probed by limited proteolysis.
Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias.
Structural organization, mapping, characterization and evolutionary relationships of CDKN2 gene family members in Xiphophorus fishes.
Structural prediction of the interaction of the tumor suppressor p27
Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.
Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.
Structure-based design of cyclin-dependent kinase inhibitors.
Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition.
Studies on the in vitro phosphorylation of HSSB-p34 and -p107 by cyclin-dependent kinases. Cyclin-substrate interactions dictate the efficiency of phosphorylation.
Study on Medication Rules of Traditional Chinese Medicine against Antineoplastic Drug-Induced Cardiotoxicity Based on Network Pharmacology and Data Mining.
Sulfated Galactans from Red Seaweed Gracilaria fisheri Target EGFR and Inhibit Cholangiocarcinoma Cell Proliferation.
Superactive human leptin antagonist (SHLA), triple Lan1 and quadruple Lan2 leptin mutein as a promising treatment for human folliculoma.
Suppression of cancer cell growth by adenovirus expressing p21(WAF1/CIP1) deficient in PCNA interaction.
Suppression of CDK2 expression by siRNA induces cell cycle arrest and cell proliferation inhibition in human cancer cells.
Suppression of human tumor cell proliferation by Smurf2-induced senescence.
Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21.
Suppression of survival in human SKBR3 breast carcinoma in response to metal-chelator complexes is preferential for copper-dithiocarbamate.
Suppressor of cytokine signaling 1 blocks mitosis in human melanoma cells.
Survival kinase genes present prognostic significance in glioblastoma.
Survivin as a target for new anticancer interventions.
Sustained accumulation of the mitotic cyclins and tyrosine-phosphorylated p34cdc2 in human G1-S-arrested cancer cells but not untransformed cells.
SV40 large tumor antigen nuclear import is regulated by the double-stranded DNA-dependent protein kinase site (serine 120) flanking the nuclear localization sequence.
SV40 T antigen increases the expression and activities of p34cdc2, cyclin A, and cyclin B prior to immortalization of human diploid fibroblasts.
Switching from life to death: the Miz-ing link between Myc and p53.
SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
Synergistic antitumor effect of chemotherapy and antisense-mediated ablation of the cell cycle inhibitor p27KIP-1.
Synergistic effects of dexamethasone and genistein on the expression of Cdk inhibitor p21WAF1/CIP1 in human hepatocellular and colorectal carcinoma cells.
Synergistic effects of multiple treatments, and both DNA and RNA direct bindings on, green tea catechins.
Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A.
Synthesis and biological activities of C-2, N-9 substituted 6-benzylaminopurine derivatives as cyclin-dependent kinase inhibitor.
Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors.
Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.
Synthesis and Biological Evaluation of Novel 99mTc-Labeled Palbociclib Derivatives Targeting Cyclin-Dependent Kinase 4/6 (CDK4/6) as Potential Cancer Imaging Agents.
Synthesis and evaluation of 3-ylideneoxindole acetamides as potent anticancer agents.
Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine.
Synthesis and Evaluation of Novel Cholestanoheterocyclic Steroids as Anticancer Agents.
Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
Synthesis and structure activity relationships of a series of 4-amino-1H-pyrazoles as covalent inhibitors of CDK14.
Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.
Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole-Indole Conjugates as Anticancer CDK Inhibitors.
Synthesis, Docking Studies into CDK-2 and Anticancer Activity of New Derivatives Based Pyrimidine Scaffold and Their Derived Glycosides.
Synthesis, Resolution, and Biological Evaluation of Atropisomeric (aR)- and (aS)-16-Methyllamellarins N: Unique Effects of the Axial Chirality on the Selectivity of Protein Kinases Inhibition.
Synthesis, structure-activity relationship studies and biological evaluation of novel 2,5-disubstituted indole derivatives as anticancer agents.
Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines.
Synthetic lethal interaction of CDK inhibition and autophagy inhibition in human solid cancer cell lines.
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.
Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth.
Tailoring breast cancer therapies to reduce mortality and improve quality of life: San Antonio Breast Cancer Symposium 2017 (part 1).
Tailoring breast cancer therapies to reduce mortality and improve quality of life: San Antonio Breast Cancer Symposium 2017 (part 2).
Talin phosphorylation by Cdk5 regulates Smurf1-mediated talin head ubiquitylation and cell migration.
Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma.
Targeted overexpression of Tumor Necrosis Factor-? increases Cyclin-dependent kinase 5 activity and TRPV1-dependent Ca2+ influx in trigeminal neurons.
Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
Targeting Breast Cancer with CDK Inhibitors.
Targeting CDK12 for cancer therapy: function, mechanism, and drug discovery.
Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer.
Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer.
Targeting CDK9 for treatment of colorectal cancer.
Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells.
Targeting cell cycle by ?-carboline alkaloids in vitro: Novel therapeutic prospects for the treatment of cancer.
Targeting cell cycle kinases for cancer therapy.
Targeting cell cycle regulators in hematologic malignancies.
Targeting Conformational Activation of CDK2 Kinase.
Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma.
Targeting cyclin-dependent kinase 6 by vanillin inhibits proliferation of breast and lung cancer cells: Combined computational and biochemical studies.
Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers.
Targeting cyclin-dependent kinases in anti-neoplastic therapy.
Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.
Targeting Cyclins and Cyclin-Dependent Kinases in Cancer: Lessons from Mice, Hopes for Therapeutic Applications in Humans.
Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer.
Targeting low molecular weight cyclin E (LMW-E) in breast cancer.
Targeting malaria with specific CDK inhibitors.
Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition.
Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation.
Targeting p38? to inhibit human colorectal cancer cell progression.
Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.
Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma.
Targeting the cell cycle and the PI3K pathway: a possible universal strategy to reactivate innate tumor suppressor programmes in cancer cells.
Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
Targeting the cyclin-dependent kinase 5 in metastatic melanoma.
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.
Targeting the RB-E2F pathway in breast cancer.
Targeting the transcription cycle and RNA processing in cancer treatment.
Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.
TCTP is essential for ?-cell proliferation and mass expansion during development and ?-cell adaptation in response to insulin resistance.
Telomerase activity in relation to p53 status and clinico-pathological parameters in breast cancer.
Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer.
Testis-specific Arf promoter expression in a transposase-aided BAC transgenic mouse model.
Tetrahydroanthraquinone Derivative (±)-4-Deoxyaustrocortilutein Induces Cell Cycle Arrest and Apoptosis in Melanoma Cells via Upregulation of p21 and p53 and Downregulation of NF-kappaB.
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.
Th e role of CDK12 in tumor bio logy.
The administration schedule of cyclin-dependent kinase inhibitor gene therapy and etoposide chemotherapy is a major determinant of cytotoxicity.
The association between methylated CDKN2A and cervical carcinogenesis, and its diagnostic value in cervical cancer: a meta-analysis.
The atypical cell cycle regulator Spy1 suppresses differentiation of the neuroblastoma stem cell population.
The awakening of the CDK10/Cyclin M protein kinase.
The Biflavonoid Amentoflavone Induces Apoptosis via Suppressing E7 Expression, Cell Cycle Arrest at Sub-G(1) Phase, and Mitochondria-Emanated Intrinsic Pathways in Human Cervical Cancer Cells.
The broken cycle: E2F dysfunction in cancer.
The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells.
The cardiac cell cycle, pocket proteins, and p300.
The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report.
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K.
The CDK Inhibitor p18(Ink4c) is a Tumor Suppressor in Medulloblastoma.
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.
The Cdk inhibitor p57(Kip2) controls LIM-kinase 1 activity and regulates actin cytoskeleton dynamics.
The CDK inhibitors in cancer research and therapy.
The CDK inhibitors: potential targets for therapeutic stem cell manipulations?
The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.
The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival.
The cell cycle in breast cancer.
The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway.
The Cell Cycle Regulators P16INK4a, P15INK4b and Cyclin D1: Relationship to Clinicopathological Parameters and Disease-free Survival in Laryngeal Carcinoma Patients.
The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor.
The centrosomal protein Tax1 binding protein 2 is a novel tumor suppressor in hepatocellular carcinoma regulated by cyclin-dependent kinase 2.
The cinnamon-derived Michael acceptor cinnamic aldehyde impairs melanoma cell proliferation, invasiveness, and tumor growth.
The clinicopathological and prognostic significance of P27kip in hepatocellular carcinoma patients: A systemic review and meta-analysis.
The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients.
The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53.
The CtBP1-p300-FOXO3a transcriptional complex represses the expression of the apoptotic regulators Bax and Bim in human osteosarcoma cells.
The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
The cyclin-dependent kinase inhibitor p21 protects the lung from oxidative stress.
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast cancers.
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
The cyclin-dependent kinase inhibitor, p21WAF1, promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells.
The cyclin-dependent kinase inhibitors p15INK4B and p21CIP1 are critical regulators of fibrillar collagen-induced tumor cell cycle arrest.
The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway.
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
The E7 protein from human papillomavirus type 16 enhances keratinocyte migration in an Akt-dependent manner.
The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review.
The effect of circadian rhythm on pharmacokinetics and metabolism of the Cdk inhibitor, roscovitine, in tumor mice model.
The effect of resveratrol supplementation on the expression levels of factors associated with cellular senescence and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: study protocol for a double-blind controlled randomised clinical trial.
The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.
The Emerging Picture of CDK11: Genetic, Functional and Medicinal Aspects.
The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.
The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer.
The emerging roles of CDK12 in tumorigenesis.
The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors.
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.
The evolving role of cyclin-dependent kinase inhibitors in cancer management.
The Expression and Prognostic Significance of Cks1 in Salivary Cancer.
The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer.
The Expression of FHIT in Salivary Carcinoma Ex Pleomorphic Adenoma.
The expression of Ki-67, MCM3, and p27 defines distinct subsets of proliferating, resting, and differentiated cells.
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma.
The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells.
The Flavonoid Metabolite 2,4,6-Trihydroxybenzoic Acid Is a CDK Inhibitor and an Anti-Proliferative Agent: A Potential Role in Cancer Prevention.
The formation of tight tumor clusters affects the efficacy of cell cycle inhibitors: A hybrid model study.
The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck.
The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing.
The genomic repertoire for cell cycle control and DNA metabolism in S. purpuratus.
The gut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter.
The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.
The hallmarks of CDKN1C (p57, KIP2) in cancer.
The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2.
The human multidrug resistance-associated protein (MRP) gene family: from biological function to drug molecular design.
The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.
The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.
The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
The impacts of single nucleotide polymorphisms in genes of cell cycle and NF-kB pathways on the efficacy and acute toxicities of radiotherapy in patients with nasopharyngeal carcinoma.
The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.
The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells-A Systematic Analysis.
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.
The level of DNA modification by (+)-syn-(11S,12R,13S,14R)- and (-)-anti-(11R,12S,13S,14R)-dihydrodiol epoxides of dibenzo[a,l]pyrene determined the effect on the proteins p53 and p21WAF1 in the human mammary carcinoma cell line MCF-7.
The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired.
The molecular determinants of R-roscovitine block of hERG channels.
The mTOR pathway and its role in human genetic diseases.
The multi-target drug BAI induces apoptosis in various human cancer cells through modulation of Bcl-xL protein.
The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
The natural sweetener metabolite steviol inhibits the proliferation of human osteosarcoma U2OS cell line.
The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer.
The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
The p16(INK4A) protein and flavopiridol restore yeast cell growth inhibited by Cdk4.
The p16(INK4A) tumor suppressor regulates cellular oxidative stress.
The p16INK4a tumor suppressor controls p21WAF1 induction in response to ultraviolet light.
The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo.
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA.
The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty?
The p53-targeting human phosphatase hCdc14A interacts with the Cdk1/cyclin B complex and is differentially expressed in human cancers.
The phenotype of a "Cdc2 kinase target site-deficient" mutant of oncoprotein 18 reveals a role of this protein in cell cycle control.
The physiology of p16(INK4A)-mediated G1 proliferative arrest.
The PI3K/Akt/FOXO3a pathway regulates regeneration following spinal cord injury in adult rats through TNF-? and p27kip1 expression.
The PISSLRE gene: structure, exon skipping, and exclusion as tumor suppressor in breast cancer.
The PITSLRE protein kinase family.
The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer.
The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma.
The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2.
The prognostic value of p27 in gastric cancer.
The promise and current status of CDK12/13 inhibition for the treatment of cancer.
The Protective Role of Decorin in Hepatic Metastasis of Colorectal Carcinoma.
The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1.
The Regulatory Effects of CDKN1A on Relevant Genes in Kaposi's Sarcoma Cells.
The Relevance of Women's Diseases, Jun Activation-domain Binding Protein 1 (JAB1) and p27(kip1).
The role for transforming growth factor-beta (TGF-beta) in human cancer.
The role of AUF1 in thyroid carcinoma progression.
The Role of CDK4/6 Inhibition in Breast Cancer.
The Role of CDK5 in Tumours and Tumour Microenvironments.
The role of cyclin D2 and p21/waf1 in human T-cell leukemia virus type 1 infected cells.
The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition.
The role of DOT1L in the proliferation and prognosis of gastric cancer.
The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.
The role of p21(CIP1/WAF1) in growth of epithelial cells exposed to hyperoxia.
The role of p27 in endometrial carcinoma.
The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine.
The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer.
The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer.
The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells.
The Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Relapsed Ectopic Male Breast Cancer.
The therapeutic potential of microbial proteasome inhibitors.
The triage of low-grade cytological abnormalities by the immunocytological expression of cyclin-dependent kinase inhibitor p16INK4a versus Human Papillomavirus test: a real possibility to predict cervical intraepithelial neoplasia CIN2 or CIN2+.
The tumor suppressor p16(INK4a) gene is a regulator of apoptosis induced by ultraviolet light and cisplatin.
The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene.
The ubiquitous transcription factor NF-Y positively regulates the transcription of human p27Kip1 through a CCAAT box located in the 5-upstream region of the p27Kip1 gene.
The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
The ZEB1 transcription factor acts in a negative feedback loop with miR200 downstream of Ras and Rb1 to regulate Bmi1 expression.
Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma.
Thyroid status modulates T lymphoma growth via cell cycle regulatory proteins and angiogenesis.
THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism.
Time course comparison of cell-cycle protein expression following partial hepatectomy and WY14,643-induced hepatic cell proliferation in F344 rats.
Time course of cell cycle-related protein expression in diethylnitrosamine-initiated rat liver.
TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein.
Tipping the balance: Cdk2 enables Myc to suppress senescence.
Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis.
TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer.
Topoisomerase IIalpha mediates E2F-1-induced chemosensitivity and is a target for p53-mediated transcriptional repression.
Tranilast inhibits the proliferation of human coronary smooth muscle cell through the activation of p21waf1.
Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21(waf1) and p53.
Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors.
Transcriptional activation of CBF? by CDK11p110 is necessary to promote osteosarcoma cell proliferation.
Transcriptional activation of cyclin-dependent kinase inhibitor, p21waf1 gene by treatment with a differentiation inducing agent, vesnarinone in a human salivary gland cancer cell line.
Transcriptional Analysis of an E2F Gene Signature as a Biomarker of Activity of the Cyclin-Dependent Kinase Inhibitor PHA-793887 in Tumor and Skin Biopsies from a Phase I Clinical Study.
Transcriptional and epigenetic modulation of autophagy promotes EBV oncoprotein EBNA3C induced B-cell survival.
Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.
Transcriptional modulation of apoptosis regulators by roscovitine and related compounds.
Transcriptional profile of immediate response to ionizing radiation exposure.
Transcriptional Regulation of the p16 Tumor Suppressor Gene.
Transfection of p27(Kip1) threonine residue 187 mutant type gene, which is not influenced by ubiquitin-mediated degradation, induces cell cycle arrest in oral squamous cell carcinoma cells.
Transformation by v-Jun prevents cell cycle exit and promotes apoptosis in the absence of serum growth factors.
Transforming growth factor beta 1 (TGF beta 1) reduces cellular levels of p34cdc2, and this effect is abrogated by adenovirus independently of the E1A-associated pRB binding activity.
Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked.
Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and early therapeutic efficacy of SAR439859, a novel selective estrogen receptor degrader.
Treatment of T-cell non-Hodgkin's lymphoma.
Triazole based isatin derivatives as potential inhibitor of key cancer promoting kinases- insight from electronic structure, docking and molecular dynamics simulations.
Trichinella pseudospiralis infection is characterized by more continuous and diffuse myopathy than T. spiralis infection.
TRIGGERING ANAPHASE CATASTROPHE TO COMBAT ANEUPLOID CANCERS.
Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization.
Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients.
Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer.
Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway.
Tumor necrosis factor-alpha regulates cyclin-dependent kinase 5 activity during pain signaling through transcriptional activation of p35.
Tumor necrosis factor-alpha-induced accumulation of tumor suppressor protein p53 and cyclin-dependent protein kinase inhibitory protein p21 is inhibited by insulin in ME-180S cells.
Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1.
Tumor suppression by p21WAF1.
Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype.
Tumor suppressor functions for the Cdk inhibitor p21 in the mouse colon.
Tumor suppressor INK4: quantitative structure-function analyses of p18INK4C as an inhibitor of cyclin-dependent kinase 4.
Tumor suppressor INK4: refinement of p16INK4A structure and determination of p15INK4B structure by comparative modeling and NMR data.
Tumor suppressor p16INK4a inhibits cancer cell growth by down-regulating eEF1A2 through a direct interaction.
Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4.
Tumor suppressor protein C53 antagonizes checkpoint kinases to promote cyclin-dependent kinase 1 activation.
Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors.
Tumorigenesis in p27/p53- and p18/p53-double null mice: functional collaboration between the pRb and p53 pathways.
Tumour suppressor genes in chemotherapeutic drug response.
Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition.
Two loci controlling susceptibility to radiation-induced lymphomagenesis on mouse chromosome 4: cdkn2a, a candidate for one locus, and a novel locus distinct from cdkn2a.
Two tracks but one race? Cancer genetics.
Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells.
Tyrosine phosphorylation in mouse mammary hyperplasias.
Ubiquitin-dependent signaling: the role of ubiquitination in the response of cells to their environment.
Ubiquitin-mediated control of oncogene and tumor suppressor gene products.
UCN-01 (7-hydroxystaurosporine) inhibits the growth of human breast cancer xenografts through disruption of signal transduction.
UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway.
Ultraviolet B light induces G1 arrest in human melanocytes by prolonged inhibition of retinoblastoma protein phosphorylation associated with long-term expression of the p21Waf-1/SDI-1/Cip-1 protein.
Ultraviolet light and ocular diseases.
Uncovering the pharmacological response of novel sesquiterpene derivatives that differentially alter gene expression and modulate the cell cycle in cancer cells.
Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas.
Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.
Understanding Obesity as a Risk Factor for Uterine Tumors Using Drosophila.
Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization.
Unraveling the complexity of endocrine resistance in breast cancer by functional genomics.
Unscheduled expression of cyclins D1 and D3 in human tumour cell lines.
Unusual deregulation of cell cycle components in early and frank estrogen-induced renal neoplasias in the Syrian hamster.
Up-regulated p27Kip1 reduces matrix metalloproteinase-9 and inhibits invasion of human breast cancer cells.
Up-regulation of cyclin B1 and cdc2 expression during 9-nitrocamptothecin-induced regression of DU145 prostate tumor.
Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors.
Up-regulation of GPR48 induced by down-regulation of p27Kip1 enhances carcinoma cell invasiveness and metastasis.
Upregulated CDK16 Expression in Serous Epithelial Ovarian Cancer Cells.
Upregulated lncRNA Cyclin-dependent kinase inhibitor 2B antisense RNA 1 induces the proliferation and migration of colorectal cancer by miR-378b/CAPRIN2 axis.
Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer.
Upregulation of miR-572 transcriptionally suppresses SOCS1 and p21 and contributes to human ovarian cancer progression.
Upregulation of p21(WAF1/Cip1) precedes tumor necrosis factor-induced necrosis-like cell death.
Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma.
Vaginal Squamous Cell Carcinoma Develops in Mice with Conditional Arid1a Loss and Gain of Oncogenic Kras Driven by Progesterone Receptor Cre.
Vanadyl bisacetylacetonate induced G1/S cell cycle arrest via high-intensity ERK phosphorylation in HepG2 cells.
Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women.
Variolin B and its derivate deoxy-variolin B: new marine natural compounds with cyclin-dependent kinase inhibitor activity.
Vitamin C Promotes Apoptosis and Cell Cycle Arrest in Oral Squamous Cell Carcinoma.
Vitamin C supplementation had no side effect in non-cancer, but had anticancer properties in ovarian cancer cells.
Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells.
What makes the engine hum: Rad6, a cell cycle supercharger.
Whether to target single or multiple CDKs for therapy? That is the question.
Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner.
Wild-type p16INK4a suppresses cell growth, telomerase activity and DNA repair in human breast cancer MCF-7 cells.
Wnt-induced proteolytic targeting.
XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies.
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Yin-yang regulating effects of cancer-associated genes, proteins, and cells: An ancient Chinese concept in vogue in modern cancer research.
ZAC, LIT1 (KCNQ1OT1) and p57KIP2 (CDKN1C) are in an imprinted gene network that may play a role in Beckwith-Wiedemann syndrome.
Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression.
[A new therapy with bortezomib, an oncologic medicinal product of the year 2004]
[A novel small molecule cyclin-dependent kinase inhibitor flavopiridol in cancer therapy]
[Cancer and the cell cycle: a current merry-go-round in oncology of clinical relevance]
[Cdk inhibiting proteins]
[CDK inhibitors for therapy of cancer]
[Coordination inhibition of the proliferation of MCF-7 by enhancing expression of p53,p21 and decreasing expression of c-myc]
[Cyclin dependent kinases. From molecular biology to pathology]
[Cyclin-dependent kinase 4 inhibitor a and tumor]
[Deregulation of cell cycle control in lung cancer]
[Detection of expression of p53, p16, and cyclooxygenase 2 in pancreatic cancer by tissue microarray and correlation among these three genes]
[Dual regulation of cell cycles by Shuanghuang Shengbai Granule in Lewis-bearing mice with chemotherapy-induced myelosuppression and its mechanism.]
[Effect of phenelzine on the proliferation, apoptosis and histone methylation and acetylation of Molt-4 cells].
[Expression of cyclin dependent kinase inhibitors of KIP family in gastric cancer]
[Expression of p16 gene and protein in the evaluation of dynamics of laryngeal cancer growth]
[Function of CDK12 in Tumor initiation and progression and its clinical consequences].
[Impact of p16INK4A and p15INK4B on human hepatocellular carcinoma cell proliferation and apoptosis]
[Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology]
[p16(INK4A)/CDKN2--the "melanoma gene"? Status of research and outlook]
[p16/CDKN2/MTS1 gene abnormality in lung cancer]
[Pharmacological profile and clinical findings of palbociclib (IBRANCE® capsule 25?mg/125?mg)].
[Prognostic significance of cyclin-dependent kinase inhibitor p27kip1 expression in human breast cancer]
[SCP Phosphatases and Oncogenesis].
[The cell cycle and the tumor suppressor genes]
[The efficacy of p16, p53 and p21 genes on the proliferation of lung cancer cells in vitro]
[Viral carcinogenesis of head and neck tumors]
Neoplasms, Germ Cell and Embryonal
Cell cycle regulators in testicular cancer: loss of p18INK4C marks progression from carcinoma in situ to invasive germ cell tumours.
Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Differential Akt signalling in non-seminomatous testicular germ cell tumors.
Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors.
Neoplasms, Squamous Cell
CDK6 inhibits lymphoid cell infiltration and represents a prognostic marker in HPV+ squamous cell carcinoma of head and neck.
Neoplastic Cells, Circulating
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer.
Tailoring breast cancer therapies to reduce mortality and improve quality of life: San Antonio Breast Cancer Symposium 2017 (part 1).
Tailoring breast cancer therapies to reduce mortality and improve quality of life: San Antonio Breast Cancer Symposium 2017 (part 2).
Nephritis
Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus.
Nephrosis, Lipoid
Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation.
Nervous System Diseases
CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders.
Characterisation of Cdkl5 transcript isoforms in rat.
Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders.
Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Elevation of p-NR2A(S1232) by Cdk5/p35 contributes to retinal ganglion cell apoptosis in a rat experimental glaucoma model.
Extra-cell cycle regulatory functions of cyclin-dependent kinases (CDK) and CDK inhibitor proteins contribute to brain development and neurological disorders.
Implication of the transcription factor E2F-1 in the modulation of neuronal apoptosis.
Inducible Knockout of the Cyclin-Dependent Kinase 5 Activator p35 Alters Hippocampal Spatial Coding and Neuronal Excitability.
Inhibition of Cdk5 rejuvenates inhibitory circuits and restores experience-dependent plasticity in adult visual cortex.
Regulation of hippocampal and behavioral excitability by cyclin-dependent kinase 5.
Role of Cell Cycle Re-Entry in Neurons: A Common Apoptotic Mechanism of Neuronal Cell Death.
Targeting malaria with specific CDK inhibitors.
The antidepressant tianeptine reverts synaptic AMPA receptor defects caused by deficiency of CDKL5.
The Ever-Changing Morphology of Hippocampal Granule Neurons in Physiology and Pathology.
The role of CDK5/P25 formation/inhibition in neurodegeneration.
Neural Tube Defects
Neural tube development requires the cooperation of p53- and Gadd45a-associated pathways.
Neuralgia
Crosstalk between Cdk5/p35 and ERK1/2 signalling mediates spinal astrocyte activity via the PPAR? pathway in a rat model of chronic constriction injury.
Decreased Activity in Neuropathic Pain Form and Gene Expression of Cyclin-Dependent Kinase5 and Glycogen Synthase Kinase-3 Beta in Soleus Muscle of Wistar Male Rats.
Differential expression of Cdk5-phosphorylated CRMP2 following a spared nerve injury.
Long Noncoding RNA H19 Induces Neuropathic Pain by Upregulating Cyclin-Dependent Kinase 5-Mediated Phosphorylation of cAMP Response Element Binding Protein [Retraction].
Long Noncoding RNA H19 Induces Neuropathic Pain by Upregulating Cyclin-Dependent Kinase 5-Mediated Phosphorylation of cAMP Response Element Binding Protein.
The role of cyclin-dependent kinase 5 in neuropathic pain.
Neuroblastoma
(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis.
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma.
Analysis of location and integrity of the human PITSLRE (p58(cdc2L1)) genes in neuroblastoma cell genomes.
Bioinformatics analysis of the CDK2 functions in neuroblastoma.
Caspase 8/10 are not mediating apoptosis in neuroblastoma cells treated with CDK inhibitory drugs.
CDK inhibitors reduce cell proliferation and reverse hypoxia-induced metastasis of neuroblastoma tumours in a chick embryo model.
CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells.
CDK-5-mediated neurofilament phosphorylation in SHSY5Y human neuroblastoma cells.
CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.
CDK4 and CDK5 Inhibition Have Comparable Mild Hypothermia Effects in Preventing Drp1-Dependent Mitochondrial Fission and Neuron Death Induced by MPP
CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.
Choline availability modulates human neuroblastoma cell proliferation and alters the methylation of the promoter region of the cyclin-dependent kinase inhibitor 3 gene.
Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification.
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
Differential growth factor regulation of aspartyl-(asparaginyl)-beta-hydroxylase family genes in SH-Sy5y human neuroblastoma cells.
Differential regulation of cyclin-dependent kinase inhibitors in neuroblastoma cells.
Differentiation-associated expression and intracellular localization of cyclin-dependent kinase inhibitor p27KIP1 and c-Jun co-activator JAB1 in neuroblastoma.
DREAM target reactivation by core transcriptional regulators supports neuroblastoma growth.
Epigenetic Targeting of TERT-Associated Gene Expression Signature in Human Neuroblastoma with TERT Overexpression.
Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27(KIP1) as a consequence of c-Abl inhibition.
Gene replacement ameliorates deficits in mouse and human models of cyclin-dependent kinase-like 5 disorder.
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.
Increase in the expression of the neuronal cyclin-dependent protein kinase cdk-5 during differentiation of N2A neuroblastoma cells.
Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons.
Increased expression of cdk5/p25 in N2a cells leads to hyperphosphorylation and impaired axonal transport of neurofilament proteins.
Induction of cyclin-dependent kinase 5 and its activator p35 through the extracellular-signal-regulated kinase and protein kinase A pathways during retinoic-acid mediated neuronal differentiation in human neuroblastoma SK-N-BE(2)C cells.
Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells.
Inhibition of the mRNA-Binding Protein IGF2BP1 Suppresses Proliferation and Sensitizes Neuroblastoma Cells to Chemotherapeutic Agents.
Membrane depolarization stimulates the proliferation of SH-SY5Y human neuroblastoma cells by increasing retinoblastoma protein (RB) phosphorylation through the activation of cyclin-dependent kinase 2 (Cdk2).
MicroRNA-H4-5p encoded by HSV-1 latency-associated transcript promotes cell proliferation, invasion and cell cycle progression via p16-mediated PI3K-Akt signaling pathway in SHSY5Y cells.
Mitotic mechanisms in Alzheimer's disease?
Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas.
Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
p27Kip1 accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation.
Participation of type II protein kinase A in the retinoic acid-induced growth inhibition of SH-SY5Y human neuroblastoma cells.
Phosphorylation of endogenous proteins by adenosine 3':5'-monophosphate-dependent protein kinase in mouse neuroblastoma cells.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Regulation of neuronal cav3.1 channels by cyclin-dependent kinase 5 (cdk5).
Retinoic acid downregulates Rae1 leading to APC(Cdh1) activation and neuroblastoma SH-SY5Y differentiation.
Retinoic acid negatively regulates p34cdc2 expression during human neuroblastoma differentiation.
Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors.
Structural and functional analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma.
Subcellular distribution of cyclin-dependent kinase-like 5 (CDKL5) is regulated through phosphorylation by dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A).
Synthesis of novel 5-substituted indirubins as protein kinases inhibitors.
Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.
Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs.
The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells.
The PITSLRE protein kinase family.
Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons.
Neurodegenerative Diseases
AAV9-Mediated Cdk5 Inhibitory Peptide Reduces Hyperphosphorylated Tau and Inflammation and Ameliorates Behavioral Changes Caused by Overexpression of p25 in the Brain.
Acetylation of cyclin-dependent kinase 5 is mediated by GCN5.
Acute and chronic stress differentially regulate cyclin-dependent kinase 5 in mouse brain: implications to glucocorticoid actions and major depression.
Both N-methyl-D-aspartate (NMDA) and non-NMDA receptors mediate glutamate-induced cleavage of the cyclin-dependent kinase 5 (cdk5) activator p35 in cultured rat hippocampal neurons.
Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces A? and P25 accumulation in 5XFAD mice.
Callyspongisines A-D: bromopyrrole alkaloids from an Australian marine sponge, Callyspongia sp.
Cdk1-FOXO1: a mitotic signal takes center stage in post-mitotic neurons.
Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses.
CDK5 in oncology: recent advances and future prospects.
Cdk5 Inhibitory Peptide Prevents Loss of Dopaminergic Neurons and Alleviates Behavioral Changes in an MPTP Induced Parkinson's Disease Mouse Model.
Cdk5-mediated phosphorylation of endophilin B1 is required for induced autophagy in models of Parkinson's disease.
Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration.
Cdk5: a multifaceted kinase in neurodegenerative diseases.
Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1.
Cell cycle regulatory protein 5 (Cdk5) is a novel downstream target of ERK in carboplatin induced death of breast cancer cells.
Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.
Chronic administration of melatonin reduces cerebral injury biomarkers in SAMP8.
Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders.
Cyclin-dependent kinase 5 (Cdk5): a potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus.
Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis.
Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress.
Cyclin-dependent kinase 5 modulates the transcriptional activity of the mineralocorticoid receptor and regulates expression of brain-derived neurotrophic factor.
Cyclin-dependent kinase 5 phosphorylates the N-terminal domain of the postsynaptic density protein PSD-95 in neurons.
Cyclin-Dependent Kinase 5 Regulates PSD-95 Ubiquitination in Neurons.
Cyclin-dependent kinase 5 regulates steroidogenic acute regulatory protein and androgen production in mouse Leydig cells.
Cyclin-dependent kinase 5 supports neuronal survival through phosphorylation of Bcl-2.
Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians.
Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Functional characterization of CDK5 and CDK5R1 mutations identified in patients with non-syndromic intellectual disability.
Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors.
Identification of non-muscle myosin heavy chain as a substrate for Cdk5 and tool for drug screening.
Identification of the N-terminal functional domains of Cdk5 by molecular truncation and computer modeling.
Identifying novel substrates for mouse Cdk5 kinase using the yeast Saccharomyces cerevisiae.
Inactivation of CDK/pRb pathway normalizes survival pattern of lymphoblasts expressing the FTLD-progranulin mutation c.709-1G>A.
Increased immunoreactivity of cdk5 activators in hippocampal sclerosis.
Inhibition of ataxia telangiectasia-p53-E2F-1 pathway in neurons as a target for the prevention of neuronal apoptosis.
Inhibition of cyclin-dependent kinase 5 activity alleviates diabetes-related cognitive deficits.
Inhibition of p25/Cdk5 attenuates tauopathy in mouse and iPSC models of frontotemporal dementia.
Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease.
Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action.
Interplay Between the p53 Tumor Suppressor Protein Family and Cdk5: Novel Therapeutic Approaches for the Treatment of Neurodegenerative Diseases Using Selective Cdk Inhibitors.
Involvement of cyclin-dependent kinase-5 in the kainic acid-mediated degeneration of glutamatergic synapses in the rat hippocampus.
Kinase inhibitor scaffolds against neurodegenerative diseases from a Southern Australian ascidian, Didemnum sp.
Lithium treatment decreases activities of tau kinases in a murine model of senescence.
Mitotic activation: a convergent mechanism for a cohort of neurodegenerative diseases.
Negative regulation of cyclin-dependent kinase 5 targets by protein kinase C.
No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro.
Novel potent pharmacological cyclin-dependent kinase inhibitors.
Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory.
p25/cyclin-dependent kinase 5 promotes the progression of cell death in nucleus of endoplasmic reticulum-stressed neurons.
p53, Apaf-1, caspase-3, and -9 are dispensable for Cdk5 activation during cell death.
Phosphorylation of CHIP at Ser20 by Cdk5 promotes tAIF-mediated neuronal death.
Phosphorylation of HtrA2 by cyclin-dependent kinase-5 is important for mitochondrial function.
Potential Enzymatic Targets in Alzheimer's: A Comprehensive Review.
Potential neuroprotective flavonoid-based inhibitors of CDK5/p25 from Rhus parviflora.
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials.
Sigma-1 receptor regulates Tau phosphorylation and axon extension by shaping p35 turnover via myristic acid.
Spiralisones A-D: acylphloroglucinol hemiketals from an Australian marine brown alga, Zonaria spiralis.
Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors.
Suppression of neuroinflammation in forebrain-specific Cdk5 conditional knockout mice by PPAR? agonist improves neuronal loss and early lethality.
Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons.
Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.
Synthesis, Resolution, and Biological Evaluation of Atropisomeric (aR)- and (aS)-16-Methyllamellarins N: Unique Effects of the Axial Chirality on the Selectivity of Protein Kinases Inhibition.
The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35.
The mechanisms regulating cyclin-dependent kinase 5 in hippocampus during systemic inflammatory response: The effect on inflammatory gene expression.
When good Cdk5 turns bad.
[Roles of cyclin-dependent kinase 5 in central nervous system development and neurodegenerative diseases.]
Neuroectodermal Tumors, Primitive
Common alternative gene alterations in adult malignant astrocytomas, but not in childhood primitive neuroectodermal tumors: P 16ink4 homozygous deletions and CDK4 gene amplifications.
Expression of proline-directed protein kinase, (p34cdc2/p58cyclin A), a novel cell proliferation marker in childhood brain tumors.
p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.
Neuroendocrine Tumors
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.
Differential expression of forkhead box M1 and its downstream cyclin-dependent kinase inhibitors p27(kip1) and p21(waf1/cip1) in the diagnosis of pulmonary neuroendocrine tumours.
Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tumors.
The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
Neurofibroma, Plexiform
Combined CDK inhibition overcomes MEK inhibitor resistance in plexiform neurofibroma of neurofibromatosis type I.
Neurofibromatoses
Analysis of YAP1 and TAZ expression by immunohistochemical staining in malignant mesothelioma and reactive mesothelial cells.
Combined CDK inhibition overcomes MEK inhibitor resistance in plexiform neurofibroma of neurofibromatosis type I.
Molecular pathogenesis of malignant mesothelioma.
Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas.
Neurofibromatosis 1
Combined CDK inhibition overcomes MEK inhibitor resistance in plexiform neurofibroma of neurofibromatosis type I.
Neurofibromatosis 2
Analysis of YAP1 and TAZ expression by immunohistochemical staining in malignant mesothelioma and reactive mesothelial cells.
Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
Molecular pathogenesis of malignant mesothelioma.
Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas.
Neurofibrosarcoma
RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4/6 inhibitors.
Neuroinflammatory Diseases
Cdk5 Inhibitory Peptide Prevents Loss of Dopaminergic Neurons and Alleviates Behavioral Changes in an MPTP Induced Parkinson's Disease Mouse Model.
Cdk5 Inhibitory Peptide Prevents Loss of Neurons and Alleviates Behavioral Changes in p25 Transgenic Mice.
Selective CDK inhibitor limits neuroinflammation and progressive neurodegeneration after brain trauma.
Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo.
TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice.
Neurologic Manifestations
CR8, a novel inhibitor of CDK, limits microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury.
Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder.
Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder.
Neuroma, Acoustic
MiR-205 Inhibits Sporadic Vestibular Schwannoma Cell Proliferation by Targeting Cyclin-Dependent Kinase 14.
Neutropenia
Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer.
Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience.
Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer.
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Cyclin-dependent kinase 4/6 inhibitors: what have we learnt across studies, therapy situations and substances.
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3.
Incidence and Severity of Myelosuppression With Palbociclib After Palliative Bone Radiation in Advanced Breast Cancer: A Single Center Experience and Review of Literature.
Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib.
Targeting Breast Cancer with CDK Inhibitors.
Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value.
Nevus
Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.
Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins.
Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families.
Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions.
Niemann-Pick Disease, Type C
p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease.
The neuroprotective effects of cyclin-dependent kinase-5 inhibition in mice with Niemann-Pick disease type C.
Niemann-Pick Diseases
The neuroprotective effects of cyclin-dependent kinase-5 inhibition in mice with Niemann-Pick disease type C.
Nijmegen Breakage Syndrome
Chemical genetics reveals a specific requirement for cdk2 activity in the DNA damage response and identifies nbs1 as a cdk2 substrate in human cells.
G2-phase radiation response in lymphoblastoid cell lines from Nijmegen breakage syndrome.
Obesity
Cyclin-dependent kinase 4 is a preclinical target for diet-induced obesity.
Cyclin-dependent kinase 4/6 inhibitors require an arcuate to paraventricular hypothalamus melanocortin circuit to treat diet-induced obesity.
Cyclin-dependent kinase inhibitor, p21WAF1/CIP1, is involved in adipocyte differentiation and hypertrophy, linking to obesity, and insulin resistance.
Dissecting the nutrigenomics, diabetes, and gastrointestinal disease interface: from risk assessment to health intervention.
Increased proinflammatory cytokine production in adipose tissue of obese patients with chronic kidney disease.
Inflammation and poor response to treatment with erythropoietin in chronic kidney disease.
Loss of cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity.
Molecular Recognition of PPAR? by Kinase Cdk5/p25: Insights from a Combination of Protein-Protein Docking and Adaptive Biasing Force Simulations.
PPM1A Controls Diabetic Gene Programming through Directly Dephosphorylating PPAR? at Ser273.
Some cyclin-dependent kinase inhibitors-related genes are regulated by vitamin C in a model of diet-induced obesity.
Understanding Obesity as a Risk Factor for Uterine Tumors Using Drosophila.
Variations in the HHEX gene are associated with increased risk of type 2 diabetes in the Japanese population.
Oligodendroglioma
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Expression of cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors in oligodendrogliomas in humans.
Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas.
Immunohistochemical analysis of p18INK4C and p14ARF protein expression in 117 oligodendrogliomas: correlation with tumor grade and clinical outcome.
Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO).
The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas.
Oncogene Addiction
Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor ? and bcr-abl oncogene addiction in malignant hematologic cells.
Optic Nerve Injuries
Induction of CRMP-2 phosphorylation by CDK5 restricts the repair of damaged optic nerve.
Oral Submucous Fibrosis
The phosphorylation of survivin Thr34 by p34cdc2 in carcinogenesis of oral submucous fibrosis.
Osteoarthritis
An algorithmic strategy of surgical intervention for cervical degenerative kyphosis.
Cellular Localization of Debromohymenialdisine and Hymenialdisine in the Marine Sponge Axinella sp. Using a Newly Developed Cell Purification Protocol.
Cyclin-dependent kinase inhibitor p21, via its C-terminal domain, is essential for resolution of murine inflammatory arthritis.
Cyclin-Dependent Kinase Inhibitor-1-Deficient Mice Are Susceptible to Osteoarthritis Associated With Enhanced Inflammation.
Susceptibility of cyclin-dependent kinase inhibitor 1-deficient mice to rheumatoid arthritis arising from interleukin-1?-induced inflammation.
Osteonecrosis
Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association.
Osteosarcoma
A clinical comparison between dedifferentiated low-grade osteosarcoma and conventional osteosarcoma.
A p27(Kip1) mutant that does not inhibit CDK activity promotes centrosome amplification and micronucleation.
Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.
Antitumor and antimigration effects of Salvia clandestina L. extract on osteosarcoma cells.
Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor.
Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.
BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells.
Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response.
CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
Circular RNA circ_001621 promotes osteosarcoma cells proliferation and migration by sponging miR-578 and regulating VEGF expression.
Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.
Control of cell cycle gene expression in bone development and during c-Fos-induced osteosarcoma formation.
Correction to: Transcriptional activation of CBF? by CDK11p110 is necessary to promote osteosarcoma cell proliferation.
CRIF1 as a potential target to improve the radiosensitivity of osteosarcoma.
Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma.
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.
Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing's family tumor cells.
Cytochrome b5 reductase 2 suppresses tumor formation in nasopharyngeal carcinoma by attenuating angiogenesis.
Differential expression of degradome components in cutaneous squamous cell carcinomas.
ERK pathway mediates the activation of Cdk2 in IGF-1-induced proliferation of human osteosarcoma MG-63 cells.
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma.
Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma.
FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line.
Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase.
Functional Genetic Single-Nucleotide Polymorphisms (SNPs) in Cyclin-Dependent Kinase Inhibitor 2A/B (CDKN2A/B) Locus Are Associated with Risk and Prognosis of Osteosarcoma in Chinese Populations.
Gene expression profiling analysis of ovarian cancer.
Giant cell-rich osteosarcoma of the vertebra with murine double minute chromosome 2- and cyclin-dependent kinase 4-positive and histone H3F3A mutant p.Gly34Trp-negative immunophenotypes.
Inhibition of osteosarcoma cell progression by MacroH2A via the downregulation of cyclin D and cyclin?dependent kinase genes.
MDM2 and CDK4 expression in periosteal osteosarcoma.
MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, CDK6.
microRNA-377 suppresses the proliferation of human osteosarcoma MG-63 cells by targeting CDK6.
MicroRNA-874 inhibits cell proliferation and invasion by targeting cyclin-dependent kinase 9 in osteosarcoma.
Polydatin enhances the chemosensitivity of osteosarcoma cells to paclitaxel.
Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells.
Rhotekin 2 silencing inhibits proliferation and induces apoptosis in human osteosarcoma cells.
Selected using bioinformatics and molecular docking analyses, PHA-793887 is effective against osteosarcoma.
Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.
Small molecule TSC01682 inhibits osteosarcoma cell growth by specifically disrupting the CUL4B-DDB1 interaction and decreasing the ubiquitination of CRL4B E3 ligase substrates.
Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation.
Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system.
The CtBP1-p300-FOXO3a transcriptional complex represses the expression of the apoptotic regulators Bax and Bim in human osteosarcoma cells.
The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells.
The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells.
Transcriptional activation of CBF? by CDK11p110 is necessary to promote osteosarcoma cell proliferation.
Transcriptional repression of E2F gene by proteasome inhibitors in human osteosarcoma cells.
Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked.
Two potentially oncogenic cyclins, cyclin A and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein.
Upregulated lncRNA Cyclin-dependent kinase inhibitor 2B antisense RNA 1 induces the proliferation and migration of colorectal cancer by miR-378b/CAPRIN2 axis.
Ototoxicity
Local Drug Delivery for Prevention of Hearing Loss.
Ovarian Neoplasms
A Splice Site Variant of CDK12 and Breast Cancer in Three Eurasian Populations.
Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Binding sites for adeno-associated virus Rep proteins within the human genome.
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion.
Changes in cyclins and cyclin-dependent kinases induced by DNA damaging agents in a human ovarian cancer cell line expressing mutated or wild-type P53.
Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis.
Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.
Cyclin-Dependent Kinase 14 Promotes Cell Proliferation, Migration and Invasion in Ovarian Cancer by Inhibiting Wnt Signaling Pathway.
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.
Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Dopamine and cAMP-regulated phosphoprotein 32kDa (DARPP-32), protein phosphatase-1 and cyclin-dependent kinase 5 expression in ovarian cancer.
Effect of tumor suppressor gene cyclin-dependent kinase inhibitor 2A wild-type and A148T mutant on the cell cycle of human ovarian cancer cells.
Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells.
Evaluation of the cyclin-dependent kinase inhibitor p21Cip1 in epithelial ovarian tumors of low malignant potential and adenocarcinomas.
Expression, Purification, and Identification of Associated Proteins of the Full-length hCDK12/CyclinK Complex.
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.
Growth inhibitory effect of D-allose on human ovarian carcinoma cells in vitro.
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.
Identification of key genes for guiding chemotherapeutic management in ovarian cancer using translational bioinformatics.
Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis.
Inhibition of succinate dehydrogenase sensitizes cyclin E-driven ovarian cancer to CDK inhibition.
Integrated genomic analyses of ovarian carcinoma.
Lack of evidence for CDK12 as an ovarian cancer predisposing gene.
LncRNA KB-1471A8.2 Overexpression Suppresses Cell Proliferation and Migration and Antagonizes the Paclitaxel Resistance of Ovarian Cancer Cells.
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Lysophosphatidic acid-induced p21Waf1 expression mediates the cytostatic response of breast and ovarian cancer cells to TGF?.
Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
MiR-498 regulated FOXO3 expression and inhibited the proliferation of human ovarian cancer cells.
NUCKS nuclear elevated expression indicates progression and prognosis of ovarian cancer.
Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors.
Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.
PFTK1 regulates cell proliferation, migration and invasion in epithelial ovarian cancer.
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells.
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients.
The cyclin-dependent kinase inhibitor AT7519 augments cisplatin's efficacy in ovarian cancer via multiple oncogenic signaling pathways.
The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer.
The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.
The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells.
Ubiquitin and breast cancer.
Why a Combination of WP 631 and Epo B is an Improvement on the Drugs Singly - Involvement in the Cell Cycle and Mitotic Slippage.
[Impact of cyclin-dependent kinase inhibitor p27 on resistance of ovarian cancer multicellular spheroids to taxol]
Paget Disease, Extramammary
Overexpression of cyclin-dependent kinase 4 protein in extramammary Paget's disease.
Pancreatic Diseases
Protein deep sequencing applied to biobank samples from patients with pancreatic cancer.
Pancreatic Neoplasms
A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity.
A Transcriptome-Wide Association Study (TWAS) Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer.
Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells.
Antiproliferative Effect of 1?,25-dihydroxyvitamin D3 Involves Upregulation of Cyclin-Dependent Kinase Inhibitor p21 in Human Pancreatic Cancer Cells.
CDK12: an emerging therapeutic target for cancer.
CDK14/?-catenin/TCF4/miR-26b positive feedback regulation modulating pancreatic cancer cell phenotypes in vitro and tumor growth in mice model in vivo.
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.
Ectopic Tbx2 expression results in polyploidy and cisplatin resistance.
Epigenetic Silencing of MicroRNA miR-107 Regulates Cyclin-Dependent Kinase 6 Expression in Pancreatic Cancer.
Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma.
Expression profiles of a human pancreatic cancer cell line upon induction of apoptosis search for modulators in cancer therapy.
Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk.
Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53.
Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer.
Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB.
Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer.
Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer.
Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling.
Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin.
Knockdown of PFTK1 inhibits tumor cell proliferation, invasion and epithelial-to-mesenchymal transition in pancreatic cancer.
Mechanism of T-oligo-induced cell cycle arrest in Mia-Paca pancreatic cancer cells.
MiR-142-3p targeting NUCKS1 inhibits proliferation and invasion of pancreatic cancer cells.
Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers.
NOVEL THIOSEMICARBAZONE IRON CHELATORS INDUCE UP-REGULATION AND PHOSPHORYLATION OF THE METASTASIS SUPPRESSOR, NDRG1: A NEW STRATEGY FOR THE TREATMENT OF PANCREATIC CANCER.
Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in pancreatic cancer.
P16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation.
p21 expression is induced by activation of nuclear nerve growth factor-induced Balpha (Nur77) in pancreatic cancer cells.
Progression elevated gene-3 promoter (PEG-Prom) confers cancer cell selectivity to human polynucleotide phosphorylase (hPNPase(old-35))-mediated growth suppression.
Protein deep sequencing applied to biobank samples from patients with pancreatic cancer.
Split Cyclin-Dependent Kinase 4/6-Retinoblastoma 1 Axis in Pancreatic Cancer.
Synergistic antitumor effects of CDK inhibitor SNS?032 and an oncolytic adenovirus co?expressing TRAIL and Smac in pancreatic cancer.
Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Transient receptor potential channel TRPM8 is over-expressed and required for cellular proliferation in pancreatic adenocarcinoma.
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.
Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-beta1 in COLO-357 cells.
[Detection of expression of p53, p16, and cyclooxygenase 2 in pancreatic cancer by tissue microarray and correlation among these three genes]
Papilloma
Combinatorial expression of cell cycle regulators is more suitable for immortalization than oncogenic methods in dermal papilla cells.
Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes.
Oral Papillomas Associated With Felis catus Papillomavirus Type 1 in 2 Domestic Cats.
Prognostic value of human papillomavirus infection and p53, p16, epidermal growth factor receptor and p34cdc2 expression in patients with salivary adenoid cystic carcinoma.
Selective antitumor activity of roscovitine in head and neck cancer.
Simultaneous human papilloma virus type 16 E7 and cdk inhibitor p21 expression induces apoptosis and cathepsin B activation.
Papillomavirus Infections
Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix.
Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA.
Human papillomavirus and overexpression of P16INK4a in nonmelanoma skin cancer.
Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents.
Prognostic value of human papillomavirus infection and p53, p16, epidermal growth factor receptor and p34cdc2 expression in patients with salivary adenoid cystic carcinoma.
Protein p 16INK4A expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of uterine cervix.
The role of protein p16INK4a in non-oropharyngeal head and neck squamous cell carcinoma in Southern China.
Paralysis
An algorithmic strategy of surgical intervention for cervical degenerative kyphosis.
Parathyroid Neoplasms
Differential expression of kinase genes in primary hyperparathyroidism: adenoma versus normal and hyperplastic parathyroid tissue.
Germline and Somatic Mutations in Cyclin-Dependent Kinase Inhibitor Genes CDKN1A, CDKN2B, and CDKN2C in Sporadic Parathyroid Adenomas.
Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas.
Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas.
Parkinson Disease
A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson's disease.
Aberrant mitochondrial morphology and function associated with impaired mitophagy and DNM1L-MAPK/ERK signaling are found in aged mutant Parkinsonian LRRK2R1441G mice.
Abnormal Mitochondria in a Non-human Primate Model of MPTP-induced Parkinson's Disease: Drp1 and CDK5/p25 Signaling.
Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease.
Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration.
Commitment of 1-methyl-4-phenylpyrinidinium ion-induced neuronal cell death by proteasome-mediated degradation of p35 cyclin-dependent kinase 5 activator.
Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease.
Kinases in synaptic development and neurological diseases.
Nucks1 gene polymorphism rs823114 is associated with the positive symptoms and neurocognitive function of patients with schizophrenia in parts of southern China.
p35nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease.
Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease.
Parkinsonian Disorders
Serine-409 phosphorylation and oxidative damage define aggregation of human protein tau in yeast.
Perinatal Death
PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors.
Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death.
Peripheral Nerve Injuries
Cdk5 Phosphorylation of STAT3 in Dorsal Root Ganglion Neurons Is Involved in Promoting Axonal Regeneration After Peripheral Nerve Injury.
Cdk5-Dependent Phosphorylation of CaV3.2 T-Type Channels: Possible Role in Nerve Ligation-Induced Neuropathic Allodynia and the Compound Action Potential in Primary Afferent C Fibers.
Persistent Hyperplastic Primary Vitreous
Modulating EGFR-MTORC1-autophagy as a potential therapy for persistent fetal vasculature (PFV) disease.
Persistent Infection
Identification of key genes and pathways associated with different immune statuses of hepatitis B virus infection.
Peutz-Jeghers Syndrome
The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis.
Pheochromocytoma
A novel apoptotic cascade mediated by CDK4 in rat pheochromocytoma PC12 cells.
Constitutive overexpression of CDK2 inhibits neuronal differentiation of rat pheochromocytoma PC12 cells.
Extracellular ?-Synuclein Leads to Microtubule Destabilization via GSK-3?-Dependent Tau Phosphorylation in PC12 Cells.
Nerve growth factor regulates the expression and activity of p33cdk2 and p34cdc2 kinases in PC12 pheochromocytoma cells.
Pick Disease of the Brain
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Pinguecula
Climatic droplet keratopathy in the Argentine Patagonia.
Pituitary ACTH Hypersecretion
Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
Pituitary Neoplasms
Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours.
CDK5 and its activator P35 in normal pituitary and in pituitary adenomas: relationship to VEGF expression.
Cell cycle control of pituitary development and disease.
Cyclins and their related proteins in pituitary tumourigenesis.
Differential gene expression of p27Kip1 and Rb knockout pituitary tumors associated with altered growth and angiogenesis.
Enhanced protein kinase B/Akt signalling in pituitary tumours.
Expression of p16(INK4A) gene in human pituitary tumours.
Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors.
Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
Genetic mosaics reveal both cell-autonomous and cell-nonautonomous function of murine p27Kip1.
Molecular analysis of p21 and p27 genes in human pituitary adenomas.
Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors.
p27 (Kip1) is required to maintain proliferative quiescence in the adult cochlea and pituitary.
Phosphorylation of kinase insert domain receptor by cyclin-dependent kinase 5 at serine 229 is associated with invasive behavior and poor prognosis in prolactin pituitary adenomas.
Somatic and germline mutations in the pathogenesis of pituitary adenomas.
The Expression of AIP-Related Molecules in Elucidation of Cellular Pathways in Pituitary Adenomas.
Plasmacytoma
Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1.
Resolution and general properties of different types of ribosomal protein kinases in mouse plasmocytoma.
Roles and Mechanisms of the Long Noncoding RNAs in Cervical Cancer.
Pleural Effusion
A genomic approach to predict synergistic combinations for breast cancer treatment.
Pleurisy
Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis.
Pneumonia
CDK 4/6 inhibitor induced lung injury: a case report and review of literature.
Relationship between the Contents of Cyclins, Cyclin-Dependent Kinases, and Their Inhibitors in Whole Blood Mononuclear Leukocytes during the Postclinical Stage of Community-Acquired Pneumonia under the Influence of 1-GHz Microwaves.
The cyclin-dependent kinase inhibitor AT7519 accelerates neutrophil apoptosis in sepsis-related acute respiratory distress syndrome.
Polycystic Kidney Diseases
Cyclin-Dependent Kinase 1 Activity Is a Driver of Cyst Growth in Polycystic Kidney Disease.
Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine.
Polycystic Kidney, Autosomal Dominant
Ascofuranone: A Possible Therapeutic Tool for Autosomal Dominant Polycystic Kidney Disease? - Letter.
CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD.
p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels.
Super-enhancer-driven metabolic reprogramming promotes cystogenesis in autosomal dominant polycystic kidney disease.
Polycystic Kidney, Autosomal Recessive
Early Cyst Growth Is Associated with the Increased Nuclear Expression of Cyclin D1/Rb Protein in an Autosomal-Recessive Polycystic Kidney Disease Rat Model.
Polycystic Ovary Syndrome
Genetic variants of cyclin-dependent kinase 5 regulatory subunit associated protein 1-like 1 and transcription factor 7-like 2 are not associated with polycystic ovary syndrome in Chinese women.
Polyomavirus Infections
JC polyomavirus infection in candidates for kidney transplantation living in the Brazilian Amazon region.
Porcine Reproductive and Respiratory Syndrome
Functionally active cyclin-dependent kinase 9 is essential for porcine reproductive and respiratory syndrome virus subgenomic RNA synthesis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.
Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood.
CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia.
Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features.
Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia.
Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment.
Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1).
Methylation of CDKN2B CpG islands is associated with upregulated telomerase activity in children with acute lymphoblastic leukemia.
p27KIP1 deletions in childhood acute lymphoblastic leukemia.
The cell cycle inhibitor p16(INK4A) sensitizes lymphoblastic leukemia cells to apoptosis by physiologic glucocorticoid levels.
[Effect of CDK Inhibitor LS-007 on Acute Lymphoblastic Leukemia and Its Mechanism].
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3-amino thioacridone inhibits DNA synthesis and induce DNA damage in T-cell acute lymphoblastic leukemia (T-ALL) in a p16-dependent manner.
Beating the Clock in T-cell Acute Lymphoblastic Leukemia.
Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia.
LncRNA CDKN2B-AS1 contributes to tumorigenesis and chemoresistance in pediatric T-cell acute lymphoblastic leukemia through miR-335-3p/TRAF5 axis.
Relapsed T Cell ALL: Current Approaches and New Directions.
Primary Ovarian Insufficiency
Analysis of cyclin-dependent kinase inhibitor 1B mutation in Han Chinese women with premature ovarian failure.
Prostatic Neoplasms
2',4'-dihydroxychalcone, a flavonoid isolated from Herba oxytropis, suppresses PC-3 human prostate cancer cell growth by induction of apoptosis.
A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers.
A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells.
A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.
A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer.
Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells.
Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers.
Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells.
Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation.
Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1.
Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.
Antiproliferative activity of the dietary isothiocyanate erucin, a bioactive compound from cruciferous vegetables, on human prostate cancer cells.
Antiproliferative Effect of 1?,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation.
Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells.
Apoptosis of androgen-independent prostate cell line induced by inhibition of fatty acid synthesis.
Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitors.
Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses.
Binding patterns and structure-activity relationship of CDK8 inhibitors.
Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer.
BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.
Butyrolactone I induces cyclin B1 and causes G2/M arrest and skipping of mitosis in human prostate cell lines.
CDK Inhibitors Induce Mitochondria-Mediated Apoptosis Through The Activation Of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells.
CDK12 Changes Telling in Prostate Cancer.
CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer.
CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable?
CDK12 inactivation across solid tumors: an actionable genetic subtype.
CDK12 Mutation in Advanced Prostate Cancer: A Marker for Clinical Subtype?
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.
CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade.
CDK8-Novel Therapeutic Opportunities.
Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice.
Characterizing CDK12-Mutated Prostate Cancers.
Checkpoint kinase 1 regulates diallyl trisulfide-induced mitotic arrest in human prostate cancer cells.
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Costunolide Induces Apoptosis Through Nuclear Calcium(2+) Overload and DNA Damage Response in Human Prostate Cancer.
CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer.
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.
Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer.
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.
Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cells.
Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser727 on STAT3 in prostate cancer cells.
Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells.
Cyclin-dependent kinase inhibitor 3 (CDKN3) plays a critical role in prostate cancer via regulating cell cycle and DNA replication signaling.
Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1? and induces G2/M arrest under hypoxia in prostate cancer cells.
Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma.
Decreased skp2 expression is necessary but not sufficient for therapy-induced senescence in prostate cancer.
Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.
Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells.
Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells.
Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades.
Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival.
ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
Expression profile and prognostic importance in prostate lesions of the reverse transcriptase component of human telomerase (hTERT) and of cyclin-dependent kinase inhibitor p57 (p57(kip2a)).
Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci.
From androgen receptor to the general transcription factor TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH(2)-terminal associated coactivator.
Future Aspects of CDK5 in Prostate Cancer: From Pathogenesis to Therapeutic Implications.
Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
Human CDK12 and CDK13, multi-tasking CTD kinases for the new millennium.
Identification of distinctive patterns of USP19-mediated growth regulation in normal and malignant cells.
Identification of human male germ cell-associated kinase, a kinase transcriptionally activated by androgen in prostate cancer cells.
Identification of UBE2C as hub gene in driving prostate cancer by integrated bioinformatics analysis.
IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells.
In silico 3D structure modeling and inhibitor binding studies of human male germ cell-associated kinase.
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Indole-3-carbinol mediated cell cycle arrest of LNCaP human prostate cancer cells requires the induced production of activated p53 tumor suppressor protein.
Induction of CDK inhibitors (p21(WAF1) and p27(Kip1)) and Bak in the beta-lapachone-induced apoptosis of human prostate cancer cells.
Inhibition of cyclin-dependent kinase phosphorylation of FOXO1 and prostate cancer cell growth by a peptide derived from FOXO1.
Inhibition of extracellular signal-regulated kinase potentiates the apoptotic and antimetastatic effects of cyclin-dependent kinase inhibitors on metastatic DU145 and PC3 prostate cancer cells.
Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein.
Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis.
KHC-4 Anti-Cancer Effects on Human PC3 Prostate Cancer Cell Line.
Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer.
Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis.
Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade.
Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells.
Male germ cell-associated kinase is overexpressed in prostate cancer cells and causes mitotic defects via deregulation of APC/C(CDH1).
Male Germ Cell-Associated Kinase, a Male-Specific Kinase Regulated by Androgen, Is a Coactivator of Androgen Receptor in Prostate Cancer Cells.
Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).
MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL.
Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors.
mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men.
Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition.
Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells.
Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
p16 Is upregulated in proliferative inflammatory atrophy of the prostate.
p21/Cip1 and p27/Kip1 Are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer.
p27 Protein and cancers of the gastrointestinal tract and liver: an overview.
p53-dependent induction of heat shock protein 27 (HSP27) expression.
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.
Persistent P21Cip1 Induction Mediates G(1) Cell Cycle Arrest by Methylseleninic Acid in DU145 Prostate Cancer Cells.
Piceatannol, a natural stilbene from grapes, induces G1 cell cycle arrest in androgen-insensitive DU145 human prostate cancer cells via the inhibition of CDK activity.
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer.
Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells.
PUM1 represses CDKN1B translation and contributes to prostate cancer progression.
Quo Vadis Advanced Prostate Cancer Therapy? Novel Treatment Perspectives and Possible Future Directions.
RB independent G1-phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor and histone deacetylase inhibitor.
Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5.
Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells.
Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression.
Suppression of human prostate cancer cell growth by beta-lapachone via down-regulation of pRB phosphorylation and induction of Cdk inhibitor p21(WAF1/CIP1).
Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines.
Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines.
The effects of natural ligands of hormone receptors and their antagonists on telomerase activity in the androgen sensitive prostatic cancer cell line LNCaP.
The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma.
The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells.
The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1.
Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer.
TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer.
TNF receptor 1 is involved in the induction of apoptosis by the cyclin dependent kinase inhibitor p27Kip1 in the prostate cancer cell line PC-3.
Transient tyrosine phosphorylation of p34cdc2 is an early event in radiation-induced apoptosis of prostate cancer cells.
Ubiquitin-proteasome pathway and prostate cancer.
Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.
Upregulation of MircoRNA-370 induces proliferation in human prostate cancer cells by downregulating the transcription factor FOXO1.
Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm.
Prostatic Neoplasms, Castration-Resistant
Enhanced expression of cyclin-dependent kinase inhibitor in apoptosis of androgen-independent prostatic cancer cell line induced by calcium ionophore.
Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines.
Proteinuria
Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration.
Detecting and managing patients with type 2 diabetic kidney disease: proteinuria and cardiovascular disease.
Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus.
Proteinuria 1 year after renal transplantation is associated with impaired graft survival in children.
Pseudohypoaldosteronism
One-month-old girl presenting with pseudohypoaldosteronism leading to the diagnosis of CDK13-related disorder: a case report and review of the literature.
Psoriasis
Candidate gene polymorphisms and risk of psoriasis: A pilot study.
Cyclin-Dependent Kinase 7 Promotes Th17/Th1 Cell Differentiation in Psoriasis by Modulating Glycolytic Metabolism.
Immunohistochemical expression of cyclin-dependent kinase-2 in psoriasis.
The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis.
Psychomotor Disorders
A novel mutation in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene associated with a severe Rett phenotype.
Pterygium
Climatic droplet keratopathy in the Argentine Patagonia.
Ultraviolet light and ocular diseases.
Ultraviolet radiation and the eye: an epidemiologic study.
Puberty, Precocious
A CDKL5 mutated child with precocious puberty.
Puerperal Infection
Impact of clean delivery-kit use on newborn umbilical cord and maternal puerperal infections in Egypt.
Pulmonary Disease, Chronic Obstructive
Genetic Ablation of p16(Ink4a) Does Not Protect Against Cellular Senescence in Mouse Models of COPD/Emphysema.
Suppressed expression of T-box transcription factors is involved in senescence in chronic obstructive pulmonary disease.
Pulmonary Fibrosis
Induction of CDK inhibitor p21 gene as a new therapeutic strategy against pulmonary fibrosis.
receptor protein-tyrosine kinase deficiency
c-Met signalling is required for efficient postnatal thymic regeneration and repair.
Rectal Neoplasms
Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy.
p21, p27, cyclin D1, and p53 in rectal cancer: immunohistology with prognostic significance?
Renal Insufficiency
[Nephroprotective role of early correction of impaired nutritional status in patients with chronic disease of the kidneys at a predialysis stage]
Renal Insufficiency, Chronic
Proteinuria 1 year after renal transplantation is associated with impaired graft survival in children.
Reoviridae Infections
Reovirus-induced alterations in gene expression related to cell cycle regulation.
Reperfusion Injury
Acetyl salicylic acid augments functional recovery following sciatic nerve crush in mice.
Cyclin-dependent kinases as a therapeutic target for stroke.
Evaluating the Effects of CDK Inhibitors in Ischemia-Reperfusion Injury Models.
Inhibited histone deacetylase 3 ameliorates myocardial ischemia-reperfusion injury in a rat model by elevating microRNA-19a-3p and reducing cyclin-dependent kinase 2.
Inhibition of Cyclin-dependent Kinase 2 Signaling Prevents Liver Ischemia and Reperfusion Injury.
Neuroprotective effect of Buyang Huanwu Decoction on spinal ischemia-reperfusion injury in rats is linked with inhibition of cyclin-dependent kinase 5.
p21 and mTERT are novel markers for determining different ischemic time periods in renal ischemia-reperfusion injury.
Small Molecule Cyclin-Dependent Kinase Inhibitors Protect Against Neuronal Cell Death in the Ischemic-Reperfused Rat Retina.
The neuroprotective mechanism of puerarin in the treatment of acute spinal ischemia-reperfusion injury is linked to cyclin-dependent kinase 5.
Respiratory Distress Syndrome
The cyclin-dependent kinase inhibitor AT7519 accelerates neutrophil apoptosis in sepsis-related acute respiratory distress syndrome.
Retinal Degeneration
High-resolution Imaging in Male Germ Cell-Associated Kinase (MAK)-related Retinal Degeneration.
Retinitis Pigmentosa
Exome sequencing and analysis of induced pluripotent stem cells identify the cilia-related gene male germ cell-associated kinase (MAK) as a cause of retinitis pigmentosa.
Intraretinal cystoid spaces in a patient with retinitis pigmentosa due to mutation in the MAK gene.
Slowly progressive retinitis pigmentosa caused by two novel mutations in the MAK gene.
Retinoblastoma
1-(2-Hydroxy-5-methylphenyl)-3-phenyl-1,3-propanedione Induces G1 Cell Cycle Arrest and Autophagy in HeLa Cervical Cancer Cells.
17 beta-Estradiol-mediated growth inhibition of MDA-MB-468 cells stably transfected with the estrogen receptor: cell cycle effects.
2,3,4',5-Tetrahydroxystilbene-2-0-beta-D-glucoside inhibits platelet-derived growth factor-induced proliferation of vascular smooth muscle cells by regulating cell cycle.
2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle.
25-Methoxyhispidol A, a novel triterpenoid of Poncirus trifoliata, inhibits cell growth via the modulation of EGFR/c-Src signaling pathway in MDA-MB-231 human breast cancer cells.
3-Deazaadenosine Prevents Smooth Muscle Cell Proliferation and Neointima Formation by Interfering With Ras Signaling.
5'-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells.
5-Aza-2'-deoxycytidine leads to down-regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines.
7,3',4'-trihydroxyisoflavone inhibits epidermal growth factor-induced proliferation and transformation of JB6 P+ mouse epidermal cells by suppressing cyclin-dependent kinases and phosphatidylinositol 3- kinase.
7-hydroxystaurosporine (UCN-01) and ionizing radiation combine to inhibit the growth of Bcl-2-overexpressing U937 leukemia cells through a non-apoptotic mechanism.
A clinical evaluation of treatments that target cell cycle machinery in breast cancer.
A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
A Cytostatic Ruthenium(II)-Platinum(II) Bis(terpyridyl) Anticancer Complex That Blocks Entry into S?Phase by Up-regulating p27(KIP1).
A Fas-associated death domain protein/caspase-8-signaling axis promotes S-phase entry and maintains S6 kinase activity in T cells responding to IL-2.
A General G1/S-Phase Cell-Cycle Control Module in the Flowering Plant Arabidopsis thaliana.
A high-content, high-throughput siRNA screen identifies cyclin D2 as a potent regulator of muscle progenitor cell fusion and a target to enhance muscle regeneration.
A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines.
A novel cytoplasmic substrate for cdk4 and cdk6 in normal and malignant epithelial derived cells.
A novel function of adenovirus E1A is required to overcome growth arrest by the CDK2 inhibitor p27(Kip1).
A novel polyacetylene significantly inhibits angiogenesis and promotes apoptosis in human endothelial cells through activation of the CDK inhibitors and caspase-7.
A novel role of cyclinD1 and p16 in clinical pathology and prognosis of childhood medulloblastoma.
A novel synthetic oleanolic acid derivative with amino acid conjugate suppresses tumour growth by inducing cell cycle arrest.
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and Lymphomas.
A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042).
A pipecolic acid-rich branched cyclic depsipeptide ulleungamide C from a Streptomyces species induces G0/G1 cell cycle arrest in promyelocytic leukemia cells.
A population genomics study of the Arabidopsis core cell cycle genes shows the signature of natural selection.
A proliferation control network model: the simulation of two-dimensional epithelial homeostasis.
A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer.
A secreted low-molecular-weight protein from Helicobacter pylori induces cell-cycle arrest of T cells.
A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model.
AA-PMe, a novel asiatic acid derivative, induces apoptosis and suppresses proliferation, migration, and invasion of gastric cancer cells.
Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas.
Aberrant expression of G1-phase cell cycle regulators in flat and exophytic adenomas of the human colon.
Aberrant methylation-induced dysfunction of p16 is associated with osteoblast activation caused by fluoride.
Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation.
Aberrations of the G1- and G1/S-regulating genes in human cancer.
Abnormal cell cycle regulation in malignancy.
Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas.
Acetylation at lysine 346 controls the transforming activity of the HTLV-1 Tax oncoprotein in the Rat-1 fibroblast model.
Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
Activation of Cdk2-pRB-E2F1 cell cycle pathway by repeated electroconvulsive shock in the rat frontal cortex.
Activation of protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c).
Activation of RB/E2F signaling pathway is required for the modulation of hepatitis C virus core protein-induced cell growth in liver and non-liver cells.
Activation of the p53-p21(Cip1) pathway is required for CDK2 activation and S-phase entry in primary rat hepatocytes.
Activin A induction of cell-cycle arrest involves modulation of cyclin D2 and p21CIP1/WAF1 in plasmacytic cells.
Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells.
Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression.
Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes.
Adipogenic Differentiation Is Impaired in Replicative Senescent Human Subcutaneous Adipose-Derived Stromal/Progenitor Cells.
Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.
Alteration in cell cycle-related proteins in lymphoblasts from carriers of the c.709-1G>A PGRN mutation associated with FTLD-TDP dementia.
Alteration of cell cycle-related genes in hepatocarcinogenesis.
Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma.
Altered Expression of Cell Cycle Regulators in Adult T-Cell Leukemia/ Lymphoma Patients.
Altered expression of the suppressors PML and p53 in glioblastoma cells with the antisense-EGF-receptor.
An RB insensitive to CDK regulation.
Analogs of staurosporine: potential anticancer drugs?
Analysis of multiple molecular changes in human endocrine tumours.
Analysis of phosphorylation of pRB and its regulatory proteins in breast cancer.
Analysis of site-specific phosphorylation of the retinoblastoma protein during cell cycle progression.
Anchorage dependence of mitogen-induced G1 to S transition in primary T lymphocytes.
Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression.
Angiotensin II regulates activation of Bim via Rb/E2F1 during apoptosis: involvement of interaction between AMPK?1/2 and Cdk4.
Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest.
Anti-proliferation effect on human breast cancer cells via inhibition of pRb phosphorylation by taiwanin E isolated from Eleutherococcus trifoliatus.
Anti-proliferative effects of the novel squamosamide derivative (FLZ) on HepG2 human hepatoma cells by regulating the cell cycle-related proteins are associated with decreased Ca(2+)/ROS levels.
Anticancer properties of extracts from Opuntia humifusa against human cervical carcinoma cells.
Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
Antileukemia Effect of Ciclopirox Olamine Is Mediated by Downregulation of Intracellular Ferritin and Inhibition ?-Catenin-c-Myc Signaling Pathway in Glucocorticoid Resistant T-ALL Cell Lines.
Antiproliferative activity of vanadium compounds: effects on the major malignant melanoma molecular pathways.
Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
Antiproliferative effects of a new ?-lipoic acid derivative, DHL-HisZnNa, in HT29 human colon cancer cells in vitro.
Antitumor effect of metformin in esophageal cancer: in vitro study.
Antitumor effect of metformin on cholangiocarcinoma: In vitro and in vivo studies.
Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells.
Antitumor effects of a novel benzonaphthofurandione derivative (8e) on the human colon cancer cells in vitro and in vivo through cell cycle arrest accompanied with the modulation of EGFR and mTOR signaling.
AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity.
Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
AR, the cell cycle, and prostate cancer.
Arctigenin, a natural lignan compound, induces G0/G1 cell cycle arrest and apoptosis in human glioma cells.
Arotinoid mofarotene (RO40-8757) up-regulates p21 and p27 during growth inhibition of pancreatic cancer cell lines.
Aryl hydrocarbon receptor mediates laminar fluid shear stress-induced CYP1A1 activation and cell cycle arrest in vascular endothelial cells.
Astragaloside IV ameliorates radiation-induced senescence via antioxidative mechanism.
ATM: the product of the gene mutated in ataxia-telangiectasia.
Autophagy Inhibition Sensitizes Renal Tubular Epithelial Cell to G1 Arrest Induced by Transforming Growth Factor beta (TGF-?).
B55alpha PP2A holoenzymes modulate the phosphorylation status of the retinoblastoma-related protein p107 and its activation.
BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application.
Beta-escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21(waf1/cip1) in colon cancer cells.
BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1).
Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3.
Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells.
BRCA1 effects on the cell cycle and the DNA damage response are linked to altered gene expression.
BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model.
Bruton's tyrosine-kinase-deficient murine B lymphocytes fail to enter S phase when stimulated with anti-immunoglobulin plus interleukin-4.
Butyrate alters the expression and activity of cell cycle components in anaplastic thyroid carcinoma cells.
c-Myc overexpression uncouples DNA replication from mitosis.
c-Rel regulation of the cell cycle in primary mouse B lymphocytes.
Ca(2+)-dependent stimulation of retinoblastoma gene product phosphorylation and p34cdc2 kinase activation in serum-stimulated human fibroblasts.
Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells.
Calmodulin is essential for cyclin-dependent kinase 4 (Cdk4) activity and nuclear accumulation of cyclin D1-Cdk4 during G1.
Calpain modulates cyclin-dependent kinase inhibitor 1B (p27(Kip1)) in cells of the osteoblast lineage.
Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas.
Capsaicin inhibits in vitro and in vivo angiogenesis.
Cardiovascular gene therapy.
CCAAT/enhancer-binding protein delta regulates mammary epithelial cell G0 growth arrest and apoptosis.
Cdc37 facilitates cell survival of colorectal carcinoma via activating the CDK4 signaling pathway.
CDK4 activity in mouse embryos expressing a single D-type cyclin.
CDK4 has the ability to regulate Aurora B and Cenpp expression in mouse keratinocytes.
CDK4-6 inhibitors in breast cancer: current status and future development.
Cdkn2a encodes functional variation of p16INK4a but not p19ARF, which confers selection in mouse lung tumorigenesis.
Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway.
Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.
Cell cycle arrest in G0/G1 phase by contact inhibition and TGF-beta 1 in mink Mv1Lu lung epithelial cells.
Cell cycle deregulation and xeroderma pigmentosum group C cell transformation.
Cell cycle dysregulation in oral cancer.
Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
Cell cycle exit upon myogenic differentiation.
Cell cycle function of a Medicago sativa A2-type cyclin interacting with a PSTAIRE-type cyclin-dependent kinase and a retinoblastoma protein.
Cell cycle gene regulation in reversibly differentiated new human hepatoma cell lines.
Cell cycle in alveolar epithelial type II cells: integration of Matrigel and KGF.
Cell cycle regulation by bevacizumab in ARPE-19 human retinal pigment epithelial cells.
Cell cycle regulation of retinoblastoma protein phosphorylation.
Cell cycle regulators and their abnormalities in breast cancer.
Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1.
Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1.
Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds.
Cell-cycle control in Caenorhabditis elegans: how the worm moves from G1 to S.
Cell-cycle regulators are involved in transient cerebral ischemia induced neuronal apoptosis in female rats.
Cell-cycle targeted therapies.
Centrosome aberrations and cancer.
Centrosome replication, genomic instability and cancer.
Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes.
Characterization of the abnormal pancreatic development, reduced growth and infertility in Cdk4 mutant mice.
Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets.
Chromosomes, genes, and development of testicular germ cell tumors.
Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders.
Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica.
Cloning of murine CDK9/PITALRE and its tissue-specific expression in development.
Combined antitumor activity of 7-hydroxystaurosporine (UCN-01) and tamoxifen against human breast carcinoma in vitro and in vivo.
Combined effect of navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro.
Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome.
Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.
Contragestazol (DL111-IT) inhibits proliferation of human androgen-independent prostate cancer cell line PC3 in vitro and in vivo.
Control of cell cycle progression in human natural killer cells through redox regulation of expression and phosphorylation of retinoblastoma gene product protein.
Control of cell cycle regulatory proteins and modulation of STAT1 proteins by IFN-gamma in human prostatic JCA-1 cells.
Correlation between G1 cyclins and HPV in the uterine cervix.
Cotylenin A inhibits cell proliferation and induces apoptosis and PAX6 mRNA transcripts in retinoblastoma cell lines.
Critical role of cyclin D1 nuclear import in cardiomyocyte proliferation.
Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.
Crystal structure of the homolog of the oncoprotein gankyrin, an interactor of Rb and CDK4/6.
Curcuma wenyujin extract induces apoptosis and inhibits proliferation of human cervical cancer cells in vitro and in vivo.
Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines.
Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation.
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.
Cyclin D1 fine-tunes the neurogenic output of embryonic retinal progenitor cells.
Cyclin D1 Overexpression, p16 Loss, and pRb Inactivation Play a Key Role in Pulmonary Carcinogenesis and have a Prognostic Implication for the Long-term Survival in Non-small Cell Lung Carcinoma Patients.
Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism.
Cyclin D1, p16, and retinoblastoma gene regulate mitogenic signaling of endothelin in rat mesangial cells.
Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells.
Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells.
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.
Cyclin-dependent kinase 2 signaling regulates myocardial ischemia/reperfusion injury.
Cyclin-dependent kinase 2-associating protein 1 commits murine embryonic stem cell differentiation through retinoblastoma protein regulation.
Cyclin-dependent kinase 4/6 inhibitors require an arcuate to paraventricular hypothalamus melanocortin circuit to treat diet-induced obesity.
Cyclin-dependent kinase inhibitor p16INK4A inhibits phosphorylation of RNA polymerase II by general transcription factor TFIIH.
Cyclin-dependent kinase-like function is shared by the beta- and gamma- subset of the conserved herpesvirus protein kinases.
Cycling to and from a stem cell niche: the temporal and spatial odyssey of mitotic male germ cells.
Cyclins B1, T1 and H differ in their molecular mode of interaction with cytomegalovirus protein kinase pUL97.
Cytosolic nucleic acid sensors of the innate immune system promote liver regeneration after partial hepatectomy.
D-type cyclin-dependent kinase activity in mammalian cells.
Deciphering the retinoblastoma protein phosphorylation code.
Decorin deficiency promotes hepatic carcinogenesis.
Deletions and rearrangements inactivate the p16INK4 gene in human glioma cells.
Dephosphorylation of Rb (Thr-821) in response to cell stress.
Dephosphorylation of threonine-821 of the retinoblastoma tumor suppressor protein (Rb) is required for apoptosis induced by UV and Cdk inhibition.
Deregulation of the G1/S-phase control in human testicular germ cell tumours.
Deregulation of the p16-cyclin D1/cyclin-dependent kinase 4-retinoblastoma pathway involved in the rat bladder carcinogenesis induced by terephthalic acid-calculi.
Deregulation of the RB pathway in human testicular germ cell tumours.
Development of a Novel Nonradioisotopic Assay and Cdc25B Overexpression Cell Lines for Use in Screening for Cdc25B Inhibitors.
Dietary estrogens stimulate human breast cells to enter the cell cycle.
Difference of cell cycle arrests induced by lidamycin in human breast cancer cells.
Differences in stability of repressor complexes at promoters underlie distinct roles for Rb family members.
Different roles of ERK and p38 MAP kinases during tube formation from endothelial cells cultured in 3-dimensional collagen matrices.
Differential activities of E2F family members: unique functions in regulating transcription.
Differential Apoptotic and Mitogenic Effects of Lectins in Zebrafish.
Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4.
Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesis.
Differential regulation of p27kip1 levels and CDK activities by hypertrophic and hyperplastic agents in vascular smooth muscle cells.
Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites.
Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo.
Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors.
Differentiation-inducing factor-1, a morphogen of dictyostelium, induces G(1) arrest and differentiation of vascular smooth muscle cells.
Direct association of the HPV16 E7 oncoprotein with cyclin A/CDK2 and cyclin E/CDK2 complexes.
Direct interaction of p21 cyclin-dependent kinase inhibitor with the retinoblastoma tumor suppressor protein.
Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and -independent pathways by cyclin-dependent kinase 4/6.
Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors.
Discovery of a regulatory motif that controls the exposure of specific upstream cyclin-dependent kinase sites that determine both conformation and growth suppressing activity of pRb.
Distinct action of the retinoblastoma pathway on the DNA replication machinery defines specific roles for cyclin-dependent kinase complexes in prereplication complex assembly and S-phase progression.
Docosahexaenoic acid inhibits cancer cell growth via p27Kip1, CDK2, ERK1/ERK2, and retinoblastoma phosphorylation.
Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?
Down-regulation and decreased activity of cyclin-dependent kinase 2 in H2O2-induced premature senescence.
Downregulation of Cdc2/CDK1 kinase activity induces the synthesis of noninfectious human papillomavirus type 31b virions in organotypic tissues exposed to benzo[a]pyrene.
Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein.
Downregulation of Fer induces PP1 activation and cell-cycle arrest in malignant cells.
Downregulation of P16 promotes cigarette smoke extract-induced vascular smooth muscle cell proliferation via preventing G1/S phase transition.
Downregulation of Pin1 in human atherosclerosis and its association with vascular smooth muscle cell senescence.
Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.
E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1).
E2F proteins are posttranslationally modified concomitantly with a reduction in nuclear binding activity in cells infected with herpes simplex virus 1.
E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis.
E2F-1 regulates the expression of a subset of target genes during skeletal myoblast hypertrophy.
E2f1, E2f2, and E2f3 control E2F target expression and cellular proliferation via a p53-dependent negative feedback loop.
EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management.
Effect of cyclin E overexpression on lovastatin-induced G1 arrest and RhoA inactivation in NIH3T3 cells.
Effect of energy restriction on cell cycle machinery in 1-methyl-1-nitrosourea-induced mammary carcinomas in rats.
Effect of tumor suppressors on cell cycle-regulatory genes: RB suppresses p34cdc2 expression and normal p53 suppresses cyclin A expression.
Effect of Yanggan Jiedu Sanjie formula on human hepatocellular carcinoma Bel-7402 cells.
Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60).
Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells.
Electroacupuncture promotes chondrocyte proliferation via accelerated G1/S transition in the cell cycle.
Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade.
Enhancement of radiation response with combined Ganoderma lucidum and Duchesnea chrysantha extracts in human leukemia HL-60 cells.
Epinephrine stimulates esophageal squamous-cell carcinoma cell proliferation via beta-adrenoceptor-dependent transactivation of extracellular signal-regulated kinase/cyclooxygenase-2 pathway.
Epothilone B inhibits neointimal formation after rat carotid injury through the regulation of cell cycle-related proteins.
Epothilone D, a microtubule-stabilizing compound, inhibits neointimal hyperplasia after rat carotid artery injury by cell cycle arrest via regulation of G1-checkpoint proteins.
Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7.
Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines.
ERR? metabolic nuclear receptor controls growth of colon cancer cells.
Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation.
Establishment of an immortal chicken embryo liver-derived cell line.
Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells.
Evidence for a novel anti-apoptotic pathway in human keratinocytes involving the aryl hydrocarbon receptor, E2F1, and checkpoint kinase 1.
Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells.
Expression and modulation of p42/p44 MAPKs and cell cycle regulatory proteins in rat pancreas regeneration.
Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D3 in breast cancer cells.
Expression of certain antiproliferative and growth-related genes in isolated mouse pancreatic islets: analysis by polymerase chain reaction.
Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression.
Expression of the HPV E7 oncoprotein mimics but does not evoke a p53-dependent cellular DNA damage response pathway.
Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions.
Expressions and activities of cell cycle regulatory molecules during the transition from myocyte hyperplasia to hypertrophy.
Expressions of cell cycle regulators in human colorectal cancer cell lines.
Fgf15-mediated control of neurogenic and proneural gene expression regulates dorsal midbrain neurogenesis.
Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody.
Flavopiridol displays preclinical activity in acute lymphoblastic leukemia.
FoxF1 and FoxF2 transcription factors synergistically promote rhabdomyosarcoma carcinogenesis by repressing transcription of p21(Cip1) CDK inhibitor.
Frequent alterations of cell cycle regulators in early-stage breast lesions as detected by immunohistochemistry.
Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1.
Function of cell-cycle regulators in predicting silent pituitary adenoma progression following surgical resection.
Functional conservation of the cell cycle-regulating transcription factor DRTF1/E2F and its pathway of control in Drosophila melanogaster.
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2.
G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation.
G1/S cell cycle regulators mediate effects of circadian dysregulation on tumor growth and provide targets for timed anticancer treatment.
Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo.
Gap 1 phase length and mouse embryonic stem cell self-renewal.
Garcinia cambogia suppresses adipogenesis in 3T3-L1 cells by inhibiting p90RSK and Stat3 activation during mitotic clonal expansion.
Gene and other biological therapies for vascular diseases.
Gene expression profile of butyrate-inhibited vascular smooth muscle cell proliferation.
Genetic framework of cyclin-dependent kinase function in Arabidopsis.
Genistein inhibits rat aortic smooth muscle cell proliferation through the induction of p27kip1.
Ghrelin augments murine T-cell proliferation by activation of the phosphatidylinositol-3-kinase, extracellular signal-regulated kinase and protein kinase C signaling pathways.
GL331 induces down-regulation of cyclin D1 expression via enhanced proteolysis and repressed transcription.
Glucocorticoids stimulate p21 gene expression by targeting multiple transcriptional elements within a steroid responsive region of the p21waf1/cip1 promoter in rat hepatoma cells.
Glycogen serves as an energy source that maintains astrocyte cell proliferation in the neonatal telencephalon.
Growth factors and melanomas.
Growth induction of rat primary hepatocytes using antisense oligonucleotides.
Growth inhibition and cell cycle arrest effects of epigallocatechin gallate in the NBT-II bladder tumour cell line.
Growth inhibition and G1 cell cycle arrest mediated by 25-methoxyhispidol A, a novel triterpenoid, isolated from the fruit of Poncirus trifoliata in human hepatocellular carcinoma cells.
Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1.
Guilu Erxian Glue () Inhibits Chemotherapy-Induced Bone Marrow Hematopoietic Stem Cell Senescence in Mice May via p16INK4a-Rb Signaling Pathway.
hCLP46 regulates U937 cell proliferation via Notch signaling pathway.
Heat shock protein B8, a cyclin-dependent kinase-independent cyclin D1 target gene, contributes to its effects on radiation sensitivity.
Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
Hepatitis B Virus Pre-S2 Mutant Surface Antigen Induces Degradation of Cyclin-Dependent Kinase Inhibitor p27Kip1 through c-Jun Activation Domain-Binding Protein 1.
Hepatitis C virus core functions as a suppressor of cyclin-dependent kinase-activating kinase and impairs cell cycle progression.
Hepatoprotective effects of hydroxysafflor yellow A in D-galactose-treated aging mice.
Herpes simplex virus 1 alpha regulatory protein ICP0 interacts with and stabilizes the cell cycle regulator cyclin D3.
Hesperetin, a bioflavonoid, inhibits rat aortic vascular smooth muscle cells proliferation by arresting cell cycle.
High trefoil factor 1 (TFF1) expression in human retinoblastoma cells correlates with low growth kinetics, increased cyclin-dependent kinase (CDK) inhibitor levels and a selective down-regulation of CDK6.
Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells.
HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.
HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects.
Hot spots for molecular genetic alterations in lung cancer.
How can food extracts consumed in the Mediterranean and East Asia suppress prostate cancer proliferation?
Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells.
Human cytomegalovirus-encoded viral cyclin-dependent kinase (v-CDK) UL97 phosphorylates and inactivates the retinoblastoma protein-related p107 and p130 proteins.
Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase.
Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis.
Human papillomavirus type 16 E7 oncoprotein associates with the centrosomal component gamma-tubulin.
Human retinoblastoma protein (Rb) is phosphorylated by cdc2 kinase and MAP kinase in Xenopus maturing oocytes.
Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein.
Hypoxia inhibits G1/S transition through regulation of p27 expression.
Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia.
Hypoxia-ischemia induces DNA synthesis without cell proliferation in dying neurons in adult rodent brain.
Identification of glucocorticoid-induced leucine zipper as a key regulator of tumor cell proliferation in epithelial ovarian cancer.
Identification of the E2A gene products as regulatory targets of the G1 cyclin-dependent kinases.
IGFBP-rP1 induces p21 expression through a p53-independent pathway, leading to cellular senescence of MCF-7 breast cancer cells.
Imaging bone morphogenetic protein 7 induced cell cycle arrest in experimental gliomas.
Immortalization of bovine capillary endothelial cells by hTERT alone involves inactivation of endogenous p16INK4A/pRb.
Immunohistochemical analysis for cell regulatory proteins in bladder carcinogenesis induced by N-methyl-N-nitrosourea-terephthalic acid.
Immunohistochemical analysis of the D-type cyclin-dependent kinases Cdk4 and Cdk6, using a series of monoclonal antibodies.
Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.
Immunohistochemical expression of p16(INK4a) is predictive of HR-HPV infection in cervical low-grade lesions.
Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in salivary gland tumours.
Immunohistochemical inactivation of p14ARF concomitant with MDM2 overexpression inversely correlates with p53 overexpression in oral squamous cell carcinoma.
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
In vitro effects of imatinib on CD34(+) cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase.
In vivo expression patterns of MyoD, p21, and Rb proteins in myonuclei and satellite cells of denervated rat skeletal muscle.
Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function.
Increased expression of the INK4a/ARF locus in polycythemia vera.
Increased expression of the P27KIP1 protein in human esophageal cancer cell lines that over-express cyclin D1.
Increased histone H1 phosphorylation and relaxed chromatin structure in Rb-deficient fibroblasts.
Indomethacin inhibits endothelial cell proliferation by suppressing cell cycle proteins and PRB phosphorylation: a key to its antiangiogenic action?
Induced differentiation, the cell cycle, and the treatment of cancer.
Induced expression of p16 and p21 proteins in UVB-irradiated human epidermis and cultured keratinocytes.
Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation.
Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process.
Induction of beta-cell proliferation and retinoblastoma protein phosphorylation in rat and human islets using adenovirus-mediated transfer of cyclin-dependent kinase-4 and cyclin D1.
Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin.
Induction of G1 arrest and apoptosis by schisandrin C isolated from Schizandra chinensis Baill in human leukemia U937 cells.
Induction of G1 arrest and apoptosis by Scutellaria barbata in the human promyelocytic leukemia HL-60 cell line.
Induction of G1 cell cycle arrest in human umbilical vein endothelial cells by flavone's inhibition of the extracellular signal regulated kinase cascade.
Induction of G?/M Arrest by Berberine via Activation of PI3K/Akt and p38 in Human Chondrosarcoma Cell Line.
Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation.
Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells.
ING1a expression increases during replicative senescence and induces a senescent phenotype.
Inhibition of cell-cycle effectors of proliferation in bladder tumor epithelial cells by the p75NTR tumor suppressor.
Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity.
Inhibition of cyclin D1 expression and phosphorylation of retinoblastoma protein by phosmidosine, a nucleotide antibiotic.
Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1.
Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation.
Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells.
Inhibition of cyclin-dependent kinases improves CA1 neuronal survival and behavioral performance after global ischemia in the rat.
Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein.
Inhibition of myogenesis by depletion of the glycogen-associated regulatory subunit of protein phosphatase-1 in rat skeletal muscle cells.
Inhibition of PDGF-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors.
Inhibition of retinoblastoma protein phosphorylation by myogenesis-induced changes in the subunit composition of the cyclin-dependent kinase 4 complex.
Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication.
Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells.
Inhibition of the cyclin D1/E2F pathway by PCA-4230, a potent repressor of cellular proliferation.
Inhibitory effect of fenofibrate on neointima hyperplasia via G(0)/G(1) arrest of cell proliferation.
Inhibitory Effect of Human Breast Cancer Cell Proliferation via p21-Mediated G1 Cell Cycle Arrest by Araliadiol Isolated from Aralia cordata Thunb.
Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery.
Inhibitory effects of docetaxel on platelet-derived growth factor (PDGF)-BB-induced proliferation of vascular smooth muscle cells through blocking PDGF-receptor ? phosphorylation.
Inositol hexaphosphate inhibits growth and induces G1 arrest and apoptotic death of androgen-dependent human prostate carcinoma LNCaP cells.
Insulin-like growth factor binding protein-3 induces G1 cell cycle arrest with inhibition of cyclin-dependent kinase 2 and 4 in MCF-7 human breast cancer cells.
Interaction between high glucose and TGF-beta in cell cycle protein regulations in MDCK cells.
Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
Interactions of the human papillomavirus E7 protein with cell cycle regulators.
Intercellular adhesion molecule 1 discriminates functionally different populations of human osteoblasts: characteristic involvement of cell cycle regulators.
Interferon treatment enhances the expression of underphosphorylated (biologically-active) retinoblastoma protein in human papilloma virus-infected cells through the inhibitory TGF beta 1/IFN beta cytokine pathway.
Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK).
Interleukin-1 receptor antagonist (IL-1ra) modulates endothelial cell proliferation.
Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells.
Interleukin-6-resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity.
Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein.
Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation.
Involvement of Cdc25A phosphatase in Hep3B hepatoma cell growth inhibition induced by novel K vitamin analogs.
Involvement of E2F1 transcriptional activity in cadmium-induced cell-cycle arrest at G1 in human lung fibroblasts.
Involvement of p21(Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate.
Involvement of p21cip-1 and p27kip-1 in the molecular mechanisms of steel factor-induced proliferative synergy in vitro and of p21cip-1 in the maintenance of stem/progenitor cells in vivo.
Involvement of p21WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells.
Ionizing radiation-induced chromosomal rearrangements occur in transcriptionally active regions of the genome.
Isolation and regional assignment of human chromosome 12p cDNAs.
KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway.
Karyotypically abnormal human ESCs are sensitive to HDAC inhibitors and show altered regulation of genes linked to cancers and neurological diseases.
KCl cotransport is an important modulator of human cervical cancer growth and invasion.
KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis.
Lack of germline CDK6 mutations in familial melanoma.
Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
Lack of p19INK4d in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis.
Laminar shear stress inhibits vascular endothelial cell proliferation by inducing cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1)
Lebein, a snake venom disintegrin, suppresses human colon cancer cells proliferation and tumor-induced angiogenesis through cell cycle arrest, apoptosis induction and inhibition of VEGF expression.
Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1).
Long intergenic noncoding RNA 00908 promotes proliferation and inhibits apoptosis of colorectal cancer cells by regulating KLF5 expression.
Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3? Signaling Pathway.
Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts.
Loss of functional pRB is not a ubiquitous feature of B-cell malignancies.
Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer.
LRP1 Regulates Retinal Angiogenesis by Inhibiting PARP-1 Activity and Endothelial Cell Proliferation.
Luteolin induces apoptosis in oral squamous cancer cells.
Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway.
Lyn is activated during late G1 of stem-cell-factor-induced cell cycle progression in haemopoietic cells.
Mammalian target of rapamycin as a therapeutic target in leukemia.
Mammalian target of rapamycin: a new molecular target for breast cancer.
Mechanisms controlling cell cycle exit upon terminal differentiation.
Mechanisms of p16INK4A inactivation in non small-cell lung cancers.
Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.
Mechanosensitive p27Kip1 regulation and cell cycle entry in vascular smooth muscle cells.
Melanomas, from the cell cycle point of view (Review).
Membrane depolarization stimulates the proliferation of SH-SY5Y human neuroblastoma cells by increasing retinoblastoma protein (RB) phosphorylation through the activation of cyclin-dependent kinase 2 (Cdk2).
Methylation analysis of cell cycle control genes in adult T-cell leukemia/lymphoma.
Mice lacking bi-1 gene show accelerated liver regeneration.
MicroRNAs and the cell cycle.
microRNAs in the pathogenesis of non-obstructive azoospermia: the underlying mechanisms and therapeutic potentials.
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.
miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma.
MiR-371-373 cluster acts as a tumor-suppressor-miR and promotes cell cycle arrest in unrestricted somatic stem cells.
Mirk regulates the exit of colon cancer cells from quiescence.
Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells.
Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence.
Modulation of cell cycle components by epigenetic and genetic events.
Molecular analysis of p21 and p27 genes in human pituitary adenomas.
Molecular characterisation of breast cancer patients at high and low recurrence risk.
Molecular cloning and characterization of the human p19(INK4d) gene promoter.
Molecular Determinants for the Inactivation of the Retinoblastoma Tumor Suppressor by the Viral Cyclin-dependent Kinase UL97.
Molecular mechanism of endothelial growth arrest by laminar shear stress.
Molecular mechanisms of cellular senescence and immortalization of human cells.
Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle.
Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.
mRNA Expression of CDK2AP1 in Human Breast Cancer: Correlation with Clinical and Pathological Parameters.
Multifaceted p21 in carcinogenesis, stemness of tumor and tumor therapy.
Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells.
Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.
Multiple roles for Puralpha in cellular and viral regulation.
Murine coronavirus nonstructural protein p28 arrests cell cycle in G0/G1 phase.
Murrayafoline A Induces a G0/G1-Phase Arrest in Platelet-Derived Growth Factor-Stimulated Vascular Smooth Muscle Cells.
Mutant p53 can delay growth arrest and loss of CDK2 activity in senescing human fibroblasts without reducing p21(WAF1) expression.
Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors.
Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
Naringenin is an inhibitor of T cell effector functions.
Natriuretic peptide receptor-C agonist attenuates the expression of cell cycle proteins and proliferation of vascular smooth muscle cells from spontaneously hypertensive rats: role of Gi proteins and MAPkinase/PI3kinase signaling.
NGF regulates the PC12 cell cycle machinery through specific inhibition of the Cdk kinases and induction of cyclin D1.
Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation.
Non-malignant and tumor-derived cells differ in their requirement for p27Kip1 in transforming growth factor-beta-mediated G1 arrest.
Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells.
Novel p53/p130 axis in bladder tumors.
Novel SIRT Inhibitor, MHY2256, Induces Cell Cycle Arrest, Apoptosis, and Autophagic Cell Death in HCT116 Human Colorectal Cancer Cells.
Nucleocytoplasmic shuttling of the retinoblastoma tumor suppressor protein via Cdk phosphorylation-dependent nuclear export.
Occurrence of molecular abnormalities of cell cycle in L132 cells after in vitro short-term exposure to air pollution PM(2.5).
Oncogenic function of a novel WD-domain protein, STRAP, in human carcinogenesis.
Overexpression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia.
Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri.
Overexpression of the signaling adapter FRS2 reconstitutes the cell cycle deficit of a nerve growth factor non-responsive TrkA receptor mutant.
p107 and p130 associated cyclin A has altered substrate specificity.
p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck.
p16 promotes proliferation in cervical carcinoma cells through CDK6-HuR-IL1A axis.
P16 protein abnormality in Epstein-Barr virus-associated gastric carcinomas.
p16INK4A participates in a G1 arrest checkpoint in response to DNA damage.
P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
p21 and retinoblastoma protein control the absence of DNA replication in terminally differentiated muscle cells.
p21WAF1/CIP1 protein expression in primary ovarian cancer.
p27 (Kip1) is required to maintain proliferative quiescence in the adult cochlea and pituitary.
p27(Kip1) is important in modulating pulmonary artery smooth muscle cell proliferation.
p27Kip1 regulates alpha-synuclein expression.
p34cdc2 kinase activity is maintained upon activation of the replication checkpoint in Schizosaccharomyces pombe.
p38? is essential for cell cycle progression and liver tumorigenesis.
p53 family members in myogenic differentiation and rhabdomyosarcoma development.
p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis.
p53/p21 Pathway involved in mediating cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients.
Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
Panaxydol Derived from Panax ginseng Inhibits G1 Cell Cycle Progression in Non-small Cell Lung Cancer via Upregulation of Intracellular Ca2+ Levels.
Pathways governing G1/S transition and their response to DNA damage.
PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis.
Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO).
Phosphatase 2A associated with polyomavirus small-T or middle-T antigen is an okadaic acid-sensitive tyrosyl phosphatase.
Phosphorylation of Drosophila Brahma on CDK-phosphorylation sites is important for cell cycle regulation and differentiation.
Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function.
Phosphorylation of transcriptional regulators in the retinoblastoma protein pathway by UL97, the viral cyclin-dependent kinase encoded by human cytomegalovirus.
Phosphorylation site specificity of the CDC2-related kinase PITALRE.
Physalin B inhibits cell proliferation and induces apoptosis in undifferentiated human gastric cancer HGC-27 cells.
Physical interaction of human T-cell leukemia virus type 1 Tax with cyclin-dependent kinase 4 stimulates the phosphorylation of retinoblastoma protein.
Physiological cyclic stretch causes cell cycle arrest in cultured vascular smooth muscle cells.
Piperlongumine decreases cell proliferation and the expression of cell cycle-associated proteins by inhibiting Akt pathway in human lung cancer cells.
PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro.
Pleurotus ostreatus inhibits proliferation of human breast and colon cancer cells through p53-dependent as well as p53-independent pathway.
Pocket protein p130/Rb2 is required for efficient herpes simplex virus type 1 gene expression and viral replication.
Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells.
PP2A holoenzymes negatively and positively regulate cell cycle progression by dephosphorylating pocket proteins and multiple CDK substrates.
PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a.
Presenilin 1 overexpressions in Chinese hamster ovary (CHO) cells decreases the phosphorylation of retinoblastoma protein: relevance for neurodegeneration.
Primary endobronchial liposarcoma successfully resected via bronchoscopy: A rare case report with genetic analysis.
PRMT4-mediated arginine methylation negatively regulates retinoblastoma tumor suppressor protein and promotes E2F-1 dissociation.
Production of the novel mesangial autocrine growth factors GDNF and IL-10 is regulated by the immunomodulator AS101.
Progesterone receptor isoforms and proliferation in the rat mammary gland during development.
Progesterone regulates proliferation of endothelial cells.
Proliferating cell nuclear antigen as the cell cycle sensor for an HLA-derived peptide blocking T cell proliferation.
Proliferation of intimal smooth muscle cells. Attenuation of basic fibroblast growth factor 2-stimulated proliferation is associated with increased expression of cell cycle inhibitors.
Prolyl oligopeptidase participates in cell cycle progression in a human neuroblastoma cell line.
Promoter activation and following induction of the p21/WAF1 gene by flavone is involved in G1 phase arrest in A549 lung adenocarcinoma cells.
Proproliferative phenotype of pulmonary microvascular endothelial cells.
Prostaglandin A2 blocks the activation of G1 phase cyclin-dependent kinase without altering mitogen-activated protein kinase stimulation.
Prostate cancer and inositol hexaphosphate: efficacy and mechanisms.
PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer.
Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells.
Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest.
Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade.
Protein kinase C isozyme-mediated cell cycle arrest involves induction of p21(waf1/cip1) and p27(kip1) and hypophosphorylation of the retinoblastoma protein in intestinal epithelial cells.
Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
Pterostilbene, a natural dimethylated analog of resveratrol, inhibits rat aortic vascular smooth muscle cell proliferation by blocking Akt-dependent pathway.
Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases.
Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine: Evaluation of a Novel Selective Inhibitor of Cyclin-Dependent Kinases with Antiproliferative Activity.
RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4/6 inhibitors.
RACK1 regulates G1/S progression by suppressing Src kinase activity.
Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression.
Rare mutations of the growth suppressor genes involved in negative regulation of the cell cycle.
Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer.
Regulation of CBP and Tip60 coordinates histone acetylation at local and global levels during Ras-induced transformation.
Regulation of cyclin and cyclin-dependent kinase gene expression during lens differentiation requires the retinoblastoma protein.
Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling.
Regulation of RB transcription in vivo by RB family members.
Results of immunohistochemical staining for cell cycle regulators predict the recurrence of atypical meningiomas.
Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase.
Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas.
Retinoblastoma protein phosphorylation does not require activation of p34CDC2 protein kinase.
Retinoblastoma related1 regulates asymmetric cell divisions in Arabidopsis.
Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase.
Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas.
Retinoic acid stimulates the cell cycle machinery in normal T cells: involvement of retinoic acid receptor-mediated IL-2 secretion.
Retraction for Braden et al., "Distinct Action of the Retinoblastoma Pathway on the DNA Replication Machinery Defines Specific Roles for Cyclin-Dependent Kinase Complexes in Prereplication Complex Assembly and S-Phase Progression".
Revealing the Anti-Tumor Effect of Artificial miRNA p-27-5p on Human Breast Carcinoma Cell Line T-47D.
Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity.
RNA interference against mixed lineage leukemia 5 resulted in cell cycle arrest.
Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas.
Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity.
Role of key regulators of the cell cycle in maintenance of hematopoietic stem cells.
Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.
Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Roxithromycin is an inhibitor of human coronary artery smooth muscle cells proliferation: a potential ability to prevent coronary heart disease.
S100B increases proliferation in PC12 neuronal cells and reduces their responsiveness to nerve growth factor via Akt activation.
Safety and efficacy profile of cyclin-dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta-analysis of clinical trials.
Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
Selective inhibition of HTLV-1-infected cell proliferation by a novel tetramethylnaphthalene derivative.
Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.
Serine/arginine-rich splicing factor 7 regulates p21-dependent growth arrest in colon cancer cells.
SHIP1 negatively regulates proliferation of osteoclast precursors via Akt-dependent alterations in D-type cyclins and p27.
Short time exposure to hypoxia promotes H9c2 cell growth.
Signalling In The Epidermis: The E2f Cell Cycle Regulatory Pathway In Epidermal Morphogenesis, Regeneration And Transformation.
Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.
Solid pseudopapillary neoplasms of the pancreas show an interruption of the Wnt-signaling pathway and express gene products of 11q.
Somatostatin interferes with thyrotropin-induced G1-S transition mediated by cAMP-dependent protein kinase and phosphatidylinositol 3-kinase. Involvement of RhoA and cyclin E x cyclin-dependent kinase 2 complexes.
Specific regulation of E2F family members by cyclin-dependent kinases.
Specificity of the polycation-stimulated (type-2A) and ATP,Mg-dependent (type-1) protein phosphatases toward substrates phosphorylated by P34cdc2 kinase.
Stable SREBP-1a knockdown decreases the cell proliferation rate in human preadipocyte cells without inducing senescence.
Stem-cell factor regulates the expression of cyclin A and retinoblastoma gene product in the growth and differentiation pathway of human megakaryocytic cells.
Steroid- and retinoid-mediated growth arrest and apoptosis in WEHI-231 cells: role of NF-kappaB, c-Myc and CKI p27(Kip1).
Stressing the cell cycle in senescence and aging.
Structures of inactive retinoblastoma protein reveal multiple mechanisms for cell cycle control.
Study of a novel brain relatively specific gene LRRC4 involved in glioma tumorigenesis suppression using the Tet-on system.
Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
Suppression of Src/ERK and GSK-3/?-catenin signaling by pinosylvin inhibits the growth of human colorectal cancer cells.
Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1.
T-cell apoptosis induced by granulocyte colony-stimulating factor is associated with retinoblastoma protein phosphorylation and reduced expression of cyclin-dependent kinase inhibitors.
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression.
Telomerase activity in relation to p53 status and clinico-pathological parameters in breast cancer.
The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo.
The antiproliferative effect of beta-carotene requires p21waf1/cip1 in normal human fibroblasts.
The antitumor activity of the fungicide ciclopirox.
The Biflavonoid Amentoflavone Induces Apoptosis via Suppressing E7 Expression, Cell Cycle Arrest at Sub-G(1) Phase, and Mitochondria-Emanated Intrinsic Pathways in Human Cervical Cancer Cells.
The biochemical basis of CDK phosphorylation-independent regulation of E2F1 by the retinoblastoma protein.
The CDC2-related kinase PITALRE is the catalytic subunit of active multimeric protein complexes.
The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.
The cell cycle in breast cancer.
The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53.
The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
The cyclin-dependent kinase inhibitory domain of the yeast Sic1 protein is contained within the C-terminal 70 amino acids.
The cyclopentenone 15-deoxy-delta(12,14)-prostaglandin J2 inhibits G1/S transition and retinoblastoma protein phosphorylation in immortalized lymphocytes from Alzheimer's disease patients.
The D-type cyclins and their role in tumorigenesis.
The double dealing of cyclin D1.
The E2FC-DPB Transcription Factor Controls Cell Division, Endoreplication and Lateral Root Formation in a SCF-Dependent Manner.
The effect of miR-340 over-expression on cell-cycle-related genes in triple-negative breast cancer cells.
The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer.
The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors.
The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity.
The human melanocyte: a model system to study the complexity of cellular aging and transformation in non-fibroblastic cells.
The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer.
The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.
The interplay between p16 serine phosphorylation and arginine methylation determines its function in modulating cellular apoptosis and senescence.
The kinase inhibitor staurosporine induces G1 arrest at two points: effect on retinoblastoma protein phosphorylation and cyclin-dependent kinase 2 in normal and transformed cells.
The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
The multifaceted role of cell cycle regulators in the coordination of growth and metabolism.
The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
The retinoblastoma protein physically associates with the human cdc2 kinase.
The role of activin type I receptors in activin A-induced growth arrest and apoptosis in mouse B-cell hybridoma cells.
The role of CDK5/P25 formation/inhibition in neurodegeneration.
The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma.
The soybean-derived peptide lunasin inhibits non-small cell lung cancer cell proliferation by suppressing phosphorylation of the retinoblastoma protein.
The structure of CDK4/cyclin D3 has implications for models of CDK activation.
The tumor suppressor gene p53 can mediate transforming growth [corrected] factor beta1-induced differentiation of leukemic cells independently of activation of the retinoblastoma protein.
The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B.
Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma.
Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism.
Thyrotropin and serum regulate thyroid cell proliferation through differential effects on p27 expression and localization.
TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein.
Topoisomerase IIalpha mediates E2F-1-induced chemosensitivity and is a target for p53-mediated transcriptional repression.
TRANSCRIPTIONAL DOWNREGULATION OF p27KIP1 THROUGH REGULATION OF E2F FUNCTION DURING LMP1-MEDIATED TRANSFORMATION.
Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb.
Transformation by v-Jun prevents cell cycle exit and promotes apoptosis in the absence of serum growth factors.
Transforming growth factor beta 1 (TGF beta 1) reduces cellular levels of p34cdc2, and this effect is abrogated by adenovirus independently of the E1A-associated pRB binding activity.
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.
Transforming Growth Factor-? Regulates the Growth of Valve Interstitial Cells in Vitro.
Transforming growth factor-beta antagonizes alveolar type II cell proliferation induced by keratinocyte growth factor.
Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium.
Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Treatment of T-cell non-Hodgkin's lymphoma.
Tumor suppression by IFN regulatory factor-1 is mediated by transcriptional down-regulation of cyclin D1.
Type V collagen is an epithelial cell cycle inhibitor that is induced by and mimics the effects of transforming growth factor beta1.
Ubiquitin-dependent proteolysis of cyclin D1 is associated with coxsackievirus-induced cell growth arrest.
UCN-01 (7-hydroxystaurosporine) inhibits the growth of human breast cancer xenografts through disruption of signal transduction.
Unliganded thyroid hormone receptor beta1 inhibits proliferation of murine fibroblasts by delaying the onset of the G1 cell-cycle signals.
Unscheduled expression of cyclins D1 and D3 in human tumour cell lines.
Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate.
V3 loop of human immunodeficiency virus type 1 reduces cyclin E expression and induces G1 arrest in interleukin 2-dependent T cells.
Vanadyl bisacetylacetonate induced G1/S cell cycle arrest via high-intensity ERK phosphorylation in HepG2 cells.
Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm.
Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules.
WD repeat and SOCS box containing protein 2 in the proliferation, cycle progression, and migration of melanoma cells.
What is the restriction point?
Widdrol induces cell cycle arrest, associated with MCM down-regulation, in human colon adenocarcinoma cells.
Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression.
[Cyclins and proliferative pathology]
[Expression of key cell cycle markers in squamous cell carcinoma of the cervix positive in human papillomavirus: a comparative study between Chinese and Australian populations]
[The status of gene therapy in cardiovascular medicine]
Retroviridae Infections
The impact of p53 on the early stage replication of retrovirus.
Rett Syndrome
14q12 microdeletions excluding FOXG1 give rise to a congenital variant Rett syndrome-like phenotype.
A missense mutation within the fork-head domain of the forkhead box G1 Gene (FOXG1) affects its nuclear localization.
A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders.
A new paradigm for West syndrome based on molecular and cell biology.
A novel CDKL5 mutation in a 47,XXY boy with the early-onset seizure variant of Rett syndrome.
A novel CDKL5 mutation in a Japanese patient with atypical Rett syndrome.
A novel mutation in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene associated with a severe Rett phenotype.
Aberrant mitochondrial function in patient-derived neural cells from CDKL5 deficiency disorder and Rett Syndrome.
Alteration of serum lipid profile, SRB1 loss, and impaired Nrf2 activation in CDKL5 disorder.
Alu-specific microhomology-mediated deletions in CDKL5 in females with early-onset seizure disorder.
An isoform of the severe encephalopathy-related CDKL5 gene, including a novel exon with extremely high sequence conservation, is specifically expressed in brain.
Analysis of FOXG1 Is Highly Recommended in Male and Female Patients with Rett Syndrome.
Analysis of Hungarian patients with Rett syndrome phenotype for MECP2, CDKL5 and FOXG1 gene mutations.
CDKL Family Kinases Have Evolved Distinct Structural Features and Ciliary Function.
CDKL5 alterations lead to early epileptic encephalopathy in both genders.
CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome.
CDKL5 deficiency entails sleep apneas in mice.
CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons.
CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail.
CDKL5 gene status in female patients with epilepsy and Rett-like features: two new mutations in the catalytic domain.
CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery.
CDKL5 is a brain MeCP2 target gene regulated by DNA methylation.
CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients.
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.
CDKL5, a protein associated with rett syndrome, regulates neuronal morphogenesis via Rac1 signaling.
CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms.
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Clinical Phenotype of 5 Females With a CDKL5 Mutation.
Comparing Parental Well-Being and Its Determinants Across Three Different Genetic Disorders Causing Intellectual Disability.
Comparison of Core Features in Four Developmental Encephalopathies in the Rett Natural History Study.
Current developments in the genetics of Rett and Rett-like syndrome.
Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Screening in Rett Syndrome and Related Disorders.
Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder.
Cyclin-dependent kinase-like 5 binds and phosphorylates DNA methyltransferase 1.
Cytokine Dysregulation in MECP2- and CDKL5-Related Rett Syndrome: Relationships with Aberrant Redox Homeostasis, Inflammation, and ?-3 PUFAs.
Dendritic Spine Instability in a Mouse Model of CDKL5 Disorder Is Rescued by Insulin-like Growth Factor 1.
Early onset seizures and Rett-like features associated with mutations in CDKL5.
Encephalopathy and bilateral cataract in a boy with an interstitial deletion of Xp22 comprising the CDKL5 and NHS genes.
Enrichment of mutations in chromatin regulators in people with Rett syndrome lacking mutations in MECP2.
Epigenetic mechanisms of gene expression regulation in neurological diseases.
Epilepsy and mental retardation limited to females with PCDH19 mutations can present de novo or in single generation families.
Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies.
Epileptic encephalopathy and atypical Rett syndrome with mutations in CDKL5: clinical and molecular characterization of two Brazilian patients.
Epileptic encephalopathy in a girl with an interstitial deletion of Xp22 comprising promoter and exon 1 of the CDKL5 gene.
Evoked Potentials and EEG Analysis in Rett Syndrome and Related Developmental Encephalopathies: Towards a Biomarker for Translational Research.
Expression pattern of cdkl5 during zebrafish early development: implications for use as model for atypical Rett syndrome.
Extrasynaptic NMDA receptor stimulation induces CDKL5 cytoplasmic translocation and proteasomal degradation.
FOXG1 Mutation is a Low-Incidence Genetic Cause in Atypical Rett Syndrome.
Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation.
GluD1 is a common altered player in neuronal differentiation from both MECP2-mutated and CDKL5-mutated iPS cells.
HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder.
Identification of amphiphysin 1 as an endogenous substrate for CDKL5, a protein kinase associated with X-linked neurodevelopmental disorder.
Imbalance of excitatory/inhibitory synaptic protein expression in iPSC-derived neurons from FOXG1(+/-) patients and in foxg1(+/-) mice.
Immune dysfunction in Rett syndrome patients revealed by high levels of serum anti-N(Glc) IgM antibody fraction.
Impairment of CDKL5 nuclear localisation as a cause for severe infantile encephalopathy.
In Silico Study of Rett Syndrome Treatment-Related Genes, MECP2, CDKL5, and FOXG1, by Evolutionary Classification and Disordered Region Assessment.
Inactivation of the CDKL3 gene at 5q31.1 by a balanced t(X;5) translocation associated with nonspecific mild mental retardation.
Inflammatory protein response in CDKL5-Rett syndrome: evidence of a subclinical smouldering inflammation.
Intellectual disabilities, neuronal posttranscriptional RNA metabolism, and RNA-binding proteins: three actors for a complex scenario.
Key clinical features to identify girls with CDKL5 mutations.
Lack of Cdkl5 Disrupts the Organization of Excitatory and Inhibitory Synapses and Parvalbumin Interneurons in the Primary Visual Cortex.
Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice.
Mapping pathological phenotypes in a mouse model of CDKL5 disorder.
Maternal origin of a novel C-terminal truncation mutation in CDKL5 causing a severe atypical form of Rett syndrome.
MECP2 and CDKL5 gene mutation analysis in Chinese patients with Rett syndrome.
Monogenic disorders that mimic the phenotype of Rett syndrome.
Mutation analysis of the HDAC 1, 2, 8 and CDKL5 genes in Rett syndrome patients without mutations in MECP2.
Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.
Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation.
Myoclonic encephalopathy in the CDKL5 gene mutation.
Neurobehavioral phenotype in cyclin-dependent kinase-like 5 syndrome: Case report and review of literature.
Novel CDKL5 Mutations in Czech Patients with Phenotypes of Atypical Rett Syndrome and Early-Onset Epileptic Encephalopathy.
Novel Mutations in Cyclin-Dependent Kinase-Like 5 (CDKL5) Gene in Indian Cases of Rett Syndrome.
Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes.
Palmitoylation-dependent CDKL5-PSD-95 interaction regulates synaptic targeting of CDKL5 and dendritic spine development.
Phenotypes in adult patients with Rett syndrome: results of a 13-year experience and insights into healthcare transition.
Phenotypic manifestations between male and female children with CDKL5 mutations.
Potentially Treatable Disorder Diagnosed Post Mortem by Exome Analysis in a Boy with Respiratory Distress.
Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome.
Recurrent mutations in the CDKL5 gene: genotype-phenotype relationships.
Respiratory and sleep disorders in female children with atypical Rett syndrome caused by mutations in the CDKL5 gene.
Rett Syndrome and CDKL5 Deficiency Disorder: From Bench to Clinic.
Seizures and electroencephalographic findings in CDKL5 mutations: case report and review.
Seizures in Mouse Models of Rare Neurodevelopmental Disorders.
Subcellular distribution of cyclin-dependent kinase-like 5 (CDKL5) is regulated through phosphorylation by dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A).
Synaptic Synthesis, Dephosphorylation, and Degradation: A NOVEL PARADIGM FOR AN ACTIVITY-DEPENDENT NEURONAL CONTROL OF CDKL5.
The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy.
The MEF2C-Related and 5q14.3q15 Microdeletion Syndrome.
The neurobiology of x-linked intellectual disability.
Transcription Factor 4 and Myocyte Enhancer Factor 2C mutations are not common causes of Rett syndrome.
Two Siblings With a CDKL5 Mutation: Genotype and Phenotype Evaluation.
Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients.
Variant of Rett syndrome and CDKL5 gene: clinical and autonomic description of 10 cases.
Variation in novel exons (RACEfrags) of the MECP2 gene in Rett syndrome patients and controls.
Visual impairment in FOXG1-mutated individuals and mice.
Xp22.3 Genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy.
[Methyl-CpG-binding protein 2 gene and CDKL5 gene mutation in patients with Rett syndrome: analysis of 177 Chinese pediatric patients]
Rhabdoid Tumor
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
Rhabdoid tumor growth is inhibited by flavopiridol.
Rhabdomyosarcoma
Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma.
Elevated cyclins and cyclin-dependent kinase activity in the rhabdomyosarcoma cell line RD.
Expression of cyclin-dependent kinase inhibitor p27/Kip1 and AP-1 coactivator p38/Jab1 correlates with differentiation of embryonal rhabdomyosarcoma.
FoxF1 and FoxF2 transcription factors synergistically promote rhabdomyosarcoma carcinogenesis by repressing transcription of p21(Cip1) CDK inhibitor.
Immunohistochemical expression of cyclin-dependent kinase inhibitors p16 and p57 in rhabdomyosarcoma.
In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2.
Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells.
Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells.
Rhabdomyosarcoma, Alveolar
Cyclin-Dependent Kinase 4 Phosphorylates and Positively Regulates PAX3-FOXO1 in Human Alveolar Rhabdomyosarcoma Cells.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Rhabdomyosarcoma, Embryonal
Expression of cyclin-dependent kinase inhibitor p27/Kip1 and AP-1 coactivator p38/Jab1 correlates with differentiation of embryonal rhabdomyosarcoma.
Rheumatic Diseases
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.
Salivary Gland Neoplasms
Expression of cyclin-dependent kinase inhibitor 2A 16, tumour protein 53 and epidermal growth factor receptor in salivary gland carcinomas is not associated with oncogenic virus infection.
Transcriptional activation of cyclin-dependent kinase inhibitor, p21waf1 gene by treatment with a differentiation inducing agent, vesnarinone in a human salivary gland cancer cell line.
Sarcoma
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
A versatile modular vector system for rapid combinatorial mammalian genetics.
Association between methylation of DNA damage response-related genes and DNA damage in hepatocytes of rats following subchronic exposure to vinyl chloride.
CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets.
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy.
Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors.
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.
Evidence for interaction between v-Mos and a p34cdc2 isoform, p35cdk.
G1 phase-specific suppression of the Cdk2 activity by ginsenoside Rh2 in cultured murine cells.
Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation.
Generation of knockout mouse models of cyclin-dependent kinase inhibitors by engineered nuclease-mediated genome editing.
Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
Gossypin as a Novel Selective Dual Inhibitor of v-raf Murine Sarcoma Viral Oncogene Homolog B1 and Cyclin-Dependent Kinase 4 for Melanoma.
Identification of dysregulated pathways associated with pancreatic cancer by survival analysis.
Immunohistochemical detection of senescence markers in human sarcomas.
Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma.
Levels of p27(kip1) determine Aplidin sensitivity.
Novel mutation of the cyclin-dependent kinase 4 gene in a Chinese patient with intimal sarcoma of the pulmonary artery.
p15INK4b plays a crucial role in murine lymphoid development and tumorigenesis.
Photocarcinogenesis and Skin Cancer Prevention Strategies: An Update.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells.
Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.
Supernumerary ring chromosomes derived from the long arm of chromosome 12 as the primary cytogenetic anomaly in a rare soft tissue chondroma.
Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and phase I clinical trial.
The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
The prognosis in spindle-cell sarcoma depends on the expression of cyclin-dependent kinase inhibitor p27(Kip1) and cyclin E.
The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
Use of 5'-?-Ferrocenyl Adenosine Triphosphate (Fc-ATP) Bioconjugates Having Poly(ethylene glycol) Spacers in Kinase-Catalyzed Phosphorylations.
Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma.
Viral src gene products are related to the catalytic chain of mammalian cAMP-dependent protein kinase.
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Sarcoma, Avian
Cytosolic malic dehydrogenase activity is associated with a putative substrate for the transforming gene product of Rous sarcoma virus.
Protein kinase and its regulatory effect on reverse transcriptase activity of Rous sarcoma virus.
Sarcoma, Ewing
A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.
Let-7a Functions as a Tumor Suppressor in Ewing's Sarcoma Cell Lines Partly by Targeting Cyclin-Dependent Kinase 6.
Two potentially oncogenic cyclins, cyclin A and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein.
Sarcoma, Kaposi
Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex.
Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6.
KSHV vCyclin counters the senescence/G1 arrest response triggered by NF-?B hyperactivation.
The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2.
The Regulatory Effects of CDKN1A on Relevant Genes in Kaposi's Sarcoma Cells.
Sarcoma, Synovial
Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.
Low expression of p27(Kip1), a cyclin-dependent kinase inhibitor, is a marker of poor prognosis in synovial sarcoma.
Sarcopenia
Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.
Scleroderma, Systemic
The non-neuronal cyclin-dependent kinase 5 is a fibrotic mediator potentially implicated in systemic sclerosis and a novel therapeutic target.
Scoliosis
Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome.
Seizures
14q12 microdeletions excluding FOXG1 give rise to a congenital variant Rett syndrome-like phenotype.
A case of CDKL5 disorder: improved ADL by simple treatment strategy for intractable epileptic seizures.
A distinctive seizure type in patients with CDKL5 mutations: Hypermotor-tonic-spasms sequence.
A girl with early-onset epileptic encephalopathy associated with microdeletion involving CDKL5.
A maternally inherited frameshift CDKL5 variant in a male with global developmental delay and late-onset generalized epilepsy.
A new paradigm for West syndrome based on molecular and cell biology.
A novel CDKL5 mutation in a 47,XXY boy with the early-onset seizure variant of Rett syndrome.
A novel mutation in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene associated with a severe Rett phenotype.
A novel transcript of cyclin-dependent kinase-like 5 (CDKL5) has an alternative C-terminus and is the predominant transcript in brain.
Aberrant mitochondrial function in patient-derived neural cells from CDKL5 deficiency disorder and Rett Syndrome.
Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
Altered network and rescue of human neurons derived from individuals with early-onset genetic epilepsy.
Alu-specific microhomology-mediated deletions in CDKL5 in females with early-onset seizure disorder.
AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder.
An isoform of the severe encephalopathy-related CDKL5 gene, including a novel exon with extremely high sequence conservation, is specifically expressed in brain.
Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.
CDKL5 alterations lead to early epileptic encephalopathy in both genders.
CDKL5 and ARX mutations are not responsible for early onset severe myoclonic epilepsy in infancy.
CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome.
CDKL5 controls postsynaptic localization of GluN2B-containing NMDA receptors in the hippocampus and regulates seizure susceptibility.
CDKL5 deficiency augments inhibitory input into the dentate gyrus that can be reversed by deep brain stimulation.
CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail.
CDKL5 gene status in female patients with epilepsy and Rett-like features: two new mutations in the catalytic domain.
CDKL5 Gene-Related Epileptic Encephalopathy in Estonia: Four Cases, One Novel Mutation Causing Severe Phenotype in a Boy, and Overview of the Literature.
CDKL5 localizes at the centrosome and midbody and is required for faithful cell division.
CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients.
CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy.
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.
CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms.
CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders.
Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
Clinical and electroencephalographic features in patients with CDKL5 mutations: two new Italian cases and review of the literature.
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Clinical Phenotype of 5 Females With a CDKL5 Mutation.
Comparison of Core Features in Four Developmental Encephalopathies in the Rett Natural History Study.
Content Validation of Clinician-Reported Items for a Severity Measure for CDKL5 Deficiency Disorder.
Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Screening in Rett Syndrome and Related Disorders.
Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
Early onset seizures and Rett-like features associated with mutations in CDKL5.
Early-onset seizure variant of Rett syndrome: Definition of the clinical diagnostic criteria.
Early-onset seizures due to mosaic exonic deletions of CDKL5 in a male and two females.
Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder.
Encephalopathy and bilateral cataract in a boy with an interstitial deletion of Xp22 comprising the CDKL5 and NHS genes.
Epileptic encephalopathy in a girl with an interstitial deletion of Xp22 comprising promoter and exon 1 of the CDKL5 gene.
Expanding the phenotype of the CDKL5 deficiency disorder: Are seizures mandatory?
Exploring genotype-phenotype relationships in the CDKL5 deficiency disorder using an international dataset.
Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder.
Expression pattern of cdkl5 during zebrafish early development: implications for use as model for atypical Rett syndrome.
Extrasynaptic NMDA receptor stimulation induces CDKL5 cytoplasmic translocation and proteasomal degradation.
Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation.
Gene mutation analysis of 175 Chinese patients with early-onset epileptic encephalopathy.
Genetic interactions among cortical malformation genes that influence susceptibility to convulsions in C. elegans.
Genetically determined encephalopathy: Rett syndrome.
Genotype-phenotype correlates of infantile-onset developmental & epileptic encephalopathy syndromes in South India: A single centre experience.
Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder.
Identification of a novel CDKL5 exon and pathogenic mutations in patients with severe mental retardation, early-onset seizures and Rett-like features.
Induction of cyclin-dependent kinase 5 in the hippocampus by chronic electroconvulsive seizures: role of [Delta]FosB.
Inhibition of GSK3? rescues hippocampal development and learning in a mouse model of CDKL5 disorder.
iPS cells to model CDKL5-related disorders.
Italian Rett database and biobank.
Key clinical features to identify girls with CDKL5 mutations.
Loss of CDKL5 disrupts respiratory function in mice.
Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3? signaling.
Loss of CDKL5 in Glutamatergic Neurons Disrupts Hippocampal Microcircuitry and Leads to Memory Impairment in Mice.
Molecular and genetic insights into an infantile epileptic encephalopathy - CDKL5 disorder.
Molecular characteristics of Chinese patients with Rett syndrome.
Mutation in an alternative transcript of CDKL5 in a boy with early onset seizures.
Mutation screening of the CDKL5 gene in cryptogenic infantile intractable epilepsy and review of clinical sensitivity.
Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.
Myoclonic encephalopathy in the CDKL5 gene mutation.
Network for Therapy in Rare Epilepsies (NETRE): Lessons From the Past 15 Years.
Neurobehavioral phenotype in cyclin-dependent kinase-like 5 syndrome: Case report and review of literature.
New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy.
Novel CDKL5 Mutations in Czech Patients with Phenotypes of Atypical Rett Syndrome and Early-Onset Epileptic Encephalopathy.
Novel Mutations in Cyclin-Dependent Kinase-Like 5 (CDKL5) Gene in Indian Cases of Rett Syndrome.
NTNG1 mutations are a rare cause of Rett syndrome.
Potentially Treatable Disorder Diagnosed Post Mortem by Exome Analysis in a Boy with Respiratory Distress.
Pregnenolone and pregnenolone-methyl-ether rescue neuronal defects caused by dysfunctional CLIP170 in a neuronal model of CDKL5 Deficiency Disorder.
Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome.
Reflex Seizures in a Patient with CDKL5 Deficiency Disorder.
Reigning in Excitatory Signaling in CDKL5 Deficiency.
Respiratory and sleep disorders in female children with atypical Rett syndrome caused by mutations in the CDKL5 gene.
Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy.
Rett Syndrome and CDKL5 Deficiency Disorder: From Bench to Clinic.
Rett syndrome: clinical review and genetic update.
Rett-like phenotypes: expanding the genetic heterogeneity to the KCNA2 gene and first familial case of CDKL5-related disease.
Rodent genetic models of neurodevelopmental disorders and epilepsy.
Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder.
Seizures and electroencephalographic findings in CDKL5 mutations: case report and review.
Seizures in Mouse Models of Rare Neurodevelopmental Disorders.
Site-specific abnormalities in the visual system of a mouse model of CDKL5 deficiency disorder.
Splicing Mutations Impairing CDKL5 Expression and Activity Can be Efficiently Rescued by U1snRNA-Based Therapy.
Structural Bases of Atypical Whisker Responses in a Mouse Model of CDKL5 Deficiency Disorder.
The antidepressant tianeptine reverts synaptic AMPA receptor defects caused by deficiency of CDKL5.
The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy.
The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo.
The perceived effects of cannabis products in the management of seizures in CDKL5 Deficiency Disorder.
Treatment with a GSK-3?/HDAC Dual Inhibitor Restores Neuronal Survival and Maturation in an In Vitro and In Vivo Model of CDKL5 Deficiency Disorder.
Treatment with the GSK3-beta inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, Cdkl5 knockout mice.
Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients.
Validation of high-resolution DNA melting analysis for mutation scanning of the CDKL5 gene: identification of novel mutations.
Variant of Rett syndrome and CDKL5 gene: clinical and autonomic description of 10 cases.
Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13.
X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder.
Xp22.3 Genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy.
[Rett syndrome: 50 years' history of a still not well known condition]
Seminoma
Histological groups of human postpubertal testicular germ cell tumours harbour different genetic alterations.
Identification of nuclear structural protein alterations associated with seminomas.
Sepsis
Epidermal growth factor treatment decreases mortality and is associated with improved gut integrity in sepsis.
Impact of clean delivery-kit use on newborn umbilical cord and maternal puerperal infections in Egypt.
Sertoli Cell-Only Syndrome
microRNAs in the pathogenesis of non-obstructive azoospermia: the underlying mechanisms and therapeutic potentials.
Skin Diseases
Human papillomavirus and overexpression of P16INK4a in nonmelanoma skin cancer.
Skin Neoplasms
Growth arrest of immortalized human keratinocytes and suppression of telomerase activity by p21WAF1 gene expression.
Human papillomavirus and overexpression of P16INK4a in nonmelanoma skin cancer.
Identification of new fisetin analogs as kinase inhibitors: Data on synthesis and anti-skin cancer activities evaluation.
Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers.
Sleep Apnea Syndromes
CDKL5 deficiency entails sleep apneas in mice.
Sleep Wake Disorders
Respiratory and sleep disorders in female children with atypical Rett syndrome caused by mutations in the CDKL5 gene.
Small Cell Lung Carcinoma
An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
Cyclin-dependent kinase inhibitors for the treatment of lung cancer.
Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?
Effect of suramin on p34cdc2 kinase in vitro and in extracts from human H69 cells: evidence for a double mechanism of action.
Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era.
Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer.
Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.
Smooth Muscle Tumor
Atypical uterine leiomyoma: a case report and review of the literature.
CDK-inhibitors-associated kinase activity: a possible determinant of malignant potential in smooth muscle tumors of the external soft tissue.
Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors.
Spasm
Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
CDKL5 alterations lead to early epileptic encephalopathy in both genders.
CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms.
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy.
Spasms, Infantile
A 1.1 million base pair X-chromosomal deletion covering the PDHA1 and CDKL5 genes in a female patient with west syndrome and pyruvate oxidation deficiency.
A new paradigm for West syndrome based on molecular and cell biology.
A novel C-terminal truncated mutation in hCDKL5 protein causing a severe West syndrome: Comparison with previous truncated mutations and genotype/phenotype correlation.
A novel mutation in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene associated with a severe Rett phenotype.
A novel transcript of cyclin-dependent kinase-like 5 (CDKL5) has an alternative C-terminus and is the predominant transcript in brain.
Aberrant mitochondrial function in patient-derived neural cells from CDKL5 deficiency disorder and Rett Syndrome.
Alu-specific microhomology-mediated deletions in CDKL5 in females with early-onset seizure disorder.
An isoform of the severe encephalopathy-related CDKL5 gene, including a novel exon with extremely high sequence conservation, is specifically expressed in brain.
CDKL5 disruption by t(X;18) in a girl with West syndrome.
CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail.
CDKL5 gene status in female patients with epilepsy and Rett-like features: two new mutations in the catalytic domain.
CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery.
CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients.
CDKL5 truncation due to a t(X;2)(p22.1;p25.3) in a girl with X-linked infantile spasm syndrome.
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.
CDKL5, a protein associated with rett syndrome, regulates neuronal morphogenesis via Rac1 signaling.
CDKL5-Related Disorders: From Clinical Description to Molecular Genetics.
CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms.
CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders.
Cell cloning-based transcriptome analysis in cyclin-dependent kinase-like 5 mutation patients with severe epileptic encephalopathy.
Characterisation of CDKL5 Transcript Isoforms in Human and Mouse.
Clinical manifestation of CDKL5 deficiency disorder and identified mutations in a cohort of Slovak patients.
Clinical Phenotype of 5 Females With a CDKL5 Mutation.
Cyclin-Dependent Kinase-Like 5 (CDKL5) Mutation Screening in Rett Syndrome and Related Disorders.
Extrasynaptic NMDA receptor stimulation induces CDKL5 cytoplasmic translocation and proteasomal degradation.
Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation.
Genotype-phenotype correlates of infantile-onset developmental & epileptic encephalopathy syndromes in South India: A single centre experience.
Genotype-phenotype correlation on 45 individuals with West syndrome.
High prevalence of genetic alterations in early-onset epileptic encephalopathies associated with infantile movement disorders.
Identification of amphiphysin 1 as an endogenous substrate for CDKL5, a protein kinase associated with X-linked neurodevelopmental disorder.
Impairment of CDKL5 nuclear localisation as a cause for severe infantile encephalopathy.
Inactivation of the CDKL3 gene at 5q31.1 by a balanced t(X;5) translocation associated with nonspecific mild mental retardation.
Key clinical features to identify girls with CDKL5 mutations.
Maternal origin of a novel C-terminal truncation mutation in CDKL5 causing a severe atypical form of Rett syndrome.
Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.
Mutations in the C-terminus of CDKL5: proceed with caution.
Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation.
Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation.
Myoclonic encephalopathy in the CDKL5 gene mutation.
Novel Mutations in Cyclin-Dependent Kinase-Like 5 (CDKL5) Gene in Indian Cases of Rett Syndrome.
Novel mutations in the CDKL5 gene in complex genotypes associated with West syndrome with variable phenotype: First description of somatic mosaic state.
Phenotypic manifestations between male and female children with CDKL5 mutations.
Recurrent mutations in the CDKL5 gene: genotype-phenotype relationships.
Seizures and electroencephalographic findings in CDKL5 mutations: case report and review.
The neuropathological consequences of CDKL5 mutation.
Validation of high-resolution DNA melting analysis for mutation scanning of the CDKL5 gene: identification of novel mutations.
Xp22.3 Genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy.
Spinal Cord Injuries
An algorithmic strategy of surgical intervention for cervical degenerative kyphosis.
Calpain inhibitor inhibits p35-p25-Cdk5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats.
Increased expression of CDK11(p58 )and cyclin D3 following spinal cord injury in rats.
The PI3K/Akt/FOXO3a pathway regulates regeneration following spinal cord injury in adult rats through TNF-? and p27kip1 expression.
Spondylitis, Ankylosing
Hsa_circ_0056558 regulates cyclin-dependent kinase 6 by sponging microRNA-1290 to suppress the proliferation and differentiation in ankylosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma.
Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
CDC28 protein kinase regulatory subunit 1B (CKS1B) expression and genetic status analysis in oral squamous cell carcinoma.
CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3K? Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Characteristics of antitumor activity of mutant type p27Kip1 gene in an oral cancer cell line.
Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.
Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells.
Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells.
Diagnostic value of cyclin-dependent kinase/cyclin-dependent kinase inhibitor expression ratios as biomarkers of locoregional and hematogenous dissemination risks in oral squamous cell carcinoma.
Down-regulation of Cdk inhibitor p27 in oral squamous cell carcinoma.
EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.
Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity.
Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy.
Expression of p53 and p21CIP1/WAF1 proteins in oral epithelial dysplasias and squamous cell carcinomas.
Expression of Skp2 and p27(kip1) proteins in hypopharyngeal squamous cell carcinoma and its clinical significance.
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo.
Genetic alterations of chromosome band 9p21-22 in head and neck cancer are not restricted to p16INK4a.
High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas.
Homozygous deletions and loss of expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors.
Hypermethylation of Promoter Region of LATS1 - a CDK Interacting Protein in Oral Squamous Cell Carcinomas - a Pilot Study in India.
Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in squamous cell carcinoma of the larynx.
Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas.
Long non-coding RNA CCAT1 is a prognostic biomarker for the progression of oral squamous cell carcinoma via miR-181a-mediated Wnt/?-catenin signaling pathway.
Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck squamous cell carcinoma.
miR-204 enhances p27 mRNA stability by targeting Brd4 in head and neck squamous cell carcinoma.
miR-9 induces cell arrest and apoptosis of oral squamous cell carcinoma via CDK 4/6 pathway.
Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells.
p16 as a prognostic factor for the response to induction chemotherapy in advanced hypopharyngeal squamous cell carcinoma.
Preferential cytoplasmic localization of p34cdc2 in recurrent human squamous cell carcinoma after radiotherapy.
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is an indicator of malignant behavior in oral squamous cell carcinoma.
SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
The clinical significance of CDK1 expression in oral squamous cell carcinoma.
The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells-A Systematic Analysis.
The localization of p34cdc2 in the cells of normal, hyperplastic, and malignant epithelial and lymphoid tissues of the oral cavity.
The Opioid Growth Factor (OGF) OGF Receptor Axis Uses the p16 Pathway to Inhibit Head and Neck Cancer.
Transfection of p27(Kip1) threonine residue 187 mutant type gene, which is not influenced by ubiquitin-mediated degradation, induces cell cycle arrest in oral squamous cell carcinoma cells.
Starvation
A role for cell cycle proteins in the serum-starvation resistance of Epstein-Barr virus immortalized B lymphocytes.
Autophosphorylation-induced degradation of the Pho85 cyclin Pcl5 is essential for response to amino acid limitation.
CDK-dependent Hsp70 Phosphorylation controls G1 cyclin abundance and cell-cycle progression.
Cell cycle regulation of the p34cdc2/p33cdk2-activating kinase p40MO15.
Chemical inhibition of the Pho85 cyclin-dependent kinase reveals a role in the environmental stress response.
Common regulation of growth arrest and differentiation of osteoblasts by helix-loop-helix factors.
DAF-16/FOXO regulates transcription of cki-1/Cip/Kip and repression of lin-4 during C. elegans L1 arrest.
Different domains of the essential GTPase Cdc42p required for growth and development of Saccharomyces cerevisiae.
Fission yeast TOR complex 2 activates the AGC-family Gad8 kinase essential for stress resistance and cell cycle control.
Functional characterization of the Cdc42p binding domain of yeast Ste20p protein kinase.
Histone deacetylase inhibitors specifically kill nonproliferating tumour cells.
Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse.
Interaction of yeast Rvs167 and Pho85 cyclin-dependent kinase complexes may link the cell cycle to the actin cytoskeleton.
Mcm1p binding sites in ARG1 positively regulate Gcn4p binding and SWI/SNF recruitment.
Mcm1p binding sites in the ARG1 promoter positively regulate ARG1 transcription and S. cerevisiae growth in the absence of arginine and Gcn4p.
Nutrient-regulated antisense and intragenic RNAs modulate a signal transduction pathway in yeast.
Oct1 is required for mTOR-induced G1 cell cycle arrest via the control of p27(Kip1) expression.
Polyglutamine repeats of spinocerebellar ataxia 6 impair the cell-death-preventing effect of CaV2.1 Ca2+ channel--loss-of-function cellular model of SCA6.
Pop2 phosphorylation at S39 contributes to the glucose repression of stress response genes, HSP12 and HSP26.
Quantitative proteomics identifies unanticipated regulators of nitrogen- and glucose starvation.
Regulation of a cyclin-CDK-CDK inhibitor complex by inositol pyrophosphates.
Regulation of the Pcl7-Pho85 cyclin-cdk complex by Pho81.
Requirement of PP2A-B56Par1 for the Stabilization of the CDK Inhibitor Rum1 and Activation of APC/CSte9 during Pre-Start G1 in S. pombe.
Sensitization of Melanoma Cells for Death Ligand TRAIL Is Based on Cell Cycle Arrest, ROS Production, and Activation of Proapoptotic Bcl-2 Proteins.
Sphingolipids and Inositol Phosphates Regulate the Tau Protein Phosphorylation Status in Humanized Yeast.
The geranyl acetophenone tHGA attenuates human bronchial smooth muscle proliferation via inhibition of AKT phosphorylation.
[Function of an inhibitor of cyclin-dependent kinase p27/Kip in cells transformed by E1A + E1B19 kDa + E1A + cHa-Ras, differing in their ability to realize a G1-block during serum starvation]
Stomach Neoplasms
Analysis of Cyclin-Dependent Kinase 1 as an Independent Prognostic Factor for Gastric Cancer Based on Statistical Methods.
CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene.
CDK12 and PAK2 as novel therapeutic targets for human gastric cancer.
CDK4 down-regulation induced by paclitaxel is associated with G1 arrest in gastric cancer cells.
CDK5RAP3 Inhibits the Translocation of MCM6 to Influence the Prognosis in Gastric Cancer.
Clinicopathological and biological significance of CDC28 protein kinase regulatory subunit 2 overexpression in human gastric cancer.
Constitutive activation of glycogen synthase kinase-3beta correlates with better prognosis and cyclin-dependent kinase inhibitors in human gastric cancer.
Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis.
Cyclin-Dependent Kinase 1 (CDK1) is Co-Expressed with CDCA5: Their Functions in Gastric Cancer Cell Line MGC-803.
Cyclin-dependent kinase 5 decreases in gastric cancer and its nuclear accumulation suppresses gastric tumorigenesis.
Cyclin-dependent kinase 7 inhibitor THZ2 inhibits the growth of human gastric cancer in vitro and in vivo.
Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis.
Discovering the mechanism and involvement of the methylation of cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and its special locus region in gastric cancer.
Downregulated CDK10 expression in gastric cancer: Association with tumor progression and poor prognosis.
E2F1-induced upregulation of long noncoding RNA LINC00668 predicts a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically silencing of CKIs.
Expression of CRM1 and CDK5 shows high prognostic accuracy for gastric cancer.
Expression of NUAK2 in gastric cancer tissue and its effects on the proliferation of gastric cancer cells.
Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer.
Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression.
Expressions of cyclin E, cyclin dependent kinase 2 and p57(KIP2) in human gastric cancer.
Functional role of the KLF6 tumour suppressor gene in gastric cancer.
Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis.
Genetic and epigenetic alterations in multistep carcinogenesis of the stomach.
Growth inhibition of cultured human gastric cancer cells by 9-cis-retinoic acid with induction of cdk inhibitor Waf1/Cip1/Sdi1/p21 protein.
Intracellular chloride regulates cell proliferation through the activation of stress-activated protein kinases in MKN28 human gastric cancer cells.
Knockdown of Cyclin-Dependent Kinase Inhibitor 3 Inhibits Proliferation and Invasion in Human Gastric Cancer Cells.
Knockdown of long noncoding RNA GHET1 inhibits cell?cycle progression and invasion of gastric cancer cells.
Knockdown of PFTK1 Inhibits the Migration of Glioma Cells.
Liquiritin induces apoptosis and autophagy in cisplatin (DDP)-resistant gastric cancer cells in vitro and xenograft nude mice in vivo.
Loss of cyclin-dependent kinase-like 2 predicts poor prognosis in gastric cancer, and its overexpression suppresses cells growth and invasion.
Low Expression of CDK10 Correlates with Adverse Prognosis in Gastric Carcinoma.
Low expression of CDK12 in gastric cancer is correlated with advanced stage and poor outcome.
Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells.
miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells.
Oleanolic acid reduces aerobic glycolysis-associated proliferation by inhibiting yes-associated protein in gastric cancer cells.
Overexpressed CISD2 has prognostic value in human gastric cancer and promotes gastric cancer cell proliferation and tumorigenesis via AKT signaling pathway.
Overexpression of CDKN2B is involved in poor gastric cancer prognosis.
p27kip1 expression is inversely related to the grade of gastric MALT lymphoma.
Palbociclib induces cell senescence and apoptosis of gastric cancer cells by inhibiting the Notch pathway.
PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion.
Prognostic implications of cyclin B1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer.
Prognostic Importance of Cell Cycle Regulators Cyclin D1 (CCND1) and Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B/p27) in Sporadic Gastric Cancers.
Prognostic value of the cyclin-dependent kinase inhibitor p27Kip1 in gastric cancer.
RNAi-mediated downregulation of CDKL1 inhibits growth and colony-formation ability, promotes apoptosis of human melanoma cells.
Roles of cyclin-dependent kinase 8 and ?-catenin in the oncogenesis and progression of gastric adenocarcinoma.
The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
The novel protective role of P27 in MLN4924-treated gastric cancer cells.
The prognostic value of Cyclin-Dependent Kinase 5 and Protein Phosphatase 2A in Gastric Cancer.
The Role and Clinical Implications of the Retinoblastoma (RB)-E2F Pathway in Gastric Cancer.
Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells.
Upregulation of cyclin-dependent kinase 7 and matrix metalloproteinase-14 expression contribute to metastatic properties of gastric cancer.
Upregulation of miR-370 contributes to the progression of gastric carcinoma via suppression of FOXO1.
[Correlation between cyclin-dependent kinase inhibitor p27kip1 and trastuzumab-resistance in gastric cancer].
Stomach Ulcer
Role of basic fibroblast growth factor in the suppression of apoptotic caspase-3 during chronic gastric ulcer healing.
Stomatitis
Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)-Like Pigmentation in a Metastatic Breast Cancer Patient.
Stroke
Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians.
Cyclin-dependent kinases and stroke.
Cyclin-dependent kinases as a therapeutic target for stroke.
Delayed Administration of Tat-HA-NR2B9c Promotes Recovery After Stroke in Rats.
Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models.
Essential role of cytoplasmic cdk5 and Prx2 in multiple ischemic injury models, in vivo.
Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases.
N-Methyl-D-Aspartate Receptor Signaling-Protein Kinases Crosstalk in Cerebral Ischemia.
Targeting p35/Cdk5 Signalling via CIP-Peptide Promotes Angiogenesis in Hypoxia.
Superinfection
Adeno-associated virus type 2 increases proteosome-dependent degradation of p21WAF1 in a human papillomavirus type 31b-positive cervical carcinoma line.
Tauopathies
Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice.
Cell-Cycle Markers in a Transgenic Mouse Model of Human Tauopathy: Increased Levels of Cyclin-Dependent Kinase Inhibitors p21Cip1 and p27Kip1.
Cyclin-dependent kinase 5, a node protein in diminished tauopathy: a systems biology approach.
Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase.
Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies.
RPS23RG1 modulates tau phosphorylation and axon outgrowth through regulating p35 proteasomal degradation.
Tamoxifen inhibits CDK5 kinase activity by interacting with p35/p25 and modulates the pattern of tau phosphorylation.
Targeting CDK5 post-stroke provides long-term neuroprotection and rescues synaptic plasticity.
Telangiectasia, Hereditary Hemorrhagic
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Telangiectasis
Deciphering the vascular labyrinth: role of microRNAs and candidate gene SNPs in brain AVM development - literature review.
Domain within the helicase subunit Mcm4 integrates multiple kinase signals to control DNA replication initiation and fork progression.
Middle infrared radiation induces G2/M cell cycle arrest in A549 lung cancer cells.
Tendinopathy
Ciprofloxacin-mediated cell proliferation inhibition and G2/M cell cycle arrest in rat tendon cells.
Teratocarcinoma
Correlation of ploidy and cyclin B1, P34cdc2 and PCNA expression in F9 teratocarcinoma cells.
Teratoma
Cyclin-Dependent Kinase 4/6 Inhibition for the Treatment of Unresectable Mature Teratoma: Long-Term Follow-Up of a Phase II Study.
Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
Testicular Neoplasms
Cell cycle regulators in testicular cancer: loss of p18INK4C marks progression from carcinoma in situ to invasive germ cell tumours.
Inhibin and p27 interact to regulate gonadal tumorigenesis.
Thromboembolism
Cyclin-Dependent Kinase Inhibitor-Associated Thromboembolism.
Thrombosis
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.
Thymoma
Analysis of salivary microRNA expression profiles and identification of novel biomarkers in esophageal cancer.
Cyclin-dependent kinase inhibitors, p16 and p27, demonstrate different expression patterns in thymoma and thymic carcinoma.
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
Loss of p16(INK4A) Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas.
Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.
miR-144/451 Promote Cell Proliferation via Targeting PTEN/AKT Pathway in Insulinomas.
Progress in targeted therapy for breast cancer.
Transcriptome sequencing combined with bioinformatics predicts potential genes and pathways associated with bupivacaine-induced apoptosis.
Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer.
Thyroid Cancer, Papillary
Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications.
CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/?-catenin pathway.
Cyclin-dependent kinase 7 is a potential therapeutic target in papillary thyroid carcinoma.
Downregulation of cyclin-dependent kinase 8 by microRNA-148a suppresses proliferation and invasiveness of papillary thyroid carcinomas.
Expression of p21(cip1), p27 (kip1), and p16 (INk4a) Cyclin-Dependent Kinase Inhibitors in Papillary Thyroid Carcinoma: Correlation with Clinicopathological Factors.
Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis.
Thyroid Carcinoma, Anaplastic
BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1).
Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells.
Effects of roniciclib in preclinical models of anaplastic thyroid cancer.
Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Thyroid Neoplasms
A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.
Activity of roniciclib in medullary thyroid cancer.
An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks.
CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/?-catenin pathway.
Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization.
Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas.
Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Interleukin-1alpha regulates G1 cell cycle progression and arrest in thyroid carcinoma cell lines NIM1 and NPA.
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma.
Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells.
Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer.
Prognostic Value of p27 in Follicular Thyroid Carcinoma and its Relation to Radioactive Iodine Response: Does it Aid in the Modification of Risk Stratification?
PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1.
The role of AUF1 in thyroid carcinoma progression.
Trichothiodystrophy Syndromes
ARCH domain of XPD, an anchoring platform for CAK that conditions TFIIH DNA repair and transcription activities.
Triple Negative Breast Neoplasms
A clinical evaluation of treatments that target cell cycle machinery in breast cancer.
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease.
Cyclin-dependent kinase like 3 promotes triple-negative breast cancer progression via inhibiting the p53 signaling pathway.
G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells.
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
No driver behind the wheel? Targeting transcription in cancer.
Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer.
Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer.
Targeted Treatment of Triple-Negative Breast Cancer.
Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
Thioridazine hydrochloride: an antipsychotic agent that inhibits tumor growth and lung metastasis in triple-negative breast cancer via inducing G0/G1 arrest and apoptosis.
Trophoblastic Neoplasms
[The expressions of p16, CDK4 and PCNA proteins in trophoblastic tumors]
Trypanosomiasis
Identification and Functional Characterisation of CRK12:CYC9, a Novel Cyclin-Dependent Kinase (CDK)-Cyclin Complex in Trypanosoma brucei.
Tuberous Sclerosis
Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B.
Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2.
Markers of cellular proliferation are expressed in cortical tubers.
RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
The mTOR pathway and its role in human genetic diseases.
The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27.
Tuberin and p27 expression in breast cancer patients with or without BRCA germline mutations.
Tumor Lysis Syndrome
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
Urinary Bladder Neck Obstruction
The physiological significance of p27(KIP1) expression in detrusor function.
Urinary Bladder Neoplasms
Analysis of the cyclin-dependent kinase inhibitor p27Kip1 in muscle invasive bladder cancer.
CDK12 inactivation across solid tumors: an actionable genetic subtype.
Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells.
Cyclin-dependent kinase inhibitor P27(KIP1) is expressed preferentially in early stages of urothelial carcinoma.
Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53.
Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: is it a good predictor for tumor behavior?
Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
Growth inhibition and cell cycle arrest effects of epigallocatechin gallate in the NBT-II bladder tumour cell line.
High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.
Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B.
Increased cyclin-dependent kinase 6 expression in bladder cancer.
Isoliquiritigenin induces apoptosis of human bladder cancer T24 cells via a cyclin-dependent kinase-independent mechanism.
Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines.
MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6.
MiR-124 retards bladder cancer growth by directly targeting CDK4.
Screening biomarkers of bladder cancer using combined miRNA and mRNA microarray analysis.
Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5.
Urologic Diseases
Loss of p27(Kip1) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer.
Prognostic significance of p27(Kip 1) expression in renal cell carcinoma.
Uterine Cervical Neoplasms
2,4-bis (p-hydroxyphenyl)-2-butenal (HPB242) induces apoptosis via modulating E7 expression and inhibition of PI3K/Akt pathway in SiHa human cervical cancer cells.
Absence of High-Risk Human Papillomavirus (HPV) Detection in Endocervical Adenocarcinoma with Gastric Morphology and Phenotype.
Anti-Condyloma acuminata mechanism of microRNAs-375 modulates HPV in cervical cancer cells via the UBE3A and IGF-1R pathway.
Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS?032, on cervical cancer.
CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration.
CDK9 Inhibitor FIT-039 Suppresses Viral Oncogenes E6 and E7 and Has a Therapeutic Effect on HPV-Induced Neoplasia.
CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer.
Comparison of p16INK4A and Hybrid Capture 2 human papillomavirus testing as adjunctive tests in liquid-based gynecologic SurePath preparations.
Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway.
Cyclin-dependent kinase inhibitors, roscovitine and purvalanol, induce apoptosis and autophagy related to unfolded protein response in HeLa cervical cancer cells.
Expression of Concern: MicroRNA-505-5p functions as a tumor suppressor by targeting Cyclin-Dependent Kinase 5 in cervical cancer.
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis.
Hsa_circ_0000520 overexpression increases CDK2 expression via miR-1296 to facilitate cervical cancer cell proliferation.
KCl cotransport is an important modulator of human cervical cancer growth and invasion.
Low P16INK4A Expression Associated with High Expression of Cancer Stem Cell Markers Predicts Poor Prognosis in Cervical Cancer after Radiotherapy.
MicroRNA-150 suppresses p27Kip1 expression and promotes cell proliferation in HeLa human cervical cancer cells.
MicroRNA-372 Is Down-regulated and Targets Cyclin-dependent Kinase 2 (CDK2) and Cyclin A1 in Human Cervical Cancer, Which May Contribute to Tumorigenesis.
MicroRNA-505-5p functions as a tumor suppressor by targeting cyclin-dependent kinase 5 in cervical cancer.
MiR-495-3p and miR-143-3p co-target CDK1 to inhibit the development of cervical cancer.
Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer.
p16 promotes proliferation in cervical carcinoma cells through CDK6-HuR-IL1A axis.
p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia.
PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer.
Retraction: MicroRNA-505-5p functions as a tumor suppressor by targeting Cyclin-Dependent Kinase 5 in cervical cancer.
Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
Roscovitine-treated HeLa cells finalize autophagy later than apoptosis by downregulating Bcl?2.
Silencing of circular RNA_0000326 inhibits cervical cancer cell proliferation, migration and invasion by boosting microRNA-338-3p-dependent down-regulation of CDK4.
Targeting CDKN3 in cervical cancer.
The association between methylated CDKN2A and cervical carcinogenesis, and its diagnostic value in cervical cancer: a meta-analysis.
The Biflavonoid Amentoflavone Induces Apoptosis via Suppressing E7 Expression, Cell Cycle Arrest at Sub-G(1) Phase, and Mitochondria-Emanated Intrinsic Pathways in Human Cervical Cancer Cells.
The histone demethylase RBP2 is over-expressed in gastric cancer and its inhibition triggers senescence of cancer cells.
Ultrasensitive electrochemical immunosensor based on dual signal amplification process for p16(INK4a) cervical cancer detection in clinical samples.
Uterine Neoplasms
CDK12 inactivation across solid tumors: an actionable genetic subtype.
Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines.
Vaccinia
Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses.
The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase.
Vaccinia virus regulates expression of p21WAF1/Cip1 in A431 cells.
Vascular Calcification
The CDK 9-cyclin T1 complex mediates saturated fatty acid-induced vascular calcification by inducing expression of the transcription factor CHOP.
Vascular Diseases
A meta-analysis on associations of CDKN2B-AS variants with atherosclerotic cardio-cerebral vascular diseases.
Deletion of chromosome 9p21 noncoding cardiovascular risk interval in mice alters Smad2 signaling and promotes vascular aneurysm.
Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation.
Expression of cyclin-dependent kinase inhibitors in vascular disease.
p27kip1-838C>A single nucleotide polymorphism is associated with restenosis risk after coronary stenting and modulates p27kip1 promoter activity.
Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells.
Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury.
Vascular System Injuries
Induction of apoptosis after stent implantation in canine portal vein.
Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.
Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
The proteasome inhibitor lactacystin attenuates growth and migration of vascular smooth muscle cells and limits the response to arterial injury.
Venous Thromboembolism
Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors.
Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials.
Ventilator-Induced Lung Injury
Cyclin-dependent kinase inhibition reduces lung damage in a mouse model of ventilator-induced lung injury.
Virus Diseases
ATP-site directed inhibitors of cyclin-dependent kinases.
Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics.
Direct Substrate Identification with an Analog Sensitive (AS) Viral Cyclin-Dependent Kinase (v-Cdk).
Expression of cyclin-dependent kinase inhibitor 2A 16, tumour protein 53 and epidermal growth factor receptor in salivary gland carcinomas is not associated with oncogenic virus infection.
Functionally active cyclin-dependent kinase 9 is essential for porcine reproductive and respiratory syndrome virus subgenomic RNA synthesis.
Regulation of memory CD8 T-cell differentiation by cyclin-dependent kinase inhibitor p27Kip1.
Roles of Arabidopsis cyclin-dependent kinase C complexes in cauliflower mosaic virus infection, plant growth, and development.
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials.
Simian virus 40 activates ATR-Delta p53 signaling to override cell cycle and DNA replication control.
The CDK inhibitors in cancer research and therapy.
Varicella-zoster virus infection of human foreskin fibroblast cells results in atypical cyclin expression and cyclin-dependent kinase activity.
Vision Disorders
Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.
Cerebral visual impairment in CDKL5 deficiency disorder: vision as an outcome measure.
Searching for biomarkers of CDKL5 disorder: early-onset visual impairment in CDKL5 mutant mice.
Treatment with a GSK-3?/HDAC Dual Inhibitor Restores Neuronal Survival and Maturation in an In Vitro and In Vivo Model of CDKL5 Deficiency Disorder.
Visual impairment in FOXG1-mutated individuals and mice.
Vitamin D Deficiency
Podocytes as target of vitamin D.
Vitiligo
Integrative Analysis of Omics Data Reveals Regulatory Network of CDK10 in Vitiligo Risk.
von Hippel-Lindau Disease
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Warts
Molecular analysis of the effect of topical imiquimod treatment of HPV 2/27/57-induced common warts.
Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts.
Whooping Cough
Responses of pertussis toxin-treated microvascular endothelial cells to transforming growth factor beta 1. No evidence for pertussis-sensitive G-protein involvement in TGF-beta signal transduction.
The GTP-binding protein G(ialpha) translocates to kinetochores and regulates the M-G(1) cell cycle transition of Swiss 3T3 cells.
Wilms Tumor
1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat.
Cell-cycle mechanisms involved in podocyte proliferation in cellular lesion of focal segmental glomerulosclerosis.
Decreased expression of the INK4 family of cyclin-dependent kinase inhibitors in Wilms tumor.
Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
MIB-1 (KI-67) proliferation index and cyclin-dependent kinase inhibitor p27(Kip1) protein expression in nephroblastoma.
p57K1P2 is expressed in Wilms' tumor with LOH of 11p15.5.
Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition.
Reduced expression of the cyclin-dependent kinase inhibitor gene p57KIP2 in Wilms' tumor.
Wiskott-Aldrich Syndrome
Close encounters of the third kind: disordered domains and the interactions of proteins.
How signaling proteins integrate multiple inputs: a comparison of N-WASP and Cdk2.
Xeroderma Pigmentosum
Neural tube development requires the cooperation of p53- and Gadd45a-associated pathways.
Spironolactone-induced XPB degradation requires TFIIH integrity and ubiquitin-selective segregase VCP/p97.
TFIIH action in transcription initiation and promoter escape requires distinct regions of downstream promoter DNA.